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As rheumatoid arthritis (RA) is a heterogeneous disease whose course and treatment 
response varies between patients, a stratified approach to its management is required. 
This thesis aimed to facilitate the risk prediction that underpins stratified medicine in 
RA. Its primary aim was to improve the knowledge of which clinical and genetic 
factors predict RA’s onset, disease course and treatment responses. Its secondary aim 
was to develop a prediction modelling framework that harnessed these factors to 
inform clinical care. There were five key findings. 
 
Firstly, it demonstrated a significant inverse association between alcohol 
consumption and RA development when the evidence across published studies was 
pooled using meta-analytical techniques. This suggests alcohol may protect against 
RA. Secondly, it demonstrated that only HLA RA susceptibility variants associated 
with radiological progression in a clinical trial cohort of early, active RA patients. 
This suggests the non-HLA genetic architectures of RA susceptibility and severity 
may, at least partially, differ. Thirdly, it provided evidence that anti-citrullinated 
protein antibodies (ACPA) can identify patients with early, active RA that are most 
likely to benefit from combination treatments. Fourthly, it demonstrated that 
estimating an asymptomatic individual’s risk of RA is possible, through developing 
and validating a risk prediction model that uses computer simulation to improve 
upon the discriminative abilities of existing RA prediction models. Finally, it 
highlighted the importance of considering RA’s heterogeneity when assessing its 
predictive factors; alcohol’s likely protective effect was predominantly seen in 
ACPA-positive disease and genetic and environmental factors had different impacts 
on the risk of developing younger and older onset RA. 
 
In conclusion this thesis has contributed to stratified medicine in RA by better 
characterising which predictive factors are relevant to its development, severity, 
treatment needs and responses and developing a risk prediction modelling framework 
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CHAPTER 1.   INTRODUCTION 
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1.1. An Overview of Rheumatoid Arthritis 
1.1.1. Historical Background 
Rheumatoid arthritis (RA) was first described by Augustin Landré-Beauvais, a 
physician in France in the 1800s. He managed several patients with severe joint pain, 
which in contrast to gout mainly affected the poor and women. He termed this 
condition “Primary Asthenic Gout” (Entezami, et al., 2011).  Sir Alfred Garrod, an 
academic clinician in London in 1859, subsequently made the distinction of this 
condition from gout, based on the absence of high uric acid levels in the blood. His 
son, Sir Archibald Garrod, finally named the condition “Rheumatoid Arthritis” in 
1890 (Entezami et al, 2011). It took several decades for the term RA to be 
universally recognised; it was not officially used by the American Rheumatism 
Association (ARA) until the 1940s. 
 
1.1.2. Classification Criteria 
As with many medical conditions, RA lacks a single pathognomonic feature.  It can 
therefore be difficult to differentiate it from other inflammatory arthritidies; this is 
especially true in early disease. The diagnosis of RA relies on the presence of a 
combination of clinical, laboratory and radiological findings. Classification criteria 
have been developed, which combine these features to classify an individual as 
having RA for the purposes of understanding its aetiology and disease course (Fries, 
et al., 1994). Whilst these are often used as diagnostic criteria in clinical practice, 
they were not designed for this purpose as misclassification can occur. The gold 
standard for RA diagnosis is that of an experienced rheumatologist’s opinion.  
 
The first attempts to develop RA classification criteria were undertaken in the 1950s. 
The 1958 ARA criteria used a hierarchy of diagnostic certainty, which ranged from 
"possible" to "classical" disease (Ropes, et al., 1958). They were subsequently 
revised in 1987 by the American College of Rheumatology (ACR), during which the 
diagnostic certainty category was removed (Arnett, et al., 1988).  According to the 
1987 ACR criteria an individual is classified as having RA when 4 of 7 qualifying 
criteria are fulfilled (Table 1-1). Although the 1987 criteria have a high overall 
sensitivity and specificity, they were developed from patients with established 
20 
 
disease and therefore lack accuracy in classifying RA in its early stages (Banal, et al., 
2009).  
 
Table 1-1. 1987 ACR Classification Criteria for RA 
Criteria Definition 
1. Early morning 
stiffness 
Morning stiffness in and around the joints, lasting >1 hour 
before maximal improvement 
2. Arthritis involving 
three or more joint 
areas 
At least 3 joint areas have simultaneously had soft tissue 
swelling or fluid (not bony overgrowth alone) observed by a 
physician. The 14 possible areas comprise the PIP, MCP, 
wrist, elbow, knee, ankle and MTP joints 
3. Arthritis of the 
hand joints 
At least 1 area swollen (as defined in criteria 2) in a wrist, 
MCP, or PIP joint 
4. Symmetrical 
arthritis 
Simultaneous involvement of the same joint areas on both 
sides of the body (bilateral involvement of PIPs, MCPs, or 
MTPs is acceptable without absolute symmetry) 
5. Rheumatoid 
nodules 
Subcutaneous nodules, over bony prominences, or extensor 
surfaces, or in juxta-articular regions, observed by a 
physician 
6. Positive serum 
rheumatoid factor 
(RF) 
Demonstration of abnormal amounts of serum RF by any 
method for which the result has been positive in <5% of 
normal control subjects 
7. Radiographic 
evidence of RA 
Radiographic changes typical of RA on posteroanterior 
hand and wrist radiographs, which must include erosions or 
unequivocal bony decalcification localised in or most 
marked adjacent to the involved joints (OA changes alone 
do not qualify) 
To classify a patient as having RA, criteria 1-4 must have been present for at least 6 
weeks and 4 or more criteria must be present. The classification of RA should not be 
made by these criteria alone if another systemic disease associated with arthritis is 
definitely present. PIP = proximal interphalangeal; MCP = metacarpophalangeal; 
MTP = metatarsophalangeal; OA = osteoarthritis. 
 
Over the last few years there has been a major shift in the paradigm of RA 
management towards attaining an early diagnosis and initiating prompt intensive 
treatment (Deighton, et al., 2009). This approach improves both short-term and long-
term outcomes (Boers, et al., 1997b, Choy, et al., 2008, Landewe, et al., 2002). As a 
result the 1987 ACR RA classification criteria have been updated by a joint working 
group of the ACR and European League Against Rheumatism (EULAR); these new 
criteria aim to identify patients with an undifferentiated arthritis that are likely to 
develop a chronic, erosive disease (Aletaha, et al., 2010). They classify the presence 
of RA based on synovitis in at least 1 joint, the absence of an alternative diagnosis 
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and the achievement of a total score of at least 6 points (from a possible 10) across 4 
domains (Table 1-2). 
 
Table 1-2. 2010 ACR/EULAR Classification Criteria for RA 
1. Definite clinical synovitis (swelling) of ≥ 1 joint and 
2. Synovitis not better explained by another pathology and 
3. Score of ≥6/10 from the following 4 domains: 
i. Joint involvement 
 1 large joint = 0 points 
 2-10 large joints = 1 point 
 1-3 small joints = 2 points 
 4-10 small joints = 3 points 
 >10 joints (at least 1 small joint) = 5 points 
ii. Serology 
 Negative RF and negative ACPA = 0 points 
 Low-positive RF or low-positive ACPA = 2 points 
 High-positive RF or high-positive ACPA = 3 points 
iii. Acute-phase response 
 Normal CRP and ESR = 0 points 
 Abnormal CRP or ESR = 1 point 
iv. Duration of symptoms 
 <6 weeks = 0 points 
 ≥6 weeks = 1 point 
To classify RA, patients must satisfy all three criteria. Low positive serological tests 
refer to values ≤3 times the upper limit of normal; high positive refers to values >3 
times the upper limit of normal; RF = rheumatoid factor; ACPA = anti-citrullinated 
protein antibodies; ESR = erythrocyte sedimentation rate; CRP = C-reactive 
protein. 
 
The 2010 criteria have an increased sensitivity compared to their 1987 predecessor. 
This reflects the designing working group’s remit to increase the sensitivity of 
classification criteria in early disease. As a result, their specificity is lower, although 
this can be improved providing a careful exclusion of alternative diagnoses is 
undertaken prior to their application (Mjaavatten and Bykerk, 2013). Another key 
difference is their weighting towards scoring highly for the presence of RA specific 
autoantibodies; they therefore preferentially classify seropositive patients as having 
RA. In order for a seronegative patient to fulfil the 2010 criteria they need to have 
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more than 10 joints involved; the criteria therefore have low sensitivity for 
classifying seronegative RA (Kaneko, et al., 2011). 
 
1.1.3. Epidemiology 
RA is a relatively common disease. Its prevalence rate within the UK is often quoted 
as 1%. This is based on a historical survey of 1,236 males and 1,354 females in two 
Northern UK areas, which used the 1958 ARA RA Classification Criteria (Lawrence, 
1961). A more recent study, undertaken within the Norfolk Arthritis Register 
(NOAR) and using the 1987 ACR classification criteria, suggests that the prevalence 
of RA in females is falling. Extrapolating NOAR data to the UK population indicates 
an overall RA prevalence in adults of 0.81% (1.16% in women and 0.44% in men) 
(Symmons, et al., 2002). The prevalence of RA increases with age and differs 
between genders, being approximately 3 times commoner in women. It also varies 
geographically; RA is substantially commoner in developed areas such as Northern 
Europe and Northern America, when compared with developing areas. The 
prevalence of RA in developing countries like South Africa, Nigeria, Indonesia, 
Pakistan, China, the Philippines and Argentina has been estimated at <0.5% (Kalla 
and Tikly, 2003). Such geographical discrepancies suggest differing environmental 
exposures and/or genetic susceptibility factors. 
 
1.1.4. Clinical Features 
1.1.4.1.Joint Involvement 
The cardinal features of RA are synovitis and tenosynovitis. The main symptom 
patients report is, therefore, that of joint pain with swelling and early morning 
stiffness. This latter feature is attributable to circadian variations in endogenous 
corticosteroids. 
  
RA has a predilection for the peripheral small joints although any joint can be 
affected. In most patients the proximal interphalangeal (PIP), metacarpophalangeal 
(MCP), thumb interphalangeal and wrist joints are involved. Joint involvement is 
often symmetrical. If synovitis is not suppressed with treatment, joint damage and 
deformity can occur. Characteristic deformities comprise ulnar deviation of the 
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fingers (due to MCP joint subluxation), swan-neck deformities, boutonnière 
deformities, and a Z-shaped thumb deformity. 
 
1.1.4.2.Extra-Articular Manifestations 
The extra-articular features of RA are protean (Table 1-3). They affect up to 40% of 
patients and are commoner in individuals that are seropositive, smokers or have early 
disability (Turesson, et al., 2003).  Although the occurrence of rheumatoid vasculitis 
appears to be falling, extra-articular features remain a common complication of RA 
that are associated with an excess mortality (Myasoedova, et al., 2011). 
 






Small vessel vasculitis 
Palmar erythema 
Pyoderma gangrenosum 
Pulmonary Lung nodules 
Pleural effusion (exudate) 






Valvular heart disease 
Neurological Cervical myelopathy 
Peripheral neuropathy 
Mononeuritis multiplex 





1.1.5. Current Management 
Historically, RA was treated with disease-modifying anti-rheumatic drug (DMARD) 
monotherapy with treatment titrated slowly until disease activity was deemed to be 
adequately controlled or side-effects occurred. The last few years have seen a key 
shift in the paradigm of RA management towards early, intensive combination 
DMARDs and corticosteroids. These are titrated until a target of remission has been 
attained (Deighton et al, 2009). In refractory cases biologic agents are instituted at an 
early stage. 
 
1.1.5.1.Disease-Modifying Anti-Rheumatic Drugs 
DMARDs are a diverse group of drugs that are categorised together as they not only 
improve RA symptoms but also modify the disease course, reducing joint damage 
and disability. 
 
Methotrexate is the dominant drug with National Institute for Health and Care 
Excellence (NICE) guidelines advocating its use in all early, active RA patients 
(Deighton et al, 2009).  Other commonly used DMARDs comprise sulfasalazine, 
hydroxychloroquine and leflunomide. DMARDs that are rarely used comprise gold, 
penicillamine and ciclosporin. All DMARDs have potentially serious side-effects, 
chiefly haematological abnormalities and liver toxicity; they therefore require 
monitoring, usually in the form of regular blood tests. 
 
Although methotrexate is widely considered to be the most effective DMARD, this is 
not clearly supported by published data. A systematic review by the Agency for 
Health Care Research and Quality (AHRQ) summarised the evidence for DMARD 
efficacy; it reported inconclusive evidence for differences in efficacy between oral 
methotrexate, sulfasalazine and leflunomide, although heterogeneity in methotrexate 
dosing across trials limited their comparability (Singh and Cameron, 2012). 
 
1.1.5.2.Biologic Agents 
In contrast to DMARDs, which have a general effect on the immune system, 
biologics target specific immune system components such as the pro-inflammatory 
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cytokines, TNF-α and IL-6 (Strand, et al., 2007). There are currently 5 different 
classes of biologics licensed for the treatment of RA (Table 1-4).  
 
Table 1-4. Current Biologic Agents for the Treatment of RA 






B-cell inhibition Rituximab 
T-cell inhibition Abatacept 
Interleukin-6 inhibition Tocilizumab 
Interleukin-1 receptor antagonist* Anakinra 
* = not approved by NICE for RA management. 
 
Initial agents of choice for RA are TNF or IL-6 inhibitors. Their use in the UK is 
restricted by NICE to patients who have failed two conventional DMARDs, 
including methotrexate and have severely active disease defined as having a DAS28 
score >5.1 on two occasions one month apart (National Institute for Health and Care 
Excellence, 2007).  The other biologic classes are used in patients who have failed or 
have a contra-indication to these agents. The initial biologic in these instances is 
rituximab (National Institute for Health and Care Excellence, 2010); abatacept is 
used in cases of anti-TNF or IL-6 inhibitor and rituximab failure or contra-indication 
(National Institute for Health and Care Excellence, 2010). Figure 1-1 outlines the 





Figure 1-1. Current Biologic Treatment Pathway for RA 
 
1.1.5.3.Small Molecule Drugs 
Biologics have their limitations (Singh, et al., 2010); they are costly, require 
parenteral administration, have long half-lives and lack efficacy in some 
patients. There is therefore an ongoing need to identify novel, orally 
administered drugs. Pharmaceutical companies have recently focussed their 
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attention on identifying efficacious small-molecule agents (Stanczyk, et al., 
2008). These drugs interrupt intracellular signalling by inhibiting kinases. Mitogen-
Activated Protein Kinases (MAPKs), Protein Tyrosine Kinases (PTKs), Janus-
Associated Kinases (JAKs) and Spleen Tyrosine Kinase have all been potential 
targets of interest in RA management. To date only a single kinase inhibitor, 
tofacitinib, has been licensed for RA management. Tofacitinib is an inhibitor of JAK; 
it inhibits multiple JAKs.  Several large randomised controlled trials (RCTs) have 
evaluated tofacitinib; the results support its efficacy (Burmester, et al., 2013, 
Fleischmann, et al., 2012). It is approved for use in the United States of America 
(USA) but has not yet been approved within the UK. 
 
1.1.6. The Concept of RA as a Syndrome 
It is becoming increasingly clear that as opposed to representing a single disease, RA 
is in fact a clinical syndrome that spans several different disease subsets (Van Der 
Helm-Van Mil and Huizinga, 2008). The current main division is by autoantibody 
status, particularly ACPA, although other subsets probably exist. Evidence for this 
division stems from studies demonstrating that ACPA-positive and ACPA-negative 
have differing genetic (Eyre, et al., 2012) and environmental risk factors (Klareskog, 
et al., 2006b, Scott, et al., 2013c), phenotypes (Van Der Helm-Van Mil, et al., 2005) 
and treatment responses (Gottenberg, et al., 2012, Isaacs, et al., 2013, Potter, et al., 
2009). It is crucial to consider this disease heterogeneity when researching and 
treating patients with RA. 
 
1.1.7. Immunopathology 
RA is characterised by chronic systemic and articular inflammation. Although the 
precise immunopathological mechanisms that underlie RA have not been completely 
defined this process is driven by both the innate and adaptive immune systems with 






Macrophages and their precursor’s monocytes act both systemically, through the 
production of classical RA pro-inflammatory cytokines i.e. IL-1 and TNF-α 
(Firestein, et al., 1990) and locally, through synovial infiltration with 
macrophages/monocytes being enriched in the rheumatoid synovium and destructive 
pannus tissue (Burmester, et al., 1997).  
 
1.1.7.2.T Cells 
T cells are well established as key components of RA immunopathology. Evidence 
for this stems from the strong association of RA with the shared epitope (SE) alleles 
encoding the major histocompatibility complex (MHC) (indicating that antigen 
presentation to T cells is an important process in RA), the prevalence of CD4+ T 
cells within rheumatoid synovium and the efficacy of the selective T cell co-
stimulation modulator, abatacept (Genovese, et al., 2005). Antigen-dependent T cell 
responses may be important in initiating the inflammatory response during RA 
(Andersson, et al., 2008). They may also act independently of antigenic stimulation 
to perpetuate inflammation through activating monocytes/macrophages to produce 
pro-inflammatory cytokines (Sebbag, et al., 1997). Additionally T helper 17 cells 
produce IL17, which has pleiotropic effects on many RA effector cells causing 




The importance of B cells in RA is highlighted by the efficacy of B cell depletion 
therapy with the anti-CD20 monoclonal antibody, rituximab (Cohen, et al., 2006). B 
cells have multiple functions in RA. They can act as antigen presenting cells (APCs) 
presenting antigens via MHC class II molecules to T cells activating them with 
consequent downstream macrophage activation and TNF-α production. They 
produce pro-inflammatory cytokines and chemokines directly via Toll-like receptor 
activation (Martinez-Gamboa, et al., 2006). B cells are responsible for autoantibody 
production, with RF and ACPA forming immune complexes with immune responses 
via Fc and complement receptors (Carroll, 2004). Additionally in many RA patients 
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synovial extra-follicular germinal centres develop with B lymphocytes surrounded by 
T cells, acting as functional ectopic germinal centres (Schroder, et al., 1996). 
 
1.1.7.4.Synovial Fibroblasts 
Fibroblast-like synoviocytes (FLS) are prevalent in RA synovium where they have a 
unique phenotype with aggressive and invasive properties; they drive cartilage 
erosion through matrix metalloproteinase production and are dominant producers of 
IL-6 (Bartok and Firestein, 2010). 
 
1.2. Rheumatoid Arthritis Susceptibility Factors 
1.2.1. An Overview 
RA is considered to occur when genetically predisposed individuals are exposed to 
specific environmental risk factors. These gene-environment risks interact to trigger 
perturbations in the immune system, with autoantibody (RF and/or ACPA) 
generation in the majority of cases, followed by pro-inflammatory cytokine 
production and a consequent inflammatory arthritis (Scott, et al., 2011). 
 
Over the last few decades epidemiological studies have proposed a variety of 
different environmental risk factors for RA. With the exception of cigarette smoking 
(Sugiyama, et al., 2010), their associations are often shown in case-control, but not 
cohort studies; their links to RA development are therefore uncertain. 
 
Recent advances in affordable genotyping techniques have allowed the genome-wide 
analysis of large numbers of individuals with and without RA. The genetic 
architecture of RA susceptibility is therefore relatively well characterised, with 101 
validated independent RA susceptibility loci identified in a recent meta-analysis of 
genome-wide association studies (GWASs) (Okada, et al., 2013). Recent estimates 
suggest that in European populations approximately half of the proportion of RA 
heritability has been identified, of which 15% and 36% is explained by non-MHC 





1.2.2. Genetic RA Susceptibility Factors 
Genetic factors dominate an individual’s risk of RA. They are estimated to account 
for approximately two-thirds of the overall risk burden for both ACPA-positive and 
ACPA-negative disease (Van Der Woude, et al., 2009). The genetic architecture of 
ACPA-positive RA is better defined. This partly reflects the fact that existing GWAS 
meta-analyses have examined smaller numbers of ACPA-negative patients (Eyre et 
al, 2012); it also stems from the fact that ACPA-positive RA is a more easily defined 
phenotype, which is at less risk of misclassification.  
 
1.2.2.1.HLA Risk 
The majority of genetic risk for seropositive RA is derived from the HLA region, 
specifically HLA-DRB1.  This group of alleles encode the HLA class II DRβ-chain, 
which plays a pivotal role in antigen presentation; it probably influences RA 
susceptibility by affecting the binding and presentation of arthritogenic peptides to 
auto-reactive CD4+ T cells (Hill, et al., 2003).  
 
Historically, the relationship between the HLA region and seropositive RA has been 
explained by the presence of a group of amino acid sequences (QRRAA, RRRAA 
and QKRAA) spanning positions 70-74 of the HLA-DRβ1 molecule. The classical 
HLA-DRB1 alleles encoding these sequences are termed the SE alleles (Gregersen, et 
al., 1987). Studies defining this association used immunological reagents that 
preferentially determined sequences on the exposed rim of the HLA-DR molecule. 
Using these techniques RA’s association with less accessible regions of the molecule 
were poorly defined. Recent advances in computational methods alongside denser 
genome coverage on reference panels have enabled exploration of these regions 
through amino acid imputation. This was undertaken in a recent study by 
Raychaudhuri et al, which used HLA imputation to evaluate the association of amino 
acid polymorphisms across the HLA region with susceptibility to ACPA-positive RA 
(Raychaudhuri, et al., 2012). This novel analysis found the majority of the MHC’s 
association with RA susceptibility was determined by polymorphisms in three amino 
acid positions (11, 71 and 74) in the HLA-DRβ1 protein and position 9 in HLA-B 
and HLA-DPβ1 proteins. All these positions are located within peptide-binding 
grooves; they therefore have a biologically plausible association with RA 
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development via antigen presentation. As only two of the five amino acid positions 
lie within the SE region this component of the HLA-DRβ1 molecule may not be the 
driving force behind seropositive RA development it was previously considered to 
be. 
  
The HLA region has a more modest effect on susceptibility to seronegative RA. 
Although several small studies reported an association between HLA-DRB1*03 and 
ACPA-negative RA (Irigoyen, et al., 2005, Verpoort, et al., 2005), this was not 
confirmed in larger populations (Ding, et al., 2009, Padyukov, et al., 2011). Possible 
explanations for this non-replication included low power (studies of ACPA-negative 
patients are substantially smaller than those of ACPA-positive patients (Padyukov et 
al, 2011)) and misclassification (chiefly ACPA-negative cases having an alternative 
type of inflammatory arthritis). A recent study has attempted to overcome these 
limitations by analysing HLA associations in large numbers of ACPA-negative 
patients (2,406 cases and 13,930 controls) and using statistical methodology to 
regress out the effects of misclassified HLA-B27-positive seronegative arthritis cases 
(Han, et al., 2014). Controlling for misclassification effects, this study demonstrated 
independent associations for serine and leucine at position 11 in HLA-DRβ1 
(P=1.4x10
-13
) and for aspartate at position 9 in HLA-B (P=2.7x10
-12
) within the 
peptide binding grooves. These positions induced associations at HLA-DRB1*03 
(encoding serine at 11) and HLA-B*08 (encoding aspartate at 9). 
 
1.2.2.2.Non-HLA Risk Loci 
Through collaborative efforts the number of validated non-HLA risk variants has 
rapidly expanded. The largest, most recent GWAS meta-analysis has identified 100 
non-HLA RA susceptibility loci (Okada et al, 2013). This study combined GWASs 
of European and Asian ancestry patients, in order to optimise power to detect novel 
risk loci. Figure 1-2 shows the ORs from this meta-analysis for RA at each locus that 
has a replicated genome-wide significant association with susceptibility in 
Europeans. The largest risks are observed for HLA-DRB1, PTPN22, ILF3, TYK2, 
IL20RB and TNFAIP3 (all of which has ORs >1.40). For most loci the effect sizes 
are very modest; approximately half have ORs ≤1.10. 
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Figure 1-2. Odds Ratios for Validated European RA Susceptibility Loci 
 
Figure adapted using data from Okada et al meta-analysis (Okada et al, 2013).
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The meta-analysis by Okada et al did not evaluate risk stratified by serological 
status.  The penultimate RA GWAS meta-analysis by Eyre et al undertook a specific 
analysis comparing the associations between RA subsets defined by ACPA status 
(Eyre et al, 2012). Of 45 non-HLA loci, approximately half had a significantly larger 
effect size in ACPA-positive disease, with 5 loci (PTPN22, CCR6, CD40, RASGRP1 
and TAGAP) having a markedly stronger association with this RA subset. Their 
findings support the concept that ACPA-positive and ACPA-negative RA have 
differing non-HLA genetic risk profiles.  
 
1.2.2.3.Missing Heritability 
Current estimates of the proportion of heritability explained by identified genetic risk 
factors suggest that approximately 50% remains unaccounted for (Eyre et al, 2012). 
There are several potential explanations for this. Firstly, GWASs were designed to 
detect associations with common variants. Rare variants could explain a substantial 
proportion of complex disease risk with a recent analysis using deep sequencing data 
suggesting that 96% of functionally important single-nucleotide variants are rare (as 
defined by a MAF of <0.5%) (Tennessen, et al., 2012). This appears to be the case in 
RA with Diogo et al observing an accumulation of rare nonsynonymous variants in 
IL2RA and IL2RB in 500 RA cases in whom deep exon sequencing of biological 
candidate genes in known risk loci was undertaken (Diogo, et al., 2013). Next-
generation sequencing of large patient populations should identify functionally 
relevant rare variants; these will have larger effect sizes than those of SNPs.  
 
Secondly, it may be that existing GWASs are underpowered to detect relevant 
susceptibility loci. This concept is supported by Stahl et al, who through the use of 
polygenic models demonstrated that common variants of low effect sizes accounted 
for a substantial proportion of RA’s missing heritability (Stahl, et al., 2012). 
 
Thirdly, current GWAS technologies do not evaluate the impact of epigenetic 
genome modifications on RA risk. Epigenetics is defined as “changes in gene 
function that are heritable and do not entail a change in the DNA sequence” (Dupont, 
et al., 2009). Two well characterised epigenetic mechanisms comprise post-
translational histone modifications and DNA methylation; both have important 
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impacts on gene expression (Jaenisch and Bird, 2003). Only a few studies have 
evaluated the role of epigenetic mechanisms in RA susceptibility. Nakano et al 
performed a genome-wide evaluation of DNA methylation loci in fibroblast-like 
synoviocytes (FLS) isolated from female RA and OA patients at the time of joint 
replacement surgery (Nakano, et al., 2013). They demonstrated that RA and control 
FLS had 1,859 differentially methylated loci. Hypomethylated loci were identified in 
key genes relevant to RA including STAT3 and MAP3K5. Liu et al undertook an 
epigenome-wide association study of 354 ACPA-positive RA cases and 337 controls. 
They identified 10 differentially methylated positions (DMPs), whose methylation 
levels could mediate genetic susceptibility in RA; 9 were within, and 1 was external 
to the MHC region (Liu, et al., 2013). Epigenetic studies have two potentially 
important confounding factors. Firstly, methylation differences may result from 
cellular heterogeneity within the sample material. Most DNA methylation analyses 
use DNA samples obtained from whole blood samples; this comprises many distinct 
cell populations that have been shown to vary in their methylation profiles (Reinius, 
et al., 2012). Secondly, as most use case-control designs they evaluate methylation 
profiles post-RA onset; any differential methylation patterns may therefore arise as a 
consequence of the disease as opposed to being causative. Liu et al accounted for 
these factors by adjusting for cell-type proportions and using mediation analyses, 
although the optimal strategy to exclude disease consequence methylation patterns 
would be to undertake epigenetic studies in a prospective cohort study, evaluating 
samples before and after RA onset. 
 
Fourthly, epistasis and gene-environmental interactions may explain a significant 
proportion of RA heritability. This is present in seropositive RA, with the interactive 
effect of smoking and the SE alleles on RA risk being well established (Padyukov, et 
al., 2004, Pedersen, et al., 2007). Interactions between SE alleles and PTPN22 on 





1.2.3. Environmental Risk Factors for RA 
1.2.3.1.Cigarette Smoking 
Cigarette smoking is the dominant environmental risk factor for RA. It has been 
shown to associate with disease onset in both case-control and prospective cohort 
studies. Its impact appears limited to individuals with seropositive (particularly 
ACPA-positive) RA (Padyukov et al, 2004, Pedersen et al, 2007). Its influence is 
also greater in males compared with females (Sugiyama et al, 2010). A recent meta-
analysis of 16 observational studies reported a summary OR for RA of 1.89 (95% CI 
1.56-2.28) and 1.27 (95% CI 1.12-1.44) in male and female ever-smokers, 
respectively (Sugiyama et al, 2010). The risks were higher for RF-positive RA in 
male ever-smokers (OR 3.02; 95% CI 2.35-3.88). In female ever-smokers a non-
significant association with RF-positive RA was observed (OR 1.34; 95% CI 0.99-
1.80). This gender discrepancy probably reflects the fact that males smoke more 
heavily than females. Heavy smoking does associate with RA development in 
women, with a clear dose-dependent effect seen. Data from the Nurses’ Health Study 
(NHS) indicates a linear relationship exists between RA and increasing pack years of 
smoking (Figure 1-3). In this cohort the age adjusted RR for RA in females with a 
>40 pack-year history of smoking comprised 1.99 (95% CI 1.57-2.53); in females 
with a 1-10 pack year history the RR comprised 1.08 (95% CI 0.86-1.36) 





Figure 1-3. Relative Risk of RA in Women by Smoking Pack-Years 
 
 
Figure adapted using data from Costenbader et al (Costenbader et al, 2006) and 
reproduced with permission from Scott et al (Scott et al, 2011). 
 
It has been proposed that smoking leads to seropositive RA through the citrullination 
of arginine residues; these neutrally charted neoepitopes are preferentially bound by 
the positively-charged pocket 4 (P4) within the SE, driving the development of 
ACPA and subsequently ACPA-positive RA (Wegner, et al., 2010a). This 





Alcohol consumption appears to protect against RA development. Three case-control 
studies have shown large reductions in RA risk in alcohol drinkers compared with 
non-drinkers (Kallberg, et al., 2009, Maxwell, et al., 2010). Källberg et al evaluated 
data from two independent studies: the Epidemiological Investigation of Rheumatoid 
Arthritis (EIRA) and the Case-Control study in Rheumatoid Arthritis (CACORA) 
studies. In their analysis individuals consuming the highest levels of alcohol (defined 
as ≥5 drinks/week) had approximately half the risk of RA when compared to those 
consuming little/no alcohol (Kallberg et al, 2009). This protective effect was greatest 
for ACPA-positive disease. As with smoking, a dose-response effect was also 
observed (Figure 1-4). Maxwell et al reported the OR for RA in non-drinkers vs. 
individuals consuming alcohol on >10 days/month was 4.17 (95% CI 3.01-5.77) in a 
UK case-control study; this effect was also greater for ACPA-positive RA (Maxwell 
et al, 2010). 
 
The chief criticism of these 3 case-control studies is that they asked patients to 
retrospectively confirm their alcohol intake after the development of RA; they were 
therefore subject to recall bias. Their findings have, however, recently been 
reproduced in 3 cohort studies, suggesting this relationship may be causal. The 
EPIC-2-NOAR study reported an age and sex adjusted hazard ratio (HR) of 0.83 
(95% CI 0.69-0.98) for seropositive inflammatory arthritis for every 7 units of 
alcohol consumed/week (Lahiri, et al., 2014). Giuseppe et al reported an inverse 
association between moderate alcohol consumption and RA risk in 34,141 women in 
Sweden. Females consuming >3 glasses of alcohol/week in both 1987 and 1997 had 
a 52% reduced risk of RA compared with never-drinkers (Di Giuseppe, et al., 2012). 
Finally, in the NHS the pooled multivariable adjusted HR for seropositive RA in 
individuals consuming 5.0-9.9 grams of alcohol/day compared with non-drinkers was 








Low alcohol intake:  >0 units but ≤median level of consumption by controls; 
Moderate alcohol intake:  >median but ≤75th percentile of consumption by controls; 
High alcohol intake:  >75
th
 percentile of consumption by controls. All trends are 
significant apart from the ACPA-negative CACORA group. Figure adapted using 
data from Källberg et al (Kallberg et al, 2009) and reproduced with permission from 





Alcohol may protect against RA through attenuation of the innate immune system. In 
animal models alcohol inhibited the onset of a collagen-induced inflammatory 
arthritis through down-regulating leukocyte migration, up-regulating testosterone 
secretion and reducing NF-κB activation (Jonsson, et al., 2007). Alcohol has also 
been shown to have anti-inflammatory effects in humans through similar 
mechanisms, reducing NF-κB driven inflammatory mediator production by 
monocytes (Mandrekar, et al., 2006), which is a key cellular pathway in RA 
(Dichamp, et al., 2007).  
 
1.2.3.3.Periodontitis 
Periodontitis (PD) is a destructive inflammatory disease of the teeth’s supporting 
tissues. Its role in RA pathogenesis has received much interest for two reasons. 
Firstly, PD appears to be prevalent in RA patients (De Pablo, et al., 2008). Secondly, 
the best characterised causative organism for PD is Porphyromonas gingivalis; this is 
the only known prokaryote to possess a functional peptidylarginine deiminase 
enzyme, termed PPAD. PPAD has been show to citrullinate itself as well as other 
proteins (Wegner, et al., 2010b, Quirke, et al., 2014); it may therefore be responsible 
for the breakdown of immune tolerance to citrullinated autoantigens, driving ACPA 
formation in a similar manner to smoking (Mangat, et al., 2010).  
 
Several studies have evaluated the link between PD and RA (Table 1-5). Most 
showed significant associations, although they were predominantly case-control 
studies, consisting of small patient numbers and using variable definitions of PD 
(some used dental examination outcomes like periodontal pocket depths (Abou-
Raya, et al., 2008); others used self-reported histories of periodontal surgery 
(Arkema, et al., 2010)). The largest case-control study was a cross-sectional survey 
of 4,461 USA civilians. It reported that individuals with RA were more likely to be 
edentulous (OR 2.27; 95% CI 1.56-3.31) and have PD (OR 1.82; 95% CI 1.04-3.20) 
(De Pablo et al, 2008). To date the relationship between PD and RA has only been 
examined in a single prospective cohort study (Arkema et al, 2010). In the NHS no 
significant association was found between a history of periodontal surgery or tooth 
loss (evaluated via a self-reported questionnaire) over 12 years of follow-up. The 
multivariate adjusted RRs of developing RA were 1.24 (95% CI 0.83-1.83), 1.02 
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(95% CI 0.74-1.43) and 1.18 (95% CI 0.47-2.95) in those with previous periodontal 
surgery, those who had lost 1-4 teeth and those who had lost 5 or more teeth, 
respectively.  
 
Table 1-5. Studies of Periodontitis as an RA Risk Factor 
Study Design Size Key Findings 
Abou-Raya et al 
(Abou-Raya et al, 
2008) 
Case-control 100 cases 
50 controls 
72% cases and 10% 
controls had PD 
Arkema et al 




RA cases from 
81,132 females 
No association between 
history of periodontal 
surgery (RR 1.24; 95% 
CI 0.83-1.83) or tooth 
loss (RR 1.18; 95% CI 
0.47-2.95) and RA 
De Pablo et al 
(De Pablo et al, 2008) 
Case-control 103 cases 
4,358 controls 
Cases more likely to 
have PD (OR 1.82; 
95% CI 1.04-3.20) 
Dissick et al  
(Dissick, et al., 2010) 
Case -control 69 cases 
35 controls 
Moderate-severe PD 
commoner in cases 
(51%) than controls 
(26%) (P=0.03) 
Mercado et al 
(Mercado, et al., 2001) 
Case-control 65 cases 
65 controls 
Higher numbers of 
missing teeth in cases 
(mean 11.6) compared 
with controls (mean 
6.7) (P<0.001) 
Pischon et al 
(Pischon, et al., 2008) 
Case-control 57 cases 
52 controls 
OR 8.05 (95% CI 2.93-
22.09) for PD in cases 
compared with controls 
Wolf et al  
(Wolff, et al., 2013) 
Case-control 22 cases 
22 controls 
Cases had more 
advanced forms of PD 
compared with controls 
PD= periodontitis; RR = relative risk; CI = confidence interval; OR = odds ratio 
 
1.2.3.4.Pregnancy 
RA’s predilection for women has led to a marked interest in examining risk factors 
that females are exclusively exposed to. One such factor is pregnancy, whose 
relationship with RA development appears complex. In the immediate post-partum 
period there appears to be an increased risk of RA development; however over the 




Silman et al examined the relationship between the time interval from pregnancy and 
RA onset in 88 cases and 144 age-matched female controls (the latter group were 
assigned a “dummy date” for RA onset) (Silman, et al., 1992). They observed a 
reduced risk of RA onset during pregnancy (adjusted OR 0.30; 95% CI 0.04-2.6) and 
a subsequent increased risk in the first 3 months postpartum (OR 5.6; 95% CI 1.8-
17.6). Similarly, Wallenius et al found that in 183 parous RA women the incidence 
rate ratio (IRR) for diagnosis during 0-24 months vs. 25-48 months post-partum was 
1.73 (95% CI 1.11-2.70) (Wallenius, et al., 2010). 
 
Multiple studies have examined the relationship between parity and RA.  To date 12 
case-control (Brennan and Silman, 1994, Guthrie, et al., 2010, Hazes, et al., 1990, 
Pedersen, et al., 2006b, Pikwer, et al., 2009, Pope, et al., 1999, Reckner Olsson, et 
al., 2001, Silman et al, 1992, Spector, et al., 1990, Symmons, et al., 1997, Turner and 
Cherry, 2000, Voigt, et al., 1994) and 4 cohort studies (Heliovaara, et al., 1995, 
Jorgensen, et al., 2010, Karlson, et al., 2004, Merlino, et al., 2003) have reported 
ORs/RRs for RA in ever- vs. never-parous women (or have provided crude data 
allowing for their calculation). Estimating pooled ORs for these studies using a 
random-effects model (due to heterogeneity) highlights a significantly reduced risk 
of RA in women with a history of parity (Figure 1-5); the pooled OR for RA in ever- 
vs. never-parous females is 0.80 (95% CI 0.68-0.93). Stratifying the meta-analysis by 
study design indicates this relationship is limited to case-control studies (OR 0.69; 
95% CI 0.58-0.83), although a trend towards a reduced risk is also seen across cohort 




Figure 1-5. Forest Plot of RA Risk in Ever- Vs. Never-Pregnant Women 
 
Meta-analysis performed using Stata, version 10.1 (Stata Corp., College Station, TX, 
USA) 
 
One proposed mechanism by which pregnancy could protect against RA is through 
the transfer of paternally inherited protective HLA molecules from the foetus to the 
mother in a process called microchimerism. Examples of such HLA molecules are 
those containing the “DERAA” sequence (comprising aspartic acid, glutamic acid, 
arginine, alanine, alanine) at HLA-DRB1 positions 70-74; these are encoded by the 
HLA-DRB1 alleles *01:03, *04:02, *11:02, *11:03, *13:01, *13:02 and *13:04 
(Feitsma, et al., 2008). For this to be a convincing explanation it would require either 
protective HLA alleles to be transferred preferentially over susceptibility HLA 
alleles or males to carry a greater burden of protective HLA alleles; both of these 





As with pregnancy, breast-feeding is another factor that women are exclusively 
exposed to. Several studies have examined its impact on RA risk (Table 1-6). Of the 
6 case-control studies evaluating this issue, half showed an increased risk and half a 
reduced risk of RA in women that had ever-breastfed. Results from the 3 cohort 
studies are more consistent. All showed a trend towards a reduced risk of RA with 
breast-feeding; this was significant in the Chinese Guangzhou Biobank Cohort 
(Adab, et al., 2014) and the American NHS (Karlson et al, 2004). In these two 
studies a dose-dependent risk reduction was observed, with significant trend tests for 
risk stratified by breast-feeding duration. In the Guangzhou Biobank study the 
adjusted OR for RA in females breast-feeding for 1-11, 12-35 and ≥36 months 
comprised 0.84 (95% CI 0.42-1.69), 0.58 (95% CI 0.33-1.04) and 0.54 (95% CI 
0.29-1.01), respectively (P for trend=0.04). In the NHS the adjusted RR for RA in 
females breast-feeding for ≤3, 4-11, 12-23 and ≥24 months comprised 1.0 (95% CI 
0.8-1.2), 0.9 (95% CI 0.7-1.1), 0.8 (95% CI 0.6-1.0) and 0.5 (95% CI 0.3-0.8), 
respectively (P for trend=0.001). 
 
The cohort study data suggest that breast-feeding may reduce the risk of RA. Its role 
has some biological plausibility with higher cortisol levels observed in post-
menopausal women that had previously breastfed for ≥1 year (Lankarani-Fard, et al., 
2001); breast-feeding could therefore influence RA risk through perturbations in 
endogenous steroid levels. Another proposed mechanism is an anti-inflammatory 
effect from progesterone, which is mediated via an increase in the number of 
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Birth year, year RA 
diagnosis 
Pikwer et al 







Number of children 
Reckner et al 
(Reckner 








Adab et al 
(Adab et al, 
2014) 





Age, marital status, BMI, 
smoking, education, parity 
Karlson et al 
(Karlson et al, 
2004) 







Age, smoking, BMI, age at 
menarche, age at first birth, 
parity, OCP use, menstrual 
cycle regularity, HRT use 
Merlino et al 
(Merlino et al, 
2003) 






a = OR calculated using crude data; b = risk assessed in parous women only; c = 
adjusted risks reported stratified by breast-feeding duration, which were combined 
into one common OR using an inverse variance fixed-effects model; BMI = body 
mass index, OCP = oral contraceptive pill; HRT = hormone replacement therapy. 
 
1.2.3.6.Oral Contraceptive Pill Use 
The impact of oral contraceptive pill (OCP) exposure on RA susceptibility has been 
extensively reviewed over the last decade. Its role was first examined in the 1970s, 
with a reduced incidence of RA in OCP users observed in the Royal College of 
General Practitioners’ Oral Contraception Study (Wingrave and Kay, 1978). Since 
then a number of case-control and cohort studies have examined its association with 
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variable findings. A meta-analysis of 9 studies by Spector and Hochberg indicated 
that, as opposed to protecting against disease onset, OCP use may protect against the 
progression to a severe RA phenotype (Spector and Hochberg, 1990). Although an 
overall protective effect of OCP use on RA risk was observed in case-control studies, 
when their meta-analysis was subdivided by studies using cases enrolled from 
hospitals or the community different impacts on disease risk were observed. In case-
control studies evaluating hospital based cases the OR for RA in OCP users was 0.49 
(95% CI 0.39-0.63); in those evaluating population derived cases the OR was 0.95 
(95% CI 0.78-1.16). The authors concluded that the most likely explanation for this 
discrepancy was that rather than preventing RA development, OCP use modified the 
disease process maintaining it as a mild or transient disorder.  
 
1.2.3.7.Obesity 
Adipose tissue is a highly dynamic organ, which releases a diverse mix of immune 
and inflammatory mediators involved in rheumatic disorders (Gomez, et al., 2011). 
The role of obesity in both RA and psoriatic arthritis development has gathered 
increasing interest.  
 
Six studies (Table 1-7) have examined the association between obesity and RA 
development. Although the findings are variable their underlying methodology was 
highly heterogeneous: studies differed in their body mass index (BMI) definitions of 
obesity, the time point in an individual’s lifetime at which obesity was considered a 





Table 1-7. Studies Evaluating Obesity as an RA Risk Factor 
Study Size Key Findings 
Case-Control Studies 





OR 1.24 (95% CI 1.01-1.53) for BMI ≥30 
vs. BMI <30 
Pedersen et al 




OR 1.57 (95% CI 1.01-2.44) for BMI ≥30 
vs. BMI 18.5 to <25 





OR 0.95 (95% CI 0.68-1.34) for BMI ≥30 
vs. BMI 20 to ≤25 





OR 3.74 (95% CI 1.14-12.27) for BMI ≥30 
vs. BMI <25 
Cohort Studies 
Cerhan et al 
(Cerhan, et al., 
2002) 
158 cases from 
31,336 women 
RR 1.01 (95% CI 0.65-1.56) for BMI >29.2 
vs. BMI <23.4 
Hernandez 
Avila et al 
(Hernandez 
Avila, et al., 
1990) 
217 cases from 
116,779 women 
RR 1.1 (95% CI 0.7-1.9) for BMI >29 vs. 
BMI <21
 
BMI = body mass index; BMI in kg/m
2
; OR = odds ratio; RR = relative risk. 
 
Three case-control studies (Table 1-7) demonstrated a significantly increased risk of 
RA in obese individuals (Pedersen et al, 2006b, Symmons et al, 1997); one showed 
the risk was higher for RF/ACPA-positive RA (Crowson et al, 2013); another 
showed the risk was only significantly associated with ACPA-negative RA (Pedersen 
et al, 2006b). Cohort studies examining this issue showed no association between 
obesity and RA development (Cerhan et al, 2002, Hernandez Avila et al, 1990). 
Crowson et al proposed the lack of replication across studies could stem from the 
fact that the risk conferred by obesity is modest and the low prevalence of obesity in 
older studies meant they were underpowered to detect an effect (Crowson et al, 
2013). However, in the absence of prospective cohort studies demonstrating a link, 




1.2.3.8. Dietary Factors 
A range of dietary factors have been examined for their association with RA; the 
results are variable. This may reflect the difficulties in capturing accurate dietary 
intake data, which is mainly undertaken through self-reported questionnaires. 
 
A key example is vitamin D intake. There is a growing appreciation of the role 
vitamin D has in autoimmunity, with its active form producing and maintaining 
immunological self-tolerance (Ginanjar, et al., 2007). Analysis of data from the Iowa 
women’s health study – a prospective cohort study of 29,368 women aged 55-69, of 
whom 152 developed RA over 11 years of follow-up – demonstrated an inverse 
relationship between vitamin D intake and RA (Merlino, et al., 2004). Individuals 
with the highest vitamin D intake had a RR of 0.67 (95% CI 0.44-1.00) for RA 
compared to individuals with the lowest intake. This relationship has not been 
reproduced in other datasets, like the NHS (Costenbader, et al., 2008) . 
 
Another well evaluated dietary factor is caffeine intake. This has been assessed in 3 
cohort studies. Heliövaara et al reported a significant association between coffee 
consumption and RF-positive RA in 18,981 individuals (Heliovaara, et al., 2000). 
Mikuls et al reported a significant association between decaffeinated coffee 
consumption and RA in 31,336 women (Mikuls, et al., 2002). Karlson et al reported 
no association between coffee consumption and RA risk amongst 83,124 women 
(Karlson, et al., 2003). Its link to RA development is inconsistent and therefore 
uncertain. 
  
1.2.3.9.Previous Blood Transfusion 
Allogenic blood transfusions have immunomodulatory effects; exposure to foreign 
antigens in transfused blood is associated with altered B cell populations alongside 
increased autoantibody production (Paglieroni, et al., 1995). UK and USA datasets 
have providing contrasting results for the impact of blood transfusions on RA risk. 
Data from NOAR indicated that blood transfusions increased the risk of RA (OR 
3.58; 95% CI 1.46-8.81) (Symmons et al, 1997). The USA Iowa cohort reported that 
blood transfusions associated with a reduced risk of RA, although this inverse 
relationship was not significant (RR 0.72; 95% CI 0.48–1.08) (Cerhan et al, 2002). 
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The underlying reasons for these contrasting findings are uncertain; they may reflect 
variations in international transfusion practices, although they probably simply 
represent chance findings. 
 
1.2.3.10.Socioeconomic Status 
RA is commoner in lower socioeconomic populations. The EIRA study reported that 
individuals without a university degree had a RR of 1.5 (95% CI 1.1-1.9) for RA 
when compared to those with a university degree (Bengtsson, et al., 2005). Risks 
were greater for RF-positive RA and were mainly seen in women. The association 
was not explained by higher smoking rates acting as a confounder, as the RR was 
adjusted for age, residential area, sex and smoking. These findings were reproduced 
in a Danish cohort, in which education levels were inversely associated with RA risk: 
the multivariate OR for RA in those with the longest formal education vs. those with 
the lowest education level was 0.43 (95% CI 0.24-0.76) (Pedersen, et al., 2006a). 
Again this inverse association was predominantly seen with RF-positive RA. The 
probable explanation for this link is differences in environmental exposures. 
 
1.2.4. How Gene-Environment Risk Factors Lead To RA 
The underlying paradigm of RA pathogenesis is that those individuals harbouring 
genetic susceptibility variants are exposed to environmental risk factors. In a 
proportion of individuals these gene-environment risks interact to precipitate 
immunological changes (often characterised by autoantibody production) and 
arthralgia. This may progress to an unclassified arthritis followed by a fully 
expressed RA phenotype (Gerlag, et al., 2012). 
 
Attempts to provide a unifying model in which the various risk factors interact to 
precipitate RA have been largely unsuccessful. This reflects the heterogeneous nature 
of RA (with different subsets probably precipitated by different factors) alongside 
limited characterisation of the relevant gene-environment factors involved.  
 
Several research groups have proposed a model for the development of ACPA-
positive RA. This involves interactions between two environmental risks (smoking 
and PD) and the HLA-DRB1 SE alleles, which precipitate ACPA formation and 
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consequently ACPA-positive RA. This section describes the proposed biological 
model in detail. 
 
1.2.4.1.Citrullinated Peptides 
Citrulline is a non-standard amino acid that results from post-translational 
modification of arginine residues (Wegner et al, 2010a). This modification, termed 
citrullination or deimination, is facilitated by a family of peptidylarginine deiminase 
(PAD) enzymes in a calcium-dependent manner. The substitution of arginine for 
citrulline results in key changes in the structure and ionic charge of the peptide from 
positive to neutral, with a consequent potential for functional differences. 
 
Although ACPAs are not completely confined to individuals with ACPA-positive 
RA, their presence is highly specific for this disease subset. A meta-analysis of 86 
studies reported that ACPA had a sensitivity and specificity for RA of 67% and 95%, 
respectively (Nishimura, et al., 2007). This sensitivity can be increased by using 
custom arrays specific for articular peptides. Wagner et al demonstrated that at least 
10% of RA patients testing negative for ACPAs with commercial ELISA assays, 
tested positive using a custom array of 16 citrullinated peptides/proteins detected in 
the RA synovium (Wagner, et al., 2013). 
 
ACPA’s pathological role in ACPA-positive RA is suggested by its presence in the 
serum of individuals many years prior to joint symptoms. Nielen et al analysed 
archived blood samples from blood donors: 41% of 79 RA patients had ACPAs pre-
RA onset compared with 0.6% of controls (matched for age, sex, and donation date); 
the median time from the first positive ACPA test to symptom development was 4.8 
years (Nielen, et al., 2004). Similarly, in another cohort of 90,000 blood donors from 
Sweden, which contained 83 incident cases of new onset RA, Rantapää-Dahlqvist et 
al reported that ACPAs occurred in 34% of pre-RA patients compared with 2% of 




1.2.4.2.Drivers of Protein Citrullination in Pre-RA Individuals 
There is substantial evidence that smoking and PD – the former a definite, and the 
latter a probable RA risk factor – are at least partially responsible for driving protein 
citrullination pre-RA. 
 
Smoking appears to increase citrullination through promoting alveolar cell PAD 
enzyme expression. Makrygiannakis et al reported substantial up-regulation of 
citrullinated proteins with enhanced PAD2 enzyme expression in bronchoalveolar 
lavage (BAL) cells from smokers compared with non-smokers (Makrygiannakis, et 
al., 2008). Furthermore, autoimmunity to citrulline may be promoted through 
increased thiocyanate ions produced by tobacco smoke metabolism (Quirke, et al., 
2011). Thiocyante is metabolised to homocitrulline, which is similar in shape and 
structure to citrulline. Its increased presence in smokers may promote autoantibody 
formation with cross-reactivity to citrulline.  Further evidence for the role of lung 
injury in driving neoepitope formation in pre-RA individuals is from a study of 105 
patients with early, untreated RA and 43 healthy controls, which assessed the 
structural and immunological features of the lungs in relation to ACPA and smoking. 
High resolution computed tomography (HRCT) defined lung parenchymal changes 
were significantly greater in ACPA-positive compared with ACPA-negative RA 
cases and controls after adjusting for smoking status; additionally in ACPA-positive 
RA patients, ACPA levels were higher in the BAL fluid compared with the sera, 
suggesting the local production of ACPA in the lungs (Reynisdottir, et al., 2014). 
 
As previously discussed, PD is prevalent in RA and its primary causative organism, 
P. Gingivalis, is the only known prokaryote to possess PPAD, which has been shown 
to citrullinate itself and other proteins (Wegner et al, 2010b, Quirke et al, 2014). This 
PPAD may drive citrullination pre-RA. 
 
1.2.4.3.How Immune Tolerance to Citrulline May Be Breached Pre-RA 
Hill and colleagues addressed the crucial issue of how immune tolerance to citrulline 
may be breached in pre-RA individuals (Hill et al, 2003). They examined the T cell 
response to citrullinated peptides in HLA-DRB1*04:01 transgenic mice. MHC class 
II molecules harbouring the SE contain a specific amino acid sequence within P4 - a 
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positively charged area influencing binding of antigenic peptides that favours 
negatively charged amino acid residues. Upon citrullination the positively charged 
arginine is converted to citrulline, which lacks an ionic charge and has a better 
structural conformation with P4. Hill et al identified that as a result of these 
structural and ionic alterations citrullinated peptides bound to the MHC P4 in mice 
possessing the SE with a 100-fold greater affinity when compared with their 
arginine-containing precursors. This peptide/SE complex was subsequently presented 
to CD4+ T cells, activating them. The ability of citrullinated peptides to induce a T 
cell response has been replicated in human subjects by Feitsma et al, who found that 
naturally occurring citrullinated vimentin peptides were recognised by T cells from 
ACPA-positive HLA-DRB1*04 carrying RA patients (Feitsma, et al., 2010). 
 
The ability of ACPA to drive actual joint inflammation was subsequently shown in a 
mouse model (Hill, et al., 2008). HLA-DRB1*04:01 transgenic mice were immunised 
with citrullinated human fibrinogen; their outcomes were compared to wild type 
mice. Only mice possessing the HLA transgene developed an inflammatory arthritis, 
which directly implicates citrullinated fibrinogen as an arthritogenic peptide in the 
context of SE containing MHC class II molecules. 
 
In summary it appears probable that ACPA formation is triggered by citrullinated 
peptides binding with a high-affinity to SE containing MHC molecules. This 
peptide/SE complex is then presented to CD4+ T cells, which activate B cells driving 
ACPA formation. 
 
1.2.4.4.Progression from Asymptomatic ACPA-Positivity to Clinical RA 
As ACPA can predate clinical RA by many years and not all individuals with ACPA 
develop RA, further factors are required to trigger the shift from being an 
asymptomatic individual with ACPA to having established ACPA-positive RA with 
synovitis.  
 
An important feature of pathogenic antibodies is that they possess fine specificity for 
certain antigens. It has been postulated that for ACPAs to become pathogenic and 
elicit articular damage they need to fully mature and increase their number of antigen 
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specificities. This would explain the latent period existing between ACPA formation 
and RA onset. Evidence for this maturation process in RA, termed “epitope-
spreading”, exists with Van der Woude et al reporting the number of citrullinated 
antigens recognised by ACPA increases in the time period leading up to RA onset in 
individuals with an undifferentiated arthritis (Van Der Woude, et al., 2010a).  
 
Although the precise mechanisms that stimulate epitope-spreading and the onset of 
RA remain elusive it has been proposed that a second event such as infection or 
trauma occurs, which triggers a non-specific synovitis with associated citrullination 
within the joint (Klareskog, et al., 2006a). In healthy individuals this would resolve 
without sequelae, however in those possessing ACPA and T cells reactive to them 
this would lead to a chronic inflammatory arthritis evolving into ACPA-positive RA. 
ACPA mediated immune complexes could subsequently drive macrophage TNF-α 
production alongside other pro-inflammatory cytokine pathways (Clavel, et al., 
2008). 
 
1.2.4.5.Evidence for Relationship between Smoking, the SE and ACPA-Positive 
RA 
If smoking were to lead to ACPA-positive RA through the preferential binding of 
citrullinated proteins by the SE, then one would expect to observe an interaction 
between smoking and the SE on the risk of ACPA-positive RA. This interaction has 
been confirmed in a number of well conducted case-control studies. Padyukov et al 
reported that the RR of seropositive RA was 2.4 (95% CI 1.3–4.6) in smokers with 
no SE alleles, 5.5 (95% CI 3.0–10.0) in current smokers with one SE allele and 15.7 
(95% CI 7.2–34.2) in current smokers with two SE alleles. This dose-risk 





Figure 1-6. Smoking-Shared Epitope Interactive Effect on RA Risk 
 
 
Figure adapted using data from Pedersen et al (Pedersen et al, 2007) and 
reproduced with permission from Scott et al (Scott et al, 2011). 
 
Similarly, Pedersen et al reported that the OR for ACPA-positive RA in individuals 
smoking more than 20 pack-years comprised 1.22 (95% CI 0.48-3.08) in SE non-
carriers, 9.66 (95% CI 4.38-21.3) in SE heterozygotes and 52.6 (95% CI 18.0-154) in 





1.2.4.6.How Smoking/PD May Interact with the SE to Cause ACPA-Positive RA 
In summary the following represents a biologically plausible model through smoking 
and PD interact with the SE alleles to drive ACPA-positive RA in some individuals 
(Figure 1-7). 
1. Peripheral protein citrullination occurs- either through periodontal infection with 
P. Gingivalis or smoking 
2. Structural and ionic changes resulting from protein citrullination enhance the 
binding of citrullinated self-antigens to MHC class II molecules in individuals 
possessing the SE 
3. SE/citrullinated peptide complexes are presented by antigen presenting cells to 
CD4+ T cells, activating them.  
4. These in turn activate B cells driving ACPA formation 
5. A second factor - for example trauma or infection - precipitates synovial 
inflammation and the development of citrullinated proteins within the articular 
environment. These are targeted by ACPA. 
6. ACPA-citrulline immune complexes are formed. These activate 
macrophages/monocytes driving inflammatory cytokine production and precipitating 
RA 
 
Although this model explains the possible aetiology of some individuals with ACPA-
positive RA, it fails to explain what causes this RA subset in non-smokers without 
PD or those individuals that don’t carry SE alleles. Additionally, it fails to explain 





Figure 1-7. How Gene-Environment Interactions May Cause ACPA-Positive RA 
 
 
Figure reproduced with permission from Scott et al (Scott et al, 2011). 
 
1.3. Risk Prediction Models for RA Development 
1.3.1. Why These Are Needed 
The high healthcare costs of RA, alongside the limitations of current RA treatments, 
which result in remission in only 16-42% of patients (Ma, et al., 2010) indicate that 
there is a key need to adopt novel management strategies. One facet of this could be 
instituting preventive treatments in individuals at a high-risk of developing RA. Risk 





1.3.2. Primary versus Secondary RA Prevention 
Bykerk classified RA prevention into two groups: (1) primary prevention- 
undertaken in individuals with genetic risks for RA in whom the pathogenic process 
has not yet started; (2) secondary prevention- in individuals with pre-clinical disease 
either at an early asymptomatic stage or in the late pre-clinical stages when 
symptoms are present (Bykerk, 2011).  
 
No reliable method has been devised that can accurately identify asymptomatic 
individuals at a high-risk of RA from the general population. It is therefore not 
currently possible to perform primary prevention strategies, although as our 
knowledge of RA risks advance this could become an area of therapeutic potential. 
 
Secondary prevention strategies have been instituted with some success. Patients 
with pre-clinical RA were identified by the presence of biological markers (like 
ACPA) alongside early clinical manifestations associated with progression to RA.  
 
1.3.3. Corticosteroids for Secondary Prevention 
There is some evidence that corticosteroids can attenuate RA development. Bos et al 
evaluated 83 seropositive patients with arthralgia, randomising them to receive either 
intramuscular (IM) dexamethasone or placebo. Corticosteroids reduced ACPA titres 
within one month and reduced disease activity scores at RA onset (Bos, et al., 
2010a). Similarly, Verstappen and colleagues evaluated whether treating very early 
undifferentiated inflammatory polyarthritis (VEIA) with corticosteroids reduced 
future requirements for DMARDs and RA development. VEIA patients were 
randomised to once weekly IM 80mg depomederone injections for 3 weeks or 
placebo; at 12 months the number of placebo treated patients requiring DMARDs 
was twice that of those receiving corticosteroids (Verstappen, et al., 2010). These 
studies provide some support for a role of corticosteroids in RA prevention, the 
efficacy of which may be improved with more intensive, prolonged regimes. 
 
1.3.4. Methotrexate for Secondary Prevention 
The PRObable rheumatoid arthritis: Methotrexate versus Placebo Treatment 
(PROMPT) study evaluated methotrexate as a preventative treatment for RA (Van 
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Dongen, et al., 2007). In this RCT 110 patients with an undifferentiated arthritis 
(fulfilling the ARA criteria for probable RA) were treated with methotrexate or 
placebo. The starting dose of 15mg/week methotrexate was titrated every 3 months 
until the DAS28 was ≤2.4; at 12 months treatment was tapered and stopped. By the 
end of the study period (30 months) 40% of patients in the methotrexate group had 
progressed to RA compared with 53% of the placebo group (P = 0.046). Individuals 
treated with methotrexate also developed RA at a later time point and had less 
radiological progression than those treated with placebo. This trial provides some 
evidence for the use of methotrexate for RA prevention. 
 
1.3.5. Biologics for Secondary Prevention 
The ADJUST trial examined the impact of T cell co-stimulation modulation on the 
development of RA in patients with an undifferentiated arthritis or very early RA 
(Emery, et al., 2010). Patients were randomised to 6 months treatment with abatacept 
or placebo. At 2 years a non-statistically significant reduction in individuals meeting 
the RA classification criteria was observed in those treated with abatacept versus 
placebo: 46% of abatacept treated patients were classified with RA compared with 
67% of the placebo group. Placebo treated patients also more frequently developed 
MRI structural changes.  
 
The effect of infliximab on preventing RA development was evaluated in a small 
randomised study in which 17 patients with an undifferentiated arthritis of less than 
12 months duration were randomised to infliximab or placebo for 14 weeks (Saleem, 
et al., 2008). Infliximab had no impact on progression to RA with 100% of patients 
in the treatment arm developing RA. 
 
1.3.6. Published Risk Prediction Models for RA Development 
In order for primary prevention to be possible risk prediction models are required 
that identify asymptomatic individuals at a high-risk of developing RA in the future. 
In order for secondary prevention to occur models are required that identify pre-RA 
individuals with either arthralgia or an undifferentiated arthritis that are likely to 




1.3.6.1.Methods to Assess Risk Prediction Model Accuracy 
In order to place the results of published RA prediction models into context, it is 
important to first consider how the accuracy of these models can be assessed. A 
number of methods have been developed to evaluate prediction model performance. 
The dominant test is the area under the receiver operating characteristic curve 
(AUC). This is a measure of discrimination i.e. the ability of the model to 
discriminate a diseased from a non-diseased individual. This is established 
methodology in determining genetic classification test efficacy (Metz, 1978, Lu and 
Elston, 2008). The ROC curve plots the sensitivity (true positive rate) against 1-
specificity (false positive rate) for each consecutive cut-off of the test used to define 
an outcome (in this case RA vs. no RA) (Steyerberg, et al., 2010). The AUC 
represents a summary statistic of the discriminative accuracy across the range of 
these cut-off values. Higher AUCs indicate better classification. An AUC >0.5 
signifies some discriminative ability; a perfect classifier has an AUC of 1. It has been 
proposed that an AUC of 0.75-0.80 could represent an appropriate value to establish 
if a test may be useful for disease screening; similarly an AUC of 0.99 has been 
proposed as an appropriate value for a pre-symptomatic diagnostic test (Janssens, et 
al., 2007). These values are somewhat arbitrary and there are multiple other issues to 
consider before deciding whether a prediction model is suitable for use as a screening 
test such as those proposed by Wilson and Junger in 1968 (Andermann, et al., 2008). 
The AUC has a number of other limitations when applied to assessing predictive 
tests. Firstly, it fails to consider time, which is an important factor in prediction 
models whose primary goal is to estimate an individual’s probability of developing a 
disease in the future (Cook, 2008). Secondly, AUC values are based on ranks of 
predicted probabilities as opposed to estimated probability values themselves; they 
could therefore be insensitive to differences in predicted risks between prediction 
models (Cook, 2008). Thirdly, for a risk factor to significantly impact on the AUC 
value it requires a large effect size; in the case of RA risk factors (which generally 
have small ORs) the AUC may not capture small discriminative improvements  
obtained with adding in these factors (Pepe, et al., 2004). 
 
Several other methods are available for evaluating risk prediction model accuracy. 





) of the outcome captured by the model. Secondly, tests can 
be used to assess the calibration of the model, which is the agreement between the 
observed and predicted outcomes in groups of individuals e.g. if the model predicts a 
50% absolute risk of RA, then the frequency of RA should be 50 in 100 individuals 
(Steyerberg et al, 2010). One example of a calibration test is the Hosmer-Lemeshow 
goodness-of-fit test (Lemeshow and Hosmer, 1982). This compares estimated 
observed proportions and average predicted probabilities between subgroups; a non-
significant P-value indicates a good model fit. Thirdly, reclassification tests can be 
used (Pencina, et al., 2011). These are considered to be more sensitive to 
improvements in discrimination compared with the AUC. Reclassification tests 
compare the abilities of different models to correctly classify individuals into high- 
and low-risk categories. An example is the net reclassification improvement (NRI) 
test, which compares the increase in the number of individuals correctly classified as 
high-risk and low-risk for a disease between two models that differ by the presence 
of absence of a specific predictive factor (Pencina et al, 2011).  
 
1.3.6.2.Risk Prediction Models for RA in Asymptomatic Individuals 
Risk prediction models have been developed that attempt to predict the future risk of 
disease in asymptomatic individuals using gene-environment data for a range of 
immune-mediated complex disorders. For disorders without an HLA dominant 
genetic contribution the addition of genetic information to clinical data generally 
failed to improve the prediction model’s performance. This is exemplified by a 
prediction model for type II diabetes mellitus (Talmud, et al., 2010). This report 
evaluated the role of adding genetic data from 20 SNPs associated with type II 
diabetes susceptibility to two established clinical risk models predicting disease 
development, the Cambridge risk score (combining data on age, sex, drug treatment, 
family history of type II diabetes, BMI and smoking status) and the Framingham 
offspring study type II diabetes risk score (combining data on age, sex, parental 
history of type II diabetes, BMI, high density lipoprotein cholesterol, triglycerides, 
fasting glucose). The addition of a genetic risk score failed to improve upon either of 
the clinical models discriminative or classification capabilities; the AUCs for the 
Cambridge risk score with and without genetic data were 0.72 (95% CI 0.69-0.76) 
and 0.73 (95% CI 0.69-0.76), respectively. For disorders with an HLA dominant 
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genetic contribution genetic data can be substantially more informative. One such 
disorder is coeliac disease, which has a strong association with the HLA types, 
DQ2.5, DQ8, and DQ2.2 (Abraham, et al., 2014). A recent risk prediction model, 
which devised a genetic risk score using L1-penalized support vector machine 
models, demonstrated high levels of discrimination across 6 European patient cohorts 
(AUCs 0.87 to 0.89) (Abraham et al, 2014). It is therefore likely that, owing to the 
major HLA contribution to disease susceptibility, such gene-environment prediction 
models may be effective for predicting the future risk of RA development. 
 
Several research groups have attempted to develop models in this area with some 
success (Table 1-8). All have used the same modelling approach, using a weighted 
genetic risk score (wGRS), which is formed by multiplying the number of risk alleles 
for each SNP by the weight for that SNP (the weight is the natural log of the OR for 
each allele in published reference meta-analyses), and then taking the sum across the 
risk SNPs included in the model (De Jager, et al., 2009, Karlson, et al., 2010). All 
models have used the AUC to determine their ability to discriminate cases from 
controls. 
 
Table 1-8. Existing Risk Prediction Models for RA in Asymptomatic Individuals 
Study Model Components Cohorts Tested AUC For 
Seropositive RA 
Karlson et al 
(Karlson et 
al, 2010) 
 14 SNPs 




 NHS: 289 Ca; 481 
Co 
 EIRA: 629 Ca; 
623 Co 
 
 NHS: 0.66 




et al., 2011) 
 29 SNPs  871 Ca, 1,229 Co  0.71 
Chibnik et al 
(Chibnik, et 
al., 2011) 
 31 SNPs 
 8 HLA-DRB1 alleles 
  542 Ca; 551 Co  0.65 
Yarwood et 
al (Yarwood, 
et al., 2013) 
 45 SNPs 




 Discovery cohort: 
11,366 Ca; 15,489 
Co 
 Validation cohort: 






NHS = Nurses’ Health Study; Ca = case; Co = control. 
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In RA this approach was first undertaken by Karlson et al (Karlson et al, 2010). 
Their model combined 22 genetic risk variants with the clinical factors smoking, age 
and gender. As some individuals in the general population have an increased disease 
risk and some a reduced risk, they divided their wGRS into 7 categories based on its 
Gaussian distribution in the control group and calculated the OR for seropositive RA 
for each group relative to the referent median (average-risk) group.  Using this 
approach in their tested datasets (the NHS and EIRA studies) individuals in the 
highest risk group had an approximately 3-fold increased odds of disease relative to 
the average-risk group. The addition of genetic risk factors to a model using clinical 
factors alone increased its accuracy, improving the AUC from 0.63 to 0.75. 
However, despite relatively good discrimination their predicted absolute risks of RA 
remained low: in the highest risk group these were estimated at 0.7-1.3%. The 
clinical utility of their modelling was therefore limited. They subsequently extended 
their modelling approach, increasing the number of genetic and clinical risk factors 
incorporated and validating it in alternative patient populations (Karlson et al, 2010, 
Karlson, et al., 2013). This further increased the discriminative ability of their 
modelling. The most comprehensive model included 9 environmental risk factors, 34 
genetic factors, 3 gene-environmental factor interactions and 3 environmental-
environmental factor interactions; the AUC for this model was 0.72 in women and 
0.77 in men (Karlson et al, 2013).  
 
Yarwood et al used the same modelling methodology but incorporated a broader 
range of genetic susceptibility variants comprising 45 non-HLA loci, imputed amino 
acid polymorphisms in HLA-DRβ1 (positions 11, 71 and 74), HLA-DPβ1 (position 
9) and HLA-B (position 9) alongside clinical factors (gender and smoking). The 
highest AUC for a model incorporating all these factors (tested in 1,978 cases and 
1,224 controls) was 0.80 (Yarwood et al, 2013). Their use of HLA amino acid 
polymorphisms improved prediction when compared to a model incorporating HLA-
DRB1 alleles. 
 
1.3.6.3.Risk Prediction Models for RA in Seropositive Arthralgic Patients 
Patients with arthralgia and RF or ACPA are at a substantially increased risk of 
future RA. Not all of these individuals will, however, progress to develop an 
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inflammatory arthritis (Bos, et al., 2010b). Van de Stadt et al recently developed a 
prediction model for progression to arthritis in seropositive arthralgia patients (Van 
De Stadt, et al., 2013). This model was developed in 300 seropositive (IgM-RF or 
ACPA positive) patients with arthralgia but without synovitis. Variables associated 
with remission were identified by Cox proportional hazard analysis. The prediction 
model consisted of 9 variables, comprising a positive family history of RA (in a first 
degree family member), alcohol abstinence, symptom duration <12 months, presence 
of intermittent symptoms, arthralgia in the upper and lower extremities, visual 
analogue scale pain ≥50, presence of EMS lasting ≥1 hour, a self-reported history of 
swollen joints and antibody status (4 categories ranging from seronegative to positive 
for both IgM-RF and ACPA). This model was subsequently validated in 74 
seropositive arthralgic patients recruited from the same rheumatology unit. The AUC 
value was 0.82 for the development of arthritis at 5 years. Patients could be 
categorised into three risk categories, comprising low-risk, intermediate-risk and 
high-risk. Using the low-risk group as a reference, the intermediate-risk group had a 
HR of 4.52 (95% CI 2.42–8.77) and the high-risk group had a HR of 14.86 (95% CI 
8.40–28.32) for developing an arthritis. Whilst this model appears promising the 
fraction of explained variation captured by Nagelkerke’s R2 was only 0.31, indicating 
that 69% of the variance was explained by unidentified factors. Additionally, the 
model was validated internally in patients recruited from the same unit; it therefore 
requires evaluation in other external patient populations to determine its 
generalisability. 
 
1.3.6.4.RA Risk Prediction Models in Early Undifferentiated Arthritis Patients 
The Leiden Prediction Rule is an established model for predicting which individuals 
with an early undifferentiated arthritis are likely to progress to a full RA phenotype 
(Van Der Helm-Van Mil, et al., 2007). This prediction model was developed in 570 
patients presenting with an undifferentiated arthritis that were followed-up for 12 
months. Clinical characteristics associated with RA development were identified 
through logistic regression. Their prediction rule comprised 9 clinical variables: sex, 
age, symptom localisation, EMS, TJC, SJC, CRP level, RF and ACPA-positivity. 
This provided a score ranging from 0-14. When cut-off values of 5 and 9 were 
chosen, 97% of undifferentiated arthritis patients with a score ≤5 did not progress to 
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RA and 84% of patients with a score ≥9.0 progressed to RA. Although the AUC in 
the derivation cohort was high (0.89), Nagelkerke’s R2 was 0.57, indicating that 33% 
of variance was explained by other factors. This model has been validated in several 
other patient populations (UK, German and Dutch cohorts) with similar 
discriminative abilities demonstrated (AUCs 0.82-0.95) (Van Der Helm-Van Mil, et 
al., 2008). Whilst this model performed well at identifying undifferentiated arthritis 
patients at a high and low-risk of progressing to RA, it was unable to adequately 
quantify the risk of RA in those individuals with moderate scores of between 6 and 8 
(Van Der Helm-Van Mil et al, 2008). This represents approximately one quarter of 
the patients in the validation cohorts. Further work is required to identify alternative 
predictors, which explain the missing variance, in order for this model to be used 
more readily in clinical care.  
 
1.4. Predicting Rheumatoid Arthritis Severity 
1.4.1. Defining Severe Disease 
In order to identify predictors of RA severity, the first consideration is what 
represents severe disease. In clinical practice this is often considered to be that in 
which DAS28 scores are persistently above 5.1 (Prevoo, et al., 1995). Another 
important component of severe RA is the development of disability, which is often 
recorded using the Health Assessment Questionnaire Disability Index (HAQ-DI). 
This self-reported assessment evaluates functional ability using 20 questions 
spanning 8 categories; scores of 0-1, 1-2 and 2-3 are considered to represent mild-
moderate, moderate-severe and severe-very severe disability, respectively (Bruce and 
Fries, 2003). Most studies evaluating genetic predictors of severe RA have used the 
extent or progression of radiological damage to define poor prognosis disease. The 
two main radiological outcomes in RA comprise the Sharp/van der Heijde Score 
(SvHS) and the modified Larsen score (Boini and Guillemin, 2001). The SvHS 
evaluates erosions and joint-space narrowing in 44 and 42 joints respectively 
alongside joint subluxation; the total score ranges 0-448. The modified Larsen score 
evaluates changes of erosion and joint destruction in the hands, wrists and feet 
providing a total score ranging from 0-200.  The main benefit of using radiological 
scores over other outcome measures is that they generally deteriorate over time. 
Although correlated with other outcomes like DAS28 and HAQ scores, these latter 
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measures have more variable courses over time (Drossaers-Bakker, et al., 1999). It is 
therefore easier to detect longitudinal effects of genotypes on SvHS and Larsen 
scores.   
 
1.4.2. Serological Predictors of RA Severity 
The role of RF as a predictor of disease severity is well established, with individuals 
that are seropositive for RF consistently having higher rates of joint damage and 
extra-articular manifestations. This is particularly true of the IgA-RF isotype, which 
is often reported to have a stronger association with severe disease when compared to 
IgM- and IgG-RF (Jonsson and Valdimarsson, 1998). In one longitudinal 
observational study of 135 women with early RA, whilst all three RF isotypes 
significantly associated with radiological progression and higher SJCs, IgA-RF titres 
had the strongest correlation (Van Zeben, et al., 1992). Other studies have also 
shown greater associations between IgA-RF and radiological erosions (Teitsson, et 
al., 1984, Brik, et al., 1990) and extra-articular manifestations (Jonsson, et al., 1995) 
when compared to other RF isotypes. The prognostic value of ACPA is also well 
described. In one cohort study of 93 early RA patients identified among Swedish 
blood donors the presence of ACPA prior to and at disease onset significantly 
associated with radiological outcomes (Berglin, et al., 2006). The baseline and two 
year Larsen scores in cases positive for ACPA pre-disease onset were 8 and 14, 
respectively; for individuals negative for ACPA pre-disease onset they were 5 and 9, 
respectively. These differences were statistically significant (p<0.001) at both time 
points. ACPA also predicts longer-term radiological damage. Lindqvist et al 
demonstrated this in 183 RA cases followed up for 10 or more years (Lindqvist, et 
al., 2005). In linear regression analyses Larsen scores at 10 years significantly 
associated with ACPA and CRP levels, which accounted for 32% of the variance in 
the score.  
 
1.4.3. Environmental and Epidemiological Risk Factors for RA Severity 
A variety of environmental and epidemiological factors have been linked with RA 
severity (Table 1-9). Interestingly, there is substantial overlap between RA 
susceptibility and severity factors, with smoking and alcohol abstinence both 
associating with RA development and severity.  
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Table 1-9. Environmental and Epidemiological Prognostic Factors in RA 
 
Risk Factor Study Size Type Severity Outcome(s) Main Findings 
Smoking 
Másdóttir et al 




Nodules, X-ray score, joint 
counts, HAQ 
Smoking associated with nodules, higher x-
ray scores, higher HAQ scores 
Manfredsdottir et al 
(Manfredsdottir, et al., 
2006) 
100 Ca Longitudinal 
Joint counts, pain, CRP, X-
ray score 
Current smokers had highest joint counts. 
Alcohol 
Maxwell et al (Maxwell 




X-ray score, DAS28-CRP, 
HAQ, pain  
Lower x-ray scores, DAS28-CRP, CRP, 
HAQ and pain as alcohol intake increased. 
Nissen et al (Nissen, et 
al., 2010) 
2,908 Ca Longitudinal X-ray score, HAQ 
Trend for less x-ray progression in alcohol 
drinkers: progression 0.99% (95% CI 0.89–
1.09) in drinkers; 1.13% (95% CI 1.01–1.26) 
in non-drinkers. 
Periodontitis 
Abou-Raya et al  




DAS28, HAQ, X-ray score  
Periodontitis severity correlated with DAS28 
score, ESR and CRP. 
Mercado et al (Mercado 




Joint counts, physician 
global, ESR/CRP, HAQ 
Periodontitis severity associated with higher 
joint counts, HAQ and CRP/ESR levels. 
Gender 
Jawaheer et al 
(Jawaheer, et al., 2010) 
292 Ca Longitudinal 
DAS28, HAQ, pain, 
physician global, CRP, X-
ray score  
Females had worse DAS28, global and joint 
count progression 
Ahlmén et al (Ahlmen, 
et al., 2010) 
549 Ca Longitudinal DAS28, HAQ, X-ray score Females had higher DAS28 and HAQ scores. 
Social 
Deprivation 
McEntegart et al 
(Mcentegart, et al., 1997) 
814 Ca Longitudinal 
Pain, articular index, ESR, 
CRP, HAQ 
Deprivation associated with higher HAQ 
ERAS Study Group 
(Eras Study Group, 
2000) 
869 Ca Longitudinal 
Joint counts, HAQ, Pain, 
ESR, X-ray score  
Deprivation associated with higher HAQ and 
joint counts. 
SJC = swollen joint count, HAQ = Health Assessment Questionnaire, TJC = tender joint count, VAS = visual analogue scale, Ca = case, Co = control, 




There is some evidence that smoking influences the natural history of RA. In one 
prospective study of 100 early RA patients followed up for 24 months  the SJC, TJC 
and pain visual analogue scale (VAS) scores were all significantly higher in smokers 
when compared to non-smokers (Manfredsdottir et al, 2006). The SJC at 6 months 
also significantly associated with smoking status, with current smoking increasing 
the number of swollen joints by at least 3 on average in a regression model after the 
elimination of non-significant variables. Another observational study of 63 women 
with advanced RA (average disease duration 13.7 years) showed that heavy smoking 
(defined as ≥20 pack-years) significantly associated with the presence of nodules, 
higher radiological damage rates and higher HAQ scores when compared with 
smokers of <20 pack-years or never-smokers (Masdottir et al, 2000). The impact of 
smoking is confounded by its effect on ACPA formation, which may mediate any 
effect it has on disease severity (Klareskog et al, 2006b). 
 
1.4.3.2.Alcohol Consumption 
There is some evidence that increasing alcohol intake associates with a less severe 
disease course. In one study of 873 erosive RA cases, more frequent alcohol 
consumption correlated significantly with lower DAS28-CRP, Larsen and mHAQ 
scores (Maxwell et al, 2010). These trends are shown in Figure 1-8. The median 
DAS28-CRP, Larsen and mHAQ scores in individuals drinking no alcohol in the 
month prior to assessment comprised 4.29, 38 and 1.0 respectively; these scores in 
individuals drinking on more than 10 days in the month prior to assessment 
comprised 3.72, 27 and 0.63. All of these differences were statistically significant 
(P<0.05) when evaluated by trend tests across alcohol intake categories. A protective 
effect of alcohol intake on radiographic progression was also demonstrated in a large 
Swiss observational study evaluating 2,908 RA cases nested within a national 
database of RA patients (Nissen et al, 2010). This study evaluated the impact of 
drinking alcohol on the progression of X-ray damage, scored according to the 
Ratingen method (Rau, et al., 1998). It found that in a model adjusting for multiple 
variables (comprising baseline radiological damage scores, DAS28, HAQ, presence 
of RF, sex, age, disease duration, tobacco smoking, education level and medications) 
radiographic damage at 12 months had progressed by an average of 0.99% (95% CI 
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0.89-1.09) in drinkers and 1.13% (95% CI 1.01-1.26) in non-drinkers. Interestingly, 
as with the beneficial effects of drinking on cardiovascular disease, a J-shaped dose-
response effect was seen with occasional and daily alcohol consumers having less 
radiographic progression at 12 months compared with non-drinkers and heavy 
drinkers. Taken together these studies provide some evidence that alcohol 
consumption may attenuate the inflammatory process in RA. 
 
Figure 1-8. Relationship between Alcohol Consumption and RA Outcomes 
 
P-values for trend tests are all <0.0001; figure adapted using data from Maxwell et 





The relationship between PD and RA outcomes was evaluated in a cross-sectional 
study of 100 patients with active RA. Significant correlations between PD severity 
and DAS28 scores (P<0.001), ESR (P<0.005) and high sensitivity CRP levels 
(p<0.003) were reported (Abou-Raya et al, 2008). Another small observational study 
of 65 RA patients found that individuals with moderate-severe PD had significantly 
more swollen joints, higher HAQ scores and higher CRP levels when compared to 
patients with no or mild PD (Mercado et al, 2001). As with smoking any potential 
effect of PD on RA outcomes could be mediated by ACPA. Further work is required 
with large longitudinal studies to establish this relationship, and to explore the impact 
of PD treatment on disease severity. 
 
1.4.3.4.Social Deprivation 
Several studies have highlighted that individuals from socially deprived areas have 
poorer disease outcomes (Vliet Vlieland, et al., 1994, Mcentegart et al, 1997).  This 
association was evaluated in 869 patients from the Early Rheumatoid Arthritis Study 
(ERAS), which is a large prospective cohort study of individuals with RA of less 
than 2 years duration (Eras Study Group, 2000). The authors reported that the 
Carstairs score (a composite score of male unemployment, social class, 
overcrowding and car access that represents an index of deprivation) was associated 
with more severe disease at presentation, as reflected by HAQ and joint scores; this 
association persisted and remained after 3 years of follow-up. The precise underlying 
mechanism for this association is unclear; it may represent an association between 
low socioeconomic status and lifestyle factors like smoking. 
 
1.4.3.5.Gender 
Gender differences in RA are well described, with the incidence of RA greater 
amongst women compared with men (Myasoedova, et al., 2010). There is also 
evidence that RA outcomes are worse in females. Jawaheer et al found that in a 
longitudinal prospective study of 225 women and 67 men with seropositive early 
DMARD-naive RA, women had worse disease progression over 2 years as reflected 
by DAS28 scores, physician global scores and TJCs; this was in spite of similar 
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treatments (Jawaheer et al, 2010). Men were also more likely to attain remission. 
Similarly, the Swedish BARFOT study reported that women had significantly higher 
DAS28 and HAQ scores compared with males at all time-points over a 5 year 
follow-up period; the authors attributed this DAS28 discrepancy to a higher number 
of tender joints and general health scores in women compared with men (Ahlmen et 
al, 2010). Other studies have reported similar female gender influences on RA 
progression (Kuiper, et al., 2001). 
 
1.4.4. Evidence for a Genetic Component to Radiological Damage in RA 
In contrast to the identification of genetic susceptibility variants for RA there is 
substantially less information on which genetic markers influence RA severity. The 
dominant reason for this is a lack of adequately sized cohorts containing detailed 
genotypic and longitudinal disease outcome data. Studies evaluating this topic have 
generally been of limited power to detect genome-wide significant SNPs and have 
instead mainly relied on candidate gene approaches for the identification of relevant 
loci. Despite these problems there is accumulating evidence that genetics play an 
important role in determining radiological progression in RA. A twin study found 
that the variance in radiographic joint destruction was highest in unrelated patients, 
followed by dizygotic and finally monozygotic twins (Van Der Helm-Van Mil, et al., 
2006). A more recent study has replicated the association between relatedness and 
radiological damage in 325 Icelandic patients with RA; this study quantified the 
heritability of radiological joint destruction to be between 45 to 58% (Knevel, et al., 
2012b). 
 
1.4.5. Genetics of Radiological Damage: Candidate Gene Studies 
1.4.5.1.HLA-DRB1 Alleles 
HLA-DRB1 alleles, in particular those encoding the SE, have been linked to a more 
severe RA phenotype (Gonzalez-Gay, et al., 2002). Wagner et al found that in a 
prospective study of 55 individuals with early RA, SE carriers had an OR for erosive 
disease of 13.75 (P=0.00083). A meta-analysis of 3,240 RA patients demonstrated a 
significant association between the SE (2 or 1 versus 0 SE alleles) and erosions (OR 
2.0; 95% CI 1.8–2.2) (Gorman, et al., 2004). 
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More recent studies evaluating this relationship have employed the classification 
system for HLA-DRB1 alleles proposed by du Montcel et al (Du Montcel, et al., 
2005). This broadly divides HLA-DRB1 alleles into 2 groups: S alleles and X alleles, 
which have or do not have the RAA sequence at position 72-74, respectively. Some 
S alleles i.e. S2 (containing *04:01) are associated with an increased disease risk; 
other S alleles i.e. S1 alleles (containing *13:01) are associated with a reduced 
disease risk (Barnetche, et al., 2008). Using this classification system one 
observational study of 962 RA cases found that the carriage of S2 alleles significantly 
correlated with higher Larsen scores with the median (IQR) Larsen score for 
individuals carrying one S2 copy comprising 29 (8-61) and for those carrying two S2 
copies comprising 41 (16-73) (Mewar, et al., 2008). Carriage of S1 alleles was 
associated with less radiological damage (P=0.011). Similar findings come from a 
prospective longitudinal study of 144 French Caucasian early RA patients in which 
individuals carrying S2 alleles had greater radiographic damage progression 
compared with non-carriers (P=0.004) and individuals carrying S3D alleles had 
significantly less radiographic damage progression compared with non-carriers 
(P<0.0001) (Gourraud, et al., 2006). In both instances significant gene-dose effects 
were observed.  
 
It therefore appears that, as with disease susceptibility, some HLA-DRB1 alleles are 
risk factors for, and some protect against, radiological damage in RA. As with 
smoking this association could be driven by ACPA.  
 
1.4.5.2.PTPN22 
The evidence that PTPN22, the dominant non-MHC RA susceptibility allele, 
contributes to radiological damage in RA is limited. In a cross-sectional study of 964 
RA cases, Marinou et al reported a trend towards higher rates of X-ray damage in 
RA patients carrying the PTPN22 minor allele compared to those without it. Median 
modified Larsen scores for individuals that had zero, one or two minor allele copies 
comprised 25.5, 33.0 and 50.0, respectively (Marinou, et al., 2007). This finding was, 
however, only of borderline statistical significance (P=0.04) and other studies have 
failed to replicate it such as the Brigham RA Sequential Study (BRASS) in which the 
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adjusted OR (95% CI) for an erosive phenotype in PTPN22 T allele carriers was 1.14 
(0.77-1.71) (Karlson, et al., 2008). 
 
1.4.5.3.C5orf30 
Teare et al recently demonstrated an allele-dose association between the RA risk 
variant SNP, rs26232 in the C5orf30 loci and the extent of radiological damage in 
RA (Teare, et al., 2013). In this study an allele-dose association between modified 
Larsen/SvHS scores and the number of minor alleles was demonstrated in two UK 
cohorts (the Genetics of RA (GORA) study and Yorkshire Early Arthritis Register 
(YEAR)) using a zero-inflated negative binomial model and a Dutch cohort (the 
Leiden Early Arthritis Clinic (EAC) cohort), using a linear mixed-effects model. A 
fixed-effects meta-analysis of the incidence rate ratios (IRRs) across the 3 cohorts 
revealed a pooled IRR of 0.90 (95% CI 0.84-0.96) per minor allele. This can be 
considered as representing a reduction in radiological scores of 11% per minor allele 
copy. Although there is some evidence linking C5orf30 to immune function, it is 
unknown how it could exert an effect on radiological damage at present. 
 
1.4.5.4.IL1B and IL1RN 
Cantagrel et al evaluated the relationship between two polymorphisms in the IL1B 
(interleukin 1, beta) gene and one polymorphism in the IL1RN (interleukin 1 receptor 
antagonist) gene amongst 108 patients with early RA followed up for 2 years 
(Cantagrel, et al., 1999). Although none independently associated with the 
development of erosions at 2 years, when IL1B exon 5 allele E2 carriage was 
combined with the presence of SE alleles an increased risk of erosive disease was 
observed: the OR (95% CI) for erosions was 8.20 (2.59-25.84). Buchs et al also 
examined the association between radiological damage and polymorphisms in the 
IL1B gene (within the promoter region at -511 and in exon V at +3954) and the 
IL1RN gene (in exon 2 at position +2018) amongst 297 RA cases (Buchs, et al., 
2001). They found a significant relationship between destructive RA and the carriage 
of the rare IL1B (+3954) allele 2; carriers of this polymorphism also had higher ESR 
levels compared to non-carriers. The association of the exon 5 +3953 A2 allele with 
higher DAS28 scores and ESR levels was demonstrated in a smaller study of 93 RA 




An association between an IL6 tagging SNP and radiographic severity was reported 
by Marinou et al (Marinou et al, 2007). In this cross-sectional evaluation of 964 RA 
cases the SNP, rs1800795, which tags the promoter region of the IL6 gene and is 
often referred to as the “-174” polymorphism, was significantly associated with 
radiological damage in seropositive RA. The modified Larsen scores in ACPA-
positive RA risk allele non-carriers, heterozygotes and homozygotes comprised 29, 
32 and 41 (trend test P-value=0.004). This finding has not, however, been validated 
in other cohorts and the prognostic relevance of IL6 polymorphisms are uncertain.  
 
1.4.5.6.IL10 
Marinou et al also reported a significant association between a polymorphism in 
IL10 -592C (using the tagging SNP, rs1800872) that is specific for erosive damage in 
ACPA-negative RA (Marinou et al, 2007). In this study ACPA-negative individuals 
that were homozygous for the risk allele had more severe radiographic damage 
compared with non-carriers/heterozygous individuals (pooled due to small numbers). 
The median modified Larsen score comprised 6.0 for non-carriers/heterozygotes and 
16.0 for homozygotes (P-value for trend=0.002). Another polymorphism in the IL10 
locus was shown to influence the rate of radiological progression in a cohort of 91 
patients in the Netherlands (Huizinga, et al., 2000). Although this study did not 
subdivide their analysis by ACPA-status the presence of the IL10 -1082GG genotype 
was associated with significantly greater increases in Sharp scores at 3 and 6 years 
when compared to individuals with the -1082AA genotype.  
 
1.4.5.7.TRAF1/C5 
TRAF1 encodes an intracellular protein member of the tumour necrosis factor (TNF) 
receptor-associated factor family involved in TNF-α signalling (Wajant, et al., 2001);  
the complement component 5 has been associated with RA in animal models (Wang, 
et al., 1995). In NOAR two SNPs mapping to the TRAF1/C5 locus (rs2900180 and 
rs10760130) were associated with the presence of erosions at 5 years in 
inflammatory polyarthritis (IP) patients; this was independent of ACPA status (Plant, 
et al., 2011b). At 5 years the ORs for developing erosions in IP patients after 
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adjusting for ACPA-positivity comprised 1.65 (95% CI 1.13-2.42; p=0.01) for 
individuals carrying the risk allele for rs2900180 and 1.52 (95% CI 1.00-2.29; 
p=0.05) for those carrying the rs10760130 risk allele. Another study of 278 cases 
also reported a significant association between a SNP in this locus (rs10818488) - 
which is in high linkage disequilibrium with the SNP identified in the NOAR cohort 
(rs10760130) - and radiological progression (Kurreeman, et al., 2007). A subsequent 
meta-analysis of 7 cohorts, containing a total of 2,666 RA patients with 6,282 
radiological scores failed, however, to demonstrate an association between 
rs10818488 and radiological progression (P=0.89) (Knevel, et al., 2012a). 
 
1.4.5.8.CD40 
The CD40 protein is expressed on the surface of multiple immune cells including B 
cells and monocytes; it plays a pivotal role in providing helper activity by CD4+ T 
cells in immune reactions (Kawabe, et al., 1994). The association of the CD40 locus 
was shown in 250 ACPA-positive RA cases from the Leiden EAC cohort and 393 
ACPA-positive RA cases from the North American Rheumatoid Arthritis 
Consortium (NARAC) (Van Der Linden, et al., 2009). In this analysis the SNP, 
rs4810485 yielded a 1.12 (95% CI 1.04-1.21) times greater increase in the Sharp 
score per year in those carrying the risk genotype in the EAC. The significant 
association between this SNP and the rate of joint destruction was significant after 
correcting for multiple testing. Using a perfect SNP proxy the risk genotype from the 




IL2RA is an RA susceptibility locus. Its link with radiological progression in RA was 
demonstrated by Knevel et al in a meta-analysis of 1,750 RA patients across 4 
independent datasets (Knevel, et al., 2013a). In this report the minor C allele of the 
IL2RA SNP, rs2104286 associated with lower radiological progression rates 
(P=7.2x10
-4
). The pooled effect size across cohorts was 0.97 (95% CI 09.96-0.99), 
indicating that the C allele was associated with a 0.97-fold lower rate of joint 
destruction per year.  The authors also provided functional evidence for this 
association: the minor allele associated with lower circulating levels of soluble 
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1.4.6. Genetics of Radiological Damage: Genome-Wide Studies 
To date only two GWASs have been performed, which have evaluated genetic 
associations with radiological progression in RA. The first GWAS was undertaken in 
384 ACPA-positive early RA patients from NARAC (Knevel, et al., 2013b). These 
patients had a single X-ray scored using the SvHS when they had established RA 
(mean disease duration 13.9 years). Genotyping was undertaken on the Illumina 
BeadChip (HumanHap 550k); 391,733 SNPs were available following quality 
control (QC) procedures. Estimated annual radiological progression rates were 
calculated for each patient by dividing their SvHS by the disease duration in years at 
the time the X-ray was performed. Linear regression with the log of the estimated 
annual X-ray progression rate as the response variable (SvHS are non-normally 
distributed) and genotype as the predictor variable was performed. PGWAS was 
defined as P≤2.7×10−7. The strongest association with radiological progression was 
in the Sperm-Associated AntiGen 16 (SPAG16) locus; the relevant SNP, rs7607479 
had a P-value of 1.59x10
-7
. No other SNPs fulfilled their definition of PGWAS. This 
finding was subsequently replicated in 3 other cohorts comprising 301 ACPA-
positive RA patients from the Leiden EAC and 742 RA patients from the National 
Databank for Rheumatic diseases (NDB) and Witchita cohorts. In these cohorts the 
minor rs7607479 allele was associated with a reduced rate of radiological 
progression. In NARAC, patients with one minor allele had a 0.77-fold (95% CI 
0.70-0.85) annual X-ray progression rate relative to the common genotype; patients 
carrying two minor alleles had a 0.59-fold (95% CI 0.49-0.72) annual progression 
rate. This SNP explained 6.6% of the variance in joint destruction between 
individuals in NARAC. 
 
The function of SPAG16 is largely unknown. To investigate its relevance to joint 
destruction the authors first demonstrated the presence of SPAG16 protein in patient 
synovial tissue using immunohistochemical staining. This showed its expression in 
FLS (Knevel et al, 2013b). Secondly, they demonstrated an association between the 
minor rs7607479 allele and lower serum MMP-3 levels. MMPs are known to be 
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released by FLSs and contribute to radiological destruction in RA. They therefore 
provided biological evidence for a role of this variant in reducing joint destruction in 
RA. 
 
The second GWAS was undertaken on the ImmunoChip (De Rooy, et al., 2013b), 
which although covering 195,806 SNPs and 718 small insertion-deletions associated 
with immune-mediated diseases, does not provide true genome-wide coverage. The 
ImmunoChip is an Illumina Infinium SNP microarray, which was designed in 2009 
by investigators of 11 autoimmune and inflammatory disorders including RA, 
ankylosing spondylitis (AS) and inflammatory bowel disease (IBD). It included the 
top 2,000 independent association signals for each disease from meta-analyses of 
GWASs, alongside dense coverage of a further 186 loci within confirmed GWAS 
association intervals (Parkes, et al., 2013). Its goals were to enable deep replication 
and fine mapping of GWAS confirmed loci. This study took a different analytical 
approach to existing studies (De Rooy et al, 2013b).  Over time genotypes can exert 
either a constant effect on radiological scores (at each time point the scores are 
different when patients are stratified by genotype; these differences remain constant 
over time) or an interactive effect with time on radiological scores (when patients are 
stratified by genotype at each time point their scores get gradually further apart). 
Most studies using longitudinal data have focused on this later genotype*time 
interaction term. The ImmunoChip study by de Rooy et al was undertaken in 646 
early RA patients from the Leiden EAC, with 686 North American RA patients 
providing a replication cohort. They used a marginal regression model for 
longitudinal data using the log-transformed radiological score as the response 
variable and time, age, gender and treatment strategy as predictor variables. Two 
models were compared for each SNP: the first contained genotype and 
genotype*time interaction terms and the second contained only the clinical predictor 
variables. The models were compared using a likelihood ratio test (2 degrees of 
freedom), which tested the null hypothesis that the coefficients for both the constant 
SNP effect and its interaction with time equaled zero. The resultant P-value 
represented the overall genotype effect (constant and/or interactive) on radiological 
scores. Their P-value for significance was set at 1.1x10
-6
. In the Leiden EAC 109 
SNPs passed their significance threshold; 76 were in the HLA region. Of the 33 non-
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HLA SNPs, 29 were available in the replication cohorts. Four SNPs were replicated; 
after conditional analyses 2 of these were independently associated with radiological 
damage: rs451066 (located on chromosome 14, downstream of the genes ZFP36L1 
and C14orf181) and rs11908352 (located 92 kb downstream of CD40-rs4810485, 
which is a known RA susceptibility locus). The latter variant is located within close 
proximity to the gene encoding for MMP-9 and fine mapping revealed it was in high 
LD with several variants in this region. Although these also associated with 
radiological severity, in a conditional analysis including these variants, only 
rs11908352 was significant. Subsequent serum evaluations confirmed an association 
between rs11908352 genotypes and serum MMP-9 levels; AA genotype carriers, 
which associated with more severe joint damage, had significantly higher serum 
MMP-9 levels compared to CC major allele carriers (P=0.007). This provided a 
biological mechanism through which this genotype mediates joint damage. 
 
1.4.7. Ultrasound and MRI Imaging as Predictors of Radiological Severity  
Advances in imaging technology have led to an increased use of magnetic resonance 
imaging (MRI) and, in particular, musculoskeletal ultrasound scanning (USS) in 
routine clinical practice. In early RA there is evidence that both techniques are able 
to predict longer-term radiological outcomes. 
 
1.4.7.1.Ultrasound 
Synovial inflammation involves periarticular vasodilation, synovial proliferation and 
angiogenesis; this process can be detected by the USS power Doppler (PD) modality 
(Jain and Samuels, 2011). USS and more specifically PD assessments have been 
shown to correlate with radiographic progression in several small studies. In 42 early 
RA patients (disease duration <12 months) followed up at 0, 3, 6 and 12 months, 
time-integrated values of PD USS parameters had stronger correlations with 
radiographic progression at 1 year (r=0.59; P<0.001) than clinical and laboratory 
parameters (r<0.5) (Naredo, et al., 2007). In an RCT in which 24 methotrexate 
treated RA cases were randomised to either placebo or infliximab, in the placebo arm 
there were significant positive correlations between both baseline synovial thickness 
and vascularity as measured by USS and progression in radiographic severity scores 




Several studies have shown that the presence of MRI detected bone marrow oedema 
at disease onset predicts joint damage progression years later. In one RCT of 130 
early RA patients baseline MRI bone marrow oedema was the only significant 
predictor (in a multiple linear regression analysis) of radiological progression at the 
wrist and MCP joints, explaining 41% of the variation in the SvHS (Hetland, et al., 
2009). Similarly, in a smaller prospective study of 42 RA patients the baseline MRI 
bone oedema score was predictive of the 6-year total Sharp score (P=0.01) 
(Mcqueen, et al., 2003). Palosaari et al also demonstrated the predictive value of 
bone marrow oedema on MRI; in 27 early RA patients the baseline MRI bone 
oedema score was the only baseline variable that predicted erosive progression at 24 
months in a multivariate model (OR 4.2; 95% CI 1.3-13.8) (Palosaari, et al., 2006). 
 
1.4.8. Biochemical Prognostic Markers 
The best established prognostic biomarkers in RA comprise the acute phase response 
indices, ESR and CRP, both of which correlate with disease severity (Lindqvist et al, 
2005). A number of other markers have been evaluated for their prognostic 
implications in RA. One example is the MMPs, which are zinc dependent proteases 
that regulate extracellular matrix proteolysis and are involved in the cleavage of 
cytokines, chemokines and their receptors; they are thus considered to play important 
roles in inflammation (Mohammed, et al., 2003). Another example is the bone 
turnover marker, urinary C-telopeptide of type II collagen (CTX-II), which is an 
immunoassay that uses antibodies specific for the C-terminal crosslinking telopeptide 
of type II collagen – the most abundant protein within the cartilage matrix - in the 
urine (Garnero, et al., 2002a). 
 
Young-Min et al evaluated the role of several serum biomarkers comprising MMP-1, 
MMP-13 and MMP-3, tissue inhibitor of metalloproteinases-1 (TIMP-1) and 
cartilage oligomeric matrix protein (COMP) and urinary biomarkers including CTX-
II in predicting radiographic progression in 132 early RA patients (Young-Min, et al., 
2007). They found in a multivariate analysis that a model consisting of baseline 
MMP-3 and CTX-II provided the best prediction of radiographic progression at study 
entry (AUC 0.76; 95% CI 0.66-0.85). Other research groups have shown MMP-3 to 
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be predictive of radiographic progression in other small RA cohorts. In 48 RA 
patients without radiological damage at presentation, serum MMP-3 levels at study 
entry significantly correlated with Sharp scores at 6 and 12 months and joint space 
narrowing at 6, 12 and 24 months (Posthumus, et al., 1999). Similarly, in 26 patients 
with early RA baseline serum MMP-3 levels were significantly associated with 
Larsen scores at 6 and 12 months after study entry; furthermore when the 
relationship between percentage increases in serum MMP-3 in the first 12 months 
after entry and the percentage increase in Larsen scores in each year were evaluated, 
a significant correlation was observed between the increase in serum MMP-3 during 
the first 12 months and the increase in the Larsen score in the subsequent 12–24 
months after entry (Yamanaka, et al., 2000).  
 
The role of urinary CTX-II in RA prognostic stratification has also been reproduced 
in several studies. The association between baseline urinary CTX-I and CTX-II 
levels and the mean annual progression of joint destruction over a median of 4 years 
was examined in the COBRA study. In two multivariate logistic regression analyses 
that included each marker separately due to their high correlation, baseline urinary 
CTX-I and CTX-II levels both predicted long-term radiologic progression 
independently of treatment, disease activity  and RF status at baseline (Garnero, et 
al., 2002b). Additionally, Hashimoto et al reported that in 145 patients with active 
RA of less than 5 years duration baseline urinary CTX-II levels correlated 
significantly with radiological progression at week 52 (Hashimoto, et al., 2009).  
 
1.4.9. Prognostic Modelling In RA 
Several research groups have attempted to combine prognostic factors into models 
capable of identifying individuals at a high-risk of radiological progression. Some 
have used simple clinical parameters; others have integrated these with biomarkers 
and radiological indices. Genetic markers have rarely been used.  
 
Brennan et al developed a prediction model for the development of erosions in the 
hands and/or feet after 12 months in NOAR (Brennan, et al., 1996). In this study of 
175 patients with early RA, the population was randomly split into a prediction 
sample of 105 patients, in whom predictor variables for radiological progression 
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were sought, and a validation sample of 70 patients, in whom the prediction 
algorithm was tested. A simple algorithm using a combination of three variables 
(positive RF test, swelling in ≥2 large joints and disease duration >3 months) was 
best able to predict erosions. This model was able to classify 8 risk groups with a 
probability of developing erosions ranging from 0.13 (all variables absent) to 0.89 
(all variables present). It correctly predicted the development of erosive disease in 
79% of cases. The model’s negative and positive predictive values were 80% and 
76%, respectively. Its predictive abilities are illustrated in Figure 1-9. 
 
Figure 1-9. Predicted Vs. Observed Risks of Erosions Using a Prediction Model 
with Three Clinical Variables in NOAR  
 
Risk groups defined by the presence/absence of 3 variables; combination of variables 
comprising a positive rheumatoid factor, disease duration ≥ 3 months and ≥ 2 large 
joints involved in group 1 = negative/no/no; group 2 = negative/yes/no; group 3 = 
negative/no/yes; group 4 = positive/no/no; group 5 = negative/yes/yes; group 6 = 
positive/yes/no; group 7 = positive/no/yes; group 8 = positive/yes/yes. Figure 
adapted using data from Brennan et al (Brennan et al, 1996) and reproduced with 
permission from Scott et al (Scott et al, 2013a). 
 
Drossaers-Bakker et al demonstrated that prognostic modelling can be undertaken to 
predict longer-term disease outcomes at 12 years (Drossaers-Bakker, et al., 2002). 
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This study evaluated 112 female RA patients with symptoms of less than 5 years 
duration (median 1 year) at recruitment. It developed prediction models for 3 
different disease outcomes: firstly radiographic damage (measured by the SvHS 
method), secondly disability (measured by the HAQ) and thirdly a severe disease 
course (measured by calculating the area under the curve of all DAS assessments 
alongside the radiographic disease course). Individuals in the highest tertile of each 
outcome measure were defined as “severe” for that outcome and individuals in the 
lowest tertile were defined as “mild”. Using a model that contained the baseline 
parameters the SJC, RF, the presence of erosions, the Ritchie index, ESR, HAQ and 
SvHS the accuracy of the model for predicting mild radiographic damage, severe 
radiographic damage, mild HAQ, severe HAQ and a severe disease course comprised 
87%, 84%, 88%, 84% and 83% respectively. Surprisingly, additional information on 
HLA typing added little to the modelling, improving the correct prediction of 
radiographic damage by only 3%. This study, however, developed and validated its 
model within the same patient cohort; it is therefore expected that their model was 
able to define disease outcomes with relative accuracy. It requires external 
validation. 
 
More recently two research groups have developed matrix risk models for rapid 
radiological progression (RRP), which are organised into colour coded matrixes 
similar to that which is widely used in predicting the 10-year risk of fatal 
cardiovascular disease (Vastesaeger, et al., 2009). One of these matrixes was 
developed using data from 465 RA patients enrolled to the BeST RCT. This study 
randomised patients to four treatment arms comprising two arms treated with initial 
monotherapy that could be switched or extended to other DMARDs, a third arm 
treated with initial combination DMARDs and tapering high dose corticosteroids and 
a fourth arm treated with initial methotrexate and infliximab (Visser, et al., 2010). 
Patients were treated with an aim of attaining a DAS of ≤2.4. RRP was defined as an 
increase in the SvHS of ≥5 after 12 months. Predictors of RRP were identified by 
multivariate logistic regression with backward selection. Different models were 
developed for different treatment groups and included the variables CRP, erosion 
score and serology (RF and ACPA). The highest risk group was those individuals in 
the initial monotherapy treatment arm with a CRP ≥35mg/L, erosion score ≥4 and 
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both RF and ACPA positivity; their risk of RRP was 78%. The lowest risk groups 
were those individuals in the initial combination treatment with prednisolone or 
infliximab arms with a CRP <10mg/L, erosion score of 0 and negative serology; their 
risk of RRP was 1%. The AUC was 0.81 (95% CI 0.77-0.86) indicating a moderate 
ability to correctly classify individuals who will develop RRP. This study, however, 
also validated its prediction model within the prognostic factor identification cohort; 
this model therefore requires evaluating in another patient cohort to better define its 
prognostic capabilities.  
 
The other research group to develop a risk matrix for RRP developed prediction 
models in two different cohorts (Vastesaeger et al, 2009). The first cohort was the 
ASPIRE study, which comprised 1,049 methotrexate-naive early RA patients 
randomised to receive methotrexate with or without infliximab; the second cohort 
was the ATTRACT trial, which comprised 428 patients with established RA and 
active disease treated with either methotrexate and infliximab or placebo. They 
identified risk factors from the early RA cohort (the ASPIRE study) and in order to 
ensure this combination of risk factors had similar predictive capabilities in a more 
advanced RA population undergoing similar treatment generated a prediction model 
in the ATTRACT trial using the same variables. RRP was defined as a change in the 
modified SvHS of ≥5 units/year. Spearman’s rank analysis was used to identify 
baseline risk factors for RRP. Two prediction matrixes were developed, which 
contained either the ESR or CRP alongside information on the 28 SJC, RF and 
treatment (monotherapy or combination therapy). The highest risk group was those 
individuals in the ATTRACT study receiving methotrexate monotherapy with a 28 
SJC >17, RF titre >200U/ml and an ESR >50mm/h; their risk of RRP was 65%. The 
lowest risk group was those individuals in the ASPIRE study receiving methotrexate 
and infliximab with a 28 SJC <10, RF <80U/ml and an ESR <21mm/h; their risk of 
RRP was 2%. Individuals treated with methotrexate monotherapy had higher 
predicted rates of RRP when compared to those receiving infliximab. 
 
The main criticism of these models is that, with the exception of the latter model, 
they have not been validated in external populations. Additionally, with regards to 
the last two matrix models they were developed within a clinical trial setting; these 
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patients usually have more aggressive disease and receive more rigorous treatment 
than they would in a routine clinical setting. It is, therefore, unclear if their results are 
generalisable to more typical RA populations. 
 
1.5. Predicting Treatment Responses in RA 
1.5.1. Why Treatment Response Predictors Are Needed 
Current NICE guidelines advocate a single approach to the management of RA 
patients. In individuals with early active disease, combination DMARDs and short-
term corticosteroids are recommended with an escalation to biologics in refractory 
cases (Deighton et al, 2009). These guidelines provide no advice on which specific 
agents (beyond methotrexate as an anchor DMARD) should be used. This reflects 
uncertainties around which factors predict an individual’s likely response to a 
specific drug. As a result, patients are often exposed to trials of treatments that may 
not benefit them. This has important personal implications, potentially exposing 
patients to the side-effects of ineffective treatments, alongside the associated 
complications of sustained disease activity whilst an effective drug is found through 
trial and error. It also has societal implications, with the high-costs of ineffective 
trials of biologics in individual patients using health care funding that may be better 
spent in other areas of the health service. Identifying predictors of treatment 
responses is therefore a key research goal. 
 
To a certain extent predictors of RA severity also overlap with predictors of 
treatment responses. Risk factors that identify patients with a severe disease course 
indicate they are less likely to respond to non-intensive treatment regimens. One 
example of this is ACPA status, with a secondary analysis of the BeST study 
indicating that methotrexate monotherapy is unlikely to provide adequate disease 
control in ACPA-positive patients (De Vries-Bouwstra, et al., 2008).  There are, 
however, a number of factors that associate with the efficacy of specific therapeutic 





1.5.2. Predictors of Synthetic DMARD and Biologic Agent Efficacy 
A number of factors have been suggested to predict treatment responses to synthetic 
DMARDs and biologics. Overall, the results are inconsistent. In a systematic review 
of DMARD response predictors, Hider et al attributed conflicting results to 
methodological heterogeneity across studies (Hider, et al., 2005). Examples of this 
heterogeneity included the use of variable DMARD response definitions, the 
evaluation of different DMARD agents and different DMARD regimens (some 
studies assessed monotherapy and others combination therapy). Such heterogeneity 
makes drawing definitive conclusions on treatment response predictors problematic. 
 
1.5.2.1.Gender 
Overall, the evidence suggests that females with RA probably respond more poorly 
to methotrexate than males. A systematic review by Drouin et al reported that female 
gender associated with a poor methotrexate response in all 9 studies included in their 
review; the reported ORs for a clinical response in women vs. men ranged from 0.3 
to 0.7 (Drouin, et al., 2010). Similarly, in an analysis of the SWEFOT trial female 
gender was associated with a reduced likelihood of a EULAR response in 487 early 
RA patients treated with methotrexate monotherapy (OR 0.50; 95% CI 0.31-0.81) 
(Saevarsdottir, et al., 2011a). Other studies have replicated these findings (Stranzl, et 
al., 2003).  
 
A gender effect on treatment responses has not been demonstrated with other 
DMARDs. Capell et al found no effect of gender on responses to gold, 
penicillamine, sulfasalazine, or auranofin in 1,140 RA patients (Capell, et al., 1993). 
Similarly, no effect of gender on responses to gold, sulfasalazine, or penicillamine 
was found in an observational study of 681 RA patients (Situnayake and Mcconkey, 
1990). 
 
There is some evidence to suggest that females may respond less favourably to anti-
TNF. An analysis of 2,879 patients from the British Society for Rheumatology 
Biologics Register (BSRBR) found that female gender associated with a reduced 
odds of remission with etanercept (OR 0.61; 95% CI 0.38–0.94) and infliximab (OR 
0.60; 95% CI 0.40–0.89) treatment (Hyrich, et al., 2006). In another analysis of 1,257 
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established RA patients an association was found between male gender and an 
increased likelihood of attaining remission after 6 months of anti-TNF treatment 
(Mancarella, et al., 2007). This gender effect has, however, not been reproduced in 
all populations with an analysis of the South Swedish Arthritis Treatment Groups 
Register reporting no gender effect on anti-TNF responses (Kristensen, et al., 2008). 
 
1.5.2.2.Ethnicity 
There is no definitive evidence that ethnicity influences treatment responses. One 
retrospective analysis of 1,191 North European and 193 South Asian patients found 
that individuals in the latter ethnic group terminated DMARD therapy significantly 
earlier (Helliwell and Ibrahim, 2003). The 12-month survival rates of DMARDs in 
North Europeans and South Asians were 0.74 (95% CI 0.69-0.79) and 0.67 (95% CI 
0.65-0.68), respectively (P<0.00001). Although inefficacy was one reason for 
discontinuation, there were other potential reasons including side-effects. In another 
prospective study of 134 patients with early RA that were DMARD-naive at 
inception no relationship was seen between ethnicity and DMARD response at 12 
months (defined as the attainment of low disease activity assessed using the 
Simplified Disease Activity Index) (Hodkinson, et al., 2012). This study was limited 
by its small sample size, short follow-up period and unrestricted DMARD use.  
There is a lack of data on whether ethnicity affects responses to biologics. 
 
1.5.2.3.Age 
Age does not appear to affect methotrexate responses. A meta-analysis of 11 clinical 
trials evaluating methotrexate reported no association between age and treatment 
efficacy in 496 RA patients (Rheumatoid Arthritis Clinical Trial Archive Group, 
1995). One observational study found a significant association between a younger 
age and a positive response to sulfasalazine; no age effect was seen on responses to 
gold or penicillamine (Situnayake and Mcconkey, 1990). 
 
Although data from the BSRBR suggests that age does not impact on anti-TNF 
efficacy (Hyrich et al, 2006), there is some evidence that it may influence 
tocilizumab response. In an observational study of 204 RA patients in France, a 
younger age (<55 years) positively correlated with EULAR response and remission 
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rates at 6 months in patients treated with tocilizumab (Pers, et al., 2014). Data from 
the REACTION study supported this finding, with a younger age associating with an 
increased chance of remission in 229 RA patients treated with tocilizumab 
(Yamanaka, et al., 2011).  
 
1.5.2.4.Smoking 
It appears likely that current smokers respond less favourably to methotrexate and 
anti-TNF. This relationship has been reported in a number of large observational 
studies. An analysis of the EIRA study revealed that current smokers were less likely 
to achieve a good response at 3 months after initiating methotrexate (P=0.05) or anti-
TNF (P=0.03) (Saevarsdottir, et al., 2011b). In multivariate analyses adjusting for 
other relevant clinical, serological, and genetic factors, the inverse associations 
between current smoking and good treatment responses remained; the adjusted ORs 
for methotrexate and anti-TNF response in current vs. never smokers were 0.60 (95% 
CI 0.39-0.94) and 0.52 (95% CI 0.29-0.96), respectively. These differences persisted 
at later follow-up visits. Interestingly, past smoking did not affect the chance of a 
treatment response. The association between current smoking and poor methotrexate 
response was reproduced in the SWEFOT trial (Saevarsdottir et al, 2011a). In this 
study current smoking significantly reducing the odds of a EULAR response after 3-
4 months of treatment with methotrexate; the adjusted OR was 0.35 (95% CI 0.20-
0.63). Registries also indicate that current smokers are less likely to respond to anti-
TNF with data from the BSRBR demonstrating that current smoking associates with 
a reduced likelihood of etanercept and infliximab response (Hyrich et al, 2006).  
 
1.5.2.5.Serology 
In a recent comprehensive literature review, Romão et al highlighted a lack of robust 
evidence that RF status predicts DMARD responses (Romao, et al., 2013). Similarly, 
ACPA does not seem to associate with individual DMARD responses. Two studies 
of early RA found no association between ACPA and methotrexate response 
(Wessels, et al., 2007, Saevarsdottir et al, 2011a). Gosec et al also reported no 
influence of ACPA on remission rates in 191 early RA patients receiving a range of 




Serological status may affect biologic responses. Clinical trial data suggests that 
rituximab is slightly more effective in seropositive disease. A meta-analysis of four 
RCTs identified a modest but significant effect of seropositivity (presence of RF 
and/or ACPA) on the response to rituximab; the 24 week reduction in DAS28 scores 
in seropositive patients was 0.35 units (95% CI 0.12 to 0.84) larger than in 
seronegative patients (Isaacs et al, 2013). Abatacept also appears to be more effective 
in ACPA-positive RA with the Orencia Rheumatoid Arthritis (ORA) registry 
reporting that ACPA positivity associated with good EULAR responses in RA 
patients receiving abatacept (76% and 62% of good/moderate and non-EULAR 
responders, respectively were ACPA-positive) (Gottenberg et al, 2012). By contrast 
TNF-inhibitors seem more efficacious in ACPA-negative disease. In an analysis of 
617 RA patients from the Rheumatic Diseases Portuguese Register, ACPA provided 
an OR of 0.97 (95% CI 0.95-0.98; P<0.0001) for attaining a EULAR good response 
when treated with adalimumab, etanercept or infliximab. Potter et al also reported 
that in 642 UK RA patients, those that were ACPA-negative had a 0.39 (95% CI 0.07 
to 0.71) greater mean improvement in DAS28 when treated with anti-TNF compared 
to patients that were ACPA-positive (Potter et al, 2009).  
 
1.5.2.6.Disease Duration 
It is well established that very early treatment in RA associates with better outcomes 
(Breedveld, 2011). This concept, termed the “window of opportunity” may be as 
short as the first 3 months of disease (Raza, et al., 2012). This is demonstrated in a 
meta-analysis of 14 RCTs, which evaluated predictors of treatment responses in a 
variety of DMARD regimens. Disease duration was a major predictor of treatment 
responses (Anderson, et al., 2000). In a pooled analysis among patients receiving 
active treatment, the percentage of patients attaining an ACR 20 response comprised 
53%, 43%, 44%, 38% and 35% for patients with disease durations of <1 year, 1- 2 
years, 2–5 years, 5–10 years and >10 years, respectively. 
 
There does not appear to be an effect of disease duration on anti-TNF responses. The 
BSRBR reported no association between disease duration and responses to anti-TNF 
therapy, although most patients in their cohort had established disease (mean disease 
duration 14 years) (Hyrich et al, 2006). Similarly, data from the Swedish registry 
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indicated no effect of disease duration on anti-TNF responses; again most individuals 
had established disease with a mean duration of 11 years in males and 12 years in 
females (Kristensen et al, 2008). 
 
1.5.2.7.Genetics 
Multiple studies have attempted to identify genetic loci in the methotrexate cellular 
pathway that predict methotrexate responses in RA. Their sample sizes are small and 
their findings often not replicated. A recent systematic literature review of this topic 
identified 4 methotrexate cellular pathway SNPs that were examined in 5 or more 
studies for their association with methotrexate efficacy and toxicity (Malik and 
Ranganathan, 2013). These comprised two SNPs in the MTHFR gene (rs1801133 
and rs1801131), one in the SLC19A1 gene (rs1051266) and another in the ATIC gene 
(rs2372536). Of the 20 studies evaluating the association between rs1801133 and 
methotrexate efficacy only 3 reported a significant result; of these 1 reported greater 
efficacy in patients carrying the T allele of this SNP and the other 2 reported lower 
efficacy in patients carrying the T allele. Similar inconsistencies were seen in studies 
evaluating the other 3 SNPs. All studies have used a candidate gene approach; no 
genome-wide studies have evaluated genetic loci associated with methotrexate 
response. 
 
To date three GWASs have been undertaken to evaluate genetic associations with 
anti-TNF responses. Two of these identified several loci at a level of significance 
suggestive of an association (Plant, et al., 2011a, Liu, et al., 2008). They were, 
however, of limited sample sizes (one comprised 89 and the other 566 patients) and 
therefore had limited power to detect SNPs attaining PGWAS. The third GWAS 
evaluated a substantially larger patient cohort, comprising 2,706 RA patients from 13 
collections (Cui, et al., 2013). All patients had received etanercept, infliximab or 
adalimumab. DAS28 scores were collected at baseline and at one time point after 
anti-TNF therapy administration. This study evaluated genetic associations with the 
change in DAS28 score from baseline.  One SNP (rs6427528) at the 1q23 locus 
associated with change in DAS28 in the etanercept subset of patients (P=8×10
−8
). 
This SNP was predicted to disrupt transcription factor binding site motifs in the 3′ 
UTR of an immune-related gene, CD84. The allele that associated with a better 
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etanercept response also significantly associated with higher CD84 gene expression 
in peripheral blood mononuclear cells. 
 
A recent GWAS has also evaluated predictors of tocilizumab response in 1,683 RA 
patients from 6 clinical studies (Wang, et al., 2013). To optimise the power to detect 
relevant associations a conservative definition for a likely association with changes 
in RA outcomes (DAS28, SJC, TJC, HAQ, CRP) and ACR20 responses was used. 
The authors selected candidate SNPs for replication that met one or more of the 
following criteria: (1) P<10
-5
 in white subjects; (2) P<10
-4
 in White subjects and a 
lower P-value in all ethnicities; or (3) those selected by least absolute shrinkage and 
selection operator (LASSO) penalized regression analysis of White subjects or all 
ethnicities. Using this definition 207 markers were identiﬁed as having 253 
significant associations. Seven of these achieved confirmation at P<0.05 with the 
same outcome in the replication cohort. None of these markers were obviously linked 
to the IL-6 pathway. In total 4 SNPs attained true PGWAS; none of these were 
replicated. The study authors concluded that it is unlikely that a major genetic 
determinant of tocilizumab response exists. 
 
1.5.2.8.Other Biomarkers 
A number of studies have examined other biomarkers for their impact on treatment 
responses. Although promising these markers lack clinical utility, as they have 
generally been examined in small sample sizes, have not been replicated in larger 
patient cohorts or associate with only small differences in treatment responses. 
Examples include serum MMP-3 levels (Posthumus, et al., 2002) and red blood cell 
levels of methotrexate polyglutamates (Dervieux, et al., 2005), which have been 
studied for their association with methotrexate responses and stimulated whole blood 
cell pro-inflammatory cytokine levels (Kayakabe, et al., 2012) and serum proteins 
(Ortea, et al., 2012), which have been studied for their association with anti-TNF 
efficacy. 
 
1.5.3. Prediction Models for Treatment Responses in RA 
To a certain extent the previously described matrix models that predict the risk of 
RRP with different RA treatment regimens can be considered to predict responses to 
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those treatment strategies (Vastesaeger et al, 2009, Visser et al, 2010). Another 
research group has developed a model that predicts response to a specific therapeutic 
agent (methotrexate) within 205 early, active RA patients (from the methotrexate 
monotherapy treatment arm of the BeST study) (Wessels et al, 2007). Four clinical 
and four genetic variables were used to generate a clinical score, which predicted the 
likelihood of a treatment response (defined as a DAS ≤2.4 at 6 months). These 
comprised sex, RF, smoking status, baseline DAS, and 4 SNPs (in AMPD1, ATIC, 
ITPA, and MTHFD1 loci). There variables were chosen from a panel of 24 potential 
baseline variables through backward selection. The clinical score used simplified 
regression coefficients of the independent variables, providing a score ranging from 
0 to 11.5. Using a score cut-off of ≤3.5 points for responders provided a true positive 
rate of 95%; using a score cut-off of ≥6 points for non-responders provided a true 
negative response rate of 86%. The R
2
 value for the model was 0.35; the AUC 
following cross-validation was 0.79. 
 
This model has been externally validated in two small replication cohorts. The first 
cohort comprised 38 early RA patients (Wessels et al, 2007); the true positive 
response rate was 70% and the true negative response rate was 72%. No AUC values 
were provided for this replication cohort. The second cohort comprised 75 patients 
with established RA (Fransen, et al., 2012); the true positive rate was 47% and the 
true negative response rate was 81%. The AUC value in this cohort was 0.77 and the 
R
2
 0.28. Therefore, despite similar levels of discrimination between responders and 
non-responders and similar abilities to predict non-responders, the model was 
substantially less accurate at predicting methotrexate responders in established RA, 
when compared with the early RA cohort.  An important limitation of this model is 
the size of its intermediate risk group (approximately half of actual responders are 
classified as having an “intermediate risk” of responding). Identifying risk factors 
that account for the remaining variance in methotrexate response should reduce the 
size of this group. In addition the model requires validation in larger sized, 
prospective RA cohorts. Similar prediction models are yet to be developed for other 




1.6. Aims and Objectives 
1.6.1. Research Rationale 
RA is a highly heterogeneous disorder. Its variability can be seen from several 
perspectives. Firstly, there are substantial differences in the risk factors which 
precipitate RA in different patients. The two dominant RA susceptibility factors ‒ 
cigarette smoking and HLA-DRB1 SE allele carriage ‒ are not present in all RA 
patients. In addition not all smokers with the SE develop RA. Secondly, there is 
marked variation in the clinical course of RA. Some patients have an aggressive 
phenotype, which is characterised by the early development of radiological erosions 
and disability. In other patients there is a relatively benign course with normal 
radiographs and no functional decline. Finally, RA patients vary in their responses to 
treatment.  An important example of this variability is that one third of RA patients 
fail to achieve ACR 20 responses after being treated with a TNF-inhibitor (Rubbert-
Roth and Finckh, 2009), which is the standard treatment advocated for all patients 
with active, DMARD-refractory disease. 
 
One important consequence of the heterogeneity of RA is that delivering high quality 
care depends upon adopting a stratified approach to its management (a concept 
termed “stratified medicine”). This stratified approach uses clinical characteristics 
and biomarkers to identify groups of individuals that are most likely to respond to 
specific treatment strategies (Plant, et al., 2014). Such strategies include not only the 
treatment of established disease but also its prevention in high-risk patient strata. 
This approach contrasts with current NICE RA guidelines, which advocate empirical 
practice with patients managed as a single group (Emery et al, 2010).  
 
Stratified medicine and risk prediction are overlapping concepts. Stratified medicine 
involves identifying subgroups of patients with distinct mechanisms of disease or 
particular treatment responses (Medical Research Council, 2014). Such an approach 
enables the identification and development of treatment strategies, which are 
effective for specific groups of patients. Its ultimate goal is to ensure the right patient 
gets the right treatment at the right time (Medical Research Council, 2014). Risk 
prediction involves developing models in which one or more predictors are used to 
estimate the risk that one or more outcomes are present (diagnostic prediction model) 
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or will occur within a specific time period (prognostic prediction model) in an 
individual with a particular predictor profile (Moons, et al., 2012). Risk prediction 
therefore facilitates stratified medicine. Identifying relevant predictive factors and 
incorporating them in accurate risk prediction models is a crucial first step in moving 
from empirical clinical practice towards following the ethos of stratified medicine in 
clinical care. 
 
1.6.2. Overall Aim 
For risk prediction and stratified medicine in RA to be possible the following two 
requirements must be met. Firstly, the factors that define subgroups of individuals 
likely to a) develop RA (and thus benefit from preventive treatments); b) have a 
severe disease course requiring aggressive treatment; and c) respond to specific 
medications must be identified. Secondly, prediction modelling frameworks are 
required that harness these factors to stratify individuals into subgroups that are 
either likely to develop RA or have an established RA phenotype that is likely to 
benefit from a specific management strategy. 
 
This thesis addresses these two requirements. Its overall goal is to facilitate the risk 
prediction that underpins stratified medicine in RA. Its primary aim is to improve the 
knowledge of which clinical and genetic factors predict RA’s onset, disease course 
and treatment responses. Its secondary aim is to develop a risk prediction modelling 
framework that harnesses these factors to inform clinical care. Due to this broad 
conceptual framework, the thesis does not test a single hypothesis; instead it tests a 
series of five inter-related hypotheses, which are outlined below. 
 
1.6.3. Specific Objectives 
The research in this thesis addresses the overall aim by focusing on five specific 
objectives. The first objective is to evaluate published data on a proposed 
environmental risk factor for RA (alcohol abstinence) to improve the understanding 
of its relevance to disease development. The second and third objectives are to 
identify novel genetic predictors for RA severity using candidate gene and genome-
wide approaches, respectively. The fourth objective is to evaluate the role of 
serology (ACPA status) in predicting treatment needs and responses in early, active 
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RA patients. The final objective is to incorporate published RA risk factor data 
within a novel prediction modelling framework to better understand how such factors 
can be applied to stratify individuals into disease-risk groups. 
 
1.6.3.1.Evaluating Alcohol as a Protective Factor against RA 
Recent studies have reported an inverse association between alcohol consumption 
and the risk of RA development. This suggests that alcohol may protect against RA. 
As with many environmental factors this relationship is mainly observed in case-
control (Kallberg et al, 2009, Maxwell et al, 2010) and not cohort studies (Cerhan et 
al, 2002); a causative role is therefore uncertain. 
 
This research objective is to establish if alcohol intake protects against RA 
development and to determine if this effect is influenced by alcohol dose, duration 
and serological status. It tests the hypothesis that alcohol intake influences the 
likelihood of RA development and that this association varies by serological status 
and the level and duration of alcohol intake. The research addressing this objective is 
presented in the form of a published manuscript (Scott et al, 2013c) in Chapter 2 of 
this thesis. 
 
1.6.3.2.Genetic Predictors of X-ray Progression: Candidate Gene Approach 
Radiological damage is considered an important marker of RA severity with the 
presence of X-ray damage often used to guide treatment decisions in clinical practice 
(Garrood, et al., 2011). Identifying patient-specific factors that predict radiological 
damage are, therefore, highly desirable. Despite the moderate heritability of RA 
radiological progression rates (Knevel et al, 2012b) there is limited data on the 
genetic variants influencing this trait. 
 
Several studies have tested the hypothesis that RA susceptibility variants associate 
with radiological progression. Their findings are often not replicated; additionally 
they have examined only a proportion of risk loci and evaluated each locus 
separately, despite limited power. Two recent meta-analyses of genetic studies have 
expanded the number of genetic loci and HLA protein amino acid polymorphisms 
associated with RA susceptibility (Okada et al, 2013, Raychaudhuri et al, 2012). This 
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research objective is to establish if these variants associate with radiological 
progression in early, active RA patients, when they are assessed both individually 
and cumulatively, using a genetic risk score combining risk loci. It tests the 
hypothesis that RA genetic susceptibility variants associate with radiological 
progression in patients with early, active disease. The research addressing this 
objective is presented in the form of a traditional thesis section in Chapter 3. 
 
1.6.3.3.Genetic Predictors of X-ray Progression: Genome-Wide Approach 
This objective is directly related to objective 3. As opposed to taking a candidate 
gene approach (examining the role of susceptibility variants in radiological 
progression) it will attempt to identify novel genetic associations with X-ray 
progression on a genome-wide scale (covering 138,488 genetic markers with 
established links to immune-mediated diseases present on the ImmunoChip). This 
research objective is to identify novel genetic associations with radiological 
progression in early, active RA patients. It tests the hypothesis that genetic markers 
present on the ImmunoChip associate with radiological progression in patients with 
early, active RA. The research addressing this objective is presented in the form of a 
traditional thesis section in Chapter 4. 
 
1.6.3.4.ACPA as a Predictor of Treatment Needs and Responses 
Current UK guidelines recommend that all patients with early, active RA receive 
combination DMARDs and short-term corticosteroids (Deighton et al, 2009). It is 
uncertain if this approach is relevant to all patients. Evidence suggests that DMARD 
monotherapy may be sufficient in some individuals (De Vries-Bouwstra et al, 2008). 
Additionally, studies indicate that differential treatment responses exist between 
ACPA RA subsets (Isaacs et al, 2013, Potter et al, 2009). When this is considered 
alongside the fact that ACPA-positive and ACPA-negative RA have different 
susceptibility factors and disease courses (Daha and Toes, 2011), it appears that 
ACPA status may be an important biomarker in establishing patient subgroups that 
are likely to respond to specific treatments. This research objective is to establish if 
patients with early, active ACPA-positive and ACPA-negative RA differ in their 
responses to intensive treatment with combination DMARDs and corticosteroids. It 
tests the hypothesis that responses to intensive combination treatments in early, 
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active RA patients differ by ACPA status. The research addressing this objective is 
presented in the form of a published manuscript (Seegobin, et al., 2014) in Chapter 5 
of this thesis. 
 
1.6.3.5.Developing and Validating a Risk Prediction Model for RA 
In order for stratified medicine to be possible, risk prediction modelling frameworks 
are required that use information on patient-specific factors to stratify individuals 
into subgroups likely to benefit from specific management strategies. As outlined in 
the introductory section of this thesis, the factors that predict an RA patient’s likely 
disease course and treatment response are poorly defined. In contrast, the genetic 
factors that predict an individual’s risk of RA development are well established, with 
the most recent meta-analysis of GWASs identifying over 100 RA genetic 
susceptibility loci (Okada et al, 2013). Developing a prediction modelling framework 
that uses these genetic factors to stratify patients to disease-risk groups is of crucial 
importance. Such a model could be used to identify individuals at a very high-risk of 
RA with a longer term goal of evaluating primary prevention strategies. Furthermore, 
once validated, such a framework could be applied to many aspects of stratified 
medicine, combining patient-specific factors for disease severity and treatment 
responses (once they are established) to inform management decisions in an 
established RA phenotype. 
 
Previous attempts to combine RA genetic susceptibility factors in risk prediction 
models have failed to generate clinically relevant predictive data (Chibnik et al, 
2011, Karlson et al, 2010, Karlson et al, 2013, Yarwood et al, 2013). This research 
objective is, therefore, to evaluate if an alternative approach to prediction modelling 
(using computer simulation to categorise risk) will generate clinically applicable data 
and to establish if it can better identify younger onset RA (YORA), an RA subset 
that is particularly desirable to prevent due to higher associated health-care costs 
(Lajas, et al., 2003). It tests the hypothesis that RA risk factors can be combined to 
predict an individual’s future risk of disease development. The research addressing 
this objective is presented in the form of a published manuscript (Scott, et al., 2013b) 
in Chapter 6 of this thesis. 
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CHAPTER 2.   ALCOHOL AS A PROTECTIVE FACTOR  
 
This chapter is presented as a published paper and is a copy of the following 
journal publication: 
Scott IC, Tan R, Stahl D, Steer S, Lewis CM, Cope AP. The protective effect of 
alcohol on developing rheumatoid arthritis: a systematic review and meta-analysis. 
Rheumatology (Oxford) 2013; 52: 856-67. 
 
This publication is available at: 
http://rheumatology.oxfordjournals.org/content/52/5/856.long.
Original article
The protective effect of alcohol on developing
rheumatoid arthritis: a systematic review and
meta-analysis
Ian C. Scott1,2, Rachael Tan1, Daniel Stahl3, Sophia Steer4, Cathryn M. Lewis2
and Andrew P. Cope1
Abstract
Objectives. Our aim was to establish whether alcohol protects against RA development and to determine
whether this effect is influenced by alcohol dose, duration and serological status through systematically
reviewing the literature and undertaking a meta-analysis.
Methods. We searched Medline/EMBASE (1946 to July 2012) using the terms rheumatoid arthritis.mp or
arthritis, rheumatoid/ and alcohol.mp or ethanol/. Manuscript bibliographies were reviewed. Observational
studies were included that were casecontrol/cohort, examined the relationship between alcohol and
RA risk and reported or allowed the calculation of effect size data [odds ratios (ORs)/relative risks
(RRs) with 95% CIs] in drinkers vs non-drinkers. A random-effects model was used to estimate pooled
ORs/RRs. Doserisk relationships were evaluated by trend tests.
Results. Nine studies (from 893 articles) met our inclusion criteria, comprising six casecontrol (3564
cases; 8477 controls) and three cohort studies (444 RA cases; 84 421 individuals). A significant protective
effect of alcohol on RA risk was observed—summary OR for RA in drinkers vs non-drinkers 0.78 (95% CI
0.63, 0.96). This effect was confined to ACPA-positive RA—summary OR 0.52 (95% CI 0.36, 0.76), with no
significant risk reduction seen for ACPA-negative RA—summary OR 0.74 (95% CI 0.53, 1.05). Subgroup
analysis by study design identified a significant relationship in casecontrol but not cohort studies.
Conclusion. Alcohol intake is inversely associated with ACPA-positive RA, suggesting a protective effect.
As this finding is confined to casecontrol studies further research is required with prospective cohort
studies incorporating ACPA status to confirm this relationship.
Key words: rheumatoid arthritis, alcohol, cyclic peptides, systematic review.
Introduction
Many risk factors have been implicated in the develop-
ment of RA [1]. Their impact varies according to patients’
RF and antibodies to citrullinated protein antigen (ACPA)
status [2]. Genetic risk factors have been studied in the
most detail with over 30 risk loci established for seroposi-
tive RA [3]. Smoking is the main environmental risk factor
identified to date, which also predominantly predisposes
to seropositive RA [4]. The roles of other environmental
risk factors are less clear. The emergence of risk predic-
tion models, which combine geneenvironment factors
to identify individuals at a high risk of RA, highlight the
importance of accurately defining RA’s underlying risk
factors [5].
Recent casecontrol studies show that fewer RA pa-
tients drink alcohol when compared with controls; this
finding suggests that alcohol intake may protect against
the development of RA [6, 7]. As with smoking this rela-
tionship is greater for ACPA-positive RA and increases
with exposure. This beneficial effect of alcohol, which
has attracted substantial media interest, has not been
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identified in a number of earlier studies [8, 9]. As a con-
sequence its significance is controversial.
We therefore systematically reviewed observational
studies evaluating the relationship between alcohol
intake and the development of RA and undertook a
meta-analysis. Our primary aim was to examine if alcohol
affected the risk of RA, through testing the hypothesis that
alcohol intake influenced the likelihood of RA develop-
ment. Our secondary aims were to establish if this rela-
tionship varied by serological status and according to the
level and duration of alcohol consumed, through testing
the hypotheses that alcohol intake predominantly affected
seropositive RA risk and that this risk varied according to
the level and duration of alcohol intake.
Methods
Reporting structure and data extraction
We adopted the Meta-analysis Of Observational Studies
in Epidemiology (MOOSE) checklist for the reporting of
this review [10]. Our literature search, data extraction
and study quality assessments were performed in an
independent, unblinded manner by two authors (I.C.S.
and R.T.). Discrepancies were resolved by discussion.
Inclusion criteria and analytical methods were
pre-specified in a protocol.
Search strategy
Medline (from 1946 to July 2012) and EMBASE (from 1947
to July 2012) were searched using the Ovid platform
(search last performed July 2012). The search terms com-
prised: rheumatoid arthritis.mp or arthritis, rheumatoid/
and alcohol.mp or ethanol/. Reference lists of included
manuscripts were reviewed for relevant papers. EndNote
version X5 (Thomson Reuters, NY, USA) was used for cit-
ation management.
Selection criteria
Observational studies were included that: (i) were
casecontrol or cohort design; (ii) examined the relation-
ship between alcohol intake and the risk of RA develop-
ment; and (iii) reported effect size data as odds ratios
(ORs) or relative risks (RRs) with 95% CIs or provided
data allowing for their calculation.
We excluded: (i) additional studies evaluating the same
cohort (only the largest study with the most complete
information was included); and (ii) unpublished studies
(conference abstracts). All identified abstracts were pub-
lished in English; we did not identify any studies in
non-English languages fulfilling our inclusion criteria from
abstract review.
Data extraction
We extracted the following data: author and manuscript
names, study design, publication year, sample size,
demographics (age and gender), RA characteristics
(disease duration, disease activity, serology and
radiographic erosions), information on alcohol intake,
effect size data (ORs or RRs with 95% CIs), adjust-
ment factors included in the analyses and geographical
area.
Assessment of study quality
To evaluate the validity of the included studies their quality
was assessed using the NewcastleOttawa Scale (advo-
cated by the Cochrane Non-Randomised Studies
Methods Working Group) [11, 12]. This provides points
(termed stars) for eight items across three domains com-
prising group selection (maximum 4 points), comparability
of cohorts or cases and controls (maximum 2 points) and
ascertainment of outcome of interest or exposure (max-
imum 3 points). Individual components of each domain
are detailed in supplementary Tables S1 and S2 (available
as supplementary data at Rheumatology Online). The
total score ranges from 0 to 9. Study quality scores
have been criticized within the literature because they
often incorporate diverse items that are weighted differ-
ently [13]; we have, therefore, provided a breakdown
score for each domain subscale in addition to the total
summary score.
Statistical analysis
We estimated pooled ORs/RRs and standard errors using
a random-effects model based on DerSimonian and
Laird’s approach [14]. This model was adopted because
it considers heterogeneity, which was present between
our studies. It assumes that, in addition to the presence
of random sampling error, any variability in mean effect
size is also due to variation in study populations and pro-
cedures (between-study heterogeneity).
Due to the low prevalence of RA, which is estimated to
affect 0.81% of the UK adult population [15], ORs and
RRs were used interchangeably [16]. Individual study
and overall effect size data were summarized using
forest plots. Casecontrol and cohort studies were ana-
lysed both separately and together, with pooled ORs/RRs
calculated in both instances. For all statistical tests
P< 0.05 were considered significant. Data were analysed
using the statistical environment R, version 2.14.1
(R Foundation for Statistical Computing, Vienna, Austria),
Stata, version 10.1 (Stata Corp., College Station, TX, USA)
and MetaP (Dongliang G, Duke Institute For Genome
Sciences & Policy, NC, USA) [17].
Study heterogeneity
Between-study heterogeneity was assessed using
Cochran’s Q-test and the I2-statistic. The latter describes
the percentage of total variation across studies due to
heterogeneity rather than chance. It ranges from 0% (no
heterogeneity) to 100% (high heterogeneity) with I2-values
of 25, 50 and 75% having tentatively been suggested to
represent low, moderate and high heterogeneity, respect-
ively [18]. Meta-regression was undertaken to evaluate
study publication year and quality as potential sources
of heterogeneity between studies [19].
Within-study heterogeneity (differences between cases
and controls) was evaluated descriptively.
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Primary outcome analysis
Our primary outcome measure was the OR of developing
RA in drinkers vs non-drinkers. Where possible we com-
bined OR/RRs that had adjusted for confounding vari-
ables such as age, gender and smoking. In studies only
reporting adjusted risks stratified by alcohol intake we
combined the different alcohol intake groups into one
common OR/RR to estimate the risk of RA for all drinkers
using an inverse variance fixed-effects model [19]. In stu-
dies not reporting adjusted risks, unadjusted risks were
used (calculated from crude data). Due to heterogeneity
in the reporting of alcohol intake and RA risk we used
the following categories to represent no alcohol in three
studies: 01 U/week [9], <1 or never glasses of alcohol/
week [20] and self-classification as a never-regular drinker
[6]. The latter was used because adjusted risks were
only reported for never- vs ever-regular drinkers and
this study had significant differences between cases
and controls for age, gender and smoking status, which
meant that unadjusted risks for drinkers vs non-drinkers
calculated from crude data could be affected by
confounding.
Subgroup analysis
We undertook three subgroup analyses evaluating:
(i) risk differences between ACPA/RF-positive and
ACPA/RF-negative RA; (ii) the impact of alcohol quantity
on RA risk; and (iii) the impact of drinking duration on RA
risk.
Due to variation between studies in the categories of
alcohol intake used to report risk it was not possible to
combine them to give a summary OR for each drinking
category. We therefore examined doserisk relationships
within studies using trend tests. Where these were not
reported the CochranArmitage test for trend was calcu-
lated using crude data [21]. We also combined trend test
P-values from each study using Stouffer’s Z trend test
[22]. Levels of alcohol intake were broadly grouped into
three categories—low, moderate and high—according to
individual study classifications. In studies using low alco-
hol intake as the reference group, ORs/RRs were recalcu-
lated using crude data and taking no alcohol as the
reference group. Because only two studies evaluated al-
cohol intake on more than one occasion (both reporting
risk differently) the impact of drinking duration on RA was
evaluated descriptively.
Publication bias and selection bias
Publication bias was looked for by constructing funnel
plots and applying Begg and Mazumudar’s [23] adjusted
rank correlation method and Sterne and Egger’s [24] linear
regression approach.
Examining the influence of individual studies
We repeated our analyses excluding one study at a time.
This allowed us to investigate the influence of individual
studies on the meta-analysis summary OR and ensure our




We screened 893 articles, identifying 22 potential manu-
scripts from their title or abstract (Fig. 1). Fourteen were
excluded: three evaluated the same cohort [2, 26, 27]; two
evaluated other risk factors [28, 29]; five examined other
issues [30-34]; three were not observational studies (two
letters [35, 36] and one review [37]); one did not report
effect size data or provide data for its calculation [38].
Additionally the latter study used a self-reported diagnosis
of RA that increased the likelihood of case misclassifica-
tion (reflected in its high reported RA prevalence figures of
5% in men and 7% in women). We therefore did not at-
tempt to contact its authors to obtain raw data for effect
size calculation. Eight articles were included, which re-
ported nine separate studies (Table 1). Three were
cohort and six were casecontrol designs.
Cohort studies
The minimum, maximum and median values for the cohort
study sizes comprised 18 944; 34 141 and 31 336, re-
spectively. The same values for the ages of included indi-
viduals comprised 45, 62 and 61 years, respectively. Two
studies examined only females; in the other gender was
not described. Two reported serology: one restricted ana-
lysis to RF-positive RA; in the other 61% of cases were RF
positive. Follow-up periods were 7 [20], 11 [39] and 16
years [40].
Casecontrol studies
As summary statistics for the casecontrol studies, we
present the minimum, maximum and median number of
cases evaluated by each study (135; 1204 and 501.5), the
number of controls evaluated (378; 4234 and 937.5), the
ages of included cases (49, 61 and 51 years) and the ages
of included controls (48, 52 and 50 years). Most studies
examined females: three studies evaluated only females;
in the remainder 70% were women. One study recruited
controls from the same hospital clinic as cases [41]; the
remainder recruited population-based controls. Three stu-
dies reported disease duration: two evaluated early (42
years) [7] and one established (mean duration 14 years)
RA [6]. Four studies reported serology, with seropositive
cases ranging from 50 to 79%. Only one reported data on
erosions and disease activity: all patients had erosive RA
and most moderate disease activity [6].
Alcohol intake definitions and assessment
There was marked variation in the definition of alcohol
intake between studies (Table 1), which defined alcohol
consumption on a daily, weekly, monthly or lifetime basis
and in units, number of drinks or grams of alcohol.
There was further heterogeneity between studies re-
garding alcohol intake assessment methods. Five used
questionnaires [6, 7, 20, 39, 40], three interviews [7, 8,
41] and one medical record review [9]. Alcohol intake
was also evaluated at different time points prior to or at
RA onset: two cohort studies recorded intake at cohort
www.rheumatology.oxfordjournals.org
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baseline [39, 40], one study recorded intake 10 years pre-
viously [7], two recorded current intake alongside habitual
consumption [6, 7], one recorded intake at initial presen-
tation [41], one recorded intake at an unspecified time
point [9] and two evaluated intake at multiple time points
[8, 20].
Study quality
Study quality scores are shown in Table 1. One study had
a NewcastleOttawa Score of 6, seven scored 7 and one
scored 8. Some cohort studies were not allocated points
because they used questionnaires to evaluate drinking;
additionally one study failed to adjust for smoking [39]
and another had a relatively short follow-up period of 7
years [20]. Some casecontrol studies were not allocated
points because they captured information on alcohol
intake from unblinded interviews or questionnaires, did
not fully report response rates or had differing response
rates between cases and controls.
Although a proportion of studies had differences be-
tween cases and controls with regards to age, gender
and smoking, they did not lose points for comparability
as they adjusted for these factors in their analysis.
Alcohol intake and the overall risk of RA
All studies
All nine studies evaluated alcohol intake and the risk of RA
(Table 2; Fig. 2a). Alcohol drinkers were less likely to de-
velop RA, with a significant risk reduction in drinkers vs
non-drinkers (OR 0.78; 95% CI 0.63, 0.96).
Cohort studies
When restricting our meta-analysis to cohort studies, a
non-significant inverse relationship was observed—the
OR for RA in drinkers vs non-drinkers was 0.91 (95% CI
0.78, 1.07).
Casecontrol studies
When restricting our meta-analysis to casecontrol stu-
dies a more significant inverse relationship was seen—the
OR for RA in drinkers vs non-drinkers was 0.70 (95% CI
0.51, 0.95).
FIG. 1 Search strategy.
www.rheumatology.oxfordjournals.org

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Alcohol and RA risk: a systematic review101
FIG. 2 Forest plots of the ORs for RA in alcohol drinkers vs non-drinkers.
(A) All RA, (B) ACPA-positive RA, (C) ACPA-negative RA.
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Alcohol intake and the risk of ACPA-positive and
ACPA-negative RA
Three casecontrol studies evaluated the impact of alco-
hol intake on the risk of ACPA-positive and ACPA-
negative RA (Table 2; Figs 2b and 2c). There was a
significant risk reduction for ACPA-positive RA (OR 0.52;
95% CI 0.36, 0.76). Although there was a lower risk of
ACPA-negative RA this was not statistically significant
(OR 0.74; 95% CI 0.53, 1.05).
Alcohol intake and the risk of RF-positive and
RF-negative RA
Only one casecontrol study evaluated the impact of al-
cohol on both RF subsets with significant unadjusted risk
reductions for RF-positive (OR 0.19; 95% CI 0.15, 0.24)
and RF-negative RA (OR 0.26; 95% CI 0.19, 0.37) [6]. One
cohort study evaluated risk in RF-positive patients only
with no risk reduction observed (OR 1.11; 95% CI 0.75,
1.62) [40].
Doserisk relationship between alcohol and RA
This was evaluable in all nine studies (Table 2). Four
reported a significant inverse doserisk relationship be-
tween alcohol intake and RA development. The remainder
showed no relationship. Combining trend tests across
studies provided an estimated summary P-value of 0.09;
there was therefore no overall significant doserisk rela-
tionship present.
Impact of alcohol intake duration on RA risk
One cohort study evaluated intake at two time points a
decade apart, finding that those consuming more than
three glasses of alcohol per week sustained over this
period were at a lower risk of RA compared with those
with less prolonged drinking [20]. One casecontrol study
evaluated average lifetime alcohol intake; no impact on
RA risk was observed [8].
Individual study influences
Excluding individual studies from our meta-analysis did
not radically alter the summary OR for RA (Table 3). Our
findings were therefore not solely attributable to a single
study. Excluding three casecontrol studies resulted in a
borderline significant OR (upper 95% CI 1.00).
Study heterogeneity
There was significant heterogeneity between studies
examining the overall risk of RA (P< 0.0001; I2= 80.3%)
and ACPA-positive RA (P= 0.019; I2 = 74.8%) but not
those evaluating ACPA-negative RA (P= 0.16; I2= 44.7%).
There was no evidence that study publication year
(P= 1.00) influenced RA risk when evaluated by meta-
regression (although the small number of included studies
meant this technique had limited power). The impact of
study quality was significant (P= 0.03), with increasing
quality associated with a reduced protective effect of al-
cohol. This is attributable to the lower score ascribed to
Maxwell et al. [6] and the higher score ascribed to
Helio¨vaara et al. [40], but is difficult to interpret given the
score’s limited variability.
Three studies reported differences between cases and
controls in age and gender: one study had younger con-
trols (average difference 13 years) [6] and two studies had
more female cases [6, 7]. Five studies reported differ-
ences in smoking status: in four studies smoking rates
TABLE 3 Individual study influences on RA risk in drinkers vs non-drinkers:
meta-analysis results with each study omitted
Study Study design
Summary OR (95% CI) for
RA if study omitted
Meta-analysis of all studies
Cerhan et al. [39] Cohort 0.75 (0.59, 0.96)
Di Giuseppe et al. [20] Cohort 0.77 (0.60, 0.98)
Helio¨vaara et al. [40] Cohort 0.75 (0.60, 0.94)
Hazes et al. [41] Casecontrol 0.80 (0.65, 1.00)
Ka¨llberg et al.—EIRA [7] Casecontrol 0.77 (0.60, 0.98)
Ka¨llberg et al.—CACORA [7] Casecontrol 0.81 (0.66, 1.00)
Maxwell et al. [6] Casecontrol 0.85 (0.71, 1.00)
Rodriguez et al. [9] Casecontrol 0.75 (0.59, 0.95)
Voigt et al. [8] Casecontrol 0.74 (0.59, 0.93)
Meta-analysis of studies evaluating ACPA-positive RA
Ka¨llberg et al.—EIRA [7] Casecontrol 0.43 (0.34, 0.55)
Ka¨llberg et al.—CACORA [7] Casecontrol 0.56 (0.33, 0.96)
Maxwell et al. [6] Casecontrol 0.58 (0.36, 0.95)
Meta-analysis of studies evaluating ACPA-negative RA
Ka¨llberg et al.—EIRA [7] Casecontrol 0.61 (0.43, 0.87)
Ka¨llberg et al.—CACORA [7] Casecontrol 0.73 (0.43, 1.24)
Maxwell et al. [6] Casecontrol 0.88 (0.66, 1.18)
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were higher in cases [6, 7, 9] and in one study smoking
rates were higher in controls [41]. Most studies adjusted
for these potentially confounding variables—comprising
age, gender and smoking—in multivariate analyses.
Publication bias
There was some evidence of funnel plot asymmetry
(Fig. 3), which displays two lower precision studies with
large effect sizes favouring a protective effect of alcohol
against RA and an absence of similarly lower precision
studies of effect sizes in the opposing direction.
Although this suggests publication bias may be present,
such bias was not detected by Begg’s rank correlation
(P= 0.25) or Egger’s weighted regression methods
(P= 0.22). Additionally the small number of included stu-
dies means that publication bias is difficult to assess [25].
Discussion
Our systematic review provides evidence of an inverse
relationship between the presence of RA and the con-
sumption of alcohol at or prior to disease onset. It
shows that this relationship is predominantly confined to
ACPA-positive RA, with a non-significant association
observed for ACPA-negative RA. Although these findings
suggest that alcohol protects against ACPA-positive RA
and support the concept that environmental risk factors
differ between RA subsets defined by ACPA status, cau-
tion is required in their interpretation as this significant
relationship is confined to casecontrol studies, which
have marked heterogeneity between them.
The discrepancy in risk according to ACPA status is
interesting. These two subsets are known to differ pheno-
typically with ACPA-positive RA having lower remission
rates and more radiographic erosions [42, 43]. Their
underlying genetic and environmental risk factors also
appear to differ, which is a concept mirrored by our
review. A recent genome-wide association study has indi-
cated distinct genetic architectures with risk allele fre-
quency differences between subsets [44]. A large
casecontrol study has identified divergent environmental
risks with ACPA-positive RA linked with smoking, alcohol
and oral contraceptive pill use and ACPA-negative RA
linked with obesity [2]. There is therefore growing evi-
dence that these subsets have different pathophysiolo-
gies and may be considered distinct disease entities
[45]. Our review supports this perspective. Due to a lack
of data it was not possible to establish if similar environ-
mental risk differences existed for RF-positive and
RF-negative RA, although evidence from a smoking
meta-analysis suggests these may be present [4].
One potential mechanism through which alcohol could
protect against the development of RA is via attenuation
of the innate inflammatory response. In experimental
animal models, alcohol inhibited the onset of a collagen-
induced inflammatory arthritis through down-regulating
leucocyte migration, up-regulating testosterone secretion
and reducing nuclear factor-kB (NF-kB) activation [46].
Alcohol has also been shown to have anti-inflammatory
effects in humans through similar mechanisms such as
reducing NF-kB-driven inflammatory mediator production
by monocytes [47] (a key cellular pathway in RA [48]). An
alternative explanation for this inverse relationship is that
individuals with lowmoderate alcohol intake have heal-
thier lifestyles compared with complete abstainers who
may do so for reasons such as chronic illness; RA could
therefore result from confounding lifestyle factors. This
explanation has been proposed to explain the J-shaped
relationship that exists between drinking alcohol and over-
all mortality and cardiovascular disease [49].
It would have been of interest to establish if the effects
of alcohol on RA risk differ by gender. This is present with
smoking, with substantially higher ORs for RA seen in
male compared with female smokers [4]. Due to a lack
of data we could not establish this for alcohol although
the single study that subdivided risk between sexes found
similar protective effects in both males and females [6].
Additionally we could not systematically examine the
combined effect of smoking and alcohol on RA risk,
which was only reported in two studies. These did, how-
ever, indicate a likely environmentenvironment inter-
action with a greater alcohol-related risk reduction for
ACPA-positive RA observed in ever-smokers compared
with never-smokers [7]. The importance of adjusting risk
for smoking was highlighted by Di Giuseppe et al. [20],
who found that while drinking was commoner in RA
cases because smoking was more prevalent in drinkers
the smoking adjusted risk for RA was reduced in those
who drank. We consider that as most studies adjusted
for smoking status in their analyses, the beneficial ef-
fects of alcohol on RA risk were not confounded by
smoking.
Our review has several important limitations. Firstly, an
overall significant relationship between alcohol and RA
was observed in casecontrol but not cohort studies.
Casecontrol studies are subject to recall bias, which in
this context is a distinct possibility. Numerous reasons
exist for individuals with RA to consume less alcohol
(such as DMARD use), and therefore asking them to
FIG. 3 Funnel plot of the included studies.
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recall past drinking behaviour could be influenced by their
current low intake post-diagnosis. Only one casecontrol
study evaluated alcohol intake prior to RA onset; the
remainder captured information on alcohol intake at RA
development or prior to it through retrospective question-
naires or interviews with no independent means of validat-
ing their data. These studies were thus all subject to recall
bias. Secondly, due to reporting adjusted risks with low
alcohol intake as a reference group, unadjusted risks were
used for two studies in the ACPA sub-group analysis [7].
There was, however, little difference between unadjusted
and adjusted risks (supplementary Table S3, available as
supplementary data at Rheumatology Online); we there-
fore consider that the observed relationship is unlikely to
be due to confounding variables. Thirdly, we used
self-classification as a never-regular drinker to represent
no alcohol intake in one study. Although this is not the
same as absolute abstinence the numbers of
never-regular drinkers were very similar to those reporting
no alcohol intake; this therefore represented an appropri-
ate surrogate measure. Finally, there was significant clin-
ical and methodological heterogeneity between the
studies, with important differences existing in how they
defined and captured alcohol intake; such heterogeneity
limits their suitability to be combined within a
meta-analysis.
Further research is needed to establish whether al-
cohol truly protects against the development of RA.
One possible explanation for the lack of an overall as-
sociation observed in the cohort studies was their fail-
ure to evaluate RA cases by ACPA status. Ideally, a
large prospective cohort study is required, which sub-
divides incident cases of RA by the presence or ab-
sence of ACPA and captures detailed information on
disease risk factors and outcomes. Such an approach
could provide crucial insight into many RA risk factors
in addition to alcohol. This would enable the develop-
ment of accurate prediction models combining clinical
and genetic risk factors to identify individuals at risk of
RA. The end result would be the implementation of
evidence-based preventative strategies to halt RA de-
velopment [50].
Rheumatology key messages
. Casecontrol studies suggest drinking alcohol may
be associated with a reduced risk of RA.
. Alcohol is mainly associated with ACPA-positive RA
implying that environmental risks differ by ACPA
status.
. Research is required using cohort studies subdivid-
ing RA cases by ACPA to determine causality.
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Supplementary Table 1. Description of Newcastle-Ottawa Scoring System for 
Case-Control Studies (Wells, et al., 2011) 
Scoring 
Domain 
Domain Subscale Description Of Star/Point Allocation 
Selection Adequacy of case 
definition  
1 star is allocated if the case definition is 
independently validated (e.g. more than one person is 
used to extract information or a reference is made to 
primary record source i.e. medical records). 0 stars 
are allocated if record linkage is used (e.g. ICD 
database coding), a self-reported definition is used or 
no description is given. 
Case 
representativeness 
1 star is allocated if all eligible cases are included 
with the outcome of interest over a defined time 
period or in a defined catchment area or in a defined 
hospital(s) or in a health maintenance organisation or 
an appropriate sample of those cases (e.g. random 
sample) is included. 0 stars are allocated if these 
requirements are not satisfying or not stated. 
Control selection 1 star is allocated if controls are derived from the 
same community as cases and therefore would have 
been cases had the outcome of interest been present. 
0 stars are allocated if controls are derived from a 
hospital population or no description is given. 
Control definition 1 star is allocated if it is explicitly stated that controls 
have no history of the outcome. 0 stars are allocated 
if no mention of the history of outcome is given. 
Comparability Comparability of 
cases and controls 
on the basis of 
design or analysis 
2 stars are allocated for the number of confounding 
factors that cases and controls are either matched for 
in the study design or adjusted for in the analysis. 1 
star is allocated for controlling for the most important 
factor. A second star is allocated if the study controls 
for any additional factors. 
Exposure Ascertainment of 
exposure 
1 star is allocated if a secure record (e.g. surgical 
records) or structured interview is used where the 
interviewer is blinded to the case/control status. 0 
stars are allocated if an unblinded interview or a 
written-self report or medical records only are used 
or no description is given. 
Same method of 
ascertainment for 
cases and controls 
1 star is allocated if the method of ascertainment is 
the same for cases and controls. 0 stars are allocated 
if the method is different. 
Non-response rate 1 star is allocated if the non-response rate is the same 
for both groups. 0 stars are allocated if the rate is 





Supplementary Table 2. Description of Newcastle-Ottawa Scoring System for 
Cohort Studies (Wells et al, 2011) 
Scoring 
Domain 
Domain Subscale Description Of Star/Point Allocation 
Selection Exposed cohort 
representativeness 
1 star is allocated if the exposed cohort is 
representative of the average individual at risk of RA 
in the community. 0 stars are allocated if the exposed 
cohort is a selected group of individual’s e.g. nurses or 
no description of the derivation of the cohort is given. 
Non-exposed 
cohort selection 
1 star is allocated if the non-exposed cohort is drawn 
from the same community as the exposed cohort. 0 
stars are allocated if it is drawn from a different source 
or no description of its derivation is provided. 
Ascertainment of 
exposure 
1 star is allocated if a secure record (e.g. surgical 
records) or structured interview is used. 0 stars are 
allocated if a written self-report is used or no 
description is given. 
Demonstration that 
outcome of interest 
was absent at the 
start of study 
1 star is allocated if this is demonstrated. 0 stars are 
allocated if this is not demonstrated. 
Comparability Comparability of 
cohorts on the basis 
of the design or 
analysis 
2 stars are allocated for the number of confounders that 
the exposed and non-exposed individuals are matched 
for and/or adjusted for in the analysis. 1 star is 
allocated for controlling for the most important factor. 




1 star is allocated if a blind independent assessment is 
undertaken or record linkage is used. 0 stars are 
allocated if the assessment is self-reported or no 
description is given. 
Was follow-up long 
enough for 
outcomes to occur 
1 star is allocated if an adequate follow-up length is 
used (in the case of our systematic review we 
considered 10 or more years to be an adequate follow-




1 star is allocated if follow-up is complete and all 
subjects are accounted for or if a small number of 
subjects are lost to follow-up, which is unlikely to 
introduce bias (in the case of our systematic review we 
considered ≥90% follow-up to be adequate), or a 
description is provided of those lost. 0 stars are 
allocated if the follow-up rate is less than this amount 
and no description is given of those lost or no 





Supplementary Table 3. Comparison of Adjusted and Unadjusted Odds Ratios 
for RA in Drinkers vs. Non-Drinkers from the EIRA and CACORA Studies 
Alcohol 
Intake 












1.1 (0.8-1.4) 1.0 (0.8-1.3) 1.7 (1.1-2.5) 1.7 (1.2-2.5) 
Low 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 
Mod 0.6 (0.4-0.7) 0.6 (0.4-0.7) 1.0 (0.7-1.3) 1.0 (0.7-1.3) 




1.3 (1.0-1.8) 1.1 (0.8-1.4) 2.0 (1.3-3.1) 2.0 (1.3-3.0) 
Low 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 
Mod 0.5 (0.4-0.7) 0.5 (0.4-0.7) 1.0 (0.7-1.4) 1.0 (0.7-1.4) 




0.9 (0.6-1.3) 0.9 (0.6-1.2) 1.1 (0.6-2.1) 1.2 (0.6-2.2) 
Low 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 
Mod 0.7 (0.5-0.9) 0.6 (0.5-0.9) 0.9 (0.6-1.5) 0.9 (0.6-1.4) 
High 0.5 (0.4-0.7) 0.5 (0.4-0.7) 0.9 (0.5-1.5) 0.6 (0.4-1.1) 
EIRA = Epidemiological Investigation of Rheumatoid Arthritis; CACORA = CAse-
COntrol study on Rheumatoid Arthritis (Kallberg et al, 2009).
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Rheumatoid arthritis (RA) is a heterogeneous disease whose course varies 
substantially between patients. Biomarkers that reliably identify patients with a 
severe, progressive phenotype at disease onset are therefore highly desirable; they 
could be used to inform decisions on treatment intensity. The moderate heritability of 
radiological progression in RA, which is estimated at 45 to 58% (Knevel et al, 
2012b), suggests genetic markers could be important prognostic predictors. Despite 
success in delineating the genetic architecture of RA susceptibility (Okada et al, 
2013, Raychaudhuri et al, 2012) only a few replicated loci have been linked to 
radiological progression. These have mainly been identified through candidate gene 
studies with a lack of large, genotyped, longitudinal datasets limiting the power of 
individual cohorts to identify loci at genome-wide significance.  
 
Existing reports of genetic predictors of X-ray damage in RA have assessed 
observational study cohorts (Knevel et al, 2013a, Krabben, et al., 2013). These 
comprise patients with a range of disease activities managed using a variety of 
treatment strategies. As both of these factors have major impacts on radiological 
progression, these analyses are unable to differentiate between genetic variants 
mediating X-ray damage indirectly via influences on disease activity or treatment 
effects and those having a direct effect. Additionally, as the evidence base for most 
RA treatments is from RCTs of patients with severe, active disease for genetic 
predictors to be able to inform clinical decisions they too require evaluation in such 
individuals. 
 
Several studies have examined the hypothesis that RA susceptibility variants 
associate with radiological progression. Their findings are often not replicated 
(Marinou, et al., 2010, Knevel et al, 2012a). Additionally they have examined only a 
proportion of risk loci (the largest analysis assessed 37 independent variants (De 
Rooy et al, 2013b)) and evaluated each locus separately, despite limited power. 
 
Recent meta-analyses have expanded the number of non-MHC loci, HLA-DRB1 
alleles and HLA amino acid polymorphisms associated with RA susceptibility 
(Okada et al, 2013, Raychaudhuri et al, 2012). The aim of this study was to establish 
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if these associated with radiological progression in early, active RA patients enrolled 
to two RCTs − the Combination Anti-Rheumatic Drugs in Early RA (CARDERA) 
trials − which constitute the CARDERA Genetics Cohort (CGC). Their association 
was evaluated both individually and cumulatively, using a weighted genetic risk 
score (wGRS) combining risk loci. This study represents the first analysis of genetic 
associations with radiological progression in early, active RA patients within a 
clinical trial setting. 
 
3.2. METHODS 
3.2.1. Ethical Approval 
The CARDERA-1 trial was approved by the South Thames Multicentre Research 
Ethics Committee (REC reference: MREC (1) 99/04). The CARDERA-2 trial was 
approved by the South East Research Ethics Committee (REC reference: MREC 
02/1/089). Approval was obtained to genotype archived DNA from the East of 
England - Essex Research Ethics Committee (REC reference: 11/EE/0544). All 




CARDERA-1 recruited 467 patients with early, active RA from multiple UK centres 
(Choy et al, 2008). Patients were randomised to one of four treatment arms: (1) 
monotherapy with methotrexate; (2) double therapy with methotrexate and 
ciclosporin; (3) double therapy with methotrexate and prednisolone; (4) triple 
therapy with methotrexate, ciclosporin and prednisolone. A factorial-design was 
adopted to allow the simultaneous evaluation of prednisolone and ciclosporin in a 2 x 
2 design. Patients were treated and followed-up for 2 years. 
 
3.2.2.2.CARDERA-2 
CARDERA-2 recruited 167 patients with early, active RA from multiple UK centres 
(Scott and Choy, 2007). Patients were randomised to one of two treatment arms: (1) 
monotherapy with methotrexate; (2) double therapy with anakinra (an interleukin-1 
receptor antagonist) and methotrexate. The randomised treatments were given for 12 
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months; thereafter patients were treated at the discretion of their hospital 
rheumatologist. Patients were followed-up for 2 years. 
 
3.2.3. Inclusion and Exclusion Criteria 
The inclusion and exclusion criteria for both trials were identical. Inclusion criteria 
comprised active RA (defined by having 3 out of ≥3 swollen joints, ≥6 tender joints, 
≥45 minutes morning stiffness, ESR ≥28mm/hr), which fulfilled the 1987 ACR 
classification criteria. Patients had to be able to give informed consent and be aged 
≥18 years. Exclusion criteria comprised other inflammatory arthropathies; previous 
methotrexate treatment; contraindications/intolerance of any of the trial drugs; other 
serious medical disorders; acute/chronic infection; significant neutropenia 
(<1.5x10
12
/dl); significant thrombocytopenia (<100x10
12
/dl); abnormal liver tests 
(GGT or AST/ALT >3 times or >2 times the upper limit of normal, respectively); 
severe renal impairment (creatinine clearance <30ml/min); and the use of low-dose 
oral steroids for the treatment of RA. 
 
3.2.4. Radiological Assessments 
In CARDERA-1 hand and feet radiographs were read for modified Larsen scores at 
baseline and 6-monthly for 2 years. They were assessed independently by two 
experienced observers after preliminary studies ensured comparable scoring (Choy et 
al, 2008). In CARDERA-2 hand and feet radiographs were read for modified Larsen 
scores at baseline and 12-monthly for 2 years. They were assessed by an experienced 
observer with specific expertise in RA radiological scoring; this was one of the 
observers that read X-rays in CARDERA-1. 
 
3.2.5. Genotyping 
DNA was genotyped on the Illumina ImmunoChip. The probes on this microarray 
(designed in 2009) interrogate 195,806 SNPs and 718 small insertion–deletions 
(Parkes et al, 2013). This chip provides dense coverage of GWAS confirmed 
immune-mediated disease susceptibility loci. Although it does not provide true 
genome-wide coverage, it is ideal for examining known immune disease related 
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regions. Genotyping was undertaken by staff in the Biomedical Research Centre 
Genomics laboratory (King’s College London). 
 
As the ImmunoChip contains a large number of low-frequency, rare variants 
genotype calling was performed using optiCall (Shah, et al., 2012). This algorithm 
uses SNP-wise and sample-wise calling to more accurately ascertain genotypes at 
rare, low-frequency and common variants. Genotype calling was undertaken by Dr 
Sarah L Spain. 
 
3.2.6. Quality Control Procedures 
Individual and marker-level QC procedures are described in Table 3-1. Individuals 
were removed with <95% SNP call rates (8 patients), anomalously high or low 
heterozygosity rates defined as a Wright’s inbreeding coefficient F of less than or 
greater than 3 standard deviations from the mean, respectively (2 patients; Figure 3-
1), non-European ancestry (20 patients; identified through principal components 
analysis (PCA) using imported HapMap 3 data (undertaken by Dr Sarah L Spain); 
Figure 3-1), discordance between genotype and phenotype gender data (2 patients) 
and duplicate samples (4 patients). Markers were removed that had >5% missingness 
(3,470 SNPs), were not present in the Genome Reference Consortium Human Build 
37 or were duplicate markers (1,748 SNPs), were not in Hardy-Weinberg 
Equilibrium (HWE) (P<0.00001; 3,158 SNPs) or had low MAFs of <0.01 (49,275 
SNPs). 
 
From 560 genotyped individuals, 524 were included in the final analysis (424 from 
CARDERA-1; 100 from CARDERA-2). From 196,524 genotype markers, 138,873 















Pre-QC 560 - 
<95% SNP call rates 552 8 




Relatedness 530 0 
Genotype-phenotype gender discordance 528 2 
Duplicate samples 524 4 
Post-QC 524 - 
Marker-Level QC 
QC Stage 




Pre-QC 196,524 - 
Marker missingness >5% 193,054 3,470 




MAF < 0.01 138,873 49,275 
Post-QC 138,873 - 
a= Ethnic outliers identified by PCA plots of samples merged with HapMap3 data; 
QC = quality control; No. = number; GRCh37 = Genome Reference Consortium 




Figure 3-1. Population Outlier and Heterozygosity Assessments 
 
Panel A = Identification of population outliers using principal components analysis 
(PCA); samples were clustered by ancestry based on the first and second 
eigenvectors; HapMap 3 data files provided high density coverage of CEU (Utah 
residents with Northern and Western European ancestry from the CEPH collection), 
JPT (Japanese in Tokyo, Japan), TSI (Tuscans in Italy) and YRI (Yoruba in Ibandan, 
Nigeria) populations. Plates 1 to 6 refer to the ImmunoChip plates used to genotype 
CARDERA-1 and CARDERA-2 patients. Analysis performed by Dr Sarah L Spain. 
 
Panel B = Histogram of the inbreeding coefficient F; 2 patients were removed from 
the analysis due to F levels >3 standard deviations from the mean indicating 
excessive homozygosity. 
 
3.2.7. HLA Imputation 
Classical HLA-DRB1 alleles and amino acid polymorphisms in HLA-DRβ1, HLA-B 
and HLA-DPβ1 molecules were imputed using SNP2HLA (Jia, et al., 2013), which 
uses the Beagle method for imputation. This was undertaken by Mr Jelmar Quist. 
Reference data from the Type 1 Diabetes Genetics Consortium (T1DGC) panel was 
used (Brown, et al., 2009); this contains 5,868 SNPs (genotyped using the 
ImmunoChip) that extensively tag the MHC region alongside classical four-digit 
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resolution HLA-A, -B, -C, -DPA1, -DPB1, -DQA1, -DQB1 and -DRB1 alleles in 
5,225 unrelated European ancestry individuals (Jia et al, 2013). In the absence of 
HLA tissue typing data in the CGC it was not possible to validate imputation 
accuracy within this cohort. However, SNP2HLA has been extensively validated in 
several large datasets (Han et al, 2014, Jia et al, 2013). Its precision was 
demonstrated in 918 individuals from the 1958 birth cohort, in whom it was 96.7% 
and 99.3% accurate at imputing four-digit resolution HLA-DRB1 alleles and amino 
acid polymorphisms within HLA genes using ImmunoChip genotypes, respectively 
(Jia et al, 2013). 
 
3.2.8. Susceptibility Variants Evaluated 
Confirmed European ancestry RA susceptibility SNPs from the most recent meta-
analysis by Okada et al (Okada et al, 2013) were evaluated for their association with 
radiological progression. Of 77 potential SNPs, 69 were available in the CGC 
(including 31 proxy SNPs with an r
2
>0.8; Table 3-2).  For the HLA-DRB1 locus, 
rs660895 from the Eyre et al meta-analysis (Eyre et al, 2012) was used, as the most 
strongly associated SNP identified by Okada et al (rs9268839) was unavailable in the 
CGC. Nine SNPs had missing data. These comprised rs11702844, rs11933540, 
rs1893592, rs2306627, rs2834512, rs45475795, rs9979383 (all missing 1 genotype), 
rs12108065 (4 genotypes missing) and rs9427372 (21 genotypes missing).  These 
missing genotypes were imputed by assigning them the expected allele count, which 
is twice the allele frequency, for each SNP. This procedure is commonly used to 
account for missing genotype data (Karlson et al, 2010, Yarwood et al, 2013).  
 
Seventeen four-digit HLA-DRB1 alleles attaining PGWAS<5x10
-8
 in European ancestry 
individuals from the most recent RA meta-analysis of association in the HLA region 
(Raychaudhuri et al, 2012) were evaluated.  Amino acids at positions 11, 13, 71 and 
74 in HLA-DRβ1, position 9 in HLA-B and position 9 in HLA-DPβ1 were also 
assessed. In the HLA meta-analysis these explained most of the region’s association 
with RA (Raychaudhuri et al, 2012). Positions 11 and 13 in HLA-DRβ1 were both 
included as their strong linkage disequilibrium (LD) meant causality could not be 
assigned (Raychaudhuri et al, 2012).   
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Table 3-2.Proxy SNPs Used in Analysis 












chr1:2523811 1 2523811 G/A  rs10752747 2524915 G/T 0.875 
chr17:38031857 17 38031857 G/T  rs10852935 38031674 T/C 0.979 
rs10790268 11 118729391 G/A  rs10892299 120000000 C/T 0.915 
rs71508903 10 63779871 T/C  rs11593907 63786554 C/T 0.865 
rs73194058 21 34764288 C/A  rs11702844 34759876 A/G 0.970 
rs4452313 3 17047032 T/A  rs12108065 17074871 G/A 0.925 
rs2105325 1 173349725 C/A  rs1557121 173353881 C/T 0.986 
rs6715284 2 202154397 G/C  rs16837131 202173812 A/C 0.972 
rs2736337 8 11341880 C/T  rs2061831 11339882 C/T 0.993 
rs5987194 X 153301467 C/G  rs2075596 153297392 A/G 0.989 
rs331463 11 36501787 T/A  rs2303439 36514290 C/T 0.944 
rs28411352 1 38278579 T/C  rs2306627 38260503 T/C 0.844 
chr21:35928240 21 35928240 C/T  rs2834512 35911599 G/A 0.979 
rs8083786 18 12881361 G/A  rs34846641 12875975 G/A 1.000 
chr7:128580042 7 128580042 G/A  rs3778754 128575552 G/C 0.948 
rs3824660 10 8104722 C/T  rs3802604 8102272 G/A 0.926 
rs508970 11 60906450 A/G  rs595158 60909581 A/C 0.929 
rs10774624 12 111833788 G/A  rs653178 112007756 T/C 0.861 
rs1516971 8 129542100 T/C  rs6651252 129567181 T/C 0.985 
rs1633360 12 58108052 T/C  rs701006 58106836 G/A 0.979 
rs773125 12 56394954 A/G  rs705700 56389293 T/C 0.967 
rs706778 10 6098949 T/C  rs7073236 6106552 C/T 0.910 
rs10175798 2 30449594 A/G  rs7579944 30445026 C/T 0.940 
rs9603616 13 40368069 C/T  rs7993214 40350912 C/T 0.936 
rs2234067 6 36355654 C/A  rs879036 36349890 C/T 0.964 
rs12140275 1 38633879 A/T  rs883220 38616871 C/A 0.962 
rs1950897 14 68760141 T/C  rs911263 68753593 T/C 0.994 
rs9372120 6 106667535 G/T  rs9386514 106636902 C/T 0.992 
rs72717009 1 161405053 T/C  rs9427372 161399920 C/T 0.966 
rs9826828 3 136402060 A/G  rs9858105 136219264 C/T 1.000 
rs8133843 21 36738242 A/G  rs9979383 36715761 T/C 0.894 
Proxy SNPs obtained using 1,000 Genomes European population panels 
(CEU/TSI/GBR/FIN/IBS); BP position = base pair position based on GRCh37 






3.2.9. Individual Variant Associations with X-ray Progression  
3.2.9.1.Linear Mixed-Effects Model Using Repeated Measures 
The association between Larsen score progression and each susceptibility variant 
(SNP, HLA-DRB1 allele and HLA amino acid) was examined using a linear mixed-
effects model. This assessed all repeated Larsen scores simultaneously and, through 
incorporating correlated random-effects, accounted for within-individual correlations 
in Larsen scores over time. This widely used approach for modelling repeated 
measurements is preferable to evaluating genetic associations with the 24-month 
change in Larsen scores as a single variable; by using repeated scores it provides a 
more definitive evaluation of within-individual changes over time and optimises the 
power to detect significant predictor variables (Guo, et al., 2013). Furthermore, this 
model could accommodate missing Larsen score data, by making the assumption that 
the reason they were missing was unrelated to the actual missing data values, termed 
“missing-at-random” (MAR)  (Higgins and Green, 2011). This assumption was 
reasonable with most missing data occurring in CARDERA-2 patients at 6 and 18 
months as it was not study protocol for X-rays to be performed at these time points. 
 
As Larsen scores had a positively-skewed distribution they were log-transformed 
with a constant added (due to zero unit scores) in order to approximate a normal 
distribution (Figure 3-2). Loge (Larsen score + 1) was used as the response variable. 
Time (years), clinical variables, genotype and a genotype*time interaction term, were 
included as fixed-effects predictor variables. The clinical variables comprised 
treatment (categorically coded in 5 levels with methotrexate monotherapy as the 
reference group), age, disease duration and RF status. These were chosen using 
stepwise backwards elimination in a model containing only clinical factors as 
predictor variables; clinical factors resulting in a model with a significantly lower 
Akaike Information Criterion (AIC) were included. RF status was used instead of 
ACPA status as ACPA data were missing in 25 patients. These two variables had 
modest correlation (57% of patients were ACPA-positive/RF-positive; 13% were 
ACPA-positive/RF-negative; 11% were ACPA-negative/RF-positive; 19% were 
ACPA-negative/RF-negative; phi coefficient=0.43). Any significant findings were 
reanalysed using a model containing ACPA in place of RF and omitting the 25 
individuals with unknown ACPA status. Significant genetic markers were also 
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evaluated in ACPA-positive and ACPA-negative patients separately, and the 
resultant β-values compared to those obtained in all RA patients. This established if 
their effects were independent of ACPA. β-values, as opposed to P-values, were 
considered in the ACPA subgroup analysis as the power was substantially lower due 
to the smaller sample size of each group (350 and 149 patients were ACPA-positive 
and ACPA-negative, respectively) and low X-ray progression rates in ACPA-
negative patients (24-month mean Larsen score changes 3.22 (95% CI 1.96-4.48) in 
ACPA-negative RA vs. 5.88 (95% CI 4.94-6.81) in ACPA-positive RA). 
 
Examination of residuals from a model containing time and clinical variables only 
confirmed a good fit of the model. Residual plots demonstrated a random distribution 
of points around the zero line; residuals were normally distributed (Figure 3-3). 
Using log-transformed Larsen scores therefore fulfilled the assumptions of the 
model. Genotype was coded additively.  All β-estimates were back-transformed to 
the original Larsen scale.  The genotype*time term β provided information on the 
annual increase in Larsen score per risk allele copy relative to the reference 
genotype; P-values for this term provided information on the variant’s role in 
radiological progression. The X-chromosome SNP (rs5987194) was assessed 
separately in males and females. 
 
3.2.9.2.Three-Way ANOVA Model Evaluating Change in Larsen Scores 
To ensure that the linear mixed-effects model results were not biased by missing 
Larsen scores (missing at 0, 6, 12, 18 and 24 months in 4, 103, 13, 103 and 19 
patients, respectively) an alternative modelling approach was also undertaken. This 
involved a 3-way ANOVA model including the 24-month change in Larsen scores 
(∆Larsen) as the response variable and treatment, RF-status and genotype (coded 
additively) as predictor variables. As with the linear mixed-effects model relevant 
clinical variables were chosen through stepwise backwards elimination. As ∆Larsen 
remained non-normally distributed despite log-transformation, a rank-based inverse 
normal transformation (INT) of this variable was undertaken using the Blom method 
(Beasley, et al., 2009) (Figure 3-4). Residual plots confirmed the assumptions of the 
model were fulfilled (Figure 3-5). The 19 individuals without 24-month X-ray data 
were excluded from this analysis. 
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Figure 3-2. Log-Transformation of Baseline Larsen Scores 
 
 
QQ = quantile-quantile; dotted lines in QQ plots represent 95% confidence intervals; similar findings seen for Larsen score transformations at 
other time points.  
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A = Plot of the residuals (difference between observed and predicted loge(Larsen + 1)) against the predicted loge(Larsen + 1); dotted line 
represents the zero point on the y-axis (the smoothing line approximately overlies the dotted line). 
B = Histogram of residuals.  
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Figure 3-4. Rank-Based Inverse Normal Transformation of the 24-Month Change in Larsen Scores 
 
 
Delta Larsen Score = 24-month change in Larsen score; INT = inverse normal transformation; QQ = quantile-quantile; dotted lines in QQ plots 
represent 95% confidence intervals.  
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Figure 3-5. Analysis of Residuals from an ANOVA Model Including Clinical Variables Only 
 
 
A = Plot of the residuals (difference between observed and predicted inverse rank normalised Larsen score) against the predicted score; dotted 
line represents the zero point on the y-axis (the smoothing line approximately overlies the dotted line); INT= inverse normal transformation. 
B = Histogram of residuals. 
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3.2.10. Weighted Genetic Risk Score Association with X-Ray Progression 
The association between a wGRS, derived from all susceptibility loci, and Larsen 
score progression was tested. Two different wGRSs were evaluated. The first (full 
wGRS) included all SNPs (excluding the X-chromosome marker); the second (non-
HLA wGRS) also excluded the *04:01 tagging SNP. 
 
Both wGRSs were constructed using the R package, REGENT (Risk Estimation for 
Genetic and Environmental Traits) (Scott et al, 2013b, Crouch, et al., 2013). This 
uses data on allelic ORs from reference meta-analyses to generate a genotype relative 
risk score (GRR) across loci within a multiplicative model. In this analysis, the Loge 
(GRR) represented the wGRS. Log-transforming the GRR (which is equivalent to an 
individual’s overall OR for RA) ensured the wGRS distribution was symmetrical 
around 1.00; a non-transformed GRR is limited for scores <1.00, as it cannot have a 
negative value, resulting in a skewed distribution (Bland and Altman, 2000).  
 
The wGRS replaced the genotype term in the linear mixed-effects and ANOVA 
models. Data for the genetic loci were obtained from the combined stage of the 
reference meta-analysis (Okada et al, 2013).  
 
3.2.11. Principal Components Analysis 
To account for population stratification, PCA was undertaken using EIGENSOFT 
(performed by Professor Cathryn Lewis). Analysis of the first 10 principal 
components (PCs) did not demonstrate any identifiable structure in the CGC. This 
was confirmed by running a preliminary GWAS evaluating all 138,873 genetic 
markers as predictors of the rank-based INT ∆Larsen in a simple regression model 
including genotype (coded additively) alongside the first 3 PCs as predictor 
variables. The genomic inflation factors (λ) generated by an analysis adding in each 
of the first 3 PCs, one at a time all remained <1.05 (Table 3-3), indicating minimal 
population structure and cryptic relatedness in the CGC. PCs were therefore not 





Table 3-3. Genomic Inflation Factors Generated By a Regression Model 
Including Varying Numbers of First 3 Principal Components 
PC(s) Used λ 
None 1.028 
First PC 1.029 
First and second PCs 1.030 
First, second and third PCs 1.037 
PC = principal component; λ = genomic inflation factor. 
 
3.2.12. Significance Thresholds 
For individual SNP, HLA-DRB1 alleles and amino acid association tests, Bonferroni 
corrected P-value thresholds of 0.0007 (69 markers), 0.0029 (17 markers) and 0.0019 
(27 markers), respectively were considered significant. For all other tests P-values 
<0.05 were considered significant. 
 
3.2.13. Power Calculations 
Power calculations were performed using the Genetic Power Calculator (Purcell, et 
al., 2003). Five hundred and twenty four patients provided 82.1% power to detect a 
genetic variant accounting for just 2% of the variance in radiological progression at a 
Bonferroni corrected P-value of 0.0007 (corrected for testing 69 SNPs). The study 
was, therefore, adequately powered to detect variants of a relatively small effect size. 
 
3.2.14. Statistical Programs 
Analyses were performed in R version 3.0.2 (R Foundation for Statistical 
Computing, Vienna, Austria), PLINK version 1.07 (Purcell, et al., 2007) and 







524 patients were studied (Table 3-4); most were female (69%) and seropositive 
(67% RF-positive). Their mean age was 54.7 years. Disease duration was short 
(median 1.0 month) and disease activity high (mean DAS28 5.88) at study baseline, 
reflecting the inclusion criteria of the RCTs. 
 
Table 3-4. CARDERA Genetics Cohort Patient Baseline Data 
Characteristic Summary Statistic 
Demographic Number (%) Female 359 (69%) 
Mean Age in Years (95% CI) 54.7 (53.6-55.8) 







Median Larsen Score (IQR)
 
6.50 (2.00-16.50) 
Mean DAS28 (95% CI) 5.88 (5.77-5.99) 
Mean HAQ (95% CI) 1.56 (1.50-1.62) 
Treatment Number (%) Receiving MTX 161 (31%) 
Number (%) Receiving MTX and CIC 108 (21%) 
Number (%) Receiving MTX and Pred 102 (19%) 
Number (%) Receiving Triple Therapy 107 (20%) 
Number (%) Receiving MTX and Anakinra 46 (9%) 
A = ACPA-status missing in 25 patients; CI = confidence interval; IQR = 
interquartile range; MTX = methotrexate; CIC = ciclosporin; Pred = prednisolone; 
triple therapy = methotrexate, ciclosporin and prednisolone. 
 
3.3.2. Relationship between Clinical Variables and Larsen Scores 
In a linear mixed-effects model incorporating clinical variables only time, age, 
disease duration and RF significantly associated with Larsen scores; treatment 





Table 3-5. Clinical Factors Associated With Larsen Scores in the CGC 
 
Variable  β (95% CI) P-Value 
Time  1.20 (1.17-1.24) 4.987x10
-36
 
Treatment MTX Reference - 
 
MTX/CIC 1.22 (0.95-1.56) 0.115 
 
MTX/Pred 0.95 (0.74-1.23) 0.708 
 
Triple Therapy 0.85 (0.67-1.09) 0.200 
 Anakinra 1.40 (1.01-1.95) 0.045 
Age  1.04 (1.03-1.05) 5.224x10
-25
 
Disease Duration  1.04 (1.02-1.06) 4.230x10
-05
 
RF  1.35 (1.12-1.62) 0.0016 
Effect sizes and P-values from a linear mixed-effects model including time and 
clinical factors only as fixed-effects predictor variables; CI = confidence interval; 
MTX = methotrexate; CIC = ciclosporin; Pred = prednisolone; triple therapy = 
methotrexate, ciclosporin and prednisolone. 
 
3.3.3. Radiological Progression Rates  
3.3.3.1.In the CGC 
Over 2 years, of the 505 patients in the CGC with 24-month X-ray data, 349 (69%) 
had an increase in their Larsen scores (Figure 3-6). In 277 patients (55%) this 
increase was above the MCID, defined in early active RA as an increase of ≥2.0 units 
(Bruynesteyn, et al., 2002). 
 
3.3.3.2.Compared with Observational Studies 
Studies rarely report overall X-ray progression rates. Only one observational study 
has reported the proportion of early RA patients with radiological progression over 
2-years (Sanmarti, et al., 2007); 32% of 105 early RA patients receiving sequential 
DMARD monotherapy and low dose corticosteroids had X-ray progression defined 
as an increase in Larsen scores of ≥4 units (Sanmarti et al, 2007). Using this 
definition in the CGC, 199 patients (39%) had progressed; radiological progression 
rates were, therefore, in line with non-clinical trial cohorts. These findings support 
the use of the CGC to identify genetic predictors of radiological progression. 
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Figure 3-6. Histogram of 24-Month Changes in Larsen Scores in the CARDERA Genetics Cohort 
 




3.3.4. Allele/Amino Acid Frequencies 
Risk variant frequencies in the CGC and reference meta-analyses were similar 
(Tables 3-6 to 3-8). Exceptions occurred at the HLA-DRB1 SNP, rs660895 (meta-
analysis frequency 0.46/CGC 0.37), *04:01 (0.31 meta-analysis/0.22 CGC) and 
HLA-DRβ1 amino acids, histidine at position 13 (His13; 0.45 meta-analysis/0.35 
CGC) and valine at position 11 (Val 11; 0.47 meta-analysis/0.36 CGC). These arose 
because the meta-analysis evaluated ACPA-positive RA (Raychaudhuri et al, 2012); 
they reduced when only ACPA-positive CGC patients were assessed (frequencies for 
rs660895, *04:01, His13 and Val11 comprised 0.42, 0.26, 0.40 and 0.41, 
respectively). 
 
3.3.5. SNP Testing 
Only one SNP, rs660895 (P=0.0003), had a P-value for the genotype*time 
interaction term that passed the pre-defined significance threshold when tested using 
the linear mixed-effects model (Table 3-6). This SNP tags HLA-DRB1*04:01; its β-
value of 1.074 (95% CI 1.033-1.117) indicated a 1.07-fold greater annual increase in 
modified Larsen scores for each copy of the risk (G) allele carried, relative to the 
reference (A) allele. Findings were similar in a model including ACPA as a covariate 
in place of RF; only rs660895 (P=0.0003) passed multiple testing correction 
thresholds. Restricting analyses to ACPA-positive patients (removing serology as a 
covariate) provided a similar β-value for this SNP (β=1.074; 95% CI 1.023-1.126). 
Although a lower β-value was observed in ACPA-negative patients (β=1.028; 95% 
CI 0.955-1.106) its upper 95% CI overlapped with the lower 95% CI obtained in the 
analysis of all RA patients. These findings suggested that the impact of rs660895 on 
radiological progression was probably independent of ACPA. Figure 3-7 shows the 
effect of the rs660895 G allele on radiological progression. Results for all 69 tested 
SNPs ordered by significance are given in Table 3-6. 
 
When using the ANOVA model to test the association between the 69 susceptibility 
SNPs and the ∆Larsen score the two most strongly associated SNPs − rs660895 (F-
statistic 13.70; P=0.0002) and rs10175798 (F-statistic 6.08; P=0.0140) − were the 
same as those identified by the linear mixed-effects model. Only rs660895 was 




Table 3-6. Association between 69 RA Susceptibility SNPs and Radiological 
Progression in the CGC Using a Linear Mixed-Effects Model 







rs660895 HLA-DRB1 6 G/A 0.46
A
 0.37 1.074 0.0003 
rs10175798 LBH 2 A/G 0.62 0.66 1.057 0.0074 
rs4452313 PLCL2 3 T/A 0.30 0.28 1.053 0.0194 
chr17:38031857 IKZF3-CSF3 17 G/T 0.48 0.50 0.958 0.0253 
rs10774624 SH2B3-PTPN11 12 G/A 0.48 0.49 1.044 0.0338 
rs3824660 GATA3 10 C/T 0.41 0.36 1.039 0.0615 
rs71508903 ARID5B 10 T/C 0.24 0.20 0.959 0.0836 
rs7752903 TNFAIP3 6 G/T 0.02 0.04 0.919 0.0950 
rs624988 CD2 1 T/C 0.40 0.40 0.967 0.0971 
rs678347 GRHL2 8 G/A 0.23 0.28 0.963 0.0981 
rs5987194
B 
IRAK1 X C/G 0.15 0.15 1.048 0.1309 
rs998731 TPD52 8 T/C 0.49 0.48 0.972 0.1324 
rs11889341 STAT4 2 T/C 0.23 0.25 1.036 0.1398 
rs4239702 CD40 20 C/T 0.72 0.74 1.031 0.1576 
rs968567 
FADS1-FADS2-
FADS3 11 C/T 0.83 0.84 1.037 0.1657 
rs8083786 PTPN2 18 G/A 0.15 0.17 0.965 0.1682 
rs2561477 C5orf30 5 G/A 0.68 0.69 1.028 0.1849 
rs73081554 
DNASE1L3-
ABHD6-PXK 3 T/C 0.06 0.09 0.957 0.1937 
rs17264332 TNFAIP3 6 G/A 0.17 0.26 0.974 0.2239 
rs73194058 IFNGR2 21 C/A 0.85 0.87 1.036 0.2244 
rs5987194
C 
IRAK1 X C/G 0.15 0.15 0.956 0.2284 
rs9372120 ATG5 6 G/T 0.19 0.21 0.973 0.2381 
rs1858037 SPRED2 2 T/A 0.68 0.68 0.980 0.3253 
chr1:2523811 
TNFRSF14-
MMEL1 1 G/A 0.71 0.67 1.020 0.3354 
rs508970 CD5 11 A/G 0.45 0.46 1.017 0.4006 
rs1893592 UBASH3A 21 A/C 0.72 0.73 0.983 0.4171 
rs3087243 CTLA4 2 G/A 0.55 0.55 1.015 0.4240 
rs45475795 IL2-IL21 4 A/G 0.08 0.08 0.975 0.4468 
rs8026898 LOC145837 15 A/G 0.29 0.30 1.017 0.4492 
rs1571878 CCR6 6 C/T 0.42 0.47 0.986 0.4688 
rs10985070 TRAF1-C5 9 C/A 0.43 0.41 1.012 0.5212 
rs72717009 FCGR2A 1 T/C 0.13 0.09 0.980 0.5638 
rs2234067 ETV7 6 C/A 0.88 0.88 0.983 0.5810 
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rs34695944 REL 2 C/T 0.35 0.39 1.010 0.6105 
rs9603616 COG6 13 C/T 0.67 0.69 1.011 0.6180 
rs11574914 CCL19-CCL21 9 A/G 0.32 0.37 1.010 0.6298 
rs2301888 PADI4 1 G/A 0.65 0.66 0.991 0.6404 
rs12140275 LOC339442 1 A/T 0.78 0.76 0.990 0.6522 
rs28411352 MTF1-INPP5B 1 T/C 0.26 0.30 1.009 0.6522 
rs2451258 TAGAP 6 T/C 0.64 0.62 0.991 0.6575 
rs2228145 IL6R 1 A/C 0.64 0.60 0.991 0.6624 
rs13330176 IRF8 16 A/T 0.24 0.27 1.009 0.6717 
rs909685 SYNGR1 22 A/T 0.31 0.32 1.008 0.6926 
rs3218251 IL2RB 22 A/T 0.27 0.28 0.991 0.6931 
rs17668708 PTPRC 1 C/T 0.89 0.90 1.012 0.7098 
rs331463 TRAF6-RAG1/2 11 T/A 0.87 0.87 1.011 0.7108 
rs1633360 CDK4 12 T/C 0.59 0.60 0.993 0.7338 
rs947474 PRKCQ 10 A/G 0.82 0.83 0.992 0.7412 
chr21:35928240 RCAN1 21 C/T 0.86 0.89 1.010 0.7490 
rs8133843 
RUNX1-
LOC100506403 21 A/G 0.63 0.65 1.006 0.7559 
rs10790268 CXCR5 11 G/A 0.81 0.83 0.993 0.7656 
rs67250450 JAZF1 7 T/C 0.79 0.81 0.993 0.7791 
rs773125 CDK2 12 A/G 0.62 0.62 1.005 0.7871 
rs1950897 RAD51B 14 T/C 0.67 0.73 0.994 0.7890 
rs3806624 EOMES 3 G/A 0.47 0.44 0.995 0.7896 
rs9826828 IL20RB 3 A/G 0.02 0.01 1.021 0.8146 
rs9653442 AFF3 2 C/T 0.46 0.51 1.004 0.8189 
rs706778 IL2RA 10 T/C 0.42 0.43 0.996 0.8353 
rs6715284 CFLAR-CASP8 2 G/C 0.11 0.11 1.005 0.8745 
rs8032939 RASGRP1 15 C/T 0.25 0.26 1.003 0.8830 
rs11933540 C4orf52 4 C/T 0.31 0.34 0.997 0.8874 
rs4409785 CEP57 11 C/T 0.19 0.19 0.997 0.8912 
rs2736337 BLK 8 C/T 0.25 0.25 0.997 0.8940 
rs4272 CDK6 7 G/A 0.23 0.23 1.003 0.8946 
rs1980422 CD28 2 C/T 0.26 0.22 1.002 0.9251 
rs2476601 PTPN22 1 A/G 0.09 0.15 1.002 0.9284 
rs2105325 LOC100506023 1 C/A 0.76 0.76 0.999 0.9664 
chr7:128580042 IRF5 7 G/A 0.46 0.51 1.001 0.9688 
rs34536443 TYK2 19 G/C 0.97 0.97 1.002 0.9716 
rs1516971 PVT1 8 T/C 0.90 0.88 1.001 0.9723 
Alleles ordered by significance (most significant listed first); A = A1 frequency data 
from Raychaudhuri et al meta-analysis (data unavailable in Eyre et al meta-
analysis); B = result in females; C = result in males; Chr = chromosome; unless 
otherwise stated reference meta-analysis is by Okada et al (Okada et al, 2013).
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Figure 3-7. Mean Larsen Scores Stratified By rs660895 (*04:01) Genotype 
 
Mean Larsen scores with standard error bars shown for each time point. 
 
3.3.6. HLA-DRB1 Allele Testing 
Only the HLA-DRB1*04:01 (P=0.0006) allele had a P-value for the genotype*time 
interaction term that passed the pre-defined significance threshold when tested using 
the linear mixed-effects model (Table 3-7). Its β-value of 1.087 (95% CI 1.037-
1.139) indicated a 1.09-fold greater annual increase in modified Larsen scores for 
each copy of the *04:01 allele carried, relative to a non-carrier. Findings were similar 
in a model including ACPA as a covariate in place of RF, with only *04:01 having a 
significant association (P=0.0020). Restricting analyses to ACPA-positive patients 
revealed a similar β-value (β=1.068; 95% CI 1.010-1.130). On restricting the 
analysis to ACPA-negative patients (β=1.033; 95% CI 0.931-1.147) the β-value 
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upper 95% CI overlapped with the lower 95% CI obtained in the analysis of all 
cases. These findings suggested its effect was independent of ACPA. Results for all 
17 tested HLA-DRB1 alleles ordered by significance are given in Table 3-7. 
 
When using the ANOVA model to test the association between HLA-DRB1 
susceptibility alleles and the ∆Larsen score, only *04:01 had a significant association 
(F-statistic 10.08; P=0.0016). 
 
Table 3-7. Association between RA HLA-DRB1 Susceptibility Alleles and 









*04:01 0.309 0.219 1.087 0.0006 
*04:08 0.017 0.011 1.238 0.0180 
*15:01 0.089 0.103 0.948 0.1031 
*13:02 0.012 0.021 0.893 0.1078 
*03:01 0.082 0.111 0.950 0.1086 
*13:01 0.021 0.017 0.905 0.1672 
*11:03 0.002 0.010 1.110 0.2890 
*07:01 0.064 0.085 0.967 0.3335 
*10:01 0.020 0.013 0.922 0.3373 
*01:01 0.133 0.136 1.019 0.5078 
*14:01 0.011 0.015 1.049 0.5569 
*11:01 0.028 0.032 0.978 0.6873 
*04:04 0.091 0.092 1.014 0.6906 
*14:04 0.001 0.001 1.083 0.7958 
*04:05 0.012 0.011 0.981 0.8382 
*11:04 0.008 0.018 0.989 0.8768 
*08:01 0.009 0.017 1.009 0.9063 
Alleles ordered by significance (most significant listed first); reference meta-analysis 
by Raychaudhuri et al (Raychaudhuri et al, 2012). 
 
3.3.7. HLA Protein Amino Acid Testing  
Two amino acid polymorphisms had P-values for the genotype*time interaction term 
that passed the pre-defined significance threshold when tested using the linear 
mixed-effects model (Table 3-8). These comprised His13 (β=1.073; 95% CI 1.031-
1.116; P=0.0005) and Val11 (β=1.067; 95% CI 1.026-1.110; P=0.0013) in HLA-
136 
 
DRβ1. Repeating the analysis using ACPA as a covariate in place of RF revealed 
similar results (His13 P=0.0006; Val11 P=0.0013). Restricting analyses to ACPA-
positive patients revealed similar findings (His 13 β=1.071 (95% CI 1.020-1.125); 
Val11 β=1.065 (95% CI 1.014-1.119)). Restricting analyses to ACPA-negative 
patients, revealed β-value upper 95% CIs that overlapped with the lower 95% CIs 
obtained in the analysis of all cases (His 13 β=1.022 (95% CI 0.950-1.100); Val11 
β=1.019 (95% CI 0.946-1.096)). When using the ANOVA model to test the 
association between HLA susceptibility proteins and the ∆Larsen score, His13 (F-
statistic 14.08; P=0.0002) and Val11 (F-statistic 14.42; P=0.0002) in HLA-DRβ1 
remained the most significant markers. 
 
As His13 and Val11 are in tight LD with each other (r
2
=0.943) a conditional analysis 
was undertaken. Conditioning on His13 eliminated the effect of Val 11 (linear 
mixed-effects model P=0.5279; ANOVA model P=0.5264). Conditioning on Val11 
eliminated the effect of His13 (linear mixed-effects model P=0.1498; ANOVA 
model P=0.7946). This indicates the significance at both these positions is driven by 
their high LD. 
 
None of the tested polymorphisms in the SE region (positions 71 and 74) had P-
values <0.05. However, the SE itself (sequences QRRAA, RRRAA and QKRAA in 
positions 70-74 (Gregersen et al, 1987)) significantly associated with radiological 
progression when the classical SE alleles (*01:01, *01:02, *04:01, *04:04, *04:05, 
*04:08, *10:01) were grouped together (linear mixed-effects model P=0.0001; 
ANOVA model P=0.0001). The β-value of 1.080 (95% CI 1.038-1.123) indicated a 
1.08-fold greater annual increase in modified Larsen scores for each copy of the SE 
carried, relative to a non-carrier. Other rarer SE alleles were not available for 
analysis in the imputed dataset. 
 
Although His13 and Val11 are not in LD with the individual SE positions tested, 
there is a marked correlation between their presence and carrying a SE sequence. 
His13 and Val11 are both encoded by the classical HLA-DRB1 SE alleles *04:01, 
*04:04, *04:05, *04:08 and *10:01; they are also encoded by the classical HLA-
DRB1 non-SE alleles *04:02, *04:03 and *04:07, but these are rare with an allele 
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frequency <0.01 in ACPA-positive RA (Raychaudhuri et al, 2012). A conditional 
analysis incorporating the SE as a modelling covariate was therefore undertaken. 
Conditioning on the SE eliminated the effect of His13 (linear mixed-effects model 
P=0.2412; ANOVA P=0.1409) and Val11 (linear mixed-effects model P=0.4453; 
ANOVA P=0.1371) on Larsen score progression. This indicated their association 
was probably driven by their correlation with the SE. 
 
Table 3-8. Relationship between HLA Amino Acid Polymorphisms and 
Radiological Progression in the CGC Using a Linear Mixed-Effects Model 
HLA Amino Acid 






DRβ1; position 13; Histidine 0.449 0.345 1.073 0.0005 
DRβ1; position 11; Valine 0.470 0.359 1.067 0.0013 
DRβ1; position 13; Serine 0.176 0.238 0.956 0.0499 
DRβ1; position 71; Lysine 0.397 0.339 1.042 0.0573 
DRβ1; position 71; Alanine 0.092 0.109 0.943 0.0689 
DRβ1; position 74; Alanine 0.801 0.744 1.040 0.0809 
DRβ1; position 71; Glutamic Acid 0.052 0.065 0.935 0.0855 
DRβ1; position  11; Serine 0.205 0.274 0.965 0.0926 
DRβ1; position 74; Arginine 0.082 0.111 0.950 0.1086 
DRβ1; position 11; Proline 0.104 0.120 0.952 0.1152 
DRβ1; position 13; Arginine 0.104 0.120 0.952 0.1152 
DRβ1; position 11; Aspartic Acid 0.013 0.014 0.896 0.2024 
DPβ1; position 9; Histidine 0.035 0.043 0.954 0.3203 
DRβ1; position 11; Glycine 0.064 0.085 0.967 0.3335 
DRβ1; position 13; Tyrosine 0.064 0.085 0.967 0.3335 
DRβ1; position 74; Glutamine 0.064 0.085 0.967 0.3335 
DPβ1; position 9; Phenylalanine 0.799 0.733 1.014 0.5204 
DRβ1; position 74; Leucine 0.013 0.021 1.037 0.5872 
DRβ1; position 11; Leucine 0.145 0.148 1.011 0.6949 
B; position 9; Tyrosine 0.643 0.655 1.008 0.7095 
DRβ1; position 74; Glutamic Acid 0.039 0.039 0.982 0.7182 
DRβ1; position 13; Glycine 0.028 0.036 1.018 0.7257 
B; position 9; Histidine 0.227 0.218 0.993 0.7602 
DRβ1; position 13; Phenylalanine 0.178 0.176 0.992 0.7612 
DRβ1; position 71; Arginine 0.458 0.488 1.005 0.8139 
DPβ1; position 9; Tyrosine 0.165 0.224 0.995 0.8445 
B; position 9; Aspartic Acid 0.130 0.128 0.996 0.8949 
Amino acids ordered by significance (most significant listed first); reference meta-
analysis by Raychaudhuri et al (Raychaudhuri et al, 2012). 
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3.3.8. Relationship between wGRS and Radiological Progression 
A significant association was observed between a full wGRS and radiological 
progression when assessed using the linear mixed-effects (P=0.0177; β=1.038; 95% 
CI =1.007-1.071) and ANOVA (F-statistic=6.315; P-value=0.0123) models. No 
association was observed between a non-HLA wGRS score and radiological 
progression when assessed using the linear mixed-effects (P=0.9381; β=1.002; 95% 
CI=0.961-1.044) and ANOVA (F-statistic=0.035; P-value=0.8509) models.  
 
3.4. DISCUSSION 
This study has confirmed the influence of HLA susceptibility variants on radiological 
progression in RA, by demonstrating a significant association between the main 
HLA risk variants (the HLA-DRB1*04:01 allele and amino acid polymorphisms 
valine at position 11 and histidine at position 13 in the HLA-DRβ1 molecule) and 
Larsen score progression in early, active RA patients. This effect appears to be 
independent of ACPA status, with similar effect sizes observed on restricting the 
analysis to ACPA-positive individuals.  
 
This study has also demonstrated that no significant association exists between non-
HLA susceptibility loci and radiological progression in early, active RA patients, 
when evaluating these variants both individually and cumulatively, using a wGRS. 
Although the sample size of 524 patients is substantially smaller than the combined 
GWASs evaluated to identify these susceptibility loci (Okada et al, 2013), the CGC 
was adequately powered (at >80%) to detect genetic markers accounting for just 2% 
of the variance in X-ray progression. Furthermore, this study was able to identify 
known predictors of joint destruction including RF, ACPA and the SE (Van Der 
Woude, et al., 2010b, Gorman et al, 2004). This indicates that non-HLA 
susceptibility loci do not have a clinically relevant association with radiological 
progression in early, active RA patients. It also suggests that the non-HLA genetic 
architectures of RA susceptibility and severity probably, at least in part, differ.  
 
The impact of HLA-DRB1*04:01 on radiological damage is well described. Gorman 
et al reported a significant relationship between *04:01 and erosions in a meta-
analysis of 466 RA patients: OR for erosions with 1 allele copy 3.1 (95% CI 2.0–5.0) 
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(Gorman et al, 2004). Mewar et al reported a significant association (P=0.0059) 
between S2 allele (*04:01 and *13:03) carriage and higher Larsen scores in 962 RA 
patients (Mewar et al, 2008). In contrast the impact of HLA-DRβ1 molecule 
polymorphisms on X-ray damage has not previously been evaluated. In this study the 
most significant polymorphisms (Val11 and His13) for RA development 
(Raychaudhuri et al, 2012) were also the only ones to influence radiological 
progression. Both are located in peptide-binding grooves; they could therefore 
mediate articular damage through influencing arthritogenic peptide presentation 
within the joint. Conditional analyses indicated the association at both positions was 
driven by the tight LD between them, although it was not possible to establish which 
had the dominant association. Furthermore, conditional analyses also suggested their 
association was driven by a high correlation with the SE at positions 70-74. Due to 
the broad LD across the MHC region (De Bakker, et al., 2006) alongside the modest 
size of the CGC it was not possible to characterise which HLA amino acid positions 
had a SE-independent association with joint destruction.  Further work is required to 
assess this on an HLA-wide scale across multiple large cohorts, in a similar manner 
as undertaken for RA susceptibility (Raychaudhuri et al, 2012) . 
 
Several studies have reported significant associations between susceptibility loci and 
radiological damage in RA. Recent examples include TRAF1 (Viatte, et al., 2013), 
IL2RA (Knevel et al, 2013a) and C5orf30 (Teare et al, 2013); none of these 
associated with radiological progression in the CGC (P-values for the linear mixed-
effects model were 0.5212, 0.8353 and 0.1849, respectively). As the published 
reports used two SNPs that were not in LD with those tested in this study, the precise 
SNPs were tested separately (Table 3-9); this confirmed no association. The two 
most likely explanations for this non-replication are firstly, that the CGC population 
− which comprises patients with early, severely active disease − is inherently 
different to the populations evaluated in these observational studies, which assessed 
patients with a range of disease durations and severities and secondly, the CGC 
looked at predictors of X-ray progression in the first 2 years of disease and other 
studies evaluated damage over longer time periods. Other possible explanations are 
that previous studies were not able to fully adjust for the effects of treatment, which 
may be an important confounding variable; some studies assessed genotype effects 
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on the severity of X-ray damage, as opposed to its impact on progression over time; 
and the use of different radiological scoring systems across studies. The lack of 
replication in the CGC indicates that published predictors of radiological damage are 
not generalisable across all RA patient populations. 
 
Table 3-9. Testing Susceptibility SNPs Previously Associated With Radiological 











rs26232 C5orf30 5 A/G 0.28 0.31 0.975 0.2550 
rs2900180 TRAF1/C5 9 A/G 0.33 0.33 1.003 0.8914 
rs2104286 IL2RA 10 G/A 0.14 0.27 1.003 0.8926 
Chr = chromosome; P-values from linear mixed-effects model (including RF as a 
covariate), *1,000 Genomes EUR population panel. 
 
This study has several strengths. As the CGC represents a clinical trial cohort, all 
patient assessments were performed in a timely, highly standardised manner. The 
inclusion of individuals with severely active disease meant any findings were directly 
relevant to patient populations upon which current NICE guidelines for RA 
management have been based; it also ensured that the effect of baseline disease 
activity as a confounding factor was accounted for. The regularity of Larsen scoring 
optimised the power to detect longitudinal associations. Additionally, the 
randomisation to treatment groups ensured that treatment effects could be fully 
adjusted for. Finally, it was able to identify known predictors of X-ray damage, 
spanning clinical (disease duration), serological (RF and ACPA) and genetic (HLA 
variants) factors; this indicates the study was adequately powered to detect clinically 
relevant predictors of Larsen scores. 
 
This study also has a number of important limitations. Firstly, its size of 524 patients, 
which is modest for a genetic study, limited its power to detect variants of a small 
effect size. However, these variants would be of too small an effect size to influence 
clinical decision-making. Secondly, Larsen scores were only evaluated over 24-
months; genetic variants could exert their effects over longer time periods. Thirdly, 
outcome data were missing in some patients. However, the linear mixed-effects 
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model was able to accommodate missing data, by making the assumption that these 
were MAR (Higgins and Green, 2011); as previously discussed this assumption 
appeared reasonable with most missing data occurring in CARDERA-2 patients at 6 
and 18 months as it was not study protocol for X-rays to be performed at these time 
points. Additionally, similar results were obtained for the ANOVA model, which 
excluded individuals with missing Larsen score data. Fourthly, as the CGC 
comprised individuals from RCTs, radiological progression rates could be lower than 
those seen in observational studies, further reducing the analysis power. This appears 
unlikely with radiological progression levels similar to an observational study of 
early RA patients (Sanmarti et al, 2007). Finally, the linear radiological progression 
rates observed in the CGC are unlikely to persist over time. Therefore, the β-values 
associated with each variant may only be applicable to the first few years of disease. 
 
Further work is required to define the genetic basis of radiological progression in 
RA. This study suggests that a candidate gene approach testing variants known to 
associate with RA development is unlikely to adequately characterise this trait. Any 
non-HLA variants evaluated in this study, if significant, were of too small an effect 
size for an association to be detected. A genome-wide approach may be more 
effective. Although such an analysis would result in a loss of power, by testing 
markers across the breadth of the genome any loci not previously considered a priori 
to have an impact on X-ray damage may be detected, provided they are of a large 
enough effect size. 
 
In conclusion this study has demonstrated an association between HLA susceptibility 
variants and radiological progression in a unique cohort of early, active RA patients 
assessed in a clinical trial setting. No significant relationship was seen between non-
HLA susceptibility variants and radiological progression. This suggests that these 
markers do not have a clinically relevant association with X-ray progression in early, 
active RA patients; it raises the possibility that the non-HLA genetic architectures of 
RA susceptibility and severity probably, at least in part, differ. HLA-wide and 
genome-wide analyses are required to better characterise the genetic architecture of 
radiological progression in RA. 
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Most studies have used a candidate gene design ‒ in which a single polymorphism or 
set of polymorphisms near a single gene are evaluated  (Lunetta, 2008) ‒ to identify 
loci that associate with radiological damage in RA. This approach, undertaken due to 
the limited size of most study cohorts, has several limitations. Firstly, it only assesses 
pre-specified markers that are considered likely to influence radiological damage. As 
the genome comprises over 3 billion base pairs, this approach is highly likely to miss 
important loci. Secondly, the studies that use it often fail to correct for population 
stratification (Daly and Day, 2001). Radiological damage may be more likely to 
occur in a subpopulation of a different ancestry, which may also harbour different 
allele frequencies of the candidate marker; this increases the likelihood of obtaining 
false-positive results. Thirdly, the main candidate genes for RA X-ray progression 
are those associated with its susceptibility; as demonstrated in the previous chapter of 
this thesis the effect of non-HLA RA susceptibility SNPs on joint destruction is 
uncertain with no association observed in 524 patients with early, active disease. 
Taken together these factors suggest a genome-wide approach is required to better 
characterise the genetic architecture of joint destruction in RA. 
 
To date only two GWASs have been undertaken that have examined genetic 
associations with radiological damage in RA. The first study, by Knevel et al 
identified a significant, replicable association between SNPs in the SPAG16 locus 
and radiological progression in 384 ACPA-positive established RA patients (Knevel 
et al, 2013b). The second study, by De Rooy et al identified two SNPs in the 
RAD51L1/ZFP36L1 and MMP9 loci that had replicable associations with 
radiological damage in an analysis of 646 early RA patients (De Rooy et al, 2013b). 
As the latter study utilised the ImmunoChip array it assessed loci associated with 
immune-mediated diseases on a genome-wide scale, as opposed to evaluating all 
genomic regions. 
 
The aim of this study was to undertake a genome-wide analysis to identify novel 
genetic associations with radiological progression in early, active RA patients 
enrolled to the CGC. Genetic markers across the breadth of the genome with 
established links to immune-mediated diseases present on the ImmunoChip were 
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tested for their association with modified Larsen score progression over two years 
using a linear mixed-effects model. 
 
4.2. PATIENTS AND METHODS 
4.2.1. Subjects 
The CGC (ethical approval, inclusion and exclusion criteria and RCT protocols) has 
been described in detail in Chapter 3 of this thesis. In brief, it comprises 524 patients 
with early, active RA previously enrolled to two RCTs evaluating intensive 
combination treatment and anakinra. Patients had modified Larsen scores recorded 
every 6-12 months for 2 years. 
 
4.2.2. Genotyping 
Patients were genotyped on the ImmunoChip. Post-QC 138,873 genetic markers 
were available for analysis (genotyping rate 0.999; full QC details provided in 
Chapter 3). This current study evaluated the 138,488 genetic markers on 
chromosomes 1-22, and the X-chromosome.  
 
4.2.3. Linear Mixed-Effects Model 
The association between Larsen score progression and each genetic marker was 
examined using the linear mixed-effects model described in Chapter 3. Having 
shown the validity of this approach compared with an ANOVA model evaluating the 
∆Larsen, a prospective decision was made to use the linear modelling only, as the 
use of repeated measures optimised the power of the study to detect significant 
associations (Guo et al, 2013). 
 
Loge (Larsen score + 1) was used as the response variable and time (years), clinical 
variables (treatment, age, disease duration, and RF status), genotype and a 
genotype*time interaction term, were included as fixed-effects predictor variables. 
All β-estimates were back-transformed to the original Larsen scale.  The 
genotype*time term β provided information on the annual increase in Larsen score 
per risk allele copy relative to the reference genotype; P-values for this term 
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provided information on the variant’s role in radiological progression. Examination 
of the model residuals confirmed a good fit of the model.  
 
Testing of genetic markers on the X-chromosome was undertaken separately in 
males and females. P-values from both sexes for each marker were subsequently 
combined to give a single P-value using Stouffer’s method, in which individual P-
values are transformed into the quantiles of a standard normal; the P-value of the 
average of the quantiles is subsequently identified (Burns, 2004). 
 
4.2.4. Genomic Inflation 
The genomic inflation factor (λ), which represents the ratio of the median χ2-test 
statistic to the expected median (0.456), was calculated for the genotype*time 
interaction term across all tested genetic markers (De Bakker, et al., 2008).  This 
provided an estimate of the inflation of false-positive rates due to population 
structure; a λ≤1.1 is considered an acceptable level of inflation (Yamaguchi-Kabata, 
et al., 2008). 
 
4.2.5. Significance Thresholds 
For the association of genetic markers with radiological progression a pre-defined 
significance threshold of P<9.18x10
-7
 was used. This was based on a Bonferroni 
correction for all uncorrelated genetic markers present in the post-QC ImmunoChip 
dataset (n=54,445). This was based on an r
2≥0.8. For all other tests P-values <0.05 
were considered significant. 
 
4.2.6. Power Calculations 
Power calculations were performed using the Genetic Power Calculator (Purcell et 
al, 2003). Five hundred and twenty four patients provided 83.7%, 50.3% and 12.1% 
power to detect a genetic variant accounting for 7%, 5% and 3% of the variance in 
radiological progression, respectively at a Bonferroni corrected P-value of 9.18x10
-7
. 





4.2.7. Statistical Programs 
Analyses were performed in R version 3.0.2 (R Foundation for Statistical 
Computing, Vienna, Austria) and PLINK version 1.07 (Purcell et al, 2007). 
 
4.3. RESULTS 
4.3.1. ImmunoChip Marker Associations with Larsen Score Progression 
None of the 138,488 tested genetic markers had a genome*time interaction term P-
value that passed the pre-defined significance threshold of P<9.18x10
-7
 (Figure 4-1).   
 
Figure 4-1 Manhattan Plot of Genetic Associations with Radiological 
Progression in the CARDERA Genetics Cohort 
 
 
P-values from genotype*time interaction term; green line represents the significance 
threshold of P<9.18x10
-7
; Manhattan Plot constructed using SNPEVG version 3.2 
(Wang, et al., 2012). 
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4.3.2. Genomic Inflation Factor 
The λ was 1.052, indicating the deviation of the observed χ2-test statistic from the 
expected null distribution was within acceptable limits. This is demonstrated in a Q–
Q plot of the observed versus the expected P-values for the genotype*time 
interaction term (Figure 4-2). Genomic control correction was, therefore, not 
required. 
 
Figure 4-2. Quantile–Quantile Plot of the Genotype*Time P-Values 
 
QQ plot constructed using SNPEVG version 3.2 (Wang et al, 2012).  
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4.3.3. Most Significant Associations with Larsen Score Progression 
Eight SNPs had P-values <1x10
-4
 for the genotype*time interaction term (Table 4-1). 
None were in LD. The two most significant SNPs were rs35309890 on chromosome 
3 in the EOMES locus (P=9.35x10
-6





There were some differences in MAFs between the CGC and 1,000 genomes 
European (EUR) population reference panel (1000 Genomes Project Consortium, et 
al., 2012). The largest was at the chromosome 6 marker rs114273380, which had a 
MAF of 0.22 in the CGC and 0.08 in the EUR panel. Other minor differences were 
seen at rs28381981 and rs114096659, which had slightly higher MAFs in the CGC 
and rs10962333 and rs1912185, which had slightly lower MAFs in the CGC 
(differences all ≤0.08). These were not due to genotype calling errors, as visual 
examination of the intensity clustering plots confirmed adequate cluster separation 
and genotype calling (Figure 4-3).  Furthermore all eight SNPs in Table 4-1 were in 
HWE; only one SNP (rs10962333) had a HWE exact test P-value <0.05, although 
this did not deviate from HWE when a Bonferroni correction was applied 
(P=0.0084). These differences probably represent true allele frequency variations 

















rs35309890 3 27740229 EOMES A 0.01 0.01 9.35x10
-06
 1.54 (1.28-1.87) 
rs12356376 10 81062107 ZMIZ1 A 0.06 0.08 1.15x10
-05
 1.19 (1.10-1.29) 
rs28381981 11 5686266 TRIM5 A 0.08 0.03 1.73x10
-05
 1.16 (1.09-1.25) 
rs10962333 9 16210610 C9orf92 G 0.05 0.13 3.84x10
-05
 1.19 (1.10-1.29) 
rs114096659 6 32680576 HLA-DQB1/HLA-DQA2 C 0.18 0.12 5.81x10
-05
 1.11 (1.05-1.17) 
rs80119111 5 102339176 PAM A 0.02 0.01 6.91x10
-05
 1.32 (1.15-1.52) 
rs114273380 6 31438096 HCG26 A 0.22 0.08 8.58x10
-05
 1.10 (1.05-1.15) 
rs1912185 2 215194668 SPAG16 A 0.09 0.14 8.93x10
-05
 1.14 (1.07-1.22) 
Chr = chromosome; A1 = allele 1 (minor allele); MAF = minor allele frequency; P-values from genotype*time interaction term; SNPs ordered 
by significance; *from GRCh37 assembly; ** MAFs from 1,000 Genomes phase 1 European population panel (CEU/IBS/CBR/FIN/TSI 
populations) (1000 Genomes Project Consortium et al, 2012) 
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Panel A = rs114273380 (HCG26 locus); Panel B = rs28381981 (TRIM5 locus); 
Panel C = rs114096659 (HLA-DQB1/HLA-DQA2 locus); Panel D = rs10962333 
(C9orf92 locus); Panel E = rs1912185 (SPAG16 locus); blue, purple and red dots 





The most significant SNP was rs35309890, which resides on chromosome 3 
downstream of the EOMES gene. EOMES encodes the protein eomesodermin, which 
is a T-box transcription factor expressed in activated CD8+ T cells; experimental 
studies suggest it is important in regulating CD8+ T cell activity (Intlekofer, et al., 
2005). Figure 4-4 represents a regional plot of the association between the other 
SNPs in this area and radiological progression. Two SNPs were in LD (R
2
>0.8; 
defined using the 1,000 Genomes EUR population panel) with rs35309890. One of 
these (rs1112524) had a greater trend towards an association with Larsen score 
progression (genotype*time P=1.51x10
-4
) compared to regional SNPs not in LD. 
Although the other SNP (rs7614831) had a substantially weaker association 
(P=0.0080), examining LD structure in the CGC revealed only moderate LD 
(r
2
=0.755) between rs35309890 and rs7614831 in this dataset. 
 
Figure 4-4. Regional Association Plot of SNPs within 400kb of rs35309890 with 
X-Ray Progression 
 
P-values for SNPs located within 400kb of rs35309890 (purple circle) on 
chromosome 3; LD relative to rs35309890; co-ordinates based on GRCh37 
assembly; P-values from genotype*time interaction term; plot generated using Locus 




The linear mixed-effects model estimated that the presence of the rs35309890 minor 
A allele was associated with a 1.54-fold (95% CI 1.28-1.87) greater annual increase 
in modified Larsen scores relative to the common T allele (Table 4-1). This 
association is demonstrated in Figure 4-5. In the 11 heterozygous (AT genotype) 
patients, the mean Larsen score increase over 24-months was 12.5 units; in the 513 
homozygous (TT genotype) patients the mean Larsen score increase was 4.8 units. 
This represents a 1.3-fold greater annual increase in modified Larsen scores in AT 
heterozygous patients compared with TT homozygous patients. Due to the rarity of 
this SNP (MAF=0.01) the Larsen scores in AT heterozygous patients were known 
with substantially less precision, as reflected by the wide standard error bars in 
Figure 4-5. There were no AA homozygous patients. 
 
Figure 4-5. Mean Larsen Scores Stratified By rs35309890 Genotype 
 
Mean Larsen scores with standard error bars at each time point; the slight decrease 
in mean scores in AT homozygous patients at 12 and 24 months are due to missing 




The second most significant SNP was rs12356376, which resides on chromosome 10 
in the ZMIZ1 (zinc finger, MIZ-type containing 1) locus.  The ZMIZ1 gene encodes 
the protein zinc finger MIZ type 1, which belongs to the protein inhibitor of activated 
STAT (PIAS) family (Ellinghaus, et al., 2012). This protein regulates the activity of 
a range of transcription factors, including Smad3/4 and p53 (Ellinghaus et al, 2012). 
A regional plot of the association between other SNPs in this area and radiological 
progression (Figure 4-6) indicated that no SNPs in this region were in high LD with 
rs12356376. 
 
Figure 4-6. Regional Association Plot of SNPs within 400kb of rs12356376 with 
X-Ray Progression 
 
P-values for SNPs located within 400kb of rs12356376 (purple circle) on 
chromosome 10; LD relative to rs12356376; co-ordinates based on GRCh37 
assembly; P-values from genotype*time interaction; plot generated using Locus 





The linear mixed-effects model estimated that the presence of the rs12356376 minor 
A allele associated with a 1.19-fold (95% CI  1.10-1.29) greater annual increase in 
modified Larsen scores relative to the common G allele (Table 4-1). Examining 
mean Larsen scores stratified by rs12356376 genotype (Figure 4-7) indicated this 
was an accurate approximation for the effect of carrying one copy of the A allele. 
The mean Larsen score increase over 24-months was 4.44 units in the 464 
homozygous (GG genotype) patients and 8.95 in the 58 heterozygous (AG genotype) 
patients. This represented a 1.01-fold greater annual increase in modified Larsen 
scores in AG heterozygous patients compared with GG homozygous patients. No 
significant difference between 2-year mean changes in Larsen scores in AA versus 
GG homozygous patients was seen, although the relevance of this is uncertain as 
only 2 patients were AA homozygotes. 
 
Figure 4-7 Mean Larsen Scores Stratified By rs12356376 Genotype 
 
 




In this genome-wide study, which evaluated the relationship between genetic 
markers known to associate with immune-mediated diseases and radiological 
progression in early, active RA patients, no variant attained a significant association 
that passed the pre-defined P-value threshold. This negative analysis probably 
reflects the limited size of the study, which was only powered to detect variants of a 
large effect size (defined as ≥7% of the variance in X-ray progression). This supports 
the concept that, as with disease susceptibility, joint destruction rates in RA are likely 
to be defined by multiple loci of a small effect size. 
 
The two SNPs that had the strongest associations with radiological progression were 
rs35309890 and rs12356376, in chromosomes 3 and 10, respectively. The nearest 
gene to rs35309890 is EOMES, which lies within 17.5 kb of this SNP. EOMES 
encodes the transcription factor eomesodermin, which has an important regulatory 
role in CD8+ T cell activity (Intlekofer et al, 2005). In murine studies it has been 
shown to invoke key attributes of effector CD8+ T cells such as release of the pro-
inflammatory cytokine, interferon-gamma (IFN-γ); it is also required for their full 
effector differentiation (Pearce, et al., 2003). In humans, IFN-γ has also been shown 
to be controlled by eomesodermin (Atreya, et al., 2007). Rs35309890 could therefore 
influence articular damage through attenuating CD8+ T cell effector functions. The 
latter SNP, rs12356376, is an intron variant within the ZMIZ1 locus. ZMIZ1 has an 
established association with susceptibility to both crohn’s disease and psoriasis 
(Ellinghaus et al, 2012), although its precise role in these diseases is unknown. It has 
been linked to the presence of malignancies including acute lymphoblastic leukaemia 
(due to a translocation with the protein tyrosine kinase ABL1 locus on chromosome 9 
(Soler, et al., 2008)) and breast, colonic, ovarian and cutaneous squamous cell 
carcinomas (Rogers, et al., 2013). The relevance of these two SNPs to radiological 
progression in RA is uncertain; neither attained statistical significance in the CGC 
and an association with X-ray progression has not been reported in other studies. 
 
This analysis focussed on identifying genetic predictors of radiological progression. 
This is because X-ray progression is the only RA outcome demonstrated to have a 
heritable component (Knevel et al, 2012b). The relevance of radiological progression 
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to current clinical practice is somewhat uncertain for several reasons. Firstly, there is 
evidence that the natural history of RA is changing with lower levels of radiological 
damage observed in more contemporary RA cohorts. In an analysis of 5 clinical trials 
of anti-TNF in methotrexate-experienced RA patients, baseline radiographic scores 
had fallen by more than 50% over 10 years (Rahman, et al., 2011).  Secondly, current 
treatment strategies of combination DMARDs and biologics significantly reduce 
radiological progression rates (Goekoop-Ruiterman, et al., 2008, Boers, et al., 1997a, 
Graudal and Jurgens, 2010). Major structural damage is therefore less commonly 
seen with modern treatments. Thirdly, in the context of clinical trials, radiological 
scores correlate poorly with clinical responses and improvements in physical 
function (Strand and Sharp, 2003); these are both more immediately relevant to 
patients than their X-ray scores. There is therefore a key research requirement to 
establish the heritability of other RA outcomes such as disease activity scores, 
disability levels and quality of life. If substantial heritability is demonstrated then 
identifying their genetic predictors could deliver personalised care that is more 
relevant to current clinical practice and patients. 
 
The strengths and weaknesses of this study are broadly the same as those outlined for 
the analysis undertaken in Chapter 3 of this thesis. The limited power of this study is, 
however, substantially greater in view of the large number of genetic markers tested.  
There exists debate around the optimal strategy to correct for multiple testing for 
studies undertaken using the ImmunoChip. Eyre et al used the traditional PGWAS 
threshold of <5×10
−8
 in their recent case-control association study of RA 
susceptibility variants (Eyre et al, 2012). De Rooy et al used the same approach as 
that undertaken in this study, by correcting for the number of independent tests after 
accounting for LD (De Rooy et al, 2013b). Their r
2
 threshold of >0.5 for removing 
correlated genetic markers was lower than that used in this study. When applying this 
more conservative LD value to the CGC, the P-value threshold was 1.26x10
-6
 
(39,610 uncorrelated SNPs); no genetic markers attained significance. There are 
three additional limitations to this study, beyond those discussed for the candidate 
gene approach in Chapter 3. Firstly, as with all genome-wide analyses it probably 
contains a substantial number of false-negative results due to the strict significance 
threshold used (Gibson, 2011). Secondly, the ImmunoChip only includes markers in 
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regions of the genome known to associate with immune diseases; it does not provide 
true genome-wide coverage and markers between the genomic regions present on 
this array may be more relevant to X-ray progression. Thirdly, since the 
ImmunoChip was designed in 2009 (Parkes et al, 2013), the number of validated 
susceptibility loci for the immune-mediated diseases on which it was based has 
rapidly expanded; these may not be captured on the array. 
 
Further work is needed to establish the genetic basis of radiological progression in 
RA. In the single GWAS providing true genome-wide coverage that has been 
undertaken in this area to date, only one SNP (rs7607479) attained PGWAS for an 
association with radiological damage (Knevel et al, 2013b).  When this is considered 
alongside the current analysis and the other ImmunoChip study (De Rooy et al, 
2013b), the genetic architecture of radiological progression is likely to comprise 
multiple loci of small effect sizes. As with RA susceptibility, the best approach to 
identify replicable genetic associations is, therefore, through meta-analyses of 
GWASs. In contrast to case-control association studies, such an approach will have a 
number of unique challenges with existing relevant genotyped cohorts using different 
X-ray scoring systems, having a variable number of X-rays available per individual 
and including patients of different disease durations and severities. The optimal 
strategy to undertake such analyses requires careful consideration. 
 
In conclusion this study has demonstrated that no significant association exists 
between genetic markers present on the ImmunoChip and radiological progression in 
524 patients with early, active RA. As the genetic basis of X-ray progression in RA 
probably comprises many loci of a small effect size, GWAS meta-analyses are 
required to optimise the power to identify relevant genetic variants.  
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CHAPTER 5.   ACPA AS A TREATMENT BIOMARKER  
 
This chapter is presented as a published paper and is a copy of the following 
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licensed under the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/2.0). No changes were made to the 
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Rheumatoid arthritis (RA) is a heterogeneous disease span-
ning several subsets. One crucial subdivision is defined by
the presence or absence of anti-citrullinated protein anti-
bodies (ACPA), termed ACPA-positive and ACPA-negative
RA, respectively [1]. ACPA-positive RA has a worse prog-
nosis with higher rates of erosive damage [2]. It also has
different risk factors than ACPA-negative RA with most
genetic associations [3,4] and environmental risks, such as
smoking [5] and alcohol abstinence [6], predominantly
linked to ACPA-positive disease. These disparities suggest
that RA ACPA subsets might respond differently to treat-
ment [7].
Current RA management focuses on early intensive
therapies, often using combinations of disease-modifying
antirheumatic drugs (DMARDs) and glucocorticoids with
rapid escalation to biologics in refractory cases. Guideline
recommendations for the treatment of early RA differ
across countries. UK guidelines from the National Insti-
tute for Health and Care Excellence (NICE) advocate that
all individuals with active RA are offered combination
DMARDs with short-term glucocorticoids [8]. American
College of Rheumatology (ACR) guidelines suggest reserv-
ing combination DMARDs for patients with markers of
severe disease, such as ACPA positivity [9]. The European
League Against Rheumatism (EULAR) guidelines also sug-
gest a stratified treatment approach, advocating biologics
in patients with poor prognostic markers like ACPA that
are failing to attain remission or low disease activity with
an initial treatment strategy of synthetic DMARDs [10].
There are, however, insufficient data on prognostic factors
in randomized controlled trials (RCTs) of combination
DMARDs and biologics to know which approach is best.
We used data from an RCT of combination DMARDs
and corticosteroids in early RA - the Combination Anti-
Rheumatic Drugs in Early RA (CARDERA) trial [11] - to
examine whether responses to intensive combination
treatments differ by ACPA status. Our primary aim was
to examine if combination DMARDs and corticosteroids
had different effects on radiological progression in ACPA-
positive and ACPA-negative RA. Our secondary aims were
to evaluate if any differential effects also extended to
disease activity, disability and quality of life (QoL).
Methods
Ethical approval
The CARDERA trial was approved by the South Thames
Multicentre Research Ethics Committee (REC Reference:
MREC (1) 99/04). Further ethical approval was obtained
to process the archived serum for ACPA status from the
East of England - Essex Research Ethics Committee (REC
Reference: 11/EE/0544). Informed consent was obtained
from all patients recruited to the CARDERA trial.
Subjects
The CARDERA trial recruited patients with early active
RA (of less than two years duration) from 42 UK cen-
ters; its details have previously been reported [11,12].
Patients were randomized to one of four treatment
arms: (1) monotherapy with methotrexate; (2) double
therapy with methotrexate and ciclosporin; (3) double
therapy with methotrexate and prednisolone; (4) triple
therapy with methotrexate, ciclosporin and prednisol-
one. A factorial-design was adopted to allow the simul-
taneous evaluation of prednisolone and ciclosporin in a
2 × 2 design. Treatment groups were well matched with
similar baseline characteristics [11]. Patients were
assessed every 6 months (for 24 months). Missing data
were imputed through last observations carried forward
(undertaken in 19% of patients at 24 months). We re-
stricted our current analysis to the 431 individuals
(from 467 recruited) who had their sera archived at
baseline and evaluable for ACPA.
Serological assessments
ACPA-status was evaluated using the commercial ELISA
assay, the Axis-Shield DIASTAT anti-CCP2 test (Axis-
Shield, Dundee, UK). All samples were processed in dupli-
cate with a cut-off of >5 units/ml taken as positive in
keeping with the manufacturer’s instructions. Rheumatoid
factor (RF) had been processed at recruiting center labora-
tories during the original trial.
Study treatments
Study treatments comprised: (1) methotrexate (starting
at 7.5 mg/week and increasing by 2.5 mg every two
weeks to a final dose of 15 mg/week); (2) “step-down”
prednisolone (based on the trial by Boers et al. [13],
comprising 60 mg/day in week 1, tapering to 7.5 mg/day
in weeks 7 to 28 and thereafter further reduced and
stopped by week 36) started with methotrexate; (3)
ciclosporin (based on the trial by Pasero et al. [14], com-
prising 1.5 mg/kg daily initially, increased gradually to a
target dose of 3 mg/kg daily) started three months after
methotrexate. Prednisolone and ciclosporin were given
as active tablets or placebos. Intra-articular glucocorti-
coids (40 mg methylprednisolone with lignocaine) were
given (on no more than six occasions) as required. Intra-
muscular glucocorticoids were allowed but only three
doses of 120 mg of depot methylprednisolone could be
given in a year.
Outcomes
The following disease outcomes were assessed: (1) radio-
logical damage - the onset of new erosions at 24 months
and modified Larsen scores; (2) disease activity - disease
activity scores on a 28-joint count (DAS28); (3) disability-
Health Assessment Questionnaire (HAQ); (4) QoL- SF-36
Seegobin et al. Arthritis Research & Therapy 2014, 16:R13
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physical (PCS) and mental (MCS) component summary
scores and EuroQol.
Statistical analysis
Baseline differences between ACPA-positive and ACPA-
negative patients were evaluated using t-tests, Wilcoxon
signed-rank tests or chi-squared tests depending on data
type and distribution.
To establish whether treatment response differed by
ACPA status, we used a two-staged approach; this mini-
mized the potential for inflation of type I error associated
with multiple testing. The first stage used a mixed-effects
repeated measures ANOVA model to examine the effect
of ACPA, treatment (coded categorically as one of the four
randomized treatment arms) and time (assessment visit)
on mean changes in each RA outcome (Larsen, DAS28,
HAQ, EuroQol, PCS and MCS scores). The key compo-
nent of this model was an ACPA*treatment interaction
term, which established whether treatment responses dif-
fered by ACPA status.
The second stage was restricted to outcomes associated
with significant ACPA*treatment interactions and com-
pared mean changes in these outcomes by treatment
group at each time point using t-tests in ACPA-positive
and ACPA-negative patients. Where the ratio between
variances significantly differed from 1, Satterthwaite’s ap-
proximation was used to calculate the degrees of freedom
for the critical t-statistic. This second stage allowed us to
establish which treatments differed in their effects by
ACPA status and how these differences changed over
time. This analysis followed the original factorial grouping
by comparing the following treatment groups (Figure 1):
(a) active ciclosporin vs. placebo ciclosporin; (b) active
prednisolone vs. placebo prednisolone; (c) triple therapy
(methotrexate, cicosporin and prednisolone) vs. mono-
therapy (methotrexate).
Figure 1 Number of individuals in each treatment group stratified by ACPA status. ACPA, anti-citrullinated protein antibody.
Table 1 Baseline characteristics by ACPA status
Characteristic ACPA-positive (n = 310) ACPA-negative (n = 121) Group difference
Female (number; %) 208 (67%) 89 (74%) P = 0.1932
RF positive (number; %) 244 (79%) 47 (39%) P <0.0012
Age (years) 54.0 (46.0, 64.0) 55.0 (47.0, 62.0) P = 0.6611
Disease duration (months) 2.00 (0.00, 5.00) 1.00 (0.00, 4.00) P = 0.1063
Larsen score 7.50 (2.50, 21.25)* 4.50 (1.00, 9.50) P <0.0013
DAS28 5.72 (4.91, 6.73) 5.96 (4.92, 6.85) P = 0.3051
HAQ 1.62 (1.00, 2.12) 1.62 (1.12, 2.12) P = 0.5953
EuroQol 0.60 (0.15, 0.68) 0.58 (0.08, 0.68) P = 0.5523
SF-36 PCS 28.68 (23.24, 35.95) 28.70 (22.90, 35.56) P = 0.7133
SF-36 MCS 38.64 (27.65, 53.71) 35.87 (25.37, 52.95) P = 0.2173
All data are median interquartile range (IQR) unless otherwise stated; 1 = t-test; 2 = chi-squared test; 3 = Wilcoxon signed-rank test; *baseline Larsen scores missing
in two ACPA-positive patients. ACPA, anti-citrullinated protein antibody; DAS28, disease activity scores on a 28-joint count; HAQ, Health Assessment Questionnaire;
MCS, mental component summary; PCS, physical component summary; RF, rheumatoid factor.
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Table 2 ANOVA results for the effect of ACPA, treatment and time on changes in RA outcomes
Larsen DAS28 HAQ EuroQol PCS MCS
Effects F P F P F P F P F P F P
ACPA 31.90 <0.001 4.02 0.045 7.25 0.007 9.72 0.002 4.07 0.044 2.29 0.131
Time 16.83 <0.001 1.26 0.288 1.37 0.251 0.70 0.550 0.80 0.493 0.65 0.584
Treatment 9.93 <0.001 1.71 0.163 17.76 <0.001 11.47 <0.001 5.67 0.001 1.92 0.124
ACPA*Treatment 7.05 <0.001 3.99 0.008 0.48 0.696 2.94 0.032 3.22 0.022 1.84 0.138
F = F-statistic; P = P-value; ACPA*Treatment = ACPA*Treatment interaction term. ACPA, anti-citrullinated protein antibody; DAS28, disease activity scores on a
28-joint count; HAQ, Health Assessment Questionnaire; MCS, mental component summary; PCS, physical component summary; RA, rheumatoid arthritis.
Figure 2 Treatment effect on mean changes in Larsen scores in ACPA-positive and ACPA-negative patients. Standard error bars are
shown for each time point; *denotes significance at P <0.05; **denotes significance at P ≤0.01; ***denotes significance at P ≤0.001; no asterisk
denotes P ≥0.05. ACPA, anti-citrullinated protein antibody.
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In addition, we calculated odds ratios (ORs) for the
development of new erosions with each treatment using
binary logistic regression stratified by ACPA status.
P-values of <0.05 were considered significant. Analyses




Of the 431 RA cases, 310 (72%) were ACPA-positive and
121 (28%) were ACPA-negative. Baseline characteristics
were similar between ACPA subsets with the exception of
Larsen scores and RF status (Table 1). ACPA-positive pa-
tients had more radiological damage at baseline; the differ-
ence in median Larsen scores between ACPA-subsets was
3.00 units (P <0.001). Significantly more ACPA-positive
patients were RF-positive (P <0.001). Both ACPA-positive
and ACPA-negative patients had median ages in the fifth
decade, were mainly female, had severely active RA (me-
dian DAS28 scores >5.1) of a short duration and moderate
disability (median HAQ scores 1.62). QoL was moderately
impaired (median EuroQol scores 0.58 to 0.60).
Radiological progression
The first analytical step, using the ANOVAmodel (Table 2),
showed that treatment responses differed serologically
with a significant ACPA*treatment interactive effect on
changes in Larsen scores observed (P <0.001).
The second analytical step, using the factorial approach,
showed significant reductions in Larsen score progression
in ACPA-positive patients receiving prednisolone, ciclos-
porin or triple therapy (Figure 2; Table 3). The magnitude
of effect was similar with prednisolone and ciclosporin.
Those receiving triple therapy had the largest reduction in
radiological progression; mean Larsen score increases over
24 months were 3.66 (95% confidence interval (CI) 2.27 to
5.05) with triple therapy and 9.58 (95% CI 6.76 to 12.39)
with monotherapy.
There were no significant treatment effects with any strat-
egy in ACPA-negative patients. These individuals showed
substantially less radiological progression (Figure 2; Table 3).
The mean Larsen score increase in ACPA-negative patients
treated with methotrexate monotherapy over 24 months
was 2.72 (95% CI 1.15 to 4.29); for those receiving triple
therapy the mean increase was 1.70 (95% CI 0.29 to 3.10).
Differences in radiological progression between ACPA-
subsets were also seen in the proportion of patients de-
veloping new erosions (24% of ACPA-positive patients;
7% of ACPA-negative patients). Reductions in erosion deve-
lopment in ACPA-positive patients were similar with cic-
losporin (OR 0.55; 95% CI 0.31 to 0.96; P = 0.032) and
prednisolone (OR 0.56; 95% CI 0.32 to 0.99; P= 0.045) when
compared with placebo. Triple therapy had the greatest
Table 3 Treatment effects on mean changes in Larsen and DAS28 scores in ACPA-positive and ACPA-negative RA
Time Ciclosporin Prednisolone Triple vs. monotherapy
Ciclosporin Placebo P Prednisolone Placebo P Triple Mono P
Larsen
ACPA+ 6 1.60 (0.37) 2.74 (0.44) 0.047 1.44 (0.22) 2.85 (0.53) 0.015 1.25 (0.28) 3.86 (0.80) 0.003
12 3.09 (0.47) 4.81 (0.61) 0.027 2.58 (0.35) 5.26 (0.67) 0.001 2.41 (0.52) 6.92 (1.10) <0.001
18 3.97 (0.53) 6.43 (0.78) 0.010 3.79 (0.48) 6.52 (0.80) 0.004 3.20 (0.66) 8.52 (1.39) 0.001
24 4.32 (0.58) 7.53 (0.84) 0.002 4.57 (0.57) 7.15 (0.84) 0.012 3.66 (0.70) 9.58 (1.41) <0.001
ACPA- 6 0.72 (0.30) 1.25 (0.36) 0.270 0.67 (0.29) 1.30 (0.37) 0.182 0.48 (0.35) 1.60 (0.55) 0.093
12 2.54 (1.11) 2.17 (0.59) 0.770 1.86 (0.58) 2.79 (1.04) 0.435 1.36 (0.47) 2.03 (0.66) 0.409
18 2.97 (1.30) 2.33 (0.60) 0.660 1.86 (0.56) 3.33 (1.21) 0.275 1.66 (0.64) 2.57 (0.79) 0.388
24 3.11 (1.32) 2.56 (0.61) 0.704 2.04 (0.60) 3.52 (1.22) 0.277 1.70 (0.69) 2.72 (0.77) 0.335
DAS28
ACPA+ 6 −1.61 (0.12) −1.49 (0.13) 0.488 −1.97 (0.12) −1.13 (0.11) <0.001 −1.98 (0.18) −0.99 (0.17) <0.001
12 −1.46 (0.12) −1.19 (0.14) 0.147 −1.36 (0.13) −1.29 (0.13) 0.716 −1.48 (0.18) −1.14 (0.19) 0.190
18 −1.49 (0.13) −1.36 (0.14) 0.498 −1.50 (0.14) −1.36 (0.13) 0.479 −1.64 (0.20) −1.37 (0.20) 0.356
24 −1.62 (0.13) −1.38 (0.15) 0.211 −1.62 (0.14) −1.38 (0.14) 0.203 −1.84 (0.19) −1.36 (0.22) 0.087
ACPA- 6 −1.02 (0.21) −1.42 (0.20) 0.173 −1.47 (0.24) −1.00 (0.17) 0.111 −1.43 (0.33) −1.32 (0.22) 0.792
12 −0.94 (0.21) −1.32 (0.21) 0.209 −1.01 (0.21) −1.25 (0.21) 0.421 −0.73 (0.33) −1.36 (0.33) 0.186
18 −1.33 (0.24) −1.52 (0.20) 0.552 −1.33 (0.23) −1.51 (0.22) 0.579 −1.27 (0.37) −1.62 (0.30) 0.462
24 −1.16 (0.22) −1.49 (0.20) 0.256 −1.32 (0.20) −1.34 (0.21) 0.960 −1.27 (0.32) −1.59 (0.30) 0.464
Data are mean changes (SE) unless otherwise stated; P = P-values from t-tests; Triple = triple DMARD therapy; Mono =monotherapy with methotrexate; time is in
months. ACPA, anti-citrullinated protein antibody; DAS28, disease activity scores on a 28-joint count.
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impact on reducing new erosions when compared with
monotherapy (OR 0.32; 95% CI 0.14 to 0.72; P = 0.003).
Treatment had no significant impact on preventing erosions
in ACPA-negative patients. The ORs for reduction in ero-
sion development in ACPA-negative patients comprised
0.86 (95% CI 0.16 to 4.23; P = 1.00) and 0.89 (95% CI 0.17
to 4.38; P = 1.00) with ciclosporin and prednisolone, respect-
ively, compared to placebo and 0.79 (95% CI 0.06 to 7.53;
P = 1.00) for triple therapy compared with monotherapy.
Disease activity
The ANOVA model (Table 2) showed a significant ACPA*-
treatment interactive effect on changes in DAS28 scores
(P = 0.008). Subsequent factorial analysis by treatment
showed that prednisolone (P <0.001) and triple therapy
(P <0.001) significantly reduced DAS28 scores at six
months in ACPA-positive patients (Figure 3; Table 3).
No treatment effects were seen at subsequent time
points. There were no significant treatment effects in
ACPA-negative patients.
Disability
The ANOVA model (Table 2) showed that although ACPA
status (P = 0.007) and treatment (P <0.001) influenced
changes in HAQ scores no ACPA*treatment interaction
Figure 3 Treatment effect on mean changes in DAS28 scores in ACPA-positive and ACPA-negative patients. Standard error bars are
shown for each time point; *denotes significance at P <0.05; **denotes significance at P ≤0.01; ***denotes significance at P ≤0.001; no asterisk
denotes P ≥0.05. ACPA, anti-citrullinated protein antibody; DAS28, disease activity scores on a 28 joint count.
Seegobin et al. Arthritis Research & Therapy 2014, 16:R13
http://arthritis-research.com/content/16/1/R13
164




The ANOVA model (Table 2) showed a significant ACPA*-
treatment interactive effect on changes in EuroQol scores
(P = 0.032). Subsequent factorial analysis (Figure 4; Table 4)
showed significant improvements in EuroQol scores at 6
months in ACPA-positive patients receiving prednisolone
(P = 0.001) or triple therapy (P = 0.029); a significant effect
was also seen at 12 months with ciclosporin (P = 0.044). A
significant effect of prednisolone on EuroQol scores was
seen at all time-points in ACPA-negative patients.
SF-36 PCS
The ANOVA model (Table 2) showed a significant ACPA*-
treatment interactive effect on changes in PCS scores (P =
0.022). Factorial analysis (Figure 5; Table 4) showed that in
ACPA-positive patients, prednisolone and triple therapy
significantly improved PCS scores at 6 and 12 months;
ciclosporin also improved PCS scores at 6 months (P =
0.031). In ACPA-negative patients no significant treatment
effect on PCS scores was observed.
Figure 4 Treatment effect on mean changes in EuroQol scores in ACPA-positive and ACPA-negative patients. Standard error bars are
shown for each time-point; *denotes significance at P <0.05; **denotes significance at P ≤0.01; ***denotes significance at P ≤0.001; no asterisk
denotes P ≥0.05. ACPA, anti-citrullinated protein antibody.




The ANOVA model (Table 2) showed no significant as-
sociations between ACPA, time or treatment and MCS
scores; no ACPA*treatment interaction was observed (P =
0.138). Factorial analysis was therefore not undertaken.
Discussion
Our main finding is that combination DMARDs and
high-dose tapering corticosteroids are only required to
prevent radiological progression in patients with early
active RA in whom ACPA is present. In ACPA-positive
patients, methotrexate monotherapy resulted in consid-
erable worsening of radiological damage; the average
annual Larsen score increase was 4.8 units and 38%
developed new erosions. This was significantly reduced
with combination treatment; in ACPA-positive patients
receiving triple therapy the average annual Larsen score
increase was 1.8 units and 16% developed new erosions.
In contrast, ACPA-negative patients had minimal radio-
logical progression irrespective of the treatment strategy
used; the average annual increases in Larsen scores were
below the minimal clinically important difference (MCID)
of 2.3 units [15] with all treatments and only 7% developed
new erosions.
Our other finding was that the beneficial effect of high-
dose corticosteroids on reducing disease activity and im-
proving physical health was also confined to ACPA-positive
RA. Only ACPA-positive patients had significant six-month
improvements in DAS28 and PCS scores with double and
triple therapy regimens incorporating prednisolone. Our
findings are consistent with the IMPROVED study, which
also found that high-dose corticosteroids had a significantly
larger effect on improving disease activity and remission
rates in ACPA-positive, as compared to ACPA-negative,
inflammatory arthritis patients [16]. The mechanism un-
derlying this differential steroid response is uncertain. The
fact these improvements were not maintained over time in
CARDERA is expected and consistent with the original
COBRA study [13]. Our results support the use of high-
dose tapering corticosteroids as a bridging therapy in early
RA but suggest this treatment strategy would be best
reserved for ACPA-positive patients.
The impact of ACPA status on EuroQol responses to
combination DMARDs and corticosteroids was less clear,
with similar EuroQol improvements observed in ACPA-
positive and ACPA-negative patients receiving active pred-
nisolone and triple therapy. Interestingly, ACPA-negative
patients receiving placebo prednisolone or methotrexate
monotherapy had substantially smaller EuroQol improve-
ments (maximal increase of 0.04 and 0.08 units, respect-
ively) when compared to ACPA-positive patients (maximal
increase of 0.13 and 0.12 units, respectively). This suggests
that methotrexate monotherapy could be more effective at
improving QoL in ACPA-positive disease.
Table 4 Treatment effects on mean changes in EuroQol and PCS scores in ACPA-positive and ACPA-negative RA
Ciclosporin Prednisolone Triple vs. monotherapy
Time Ciclosporin Placebo P Prednisolone Placebo P Triple Mono P
EuroQol
ACPA+ 6 0.16 (0.02) 0.16 (0.02) 0.978 0.21 (0.02) 0.11 (0.02) 0.001 0.21 (0.03) 0.11 (0.04) 0.029
12 0.16 (0.02) 0.09 (0.03) 0.044 0.14 (0.02) 0.12 (0.02) 0.481 0.19 (0.03) 0.10 (0.04) 0.063
18 0.15 (0.02) 0.11 (0.03) 0.215 0.14 (0.03) 0.13 (0.02) 0.651 0.18 (0.04) 0.12 (0.04) 0.267
24 0.17 (0.02) 0.12 (0.03) 0.176 0.16 (0.03) 0.13 (0.02) 0.403 0.20 (0.04) 0.12 (0.04) 0.152
ACPA- 6 0.08 (0.04) 0.09 (0.04) 0.876 0.16 (0.04) 0.02 (0.04) 0.011 0.19 (0.06) 0.05 (0.05) 0.074
12 0.08 (0.04) 0.06 (0.04) 0.756 0.14 (0.04) 0.01 (0.04) 0.033 0.14 (0.05) 0.00 (0.05) 0.057
18 0.10 (0.04) 0.09 (0.04) 0.776 0.16 (0.04) 0.03 (0.04) 0.036 0.19 (0.06) 0.05 (0.05) 0.058
24 0.10 (0.04) 0.09 (0.04) 0.908 0.16 (0.04) 0.04 (0.04) 0.035 0.21 (0.05) 0.08 (0.05) 0.057
PCS
ACPA+ 6 7.96 (0.89) 5.15 (0.95) 0.031 9.15 (0.96) 4.01 (0.83) <0.001 10.42 (1.30) 2.29 (1.16) <0.001
12 5.27 (0.84) 4.17 (0.94) 0.380 6.04 (0.93) 3.42 (0.84) 0.037 7.05 (1.23) 3.28 (1.27) 0.035
18 6.11 (0.89) 3.87 (1.02) 0.097 5.51 (1.01) 4.53 (0.89) 0.472 7.77 (1.39) 4.58 (1.44) 0.114
24 5.77 (0.96) 4.91 (1.03) 0.544 6.36 (1.03) 4.34 (0.95) 0.150 8.33 (1.46) 5.53 (1.49) 0.180
ACPA- 6 2.64 (1.41) 4.04 (1.21) 0.449 4.14 (1.31) 2.68 (1.29) 0.428 4.86 (2.11) 4.54 (1.78) 0.908
12 3.27 (1.35) 4.93 (1.15) 0.349 3.70 (1.25) 4.52 (1.25) 0.646 3.25 (2.07) 5.61 (1.76) 0.386
18 3.86 (1.38) 5.06 (1.24) 0.516 4.41 (1.40) 4.55 (1.23) 0.937 4.72 (2.11) 5.88 (1.67) 0.664
24 4.65 (1.69) 5.17 (1.07) 0.793 5.51 (1.58) 4.40 (1.21) 0.575 7.44 (2.70) 6.48 (1.36) 0.753
Data are mean changes (SE) unless otherwise stated; P = P-values from t-tests; Triple = triple DMARD therapy; Mono =monotherapy with methotrexate; time is in
months. ACPA, anti-citrullinated protein antibody; PCS, physical component summary.
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To our knowledge, research on the impact of ACPA sta-
tus on responses to combination DMARDs and corticoste-
roids is limited to secondary analyses or extension studies
of the BeST [17,18] and FIN-RACo [19] trials. Data from
the BeST study support our finding that DMARD mo-
notherapy is inadequate at preventing radiological prog-
ression in ACPA-positive RA; the presence of ACPA
associated with radiological progression in individuals re-
ceiving monotherapy (OR for radiological progression:
12.6; 95% CI 3.0 to 51.9) but not combination therapy
with DMARDs and corticosteroids (OR 1.7; 95% CI 0.5
to 5.4) [17]. This study also reported minimal radiological
progression in ACPA-negative patients in all treatment
groups. Although the FIN-RACo trial found that combin-
ation therapy reduced radiological progression in ACPA-
negative, but not ACPA-positive patients, the study had a
small sample size, allowed corticosteroids in both treat-
ment arms and had no treatment restrictions for the last
three years of follow-up [19]. The impact of ACPA-status
on biologic responses has been studied in greater detail,
particularly in national registries. Anti-tumor necrosis
factor (anti-TNF) therapies appear more effective in ACPA-
negative disease [20,21]. Conversely, T-cell and B-cell in-
hibition with abatacept and rituximab, respectively, appear
Figure 5 Treatment effect on mean changes in PCS scores in ACPA-positive and ACPA-negative patients. Standard error bars are shown
for each time point; *denotes significance at P <0.05; **denotes significance at P ≤0.01; ***denotes significance at P ≤0.001; no asterisk denotes
P ≥0.05. ACPA, anti-citrullinated protein antibody; PCS, physical component summary.
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more efficacious in ACPA-positive RA [22,23]. Taken
together these findings suggest that treatment responses
differ between ACPA-positive and ACPA-negative RA.
This highlights a requirement for future RCTs of RA treat-
ments to stratify their analyses by ACPA status.
Our results show that ACPA is an important prognos-
tic biomarker in early RA, with its presence signaling a
requirement for intensive combination treatment. The
heterogeneous nature of RA alongside the increasing
breadth of available therapies means that identifying
predictors of treatment responses is a key research goal.
Studies have identified several clinical parameters asso-
ciated with good anti-TNF outcomes; these include not
smoking, male gender and a younger age [20,24]. Gen-
etic markers also offer promise with a recent large
genome-wide association study reporting the first de-
finitive genetic association (in the CD84 gene) with
anti-TNF response [25]. Other smaller studies suggest
that stimulated whole blood cell pro-inflammatory cyto-
kine levels [26] and serum proteins [27] may be useful
in predicting anti-TNF efficacy. These findings are promis-
ing but lack clinical utility, since most markers require
validation in larger cohorts or associate with only small
differences in treatment response. Further work is re-
quired to identify predictors of treatment responses
in RA.
Our study has a number of strengths. These include its
large sample size, the involvement of multiple centers, the
measurement of a wide range of outcomes and the use of
two-year follow-up data. It also has several limitations. It
was a secondary analysis of a published RCT and, there-
fore, neither its primary hypothesis nor its statistical ana-
lysis plan was pre-specified. ACPA status was unknown in
8% of patients, who were excluded from our analysis. One
DMARD, ciclosporin, is not widely used in current prac-
tice. Fewer ACPA-negative patients were studied; however,
the power to detect a MCID in Larsen scores between
combination therapy and monotherapy treatment arms in
ACPA-negative patients was higher (86%) than in ACPA-
positive patients (55%). Finally, the maximal dose of me-
thotrexate was 15 mg/week; higher doses are often used in
contemporary clinical care [28].
Different guidelines, constructed using the same evi-
dence base, have drawn alternative conclusions regard-
ing the optimal treatment of early active RA. NICE
guidelines recommend offering all patients combination
DMARDs and short-term corticosteroids [8]. ACR and
EULAR guidelines recommend adopting an individual-
ized approach to treatment intensity based on prognos-
tic factors, such as ACPA [9,10]. Our findings favor this
latter approach. They show strong evidence that ACPA-
positive patients benefit from intensive combination ther-
apy but no evidence that combination treatments improve
disease outcomes beyond methotrexate monotherapy
in ACPA-negative patients. We recommend that future
trials in early RA should consider ACPA status when
evaluating treatment outcomes. When NICE and other
clinical guidelines are updated, the heterogeneity of RA
requires consideration, particularly the impact of ACPA-
status on treatment requirements and responses.
Conclusions
We have demonstrated that the requirement for, and re-
sponse to, combination DMARDs and high-dose tapering
corticosteroids differs between patients with ACPA-positive
and ACPA-negative early RA. In our study, intensive com-
bination therapy was only needed to prevent radiological
progression in ACPA-positive patients. Additionally, cor-
ticosteroids only provided significant improvements in
disease activity and physical health outcomes in ACPA-
positive RA. These findings suggest that ACPA is an
important biomarker for guiding treatment decisions in
early RA. They support ACR and EULAR RA manage-
ment guidelines, which recommend an individualized
approach to treatment intensity based on prognostic
factors such as ACPA.
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Abstract
The improved characterisation of risk factors for rheumatoid arthritis (RA) suggests they could be combined to identify
individuals at increased disease risks in whom preventive strategies may be evaluated. We aimed to develop an RA
prediction model capable of generating clinically relevant predictive data and to determine if it better predicted younger
onset RA (YORA). Our novel modelling approach combined odds ratios for 15 four-digit/10 two-digit HLA-DRB1 alleles, 31
single nucleotide polymorphisms (SNPs) and ever-smoking status in males to determine risk using computer simulation and
confidence interval based risk categorisation. Only males were evaluated in our models incorporating smoking as ever-
smoking is a significant risk factor for RA in men but not women. We developed multiple models to evaluate each risk
factor’s impact on prediction. Each model’s ability to discriminate anti-citrullinated protein antibody (ACPA)-positive RA
from controls was evaluated in two cohorts: Wellcome Trust Case Control Consortium (WTCCC: 1,516 cases; 1,647 controls);
UK RA Genetics Group Consortium (UKRAGG: 2,623 cases; 1,500 controls). HLA and smoking provided strongest prediction
with good discrimination evidenced by an HLA-smoking model area under the curve (AUC) value of 0.813 in both WTCCC
and UKRAGG. SNPs provided minimal prediction (AUC 0.660 WTCCC/0.617 UKRAGG). Whilst high individual risks were
identified, with some cases having estimated lifetime risks of 86%, only a minority overall had substantially increased odds
for RA. High risks from the HLA model were associated with YORA (P,0.0001); ever-smoking associated with older onset
disease. This latter finding suggests smoking’s impact on RA risk manifests later in life. Our modelling demonstrates that
combining risk factors provides clinically informative RA prediction; additionally HLA and smoking status can be used to
predict the risk of younger and older onset RA, respectively.
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Introduction
Rheumatoid arthritis (RA) is a common chronic inflammatory
disorder. It results in substantial morbidity and disability alongside
high medical and societal costs [1], [2]. There is therefore growing
interest in preventing its development. Such prevention requires
an ability to reliably predict who will develop RA. Advances in
characterising genetic and environmental risk factors for RA
together with developments in modelling methodology make
predicting its development a realistic possibility.
RA is a clinical syndrome spanning multiple subsets [3]. The
commonest subdivision is by the presence or absence of
rheumatoid factor (RF)/anti-citrullinated protein antibodies
(ACPA), termed seropositive and seronegative RA respectively.
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Risk factor evaluation has mainly focussed on seropositive RA with
nearly half its genetic architecture known. HLA-DRB1 alleles, in
particular those encoding the shared epitope, dominate genetic
risk accounting for approximately 36% of heritability [4]; 45 non-
HLA variants explain approximately 15% of heritability [4].
Smoking is the main environmental risk factor [5]; it predisposes
to seropositive RA and has a synergistic relationship with the
shared epitope [6], [7]. Although single factors do not provide
sufficient risk stratification, combining multiple factors within a
prediction model may identify clinically relevant high- and low-
risk groups. The large risks conferred by HLA make such
modelling an attractive prospect in RA despite limited success in
other complex disorders [8–10].
RA develops over many years prior to clinical presentation [11].
Initially, individuals with genetic susceptibility variants are
exposed to environmental risks; some may develop autoantibodies
(RF/ACPA) [12]. A proportion will subsequently develop
arthralgia, which may progress to an unclassified arthritis followed
by a fully expressed RA phenotype. Pilot studies in unclassified
arthritis indicate that secondary prevention may be possible with
corticosteroids [13], [14], methotrexate [15] and biologics [16]
attenuating the progression to RA. Although preventive treat-
ments may be more effective before immune dysregulation and
symptoms develop, primary prevention is not currently possible as
no reliable method exists to identify asymptomatic high-risk
individuals.
Prevention is likely to have a larger impact in younger onset RA
(YORA) due to the increased health costs associated with a longer
disease duration [17]. Genetic susceptibility factors may influence
RA’s age of onset with HLA-DRB1*04 alleles [18–21] and multiple
single nucleotide polymorphisms (SNPs) such as those tagging
VEGFA [22], RANKL [19], [23], MMP1-3 [22] and PTPN22 [24],
[25] loci associating with YORA.
One group has published two reports outlining predictive
models for RA. Their models, built using 8 HLA alleles, 14–31
SNPs and clinical factors, generated an aggregate weighted genetic
risk score (wGRS) formed from the product of individual-locus
odds ratios (ORs) [26], [27]. They were reasonably accurate at
determining disease status in approximately 1,200 cases and 1,200
controls, with a maximal area under the curve (AUC) of 0.752.
They also demonstrated a better ability to predict erosive RA (a
more severe phenotype). However, only a minority of the studied
populations had significantly elevated risks for RA.
We report an alternative modelling approach to predicting RA.
Our novel modelling method uses computer simulation to
categorise risk profiles; our models also incorporate a larger
number of HLA risk variants. The risk factors included in our
modelling comprise 15 four-digit/10 two-digit HLA-DRB1 alleles,
31 SNPs and male ever-smoking status (as ever-smoking is a
significant risk for RA in males only). We applied our models to
two large cohorts of European ancestry: the Wellcome Trust Case
Control Consortium (WTCCC) and the UK RA Genetics Group
(UKRAGG) Consortium. Our primary aim was to determine if
our approach would generate clinically relevant predictive values.
Our secondary aim was to determine if our modelling better
identified YORA. We demonstrate that clinically informative RA
risk prediction is possible and that the risk of younger and older




All participants in WTCCC and UKRAGG were recruited
after providing informed consent. UKRAGG was approved by the
North West Multi-Centre Research Ethics Committee (MREC
99/8/84). Authors gained written permission and approval from
WTCCC to undertake this work in the publically available
WTCCC1 collections.
Study Populations
The WTCCC dataset contains SNP data on 1,999 RA cases
and 3,004 controls [28]. Controls were obtained from the 1958
British Birth Cohort and UK Blood Services. Genotyping was
performed on the Affymetrix GeneChip 500k Mapping Array Set.
Quality control (QC) procedures were undertaken excluding
individuals with ,97% SNP call rates, high heterozygosity, non-
European ancestry or relatedness, discordance between genotype
and phenotype data and duplicate samples. In the post-QC dataset
information was available on 490,031 SNP markers; the total
genotyping rate was 1.00. Two- or four-digit resolution HLA-
DRB1 tissue typing data were available on 1,837 cases and 1,647
controls.
The UKRAGG dataset contains SNP data on 5,024 RA cases
and 4,281 controls from 6 UK centres [29]. Genotyping was
performed using the Sequenom platform. Four hundred and
four SNPs were genotyped over 8 staggered plexes; for each plex
separate QC was undertaken excluding individuals and SNPs
with ,90% data present. In the post-QC dataset total
genotyping rates were 0.73 owing to systematic differences in
samples run on each plex. Two- or four-digit resolution HLA-
DRB1 tissue typing data were available on 3,420 cases and 1,500
controls.
Both datasets contained cases fulfilling the 1987 ACR classifi-
cation criteria for RA [30]. HLA-DRB1 tissue typing was
undertaken (at two-digit or four-digit resolution) at individual
centres, using commercially available semiautomated polymerase
chain reaction-sequence-specific oligonucleotide probe (PCR-
SSOP) typing techniques (or research assays based on PCR-SSOP
linear array technology) [29]. Two-digit typing includes the allele
group (Field 1) only; four-digit typing includes both the allele
group and the allele subtype encoding a specific HLA protein
(Field 2) (http://hla.alleles.org/nomenclature/naming.html).
Author Summary
Rheumatoid arthritis (RA) is a common, incurable disease
with major individual and health service costs. Preventing
its development is therefore an important goal. Being able
to predict who will develop RA would allow researchers to
look at ways to prevent it. Many factors have been found
that increase someone’s risk of RA. These are divided into
genetic and environmental (such as smoking) factors. The
risk of RA associated with each factor has previously been
reported. Here, we demonstrate a method that combines
these risk factors in a process called ‘‘prediction modelling’’
to estimate someone’s lifetime risk of RA. We show that
firstly, our prediction models can identify people with very
high-risks of RA and secondly, they can be used to identify
people at risk of developing RA at a younger age.
Although these findings are an important first step
towards preventing RA, as only a minority of people
tested had substantially increased disease risks our models
could not be used to screen the general population.
Instead they need testing in people already at risk of RA
such as relatives of affected patients. In this context they
could identify enough numbers of high-risk people to
allow preventive methods to be evaluated.
Predicting Rheumatoid Arthritis
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We undertook prediction modelling in seropositive cases and
controls with HLA-DRB1 tissue typing data available with or
without additional SNP and smoking data (as most replicated risk
loci are for seropositive RA and genetic risk is dominated by HLA)
[4], [31]. The final cohorts comprised 1,516 cases and 1,647
controls from WTCCC and 2,623 cases and 1,500 controls from
UKRAGG (Table 1).
Prediction Modelling Overview
Our modelling was performed within the R package, REGENT
(Risk Estimation for Genetic and Environmental Traits), devel-
oped within our unit. This program incorporates published gene-
environment risk factor and disease statistics to categorise risk
using a confidence interval (CI)-based approach within a simulated
population. The methodology underlying REGENT has previ-
ously been described in detail [32], [33].
Genetic and environmental risk factors for input into REGENT
are selected from the literature. Genetic risk factors require allelic
ORs, allele frequencies, and sample sizes from relevant studies, in
order to estimate precision. Environmental risk factors require
ORs, standard errors and the proportion of the population
exposed to the risk factor. Data on these risk factors are entered
into REGENT as summary statistic input files, which are
processed in two stages: the first develops the prediction model
and the second runs the prediction model in real life data.
In the first stage REGENT simulates a population-distribution
of disease risk. Risk profiles are simulated based on the frequency
of each risk factor in the general population. Summary ORs for
each risk profile are generated through combining the ORs for
each genetic and environmental risk factor in a multiplicative
model that assumes risk factor independence. CIs are generated
using information on the variability of genetic risk factors (derived
from the sample size of the risk variant discovery cohort) and
environmental risk factors (standard error of the effect size). Each
simulated risk profile’s OR is initially calculated relative to a
profile with no risk factors present; these are subsequently adjusted
to ensure correct disease prevalence in the population, assigning a
risk profile with a mean OR as having a baseline risk of 1.0. CIs
are used to classify risk profiles into four risk categories (reduced,
average, elevated and high-risk). Starting with the risk profile of
baseline risk (OR=1.0), any risk profile whose CI overlaps with
this baseline CI is classified as being of average-risk (as this profile
is not statistically different from baseline). Any risk profile whose
CI resides fully below the baseline CI is classified as reduced-risk.
Profiles with CIs above the baseline CI are classified as elevated-
risk. Furthermore, a high-risk group is determined by profiles
whose CIs reside completely above the CI of the first risk profile
classified as elevated-risk. An example of how this process is
undertaken in a simplified model using 3 SNPs is provided in
Figure S1.
In the second stage REGENT applies this simulated population
profile to individual level data. Genotypes and environmental risk
factor exposure data on each individual in the dataset of interest
(WTCCC and UKRAGG) are entered into REGENT, which
generates two measures of disease risk. Firstly, each individual’s
summary OR (95% CI) for RA is calculated (relative to the
baseline individual with an OR of 1.0); as with the simulated
population, risk factors are combined in a multiplicative model.
This summary OR informs the individual of their risk of
developing RA. Secondly, each individual is assigned a risk
category for RA. This is undertaken through comparing the CI of
each individual’s summary OR to those of the simulated risk
distribution in the same manner as described in stage 1. This risk
category informs an individual whether they are at an increased or
reduced risk of disease, relative to the average person in the
general population.
Prediction Model Components Identified from Meta-
Analyses
Genetic Risk Factors. We identified genetic susceptibility
variants for potential inclusion in our prediction modelling from
two large, recently published meta-analyses [34], [35]. We sought
to include only susceptibility alleles attaining genome-wide
significance (PGWAS,5610
28); this ensured that the alleles
modelled were replicated RA genetic risk factors. These comprised
15 four-digit and 10 two-digit HLA-DRB1 alleles and 35 non-HLA
SNPs.
Environmental Risk Factor. We included the environmen-
tal risk factor smoking in our modelling. Other factors proposed to
influence RA risk such as alcohol were not included: firstly the
evidence underlying these is uncertain, with associations often
present in case-control and not cohort studies [36] and secondly
Table 1. Clinical characteristics of WTCCC/UKRAGG cases and controls included in modelling.
WTCCC UKRAGG
RA (n=1,516) Controls (n =1,647) RA (n =2,623) Controls (n =1,500)
Gender Female 1,151 (76.0) 739 (50.0) 1,868 (71.2) 890 (59.9)
RA Characteristics RF+ 1,452 (96.1) - 2,385 (93.1) -
ACPA+ 1,061 (86.5) - 1,508 (84.8) -
Mean Age Of Onset (95% CI) 45.3 (44.6–46.1) - 48.0 (47.5–48.6) -
Erosive Disease 1,009 (71.1) - 830 (69.7) -
Nodules - - 859 (38.3) -
Smoking Status Male Ever-Smokers 231 (80.5)a 422 (57.1)a 417 (78.8)a 149 (46.3)a
Female Ever-Smokers 552 (58.3)b 425 (57.7)b 758 (55.9)b 238 (39.3)b
Data are number (%) unless otherwise stated. The following data are missing from WTCCC: gender in 2 cases and 169 controls; RF status in 5 cases; ACPA status in 290
cases; age of onset missing/inaccurate in 63 cases; erosive status in 96 cases; smoking status in 76 male cases, 204 female cases and 3 female controls. The following
data are missing from UKRAGG: gender in 14 controls; RF status in 60 cases; ACPA status in 844 cases; age of onset missing/inaccurate in 93 cases; erosive status in 1,432
cases; nodular status in 378 cases; smoking status in 226 male cases, 513 female cases, 274 male controls and 284 female controls.
a =% of males that are ever smokers;
b =% of females that are ever smokers.
doi:10.1371/journal.pgen.1003808.t001
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detailed data on non-smoking risk factors were not captured in
WTCCC and UKRAGG.
We used published ORs from the most recent meta-analysis
evaluating smoking as an RA risk factor [5]. In this meta-analysis
ever-smoking was a significant risk for seropositive RA in males
only (OR 3.02; 95% CI 2.35–3.88) with a substantially smaller and
non-significant (CIs contain 1) impact seen in females (OR 1.34;
95% CI 0.99–1.80). We therefore hypothesized that smoking
would not improve prediction in women (confirmed in preliminary
analyses; Table S1). As a result only males were evaluated in our
modelling incorporating ever-smoking.
Although smoking interacts with the shared epitope we did not
factor this into our modelling. This is because studies reporting
summary ORs for this interaction [6], [29], [37], [38] have
marked heterogeneity between them; therefore using meta-analysis
techniques to obtain pooled ORs for shared epitope-smoking
status combinations would be inaccurate and thus inappropriate.
Examples of this heterogeneity include: (1) studies reporting risks
stratified by different smoking levels, which would require an
inverse variance fixed-effects model to obtain common ORs for all
smokers within studies in addition to a random-effects model to
estimate pooled ORs across studies; (2) two studies classifying the
shared epitope at two-digit resolution, thus incorporating non-
shared epitope alleles [6], [37]; (3) two studies not including all
known shared epitope alleles [29], [38].
Prediction Model Component Availability in WTCCC and
UKRAGG
Two-digit or four-digit HLA-DRB1 tissue typing data were
available in all evaluated individuals. In WTCCC 1,342 seropos-
itive cases, 966 ACPA-positive cases and 1,126 controls had four-
digit resolution data available on both alleles; 29 seropositive cases,
14 ACPA-positive cases and 159 controls had two-digit resolution
data available on both alleles; 145 seropositive cases, 81 ACPA-
positive cases and 362 controls had mixed-digit resolution data
(one HLA-DRB1 allele known at four-digit and the other at two-
digit resolution) available. In UKRAGG 1,534 seropositive cases,
1,108 ACPA-positive cases and 735 controls had four-digit
resolution data available on both alleles; 312 seropositive cases,
66 ACPA-positive cases and 205 controls had two-digit resolution
data available on both alleles; 777 seropositive cases, 334 ACPA-
positive cases and 560 controls had mixed-digit resolution data
available.
We excluded 4 SNPs attaining PGWAS in the meta-analysis for
the following reasons: 1 (rs11676922) was in high linkage
disequilibrium (r2.0.9; HapMap release 22 CEU population
panel) [39] with another (rs10865035) – in this case the latter SNP
was included due to a previous association with RA – and 3 SNPs/
proxy SNPs were unavailable (rs10488631, rs6859219 and
rs934734 in UKRAGG; rs6822844, rs874040 and rs951005 in
WTCCC). Eleven and two proxy SNPs were used in WTCCC
and UKRAGG respectively (Table S2) [39].
Data on ever-smoking status were available in 287 male cases
and 739 male controls in WTCCC and 529 male cases and 322
male controls in UKRAGG.
Final Prediction Models
To examine the contribution of each gene-environment
component to prediction we constructed several models. These
comprised a SNP model (with 31 SNPs), an HLA model (10 two-
digit and 15 four-digit HLA-DRB1 alleles), an HLA-SNP model
(combining HLA and SNP model components), an HLA-smoking
model (combining HLA-DRB1 alleles with ever-smoking status)
and an HLA-SNP-smoking model (combining HLA-DRB1 alleles,
28 SNPs and ever-smoking status). Only the 28 SNPs present in
both WTCCC and UKRAGG were incorporated in the last
model. The latter two models, which included smoking, were
evaluated in males only.
The decision to combine two-digit and four-digit HLA-DRB1
alleles in the HLA model was undertaken to avoid removing the
substantial number of individuals with mixed resolution typing.
Preliminary analyses confirmed the validity of this approach with
no significant differences seen in the discriminative abilities of
HLA models incorporating (1) two-digit alleles only; (2) four-digit
alleles only and (3) a mixed resolution of alleles (Table S3). Within
our mixed resolution modelling the risks for each HLA allele were
included only once per individual at the highest resolution at
which they were known.
Only individuals with available data on relevant risk factors
were included in models incorporating those risk factors.
Therefore only males with available smoking data were included
in the HLA-smoking and HLA-SNP-smoking models. Similarly
only individuals with data available on the modelled SNPs could
be included in the HLA-SNP and HLA-SNP-smoking models.
Owing to missing data the number of individuals evaluated in each
prediction model fell as more risk factors were included (Figure 1).
Statistical Analyses
Evaluating Dataset Validity. To compare the representa-
tiveness of our datasets to published RA populations we
summarised clinical features of cases and controls (Table 1) and
calculated effect allele frequencies and allelic ORs (95% CIs)
(Tables 2 and 3). For the HLA-DRB1 allele case-control association
analysis (Table 2) the two-digit resolution allele results included
both individuals with two-digit resolution typing and collapsed
four-digit resolution typing. This approach was undertaken due to
the small number of individuals with two-digit typing data in
WTCCC/UKRAGG. The meta-analysis from which we obtained
our risk alleles had almost identical allele frequencies when
comparing two-digit alleles and four-digit alleles collapsed to two-
digit resolution [35]; comparing our datasets to the meta-analysis
findings in this manner was therefore appropriate.
Comparing Model Classification Abilities. To evaluate
the ability of each model to correctly classify disease status we
constructed receiver operating characteristic (ROC) curves and
measured the AUC; this is established methodology in determin-
ing genetic classification test efficacy [40], [41]. Higher AUCs
indicate better classification. An AUC.0.5 signifies some
discriminative ability; a perfect classifier has an AUC of 1. AUCs
were calculated and compared using DeLong’s method [42]
performed within the R package, pROC [43].
Comparing Model Generated Risk Distributions. The
risk distributions for cases and controls under each model were
compared by plotting the logarithmic OR for seropositive RA for
each individual ordered by risk.
Calculating Lifetime Risk of RA. Due to the low preva-
lence of RA [44], ORs approximate relative risks [45]. Therefore
to calculate lifetime risks of seropositive RA we multiplied
published lifetime risks by the summary OR for RA generated
by our prediction models. As UK lifetime risks of RA are unknown
we used estimates from a large US cohort study (2.4% for women;
1.1% for men) [46].
Evaluating YORA Prediction. The role of HLA, SNPs
and ever-smoking status in determining age of RA onset was
evaluated using individual-level OR outputs from the REGENT
models in a Cox univariate analysis with gender, smoking status
and smoking status-gender interaction used as covariates. Factors
indicated as likely predictors of age of onset were then examined
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simultaneously in a multivariate analysis incorporating backward
elimination of non-significant factors (P.0.05). We found no
evidence of a ‘‘gender-smoking interaction’’ effect on the age of
RA onset in either dataset (WTCCC P=0.0823 and UKRAGG
P=0.8369; Table 4). This excluded a significant influence of
gender on the relationship between smoking and the age at which
RA developed. We therefore included both sexes when evaluating
smoking’s effect on the age of onset. Proportional hazards
assumptions were verified using visual inspection of log-log plots
[47]. To further demonstrate associations between significant
factors and age of onset we constructed Kaplan-Meier estimates of
the cumulative risk for cases, stratified by REGENT risk
categorisation from the relevant models, alongside the presence/
absence of other risk factors. We used a Cox multivariate
approach to establish which four-digit HLA-DRB1 alleles influ-
enced age of onset (fitting all alleles simultaneously using stepwise
selection, removing non-significant alleles from the final model).
All time to event analyses were performed using SAS version 9.3
(SAS Institute, Cary, NC).
Separate Analyses for ACPA-Positive RA
We undertook modelling separately for seropositive (RF and/or
ACPA present) RA and ACPA-positive RA since HLA-DRB1
allelic ORs were obtained from a meta-analysis evaluating
ACPA-positive RA [35], and the shared epitope alleles, non-
HLA SNPs and smoking predominantly associate with ACPA-
positive disease [4], [48–50]. We therefore hypothesised our
modelling would perform better for ACPA-positive RA. As this
was confirmed in the risk categorisation results we restricted
further analyses (AUC and lifetime risk calculations, examining




Genetic Risk Factors. In both WTCCC and UKRAGG the
effect allele frequencies and ORs for seropositive RA were
generally similar to published data (Tables 2 and 3). Exceptions
occurred at the four-digit HLA-DRB1 alleles *04:08 and *15:01
(absent from controls in WTCCC and UKRAGG respectively), at
*01:01, *11:01, *11:04, *13:01 and *15:01 in WTCCC and *08:01
in UKRAGG (significantly lower allele frequencies in controls
than expected). The absence of *04:08 in controls was probably a
chance finding since it has a frequency of 0.005. The remaining
discrepancies resulted from lower four-digit tissue typing rates for
these alleles in controls, which were more often typed at two-digits,
compared with cases. Although this could introduce bias,
Figure 1. Number of individuals evaluated in each prediction model.
doi:10.1371/journal.pgen.1003808.g001
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especially in the context of case-control association analyses, we do
not consider it significantly affected our prediction modelling
because these alleles were incorporated in our models at both two-
digit and four-digit resolution (in most cases in the reference meta-
analysis the two-digit alleles had similar allele frequencies and ORs
compared with the four-digit alleles) and our risks were obtained
from an external source [35].
SNP discrepancies occurred at rs3761847 in WTCCC and
rs26232 and rs540386 in UKRAGG, which had ORs in the
opposite direction to published results although the dataset and
meta-analysis 95% CI’s overlapped for two SNPs. Additionally the
minor allele frequencies (MAFs) in controls were similar to those
expected. These discrepancies probably represent normal varia-
tion as opposed to systematic genotyping differences.
Most HLA-DRB1 alleles had significant associations with RA,
with only 4 (16%) alleles in WTCCC and 3 (12%) alleles in
UKRAGG having 95% CIs containing 1.0. A substantial propor-
tion of SNPs – 13 (42%) in WTCCC and 15 (48%) in UKRAGG –
had 95% CIs containing 1.0 reflecting their modest effect sizes,
which required large discovery cohort sizes for detection.
Environmental Risk Factors. The ORs for seropositive RA
in ever-smokers were 3.10 (95% CI 2.22–4.37) in WTCCC and
4.32 (95% CI 3.16–5.92) in UKRAGG for males and 1.02 (95%
CI 0.84–1.25) in WTCCC and 1.96 (95% CI 1.61–2.40) in
UKRAGG for females. The meta-analysis gender discrepancy
surrounding the effect of ever-smoking on RA risk [5] was
therefore mirrored in our datasets supporting the inclusion of only
males in our smoking models.
Risk Prediction
Risk Categorisation. As hypothesized, our modelling more
accurately categorised ACPA-positive RA as high-risk compared
with seropositive RA (Figure 2 and Table S4). The HLA model
provided most prediction in both datasets, classifying approxi-
mately one third of ACPA-positive RA as high-risk and two thirds
of controls reduced-risk. Although the SNP model provided some
prediction it classified most individuals as average-risk, reflecting
the overlapping CIs generated by including many risk factors of a
small effect size.
In WTCCC, the full genetic (HLA-SNP) model performed
slightly better than HLA alone. Additional smoking data conferred
subtle improvements in categorisation; this is particularly seen with
the HLA-SNP-smoking model, which classified over half of
ACPA-positive RA elevated/high-risk and 59% of controls
reduced-risk.
In UKRAGG the addition of SNPs to HLA alleles increased the
average-risk group size with no clear predictive benefits. The
incorporation of smoking substantially improved prediction: the
Table 2. Classical HLA-DRB1 allele frequencies and their association with seropositive RA in WTCCC and UKRAGG.
Published Meta-Analysis [35] WTCCC UKRAGG
HLA-DRB1 Allele OR (95% CI) MAF Co MAF Ca OR (95% CI) MAF Co MAF Ca OR (95% CI) MAF Co MAF Ca
*01 1.30 (1.21–1.40) 0.113 0.145 1.53 (1.31–1.78) 0.104 0.151 1.27 (1.11–1.45) 0.121 0.149
*01:01 1.38 (1.28–1.50) 0.097 0.133 5.88 (4.62–7.55) 0.026 0.136 1.25 (1.06–1.47) 0.081 0.099
*03 0.59 (0.54–0.64) 0.128 0.082 0.67 (0.58–0.78) 0.148 0.105 0.76 (0.67–0.86) 0.159 0.125
*03:01 0.59 (0.54–0.64) 0.128 0.082 0.65 (0.55–0.76) 0.145 0.099 0.44 (0.37–0.51) 0.130 0.061
*04 3.71 (3.49–3.93) 0.174 0.450 2.90 (2.59–3.24) 0.213 0.439 3.19 (2.86–3.56) 0.184 0.419
*04:01 4.14 (3.86–4.44) 0.104 0.309 2.93 (2.57–3.35) 0.124 0.293 3.00 (2.63–3.42) 0.111 0.272
*04:04 3.17 (2.83–3.54) 0.036 0.091 1.86 (1.52–2.28) 0.052 0.092 2.56 (2.08–3.18) 0.039 0.093
*04:05 2.31 (1.77–3.01) 0.007 0.012 2.01 (1.12–3.73) 0.006 0.012 2.61 (1.34–5.58) 0.004 0.010
*04:08 5.48 (4.11–7.30) 0.005 0.017 -a 0.000 0.021 2.78 (1.70–4.76) 0.007 0.018
*07 0.49 (0.45–0.54) 0.133 0.064 0.48 (0.41–0.56) 0.154 0.080 0.54 (0.46–0.62) 0.142 0.081
*07:01 0.49 (0.45–0.54) 0.133 0.064 0.41 (0.35–0.49) 0.154 0.070 0.37 (0.32–0.44) 0.140 0.057
*08 0.41 (0.34–0.50) 0.029 0.013 0.39 (0.24–0.62) 0.022 0.009 0.30 (0.20–0.44) 0.029 0.009
*08:01 0.34 (0.26–0.44) 0.019 0.009 0.27 (0.13–0.53) 0.014 0.004 0.69 (0.33–1.46) 0.005 0.003
*10 2.53 (2.04–3.14) 0.008 0.020 1.97 (1.11–3.59) 0.006 0.012 1.75 (1.04–3.07) 0.007 0.012
*10:01 2.53 (2.04–3.14) 0.008 0.020 1.97 (1.11–3.59) 0.006 0.012 1.48 (0.85–2.67) 0.006 0.009
*11 0.48 (0.43–0.54) 0.094 0.039 0.50 (0.39–0.64) 0.064 0.033 0.42 (0.34–0.53) 0.065 0.028
*11:01 0.44 (0.38–0.52) 0.061 0.028 0.80 (0.55–1.14) 0.023 0.018 0.33 (0.23–0.47) 0.030 0.010
*11:04 0.15 (0.10–0.23) 0.024 0.008 0.79 (0.41–1.49) 0.008 0.006 0.38 (0.15–0.91) 0.005 0.002
*13 0.33 (0.30–0.37) 0.114 0.044 0.41 (0.33–0.50) 0.098 0.042 0.46 (0.38–0.55) 0.084 0.040
*13:01 0.28 (0.24–0.33) 0.061 0.021 0.77 (0.54–1.08) 0.026 0.020 0.42 (0.29–0.59) 0.027 0.011
*13:02 0.29 (0.23–0.38) 0.027 0.012 0.59 (0.38–0.90) 0.020 0.012 0.27 (0.18–0.42) 0.023 0.006
*14 0.50 (0.40–0.62) 0.025 0.012 0.51 (0.34–0.76) 0.024 0.013 0.45 (0.31–0.65) 0.023 0.010
*14:01 0.46 (0.36–0.59) 0.022 0.011 0.43 (0.28–0.66) 0.024 0.011 0.67 (0.34–1.33) 0.006 0.004
*15 0.59 (0.54–0.64) 0.142 0.092 0.63 (0.53–0.75) 0.128 0.084 0.60 (0.53–0.70) 0.146 0.093
*15:01 0.57 (0.53–0.62) 0.136 0.089 1.09 (0.87–1.37) 0.051 0.055 -a 0.000 0.025
All alleles attained genome-wide significance in the published meta-analysis; MAF=minor allele frequency; Co = controls; Ca =Cases;
a =OR incalculable due to no allele copies in the control group.
doi:10.1371/journal.pgen.1003808.t002
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HLA-SNP-smoking model classified 38% ACPA-positive RA vs.
3% controls as high-risk and 70% controls vs. 18% ACPA-positive
RA as reduced-risk.
The general trend of improved prediction through modelling
increasing numbers of risk factors is highlighted by the ratios of
the percentage of ACPA-positive cases to controls classified
high-risk by each model. In WTCCC these comprise 3.4 for the
SNP model, 3.8 for the HLA model, 5.8 for the HLA-SNP
model, 4.8 for the HLA-smoking model and 6.0 for the HLA-
SNP-smoking model. Similarly, the ratios of the percentage of
controls to ACPA-positive cases classified reduced-risk in
WTCCC comprise 2.3 for the SNP model, 2.4 for the HLA
model, 3.4 for the HLA-SNP model, 4.0 for the HLA-smoking
model and 4.7 for the HLA-SNP-smoking model. Similar
findings were present in UKRAGG.
AUC Assessments. In WTCCC AUCs for the SNP, HLA,
HLA-SNP, HLA-smoking and HLA-SNP-smoking models in
discriminating between ACPA-positive RA and controls com-
prised 0.660 (95% CI 0.638–0.681), 0.764 (95% CI 0.746–0.782),
0.796 (95% CI 0.779–0.813), 0.813 (95% CI 0.784–0.841) and
0.837 (95% CI 0.810–0.865), respectively (Figure 3). Significant
differences in AUCs were observed between all three genetic
models: SNP and HLA models P,0.0001; HLA and HLA-SNP
models P=0.0118. Smoking data significantly improved discrim-
Table 3. Non-HLA RA susceptibility SNP allele frequencies and their association with seropositive RA in WTCCC and UKRAGG.
Published Meta-Analysis [34] WTCCC UKRAGG
Loci SNP MAFa OR MAF Ca/Co OR (95% CI) MAF Ca/Co OR (95% CI)
PTPN22 rs2476601 0.10 1.94 (1.81–2.08) 0.18/0.10 2.02 (1.73–2.36) 0.16/0.10 1.60 (1.38–1.85)
TNFAIP3 rs6920220 0.22 1.22 (1.16–1.29) 0.27/0.23 1.26 (1.12–1.41) 0.25/0.21 1.29 (1.15–1.44)
ANKRD55, IL6ST rs6859219 0.21 0.78 (0.72–0.85) 0.17/0.20 0.80 (0.70–0.91) - -
CD40 rs4810485 0.25 0.85 (0.80–0.90) 0.22/0.24 0.87 (0.77–0.99) 0.22/0.25 0.83 (0.74–0.93)
CTLA4 rs3087243 0.44 0.87 (0.83–0.91) 0.43/0.44 0.95 (0.86–1.06) 0.43/0.47 0.86 (0.78–0.94)
TNFAIP3 rs5029937 0.04 1.40 (1.24–1.58) 0.06/0.04 1.58 (1.24–2.02) 0.05/0.04 1.39 (1.06–1.82)
IL2RA rs706778 0.40 1.14 (1.09–1.20) 0.46/0.42 1.17 (1.05–1.29) 0.43/0.40 1.13 (1.02–1.25)
RBPJ rs874040 0.30 1.14 (1.08–1.20) - - 0.33/0.31 1.11 (1.00–1.23)
TRAF1, C5 rs3761847 0.43 1.13 (1.08–1.18) 0.45/0.46 0.96 (0.87–1.07) 0.46/0.43 1.12 (1.01–1.24)
STAT4 rs7574865 0.22 1.16 (1.10–1.23) 0.21/0.19 1.12 (0.99–1.27) 0.25/0.22 1.18 (1.05–1.32)
SPRED2 rs934734 0.49 1.13 (1.08–1.19) 0.53/0.51 1.11 (1.00–1.23) - -
CCR6 rs3093023 0.43 1.13 (1.08–1.19) 0.42/0.40 1.10 (0.99–1.22) 0.47/0.44 1.16 (1.05–1.28)
PXK rs13315591 0.09 1.29 (1.17–1.43) 0.10/0.09 1.11 (0.94–1.32) 0.08/0.07 1.10 (0.91–1.33)
C5orf30 rs26232 0.32 0.88 (0.84–0.93) 0.34/0.40 0.78 (0.70–0.86) 0.31/0.31 1.03 (0.92–1.14)
CCL21 rs951005 0.16 0.84 (0.78–0.90) - - 0.13/0.15 0.86 (0.75–0.99)
REL rs13031237 0.37 1.13 (1.07–1.18) 0.45/0.43 1.07 (0.96–1.18) 0.41/0.37 1.22 (1.10–1.35)
AFF3 rs10865035 0.47 1.12 (1.07–1.17) 0.50/0.46 1.19 (1.07–1.31) 0.48/0.45 1.16 (1.05–1.27)
PRKCQ rs4750316 0.19 0.87 (0.82–0.92) 0.16/0.20 0.77 (0.67–0.87) 0.18/0.19 0.89 (0.79–1.00)
IRF5 rs10488631 0.11 1.19 (1.10–1.28) 0.12/0.10 1.22 (1.04–1.44) - -
TNFRSF14 rs3890745 0.32 0.89 (0.85–0.94) 0.29/0.32 0.85 (0.76–0.95) 0.32/0.33 0.97 (0.88–1.08)
CD2, CD58 rs11586238 0.24 1.13 (1.07–1.19) 0.26/0.24 1.08 (0.96–1.21) 0.26/0.26 1.05 (0.93–1.17)
BLK rs2736340 0.25 1.12 (1.07–1.18) 0.27/0.25 1.10 (0.98–1.24) 0.26/0.24 1.14 (1.01–1.28)
CD28 rs1980422 0.24 1.12 (1.06–1.18) 0.25/0.23 1.13 (1.01–1.28) 0.26/0.23 1.15 (1.03–1.30)
PRDM1 rs548234 0.33 1.10 (1.05–1.16) 0.36/0.34 1.11 (1.00–1.23) 0.35/0.35 1.00 (0.90–1.10)
CCL21 rs2812378 0.34 1.10 (1.05–1.16) 0.38/0.34 1.17 (1.05–1.30) 0.36/0.35 1.02 (0.92–1.13)
PTPRC rs10919563 0.13 0.88 (0.82–0.94) 0.11/0.13 0.82 (0.70–0.95) 0.13/0.14 0.93 (0.80–1.07)
KIF5A, PIP4K2C rs1678542 0.38 0.91 (0.87–0.96) 0.34/0.37 0.86 (0.77–0.95) 0.35/0.35 0.97 (0.88–1.07)
TRAF6 rs540386 0.14 0.88 (0.83–0.94) 0.11/0.13 0.90 (0.77–1.05) 0.14/0.13 1.03 (0.89–1.19)
FCGR2A rs12746613 0.12 1.13 (1.06–1.21) 0.14/0.12 1.17 (1.01–1.36) 0.14/0.11 1.26 (1.08–1.46)
TAGAP rs394581 0.30 0.91 (0.87–0.96) 0.28/0.30 0.92 (0.82–1.03) 0.28/0.29 0.94 (0.84–1.05)
TNFAIP3 rs10499194 0.27 0.91 (0.87–0.96) 0.25/0.27 0.90 (0.80–1.01) 0.26/0.28 0.90 (0.81–1.00)
IL2, IL21 rs6822844 0.18 0.90 (0.84–0.95) - - 0.15/0.19 0.80 (0.71–0.91)
IL2RA rs2104286 0.27 0.92 (0.87–0.97) 0.24/0.27 0.85 (0.76–0.96) 0.25/0.26 0.94 (0.84–1.04)
IL2RB rs3218253 0.26 1.09 (1.03–1.15) 0.29/0.25 1.22 (1.09–1.37) 0.29/0.27 1.09 (0.98–1.22)
SNPs are ordered by significance (most significant by PGWAS listed first); all alleles attained genome-wide significance in the published meta-analysis; Ca = Cases;
Co = Controls; MAF =Minor Allele Frequency;
a =MAF in controls.
doi:10.1371/journal.pgen.1003808.t003
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ination with differences observed between HLA and HLA-
smoking model AUCs (P=0.0051) and HLA-SNP and HLA-
SNP-smoking model AUCs (P=0.0120).
In UKRAGG AUCs for the SNP, HLA, HLA-SNP, HLA-
smoking and HLA-SNP-smoking models in discriminating be-
tween ACPA-positive RA and controls comprised 0.617 (95% CI
0.577–0.656), 0.748 (95% CI 0.731–0.765), 0.756 (95% CI 0.723–
0.790), 0.813 (95% CI 0.782–0.845) and 0.857 (95% CI 0.804–
0.910), respectively (Figure 3). The HLA model had significantly
better discrimination than the SNP model (P,0.0001). Combined
SNP and HLA data did not improve discrimination with no
differences observed between AUCs for the HLA and HLA-SNP
models (P=0.665) or the HLA-smoking and HLA-SNP-smoking
models (P=0.1671). Additional smoking information significantly
improved modelling discrimination with significant differences
observed between HLA and HLA-smoking model AUCs
(P=0.0003).
An overview of the main findings for each of the 5 prediction
models, alongside the differences between them is provided in
Figure S2.
Risk Distributions. In both datasets the HLA model
provided most risk prediction generating substantially higher and
lower ORs for RA in cases and controls respectively compared
with the SNP model (Figure 4).
In WTCCC the addition of other risk factors to the HLA-DRB1
alleles resulted in further small incremental increases in ORs for
RA in cases; a less pronounced reduction in risk was seen in
controls.
Table 4. Relationship between modelling components and age of RA onset.
WTCCC UKRAGG












HLAa,b 1022 ,0.0001 1.034 (1.018–1.050) 1456 0.0004 1.025 (1.011–1.038) 0.0003 1.026 (1.012–1.040)
SNPa 1022 0.1804 1.043 (0.981–1.110) 284 0.294 1.075 (0.939–1.230) - -
Genderb 1021 0.2157 0.914 (0.792–1.054) 1456 0.0107 0.864 (0.722–0.967) 0.0465 0.885 (0.786–0.998)
Smokingb 962 0.1301 0.902 (0.789–1.031) 1361 0.0009 0.830 (0.743–0.927) 0.0041 0.848 (0.757–0.949)
Gender-Smoking Interactionb 961 0.0823 0.870 (0.744–1.018) 1361 0.009 0.846 (0.746–0.959) 0.8369 -
a =HLA and SNP variables represent the summary OR scores generated by the models incorporating HLA and SNP data respectively;
b = variables included in UKRAGG multivariate model after variable pruning using backwards selection and model comparison with Akaike’s Information Criterion;
c = as only one parameter was significant in the WTCCC univariate analysis no multivariate model was fitted.
doi:10.1371/journal.pgen.1003808.t004
Figure 2. Risk categorisation of RA and controls by each prediction model. The y-axis on each graph refers to the proportion of cases/
controls in each risk category; cont = controls; sero+= seropositive RA; ACPA+=ACPA-positive RA.
doi:10.1371/journal.pgen.1003808.g002
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In UKRAGG the addition of SNPs to HLA data provided no
changes in case risk profiles, although a minority of controls had
lower ORs. Additional smoking data resulted in significantly
higher ORs for cases; only the HLA-SNP-smoking model clearly
generated lower risk profiles for controls.
Lifetime Risk Prediction. Evaluating risks using genetics
(HLA-SNP model) alone the highest risk WTCCC ACPA-positive
case had an OR for seropositive RA of 79; as a male his lifetime
risk was estimated at 86%. The highest risk control had an OR of
22; as a female her lifetime risk was estimated at 53%. Despite
such high individual odds only a relative minority had relevant
increased lifetime risks: using the same HLA-SNP model 49
(4.61%) ACPA-positive cases and 1 (0.07%) control had ORs for
seropositive RA.20 (lifetime risks .48% if female and .22% if
male) in WTCCC. In UKRAGG 9 (3.06%) ACPA-positive cases
and 1 (0.17%) control had ORs.20.
The HLA-SNP-smoking model identified the greatest propor-
tion of cases with substantially increased lifetime risks for RA. This
model identified 18 (7.53%) and 3 (3.75%) ACPA-positive male
cases to have ORs for seropositive RA.20 (lifetime risk .22%) in
WTCCC and UKRAGG respectively; no controls had ORs.20.
Younger Onset RA Prediction
In WTCCC the HLA model summary OR score was the only
significant predictor of age of RA onset (Table 4). The hazard ratio
(HR) was 1.034 (P,0.0001), which indicated that the hazard (the
rate at which RA occurred) was greater in individuals with higher
HLA derived ORs than those with lower ORs. Therefore a higher
HLA model generated risk score associated with RA occurring at a
faster rate and thus YORA. Conversely ever-smoking was
associated with older onset RA: the HR of 0.902 indicated a
smaller hazard (RA occurred at a slower rate) in ever-smokers
compared with never-smokers, although this was not significant
(P=0.1301).
In UKRAGG the HLA model summary OR score, gender and
smoking status were significant independent predictors of age of
Figure 3. Prediction model receiver operating characteristic curves. Panel A =WTCCC; Panel B =UKRAGG; ROCs calculated for discriminating
between ACPA-positive RA and controls; AUC= area under the curve. WTCCC model AUC comparisons: SNP versus HLA, P,0.0001; HLA versus HLA-
SNP, P= 0.0118; HLA-SNP versus HLA-Smoking, P=0.3327; HLA-Smoking versus HLA-SNP-Smoking, P=0.0001. UKRAGG model AUC comparisons: SNP
versus HLA, P,0.0001; HLA versus HLA-SNP, P=0.665; HLA-SNP versus HLA-Smoking, P= 0.0145; HLA-Smoking versus HLA-SNP-Smoking, P= 0.1671.
doi:10.1371/journal.pgen.1003808.g003
Figure 4. Prediction model generated risk profiles for ACPA-positive RA and controls. Panel A =WTCCC; Panel B =UKRAGG; the upper set
of lines for each model refer to RA cases; the lower set of lines refer to controls; OR= odds ratio.
doi:10.1371/journal.pgen.1003808.g004
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onset. An increasing HLA summary OR score associated with
YORA (P=0.0003, HR 1.026); ever-smoking (P=0.0041, HR
0.848) and male gender (P=0.0465, HR 0.885) associated with
older onset RA.
We considered that the non-significant relationship between
smoking and age of onset in WTCCC reflected a limited sample
size with our power to detect a 0.88 HR in the 962 WTCCC cases
approximately 51% compared with 65% for the 1,361 UKRAGG
cases. We therefore undertook a pooled analysis of both datasets
(incorporating an additional ‘‘study’’ variable to account for
dataset median age of onset differences). This confirmed that HLA
derived risk scores significantly associated with YORA (P,0.0001,
HR 1.030) and ever-smoking significantly associated with older
onset RA (P=0.0489, HR 0.889).
Kaplan-Meier curves of age of onset stratified by HLA model
risk categorisation further demonstrate the association of HLA risk
profiles with YORA (Figure 5) with cases classified high-risk
having significantly younger onset ages compared to those
classified reduced-risk. In WTCCC the difference in the median
time to RA (time point at which half the cases have developed RA)
was 3 years between those classed high- and reduced-risk (Log-
Rank= 11.43; P=0.0007). In UKRAGG a stronger association
was seen (Log-Rank= 27.33; P,0.0001) with a difference in
median time to RA onset between risk groups of 6 years. Further
stratification by ever-smoking status demonstrated a trend towards
an older onset age in ever-smokers. In WTCCC the median time
to onset difference between high-risk never-smokers and reduced-
risk ever-smokers was 7 years (Log-Rank= 14.42; P=0.0024); a
larger disparity was seen in UKRAGG with a difference of 12
years observed (Log-Rank= 46.2505; P,0.0001).
Examining which four-digit resolution HLA-DRB1 alleles
influenced onset age revealed significant associations between
age of onset and *03:01 (P=0.0313), *04:01 (P=0.0001), *04:08
(P=0.0032) and *13:02 (P=0.0097) in WTCCC and *04:01
(P,0.0001) and *04:04 (P=0.0243) in UKRAGG. Three of these
alleles (*04:01, *04:04 and *04:08) are shared-epitope alleles.
Discussion
We have demonstrated that predicting RA development is
possible with our prediction models able to identify individuals
with clinically relevant increased risks for seropositive RA. Our
modelling indicates that most prediction is provided by HLA-
DRB1 alleles and, to a lesser extent, smoking in males; non-HLA
susceptibility SNPs provide only minor predictive benefits. These
findings are consistent with the estimations of heritability variance
Figure 5. Kaplan-Meier curves: RA age of onset stratified by HLA model risk categorisation and smoking status. Panel A=WTCCC
Curves Stratified By Risk Categorisation; Panel B =UKRAGG Curves Stratified By Risk Categorisation; Panel C =WTCCC Curves Stratified By Risk
Categorisation and Ever-Smoking Status; Panel D=UKRAGG Curves Stratified By Risk Categorisation and Ever-Smoking Status; D= change in onset
age; Dm=maximum change in onset age across strata.
doi:10.1371/journal.pgen.1003808.g005
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conferred by different genetic components. We have also shown it
is possible to predict the age of RA onset, using information on
HLA and smoking to identify those at risk of younger and older
onset RA, respectively. Whilst our novel modelling approach,
which uses computer simulation-based categorisation alongside a
greater number of HLA alleles, significantly improves upon the
discriminative abilities of existing models [26], [27] it remains
unsuitable for population screening with only a minority at
significantly increased lifetime risks for RA.
Our approach provides some potential advantages over
existing RA prediction modelling [26], [27]. Firstly, by using a
simulated population to generate risk profiles we do not require
an entire population of real-life data to stratify risks. In contrast
existing approaches categorise wGRS scores using their Gauss-
ian distribution in control groups. Secondly, our CI-based
approach considers the precision with which risk factor effect
sizes are known when classifying risk; this prevents classifying
people high-risk if their risk is imprecisely known. Thirdly, our
models provide greater discrimination: the highest AUC for
existing clinical-genetic models in discerning ACPA-positive RA
from controls is 0.752; the highest AUC for our clinical-genetic
model is 0.857.
SNPs provided only minor improvements in prediction,
highlighting the limitations of genome-wide association study
(GWAS) derived data in this field. Although GWAS-established
SNPs have helped identify cellular pathways relevant to RA
pathogenesis [51] their modest effect sizes limit their predictive
utility. It has been proposed that the missing heritability of RA
may reflect the involvement of rare variants of large effect sizes or
structural variants [52]. Alternative genotyping technologies such
as next-generation sequencing may identify these variants,
although only loci with large effect sizes will substantially improve
prediction modelling.
Although individuals with clinically relevant increased lifetime
risks (such as 86%) for RA were identified there was, overall, only
a minority of individuals at a significantly elevated risk: 7% of
ACPA-positive individuals had lifetime risks of 22% or more when
evaluated using all available risk factors. Therefore despite high
AUCs our modelling is unsuitable for population level screening.
However, if its use was targeted to groups with a priori increased
risks, such as first degree relatives of RA probands [53–55], then a
substantially greater proportion of very high-risk individuals might
be identified.
Individuals classified high-risk by our HLA model were more
likely to develop RA at a younger age. This finding – mainly
attributable to the *04:01 allele – is supported by existing
literature. Hellier et al reported a higher frequency of *04 RA
associated alleles in YORA (present in 52% of 262 RA cases with
onset age ,60) compared with elderly onset RA (present in 37%
of 60 cases with onset age .60; P=0.045) [18]. Similarly, Wu et al
identified a significantly younger age of onset in Caucasian RA
patients carrying shared epitope encoding *04 alleles (P=0.0003)
[19]. Other studies report positive correlations between YORA
and shared epitope alleles [25], [56]. Our finding of ever-smoking
associating with older onset RA is less established. It has only been
examined in three relatively small studies, with contrasting
outcomes: one study reported a significant relationship between
smoking at disease onset and a younger onset age [57]; one
reported a younger onset age in current vs. never-smokers
(although ex-smokers had older onset RA in comparison to both
these groups) [58]; the final study found no association [59]. Our
findings – demonstrated in 2,323 individuals across two indepen-
dent datasets – are biologically plausible. As risk genotypes are
present from birth they can exert their effects on disease risk
throughout an individual’s lifetime; therefore possessing high-risk
HLA-DRB1 alleles predisposes to RA at a younger age. In contrast
the risk of RA increases as more cigarettes are smoked [60], [61]
and smokers are exposed to more cigarettes as they age; therefore
smokers are more likely to develop RA as they get older because
they have been exposed to more cigarettes and thus smoking
associates with older onset RA. This logic also explains why ever-
smoking associates with older onset RA in both men and women,
with heavy smoking a risk factor for RA in both genders [5]. We
were, however, unable to incorporate heavy smoking in our
prediction modelling due to a paucity of data on smoking pack-
years in WTCCC/UKRAGG.
We incorporated many genetic risk factors in our modelling but
included only one environmental risk factor, smoking. This reflects
uncertainty regarding relevant environmental risks alongside
limited environmental data within current genetic datasets.
Although many environmental factors are linked to RA their
associations are usually identified in case-control studies, which are
subject to multiple biases, rather than cohort studies. Examples
include alcohol consumption [36], parity [62], [63] and oral
contraceptive pill use [64]. Better characterisation of environmen-
tal risks will enhance predictive modelling.
Our modelling has several limitations. Firstly, WTCCC
participants were included in the meta-analyses that we
obtained our genetic risk loci data from; however WTCCC
comprised only a proportion of the meta-analyses datasets (20%
of the HLA meta-analysis; 29% of the SNP meta-analysis) and
our findings were independently replicated in UKRAGG.
Secondly, missing data meant the number of individuals
included in each model fell as more risk factors were included;
this is particularly seen in models incorporating smoking.
Thirdly, due to marked heterogeneity in published data on
gene-gene/gene-environment interactions we assumed indepen-
dence between these factors despite known interactions existing
between the shared epitope alleles and PTPN22 and smoking
[6], [7], [29], [37], [38].
Improving RA prediction requires better clarification of its
genetic and environmental risk factors. Identifying risk factors with
large effect sizes of known precision will most enhance prediction
modelling. This could be facilitated through fine-mapping studies
that better tag causal variants [65] alongside prospective cohort
studies examining environmental risk factors in RA cases
subdivided by ACPA status, with increasing evidence that risks
differ between these serological subsets [36], [66]. It is, however,
unlikely that identifying such risk factors will substantially increase
the proportion of individuals with clinically relevant high disease
risks. We therefore consider that prediction modelling requires
evaluation in a priori higher risk groups. In this context it may
identify sufficient numbers of very high-risk individuals, facilitating
a better understanding of pre-RA immunopathology and enabling
the assessment of primary prevention strategies.
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Figure S1. REGENT Stage 1-Simulation of General Population Risk Profiles: 
Example Using a Model Incorporating 3 SNPs 
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0.758 (0.733-0.782) 0.749 (0.724-0.773) 0.783 (0.760-0.806) 0.738 (0.690-0.786) 
Data are number (%) unless stated otherwise; 
a




Table S2. Proxy SNPs Used In Modelling 
WTCCC 
Meta-Analysis SNP 
(Stahl, et al., 2010) 





































(Stahl et al, 2010) 









a = proxy SNP obtained using 1,000 Genomes CEU population panel (Johnson, et al., 2008); b = proxy SNP obtained using HapMap release 22 
CEU population panel (Johnson et al, 2008); c = proxy SNP obtained using Ricopili (Broad Institute, Boston, USA) from the GWAS meta-




Table S3. Two-Digit, Four-Digit and Mixed-Digit HLA Prediction Model Results  
WTCCC 
Risk Category 

































































































0.744 (0.726-0.763) 0.765 (0.745-0.785) 0.764 (0.746-0.782) 
UKRAGG 
Risk Category 

































































































0.743 (0.725-0.760) 0.743 (0.720-0.766) 0.748 (0.731-0.765) 
Data are number (%) unless stated otherwise; Sero+ = seropositive RA; ACPA+ = ACPA-positive RA; AUCs calculated using ACPA-positive 
cases; two-digit model evaluated individuals with all available HLA data collapsed down to two-digit resolution.  
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Table S4. Prediction Model Results: Risk Categorisation 
WTCCC Prediction Models 
Risk 
Category 



























































































































































UKRAGG Prediction Models 
Risk 
Category 



























































































































































Data are number (%); Sero+ = seropositive RA; ACPA+ = ACPA-positive RA.
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CHAPTER 7.   DISCUSSION 
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7.1. Main Research Findings 
This thesis has increased the knowledge of risk prediction in RA. This is an 
important step towards the implementation of a stratified approach to the 
management of this heterogeneous disease. The research in this thesis has enhanced 
the understanding of those factors that predict RA development, the subsequent 
clinical course of the disease, and the responses of patients to different treatment 
regimens. It has also demonstrated how these factors can be combined within a novel 
risk prediction modelling framework to estimate individuals’ absolute risks of 
developing RA. This modelling could be used to stratify patients to groups that may 
benefit from preventive treatment strategies. 
 
The findings from this thesis can be divided into five key areas. Firstly, it has 
improved the knowledge of which risk factors predict RA development by 
demonstrating that a significant inverse relationship exists between alcohol 
consumption and the risk of RA when the evidence across published studies is 
pooled using meta-analytical techniques. This suggests alcohol intake may protect 
against RA development. The research underlying this is outlined in Chapter 2 of this 
thesis. 
 
Secondly, it has demonstrated an association between HLA susceptibility variants 
and radiological progression in a unique clinical trial cohort of early, active RA 
patients, whilst demonstrating that non-HLA susceptibility variants for RA and other 
immune-mediated diseases do not associate with this disease outcome in the same 
patient group. This suggests that the non-HLA genetic architectures of RA 
susceptibility and severity probably, at least in part, differ. The research underlying 
this is outlined in Chapters 3 and 4 of this thesis. 
 
Thirdly, it has shown that patients with early, active ACPA-positive and ACPA-
negative RA differ in their requirements for, and responses to, intensive combination 
DMARD and corticosteroid treatments. This suggests that ACPA status is an 
important biomarker for guiding treatment decisions in early, active RA patients. The 




Fourthly, it has demonstrated that estimating an asymptomatic individual’s future 
risk of RA is possible, through developing and validating a risk prediction model that 
uses computer simulation to significantly improve upon the discriminative abilities 
of existing prediction models for this disease. This has provided a modelling 
framework that is applicable to many aspects of stratified medicine. The research 
underlying this is outlined in Chapter 6 of this thesis. 
 
Finally, it has highlighted the importance of considering RA’s heterogeneity when 
assessing its predictive factors, by demonstrating that a) the protective effect of 
alcohol on RA development is predominantly seen in ACPA-positive disease 
(Chapter 2); b) prediction modelling is more effective for ACPA-positive (as 
opposed to seropositive) disease (Chapter 6); and c) genetic and environmental 
factors have different impacts on the risk of developing younger and older onset RA, 
with genetic and environmental risk effects greater in YORA and elderly onset RA 
(EORA), respectively (Chapter 6). 
  
7.2. Alcohol Consumption and RA Development 
7.2.1.  Principal Findings 
Through systematically reviewing and performing a meta-analysis of published 
studies this thesis has demonstrated that a significant inverse relationship exists 
between alcohol consumption and the development of RA (Scott et al, 2013c). In 
those studies evaluating risk stratified by ACPA status a significant association was 
only observed for ACPA-positive RA. Taken together these findings indicate that 
alcohol intake probably protects against RA development, particularly ACPA-
positive disease. 
 
7.2.2.  Strengths and Limitations 
The strengths of this systematic review and meta-analysis are that it was performed 
in a highly standardised and systematic manner, testing a pre-specified hypothesis 
and according to a pre-defined protocol. Its main limitation was that causality could 
not be determined as a non-significant relationship was seen when the meta-analysis 
was restricted to cohort studies. There are many reasons why RA patients may 
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consume less alcohol, such as methotrexate use, and therefore asking patients to 
recall their past alcohol consumption ‒ as would have been undertaken in most of the 
case-control studies ‒ could be affected by recall bias; this could account for the 
inverse association observed.  Another important limitation was that marked clinical 
and methodological heterogeneity existed between the included studies, which had 
significant variation in not only their findings but also how they defined and captured 
information on alcohol consumption. This limited the suitability of combining their 
results to provide an overall OR for RA. 
 
7.2.3. Further Research 
Since this literature review was performed a further two prospective cohort studies 
have been published (EPIC-2-NOAR and the NHS), which support its findings 
(Lahiri et al, 2014, Lu et al, 2014). Both studies reported risks using HRs. In EPIC-2-
NOAR the age and sex adjusted HR for seropositive inflammatory arthritis for every 
7 units of alcohol consumed/week was 0.83 (95% CI 0.69-0.98) (Lahiri et al, 2014). 
In the NHS the pooled multivariable adjusted HR for seropositive RA in alcohol 
drinkers consuming 5.0-9.9 grams/day compared to non-drinkers was 0.69 (95% CI 
0.50-0.95) (Lu et al, 2014). As these studies used HRs to quantify risk they could not 
be included in a meta-analysis with the cohort studies identified by the published 
literature review. These two studies, however, provide further support for the concept 
that alcohol has a direct protective effect on RA development. As previously 
discussed this could be mediated via attenuation of the innate immune system 
(Jonsson et al, 2007, Mandrekar et al, 2006). 
 
7.2.4.  Clinical Implications 
As most individual’s risks of developing RA are low and alcohol consumption is 
associated with many adverse outcomes, it seems inappropriate to apply the finding 
of alcohol protecting against RA development in a public health context, in which 
asymptomatic individuals are advised to consume alcohol to prevent RA. The key 
clinical implication of this work is that data on alcohol consumption could be 
incorporated within risk prediction models to improve their ability to stratify 
asymptomatic individuals into risk groups for RA development. Identifying high-risk 
individuals would enable preventive strategies to be evaluated. 
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7.3. Genetic Markers for Radiological Progression 
7.3.1. Principal Findings 
This thesis has confirmed the influence of HLA susceptibility variants on 
radiological progression in RA, by demonstrating that the three main HLA risk 
variants (the HLA-DRB1*04:01 allele and Val11 and His13 in the HLA-DRβ1 
molecule) also associated with Larsen score progression in early, active RA patients 
in the CARDERA Genetics Cohort (CGC). This effect appeared to be independent of 
ACPA status, with similar effect sizes observed on restricting the analysis to ACPA-
positive individuals. Conditional analyses indicated the association at both Val11 and 
His13 was driven by the tight LD between them, although it was not possible to 
establish which had the dominant association. Furthermore, conditional analyses also 
suggested their association was driven by a high correlation with the SE at positions 
70-74. Due to the broad LD across the MHC region (De Bakker et al, 2006) 
alongside the modest size of the CGC it was not possible to further characterise 
which HLA amino acid positions had a SE-independent association with joint 
destruction. 
 
This thesis has also demonstrated that no significant association exists between non-
HLA susceptibility loci and radiological progression in the CGC, when evaluating 
these variants both individually and cumulatively, using a wGRS. Although the 
sample size of 524 patients is substantially smaller than the combined GWASs 
evaluated to identify these susceptibility loci (Okada et al, 2013), the CGC was 
adequately powered (at >80%) to detect genetic markers accounting for just 2% of 
the variance in X-ray progression. This indicates that non-HLA susceptibility loci do 
not have a clinically relevant association with radiological progression in early, 
active RA patients. It also suggests that the non-HLA genetic architectures of RA 
susceptibility and severity probably, at least in part, differ.  
 
Finally, this thesis demonstrated no significant association between 138,488 genetic 
markers linked to a broad range of immune-mediated disorders present on the 
ImmunoChip and joint destruction rates in the CGC. When this analysis is 
considered alongside the two other similarly sized genome-wide studies, which have 
only identified 3 replicable associations with radiological progression in RA between 
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them (De Rooy et al, 2013b, Knevel et al, 2013b), it appears likely that the genetic 
architecture of radiological progression in RA is comprised of many variants of a 
small effect size. This suggests the optimal strategy to capture relevant variants is 
through the meta-analysis of GWASs. 
 
7.3.2. Strengths and Limitations 
This component of the thesis represents the first analysis of genetic associations with 
radiological progression in early, active RA patients within a clinical trial setting. As 
such it has a number of unique strengths. Firstly, as all patients had active disease it 
was able to identify genetic markers that associated with radiological progression 
independently of baseline disease activity. In contrast, existing studies use 
observational data from cohorts of patients with a range of disease activities; they 
are, therefore, unable to discern between genetic variants associating indirectly with 
radiological progression through influences on disease activity and those variants 
directly mediating radiological progression. Secondly, as the evidence base for using 
intensive combination therapy in RA is based on RCTs of patients with early, active 
disease (Boers et al, 1997a, Goekoop-Ruiterman et al, 2008, Mottonen, et al., 1999), 
if genetic predictors are to be of clinical value in guiding treatment decisions they too 
require evaluation in patients with early, active RA. Thirdly, all radiological 
assessments were performed in a timely, standardised manner. Fourthly, the 
regularity of Larsen scoring optimised the power to detect longitudinal associations. 
Fifthly, the randomisation to treatment groups ensured the effects of treatment could 
be fully adjusted for. 
 
This analysis also has a number of important limitations. Foremost is its modest 
sample size of 524 patients, which limited the power to detect genetic associations of 
a small effect size. The analysis in Chapter 3, however, was well powered to detect 
variants accounting for ≥2% of the variance in radiological progression when 
applying a Bonferroni correction for testing 69 susceptibility variants; therefore, it 
was adequately powered to detect any susceptibility markers providing clinically 
useful information. The genome-wide study in Chapter 4 was substantially less well 
powered; it therefore probably contains a high false-negative rate. Secondly, only 24-
month radiological data were available; genetic variants could exert their effects over 
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longer time periods. Thirdly, as with most longitudinal studies, outcome data were 
missing in some, albeit a minority, of patients. However, the linear mixed-effects 
model was able to accommodate missing data, by making the assumption that these 
were missing-at-random (MAR) (Higgins and Green, 2011). Additionally, similar 
results were obtained for the ANOVA model used in Chapter 3, which excluded 
individuals with missing Larsen score data. Fourthly, as the CGC comprised 
individuals from RCTs, radiological progression rates could be lower than those seen 
in observational studies, further reducing the analysis power. This seemed unlikely 
with similar proportions of CGC patients having clinically relevant Larsen score 
progression in comparison to observational studies of early RA patients (Sanmarti et 
al, 2007). Furthermore, the linear mixed-effects model was able to detect known 
associations with X-ray damage in the CGC, such as disease duration, ACPA status, 
and *04:01 carriage. Fifthly, although within the CGC radiological progression rates 
were linear, this is unlikely to persist over longer disease periods. Therefore, the β-
values associated with each variant may only be applicable to the first few years of 
disease. Finally, several validated, non-HLA genetic associations with radiological 
progression identified in other studies were not replicated in the CGC. Although this 
further questions the power of the study, this non-replication is not unique. Within 
the Leiden ImmunoChip study only 14% of the identification cohort’s significant 
SNPs present in the replication dataset attained statistical significance in this latter 
cohort (De Rooy et al, 2013b). Additionally, Knevel et al failed to replicate 
associations between TRAF1-C5 and TNFAIP3-OLIG3 variants and radiological 
progression across 6 independent cohorts (Knevel et al, 2012a). As discussed in 
Chapter 3, the two most likely explanations for this non-replication are firstly, that 
the CGC population − which comprises patients with early, severely active disease − 
is inherently different to the populations evaluated in these observational studies, 
which assessed patients with a range of disease durations and severities and 
secondly, the CGC looked at predictors of X-ray progression in the first 2 years of 
disease and other studies evaluated damage over longer time periods. Other 
explanations include the fact that previous studies were not able to fully adjust for 
the effects of treatment; some studies assessed genotype effects on the severity of X-
ray damage, as opposed to its impact on progression over time; and the use of 
different radiological scoring systems across studies. 
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7.3.3. Further Research 
There are four areas of further research, which are relevant to the candidate gene and 
genome-wide analyses undertaken in this thesis. Firstly, modern genotyped cohorts 
of RA patients with regular radiological scores present from diagnosis are needed. 
Nine observational study cohorts exist that have been widely used to identify genetic 
predictors of radiological progression in RA (Table 7-1). As most include patients 
with longstanding disease evaluated several decades ago their radiographic outcomes 
are likely to be substantially worse than those observed in currently diagnosed 
individuals and the relevance of their findings to contemporary practice is uncertain. 
Additionally, 4 of these studies only had a single X-ray score performed during 
established disease; they therefore often used estimated yearly progression (X-ray 
score divided by disease duration in years at the time of the radiograph) as the 
response variable in linear regression analyses. This makes the assumption that 
radiological progression is a linear trait, which whilst probably true in early disease 
(Hulsmans, et al., 2000) is unlikely to be valid in established RA. One observed 
pattern is that radiological progression is greatest in the first few years of disease and 
reduces thereafter (Lindqvist, et al., 2003) although a diverse range of progression 
patterns have been described (Plant, et al., 1998). This indicates a key research 
requirement to establish modern genotyped cohorts of RA patients, with radiological 
scores present at diagnosis and regular intervals thereafter. This will enable the most 
accurate modelling of X-ray progression and any positive associations are more 










Outcome X-ray Frequency Main Statistical Methods Loci Identified/Validated 
Leiden EAC 600 1993–06 7 yrs SvHS Annual Longitudinal linear model 
CD40, IL15, DKK1, IL2RA, 
GRZB, IL4, SPAG16, C5orf30, 
MMP9, ZFP36L1/C14orf181 
NARAC 385 1953–02 NA SvHS Single (duration 14 yrs) Linear regression model CD40, IL4, SPAG16 
Groningen 280 1945–01 14 yrs SvHS Multiple (variable times) Multivariate regression model IL15, DKK1, GRZB, IL4 
Lund 147 1985–90 5 yrs Larsen Annual Multivariate regression model IL15, DKK1, GRZB, IL4 
Iceland 285 1942–08 NA SvHS Single (unspecified) Linear regression model IL2RA 
Wichita 113 1963–99 10 yrs SvHS Multiple (variable times) Multivariate regression model 
IL2RA, IL4, SPAG16, MMP9, 
ZFP36L1/C14orf181 
NDB 756 1980–99 NA SvHS Single (duration 12 yrs) Linear regression model 
IL2RA, IL4, SPAG16, MMP9, 
ZFP36L1/C14orf181 
YEAR 418 2000-09 2 yrs SvHS Annual ZINB evaluating baseline SvHS C5orf30 
GORAa 885 - NA Larsen Single (duration 12 yrs) ZINB/linear regression model 
C5orf30, IL15, DKK1, GRZB, 
IL4 
Loci and the relevant cohorts are described in the following papers: CD40 (Van Der Linden et al, 2009), IL15 (Knevel, et al., 2012a), DKK1 (De 
Rooy, et al., 2013a), IL2RA (Knevel et al, 2013a), GRZB (Knevel, et al., 2013a), IL4 (Krabben et al, 2013), SPAG16 (Knevel et al, 2013b), 
C5orf30 (Teare et al, 2013), MMP9 (De Rooy et al, 2013b), ZFP36L1/C14orf181 (De Rooy et al, 2013b). EAC = Early Arthritis Clinic; NARAC 
= North American RA Consortium; NDB = National Data Bank; YEAR = Yorkshire Early Arthritis Register; GORA = Genetics of RA; Yrs = 
years; ZINB = zero-inflated negative binomial regression model; SvHS = Sharp-van der Heijde score; a = subset of 391-396 patients from the 
GORA cohort was used to evaluate IL15, DKK1, GRZB and IL4 loci.
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Secondly, meta-analyses of GWASs evaluating X-ray progression in RA are required 
to define its genetic architecture. The 12 validated genetic loci associations with 
radiological progression in RA have been estimated in the Leiden EAC to explain 
only 12-18% of the variance in joint destruction in this cohort (Van Steenbergen, et 
al., 2014); this indicates that a substantial proportion of the heritability of X-ray 
progression remains unexplained. As the genetic basis of radiological progression 
probably comprises multiple small effect size variants, the optimal strategy to define 
these is through the meta-analysis of GWASs. A collaborative study is required to 
undertake this in the existing available cohorts, although any findings will be limited 
by the heterogeneity across individual studies and the modelling assumptions 
required to undertaken a meta-analysis.  
 
Thirdly, in view of the importance of the HLA region to joint destruction in RA an 
HLA-wide analysis of its association with X-ray progression across multiple large 
cohorts is needed, in a similar manner to that undertaken for RA susceptibility 
(Raychaudhuri et al, 2012) . The broad LD across the MHC alongside the fact that 
many amino acid polymorphisms external to positions 70-74 are correlated with the 
SE sequence indicates that very large sample sizes are required in order to dissect the 
relevant amino acid positions through conditional analyses. 
 
Fourthly, further work is required to establish the heritability of other RA outcomes 
such as disease activity scores, disability levels and quality of life. The relevance of 
X-ray progression to contemporary practice is uncertain due to the lower levels of 
baseline radiographic damage observed in currently diagnosed RA patients (Rahman 
et al, 2011), the effect of combination DMARDs and biologics in limiting joint 
destruction (Goekoop-Ruiterman et al, 2008, Boers et al, 1997a, Graudal and 
Jurgens, 2010) and the limited correlation between radiological scores and other 
clinical responses (Strand and Sharp, 2003). If other RA outcomes are shown to have 
a significant genetic component then identifying their genetic predictors could 






7.3.4. Clinical Implications 
The findings from this thesis indicate that non-HLA genetic susceptibility variants 
for RA are unlikely to provide clinically informative data for guiding treatment 
decisions in early RA patients. Okada et al recently proposed that GWAS identified 
susceptibility loci could be harnessed to identify therapeutic agents currently used in 
other diseases, which could be repurposed for RA treatment (Okada et al, 2013). The 
findings from the CGC suggest this approach would be more successful in 
identifying preventative treatments, as opposed to drugs that modify the disease 
course of an established RA phenotype. 
 
7.4. ACPA Status Predicts Treatment Requirements and Responses 
7.4.1. Principal Findings 
A secondary analysis of the CARDERA-1 trial demonstrated that only ACPA-
positive, early, active RA patients benefited from intensive treatment with 
combination DMARDs and high-dose, tapering corticosteroids; no benefits beyond 
methotrexate monotherapy were observed in ACPA-negative patients. In this 
analysis intensive combination therapy was only needed to prevent radiological 
progression in ACPA-positive patients. Additionally, corticosteroids only provided 
significant improvements in disease activity and physical health outcomes in ACPA-
positive RA. Taken together these findings suggest that current NICE guidelines 
advocating combination DMARDs and short-term corticosteroids in all patients 
presenting with active disease may result in the over-treatment of ACPA-negative 
individuals. They support a stratified approach to the management of early RA 
patients, based on prognostic markers like ACPA. 
 
7.4.2. Strengths and Limitations 
The strengths of this study included its large sample size (431 patients represents a 
reasonable size for an RCT), the involvement of multiple centers throughout the UK, 
which increases the generalisability of its findings, the measurement of a wide range 




It has several limitations. As a secondary analysis of a published RCT it did not test a 
pre-specified primary hypothesis or use a pre-specified analytical plan. ACPA status 
was unknown in 8% of patients, who were excluded from the analysis. One of the 
study drugs, ciclosporin, is rarely used in current practice. Fewer ACPA-negative 
patients were studied; however, the power to detect a MCID in Larsen scores 
between combination therapy and monotherapy treatment arms in ACPA-negative 
patients was higher (86%) than in ACPA-positive patients (55%). Finally, the 
maximal dose of methotrexate was 15 mg/week; higher doses are often used in 
contemporary clinical care. 
 
7.4.3. Further Research 
Further work is required to evaluate the role of ACPA status in predicting firstly, the 
benefits of more commonly used combination DMARD regimes (such as 
methotrexate, hydroxychloroquine and sulfasalazine) and secondly, responses to low 
dose corticosteroids (such as intramuscular depomederone) in early, active RA 
patients. Additionally, there is a clear requirement for other reproducible prognostic 
and treatment response biomarkers to be identified because, as outlined in the 
introductory chapter of this thesis, current knowledge of these is limited. 
 
In addition to the main analysis undertaken in this thesis, a subsidiary study was 
completed in the CARDERA-1 trial. This assessed if clinical and serological (IgM-
RF and ACPA) markers predicted DAS28 defined remission rates in response to 
combination DMARDs. This work followed on from a previous systematic review 
by Ma et al, which demonstrated that combination DMARDs increased remission 
rates in early RA patients (Ma et al, 2010). The published results (Ma, et al., 2014) 
showed that gender, age, TJC, RF and ACPA status associated with an increased 
likelihood of attaining remission at 24-months. Patients that were male, aged over 50 
years, had ≥6 tender joints, were RF-positive or ACPA-positive were more likely to 
achieve remission at 24-months when receiving triple therapy compared to 
monotherapy (ORs for remission of 2.99, 4.95, 2.71, 2.54 and 3.52, respectively). As 
this study represented a more restricted analysis of the CARDERA-1 outcome data at 
a single time point, and focused on remission only, it has not been incorporated 
within the main body of this thesis. However, it provides supportive data for the use 
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of serology and other clinical markers to predict intensive combination treatment 
responses.  
 
7.4.4. Clinical Implications 
The findings from this analysis, which are supported by data from the BeST study 
(De Vries-Bouwstra et al, 2008), suggest that ACPA is an important biomarker for 
stratifying early, active RA patients to treatment subgroups. It would be 
inappropriate to recommend that all ACPA-negative individuals receive DMARD 
monotherapy based on the results of the CARDERA-1 trial; although they show a 
lack of benefit beyond methotrexate monotherapy in ACPA-negative patients, it is 
likely that other combination treatments will have a positive impact in these 
individuals. However, if ACPA is considered alongside other poor prognostic 
markers, like the presence of radiological erosions, then the stratification of patients 
to treatment subgroups should be possible. This approach is already being 
undertaken in the USA, with current ACR guidelines recommending that 
combination DMARD use is restricted to patient subgroups with poor prognostic 
factors such as ACPA (Singh, et al., 2012). Although in England and Wales current 
NICE guidelines do not advocate such an approach, a recent national audit of UK 
rheumatologists reported that only 50% used initial combination therapy in patients 
with newly diagnosed RA; poor prognostic markers like erosions and ACPA 
positivity were key factors in determining whether combination therapy was used 
(Garrood et al, 2011). The clinical implications of this study are, therefore, that 
stratified medicine in RA is possible, with ACPA status representing one such 
method of stratifying patients into subgroups that are more, or less likely to benefit 
from combination treatments. 
 
7.5. Improved Risk Prediction Modelling for RA 
7.5.1. Principal Findings 
The study outlined in Chapter 6 of this thesis demonstrated that it is possible to use 
validated RA risk factors to estimate an individual’s lifetime risk of developing 
seropositive RA. This is an important first step in evaluating primary preventive 
strategies in high-risk individuals. The simulated approach used in this analysis 
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provided conceptual advances in risk prediction modelling to improve upon the 
discrimination of existing prediction models. The highest AUC for a RA gene-
environment prediction model developed in this thesis comprised 0.86 (Scott et al, 
2013b); the highest previously published AUC for a RA gene-environment 
prediction model is 0.80 (Yarwood et al, 2013). 
 
7.5.2. Strengths and Limitations 
There were two main strengths to this study. Firstly, the prediction models were 
validated in two large, independent datasets (WTCCC and UKRAGG) comprising 
approximately 4,000 cases and 3,000 controls. Highly similar results were observed 
in both cohorts. Secondly, as only validated susceptibility factors were incorporated 
in the prediction models, with summary ORs obtained from large meta-analyses, 
their generalisability across patient populations was optimised. This study also had a 
number of limitations. Firstly, WTCCC participants were included in the meta-
analyses that genetic risk loci data were obtained from; however WTCCC comprised 
only a proportion of the meta-analyses datasets and the findings were independently 
replicated in UKRAGG. Secondly, missing data meant the number of individuals 
evaluated by each model fell as more risk factors were included. Thirdly, due to 
marked heterogeneity in published data on epistasis/gene-environment interactions 
independence between factors was assumed; this oversimplification fails to consider 
important interactions such as those existing between the SE alleles and smoking. 
 
There are also several important limitations in all risk prediction models that aim to 
estimate asymptomatic individuals’ risks of RA. Firstly, they use ORs, which are 
derived from cross-sectional case-control studies, to approximate risk. ORs and RRs 
are not, however, interchangeable; if an OR is considered in the same manner as a 
RR it will always overestimate the effect size (Davies, et al., 1998). Secondly, they 
are only able to provide information on the lifetime odds or absolute risks of disease, 
as opposed to data on the risk of developing RA over a specific time period. A more 
clinically useful model would provide information on the absolute risk of RA over 
the next few years, in a manner akin to the predictive data generated by the 
Framingham Heart Study calculator for future risk of cardiovascular events 
(D'agostino, et al., 2008). This would allow the evaluation of preventive measures 
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over a more realistic time period than a patient’s entire lifetime. Unfortunately, such 
modelling is not currently possible as no prospective cohort study exists that has 
genetic data on the entire dataset to derive time specific risks. Thirdly, in the general 
population the absolute risks of developing RA are low and it is only a small 
minority of individuals that are at a high-risk of disease. This is to be expected under 
Bayes’ Theorem, in which the post-test odds of developing a disease are not just 
influenced by the likelihood ratio (probability of test result in a diseased 
person/probability of test result in a non-diseased person) of a test but also the pre-
test odds of developing the disease (Prince, 1996). In the context of RA the pre-test 
probability can be considered the same as the disease prevalence, which is low at 
approximately 1%. Therefore, regardless of the prediction model’s likelihood ratio, 
the post-test probability of developing RA will be small in most individuals owing to 
its low prevalence.  It is unlikely that identifying further risk factors to incorporate 
within prediction models will substantially alter this and RA prediction models are, 
therefore, unsuitable for use as screening tools within the general population. 
 
7.5.3. Further Research 
There are three key areas of further research arising from this study. Firstly, the 
devised prediction models require evaluating in a priori high-risk populations. In this 
context they may identify clinically relevant proportions of high-risk people enabling 
preventive measures to be evaluated. One high-risk population is first-degree 
relatives (FDRs) of RA patients. Recently published data from Sweden suggests the 
familial OR for RA is approximately 3 in first-degree relatives (Frisell, et al., 2013); 
this may increase if several family members are affected. Such work is already 
underway, with the PRe-clinical EValuation of Novel Targets in RA (PREVeNT 
RA) study, led by Professor Ian Bruce (University of Manchester), currently 
establishing a UK based cohort of FDRs of RA patients (United Kingdom Clinical 
Research Network, 2013). The aim of this study is to use gene-environment 
prediction models to stratify FDRs by RA risk profiles and to undertake serological 
and proteomic profiling alongside ultrasound imaging in high-risk individuals to 





Table 7-2. Overview of the PREVeNT RA study 
 
Aims 
1. Establish a national cohort of FDRs of RA patients 
2. Use clinical-genetic risk prediction models to stratify FDRs according to 
disease risk 
3. Use serological/proteomic profiling and ultrasound imaging to evaluate 
disease evolution in high-risk FDRs 
4. Identify incident cases of IA  
5. Study cardiovascular risk biomarkers in a subset of this cohort. 
Rationale 
RA is the commonest chronic IA with high costs to the UK economy. Gene-
environment risk factors interact to influence RA development. The identification 
of high-risk individuals in the community could facilitate preventive treatments. 
Subjects 
Individuals will be included that are aged ≥30 years, UK residents, willing to 
provide consent and complete questionnaires, willing to provide a blood sample, 
willing to inform the study centre if they develop symptoms of RA, are an FDR 
of a proband with a diagnosis of RA from a Rheumatologist. 
Sample Size 
The recruitment target is 3,000 individuals. 
FDR= first degree relative, IA = inflammatory arthritis; Information on the 
PREVeNT RA study obtained from the UK Clinical Research Network Study 
Portfolio (United Kingdom Clinical Research Network, 2013). 
 
Secondly, the optimal way in which predictive data is conveyed to patients requires 
determining. A Cochrane review reported little or no effect of communicating 
genetic-based risk estimates on lifestyle modifications to reduce disease risk 
(Marteau, et al., 2010). The quality of the 14 included studies was, however, judged 
to be weak; additionally they focused on communicating DNA-based risk 
information in the form of the presence or absence of a specific risk variant, as 
opposed to communicating the absolute risks of disease development. The effects of 
communicating lifetime disease risks (as provided by the models described in this 
thesis), alongside the manner in which these are conveyed (for example face-to-face 
or telephone delivery) requires evaluation. 
 
Thirdly, the possible preventive strategies that could be used needs careful 
consideration. Simple lifestyle modifications, such as smoking cessation, are likely to 
substantially reduce the risk of ACPA-positive disease, particularly in SE carriers. 
The ethical considerations of studies assessing the role of immunomodulatory 
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treatments, such as biologic drugs, to prevent RA in entirely asymptomatic high-risk 
individuals are, however, considerable. Data on possible non-conservative strategies 
for primary prevention will be generated by studies evaluating secondary prevention 
treatments. One example of this is the Arthritis Prevention In the Pre-clinical Phase 
of RA with Abatacept (APIPPRA) study, led by Professor Andrew Cope (King’s 
College London). This double blind, placebo controlled clinical trial will evaluate the 
role of abatacept therapy in preventing RA in symptomatic subjects (arthralgia 
without joint swelling) at high-risk of developing RA (e.g. those with ACPA 
present). This study will test the hypothesis that weekly subcutaneous abatacept 
injections over 12 months will substantially reduce the proportion of individuals 
developing a clinically apparent inflammatory arthritis. 
 
7.5.4. Clinical Implications 
The high individual and societal costs of RA mean that preventing its development is 
an important research goal. Although it is difficult to capture the precise costs of RA, 
an analysis undertaken in 2001 in America reported an annual cost per RA patient of 
11,341 US dollars (Lajas et al, 2003). In the biologics era this cost will be 
substantially higher. Within the UK, in 2009 the National Audit Office estimated the 
annual cost of RA to the NHS to be approximately 560 pounds sterling (National 
Audit Office, 2009). The modelling framework developed in this thesis is an 
important first step towards the primary prevention of RA. Targeted screening of a 
priori high-risk groups like FDRs of RA patients could result in enough high-risk 
individuals being identified to enable the assessment of primary prevention strategies 
like smoking cessation. It would also enable a better understanding of the pre-clinical 
changes that lead to RA, through assessments such as the serological and proteomic 
profiling planned in the PREVeNT RA Study. 
 
Additionally, the prediction modelling framework used in this thesis can easily be 
applied to a variety of other branches of stratified medicine. Once the predictive 
factors underlying radiological progression and treatment responses in RA are 
identified, this modelling approach could be used to generate a summary OR and risk 
category for probable X-ray progression or medication responses, which could be 
used to inform clinical decision-making.  
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7.6. The Importance of RA Heterogeneity 
7.6.1. ACPA-Positive versus ACPA-Negative Disease 
This thesis has highlighted the importance of ACPA status in determining RA 
subsets by demonstrating that firstly, the inverse association between alcohol 
consumption and RA risk is only significant for ACPA-positive disease; secondly, 
ACPA-positive and ACPA-negative RA have different requirements for intensive 
combination treatments; and thirdly, prediction modelling has better discrimination 
for ACPA-positive (as opposed to seropositive) RA. This adds to the accumulating 
evidence that ACPA-positive and ACPA-negative RA probably represent distinct 
disease entities, grouped together under the umbrella term of “RA”. It provides a 
reasonable explanation for some of the contrasting results seen across studies 
examining predictive factors in RA, which often examine RA as a single group, and 
highlights a key research requirement to evaluate these subsets separately. This 
process is already beginning as any studies using the 2010 ACR RA classification 
criteria will favour the inclusion of ACPA-positive patients. It is, however, important 
that ACPA-negative RA is not overlooked as despite being a more difficult subset to 
define, which is at a higher risk of misclassification, it comprises a significant 
proportion of patients seen in rheumatology clinics. 
 
7.6.2. Younger versus Older Onset RA 
Traditionally YORA and EORA are defined categorically using an age cut-off for 
disease onset of ≤60 years and >60 years, respectively (Deal, et al., 1985). There is 
some evidence that YORA and EORA differ phenotypically, with three studies 
reporting EORA to have a more abrupt onset, characterised by higher rates of large 
joint involvement (Deal et al, 1985, Van Der Heijde, et al., 1991, Bajocchi, et al., 
2000).  They may also differ with respect to their disease course and treatment 
responses. An analysis of NOAR demonstrated a linear relationship between a 
reducing age of onset and remission, although when age of onset was dichotomised 
no association was seen (Harrison, et al., 2000). Similarly, an analysis of the Dutch 
biologics registry reported that anti-TNF was less effective in older RA patients (a 




Using an arbitrary age cut-off of 60 years to define YORA and EORA could result in 
the loss of important information on the extreme age of onset phenotypes. To 
overcome this, within the WTCCC and UKRAGG analysis outlined in this thesis, 
age of onset was evaluated as a continuous variable (Scott et al, 2013b). The 
resultant finding that high HLA-derived genetic risk scores associated with a younger 
age of RA onset and ever-smoking associated with an older age of RA onset, 
suggested that genetic and environmental factors are more important for the 
development of YORA and EORA, respectively. This novel finding has not been 
previously reported. As it was demonstrated in two large, independent datasets it 
probably represents a true finding; furthermore, as previously discussed it has 
biological plausibility. These findings are also supported by a recent register-based 
nested case-control study in Sweden, which evaluated the familial aggregation of RA 
across 3 large, independent datasets (Frisell et al, 2013). A substantially higher 
familial OR for RA was observed in YORA (defined as an age of onset <40 years). 
This was particularly true in seropositive disease: in the Swedish Rheumatology 
Quality Register the familial OR (risk of disease if an FDR is affected) for RF-
positive RA with an age of onset <40 years and >60 years comprised 6.0 (95% CI 
4.3-8.4) and 2.8 (95% CI 2.2-3.7), respectively; in the EIRA cohort the familial OR 
for ACPA-positive RA with an age of onset <40 years and >60 years comprised 6.2 
(95% CI 3.5-10.9) and 3.3 (95% CI 2.0-5.3), respectively (Frisell et al, 2013). As 
familial risk is often considered to be mainly due to genetic factors, these findings 
suggest that genetic risks have a larger impact on YORA. Overall, the findings from 
this thesis add weight to the concept that age of RA onset may be an important way 
in which RA patients can be sub-classified. 
 
7.7. Future Research 
There are two areas of further research arising directly from the work undertaken in 
this thesis. Firstly, in order to increase the power to detect genetic associations with 
radiological progression in RA, a collaborative network has been established with 
researchers in the Rheumatic Disease Epidemiology Group (Dr Jing Cui and Dr 
Elizabeth Karlson) at Harvard Medical School (Boston, USA). Secondly, in order to 
define gene-environment RA risk factors in non-European individuals, a unique 
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observational study has been developed, entitled the GENetics of Ra in individuals of 
African ancestry (GENRA) study. 
  
7.7.1. Identifying Genetic Predictors of Radiological Progression 
The aim of this study is to undertake a genome-wide analysis evaluating genetic 
associations with the progression of radiological scores in the CGC and Brigham and 
Women’s Rheumatoid Arthritis Sequential Study (BRASS) (Cui, et al., 2014). The 
proposal for this study is outlined in Table 7-3. 
 
Table 7-3. GWAS Meta-Analysis of Genetic Predictors of X-Ray Progression 
Aim 
To identify genetic associations with X-ray progression in RA patients using a 
genome-wide approach across two independent datasets (CGC and BRASS). 
Rationale 
Candidate-gene approaches to identify genetic associations with radiological 
progression have important limitations. Genome-wide analyses in large datasets 
are most likely to identify replicable genetic associations. 
Subjects 
CGC: comprises 524 patients with early, active RA previously enrolled to two 
clinical trials. Modified Larsen scores are available at 6 to 12-month time points. 
BRASS: comprises 422 ACPA-positive established RA patients enrolled to a 
prospective observational study. SvHS are available on all patients at study 
enrolment (mean disease duration 17 years). 
Genotyping 
CGC was genotyped on the ImmunoChip. BRASS was genotyped on the 
Affymetrix 6.0 platform. Both datasets have been imputed to genome-wide 
coverage using IMPUTE2 (Howie, et al., 2009), based on 1,000 Genomes Phase 
1 haplotypes. 
Statistical Analysis 
The CGC will be evaluated using the same strategy as outlined in Chapter 4 of 
this thesis. BRASS will be analysed as follows: estimated annual X-ray 
progression rates will be calculated by dividing the total SvHS by disease 
duration (in years) at the time of the radiograph. The association between log-
transformed estimated SvHS annual progression rates and genotype will be tested 
in a linear regression model. Adjustments for other relevant variables will be 
made based on their association with X-ray progression in this dataset. P-values 
from the CGC and BRASS will be combined using meta-analysis techniques to 
provide an overall P-value for radiological progression for each SNP. 
Replication Cohort 
Any associations attaining PGWAS will require replication. Suitable replication 




7.7.2. Evaluating RA Predictive Factors in Non-European Populations 
Studies of predictive factors in RA have mainly been undertaken in European or 
North American populations, in which most individuals are of European ancestry. 
This is exemplified in the meta-analysis of smoking as an RA risk factor; all of the 
16 included studies were performed in Europe or the USA (Sugiyama et al, 2010). 
The application of these predictive factors to other ethnic groups is uncertain. 
 
Within South London a significant proportion of patients seen in rheumatology 
clinics are of African ancestry; many of these individuals were either born in Africa 
or the Caribbean, with the latter patient group often having genetic admixture. Very 
little information on predictive factors in African ancestry RA patients exists. 
Although RA is predominantly a European disease, it does represent a significant 
healthcare problem in Africa, particularly in urban regions. A recent cross-sectional 
study in Kinshasa ‒ an urban area in the Democratic Republic of Congo ‒ reported 
the prevalence rate of RA (fulfilling the 1987 ACR classification criteria) was 0.6-
0.9%, which is only slightly below that reported in European populations (Malemba, 
et al., 2012). 
 
The most comprehensive assessment of risk factors for RA in African ancestry 
individuals has been undertaken in African Americans recruited to the Consortium 
for the Longitudinal Evaluation of African Americans with Early RA (CLEAR) 
registry. In this dataset, cigarette smoking was a significant RA risk factor; the age 
and sex adjusted OR for RA in ever-smokers was 1.45 (95% CI 1.07-1.97) (Mikuls, 
et al., 2010). The CLEAR registry has also demonstrated that the SE is an important 
RA risk factor in African Americans, providing an OR for RA of 2.35 (95% CI 1.84–
3.00) (Hughes, et al., 2008). Its prevalence of 25.2% was, however, substantially 
lower than the 50-70% often reported in European RA patients, indicating that non-
SE factors may be more important for precipitating disease in African ancestry 
individuals (Hughes et al, 2008). Furthermore, the presence of SE alleles was 
associated with a higher degree of European ancestry (assessed using a panel of 
>1,200 ancestry-informative markers); for every 1% increase in European ancestry 
the odds of carrying an HLA-DRB1*04:01 allele increased by a factor of 1.035 (95% 
CI 1.004-1.068) (Hughes et al, 2008). It therefore appears likely that risk factor 
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similarities between European and African American individuals are, at least in part, 
driven by European admixture in the latter patient group. 
 
Research evaluating RA risk factors in African ancestry individuals born in Africa is 
limited to a few small observational studies. In one case-control study of 56 
Cameroonian RA patients and 50 healthy controls (medical students and hospital 
workers) attending an outpatient unit in Yaoundé (Cameroon) the SE was 
significantly commoner in cases (30% SE-positive) compared with controls (10% 
SE-positive) (Singwe-Ngandeu, et al., 2010). Its prevalence was, however, 
substantially lower than in Europeans and no individual carried *04:01, which is the 
commonest SE allele in Europeans (Raychaudhuri et al, 2012). As seropositivity 
rates were similar to European RA patients these findings suggest that the SE alleles 
play a lesser role in ACPA formation in Cameroonian RA patients. Another small 
study of 34 Senegalese RA patients and 220 controls reported an increased risk of 
RA in HLA-DR3 and HLA-DR10 carriers but not HLA-DR4 carriers (Dieye, et al., 
1997). Regarding non-HLA genetic associations, several small studies have used a 
candidate gene approach to test non-HLA susceptibility loci in sub-Saharan African 
(Tunisian (Chabchoub, et al., 2009, Ben Hamad, et al., 2012, Chabchoub, et al., 
2006) and Egyptian (Mohamed, et al., 2012)) and Black South African (Moodley, et 
al., 2010) populations; their findings are generally negative. The most comprehensive 
assessment of non-HLA loci was carried out in 44 Cameroonian cases and 163 
West/Central Africa controls. No association was observed between a wGRS formed 
from 28 validated European non-HLA susceptibility SNPs and RA in Africans (OR 
0.71; 95% CI 0.29-1.74; P=0.456) (Viatte, et al., 2012). 
 
There is, therefore, an important research need to better define environmental and 
genetic RA risk factors in African ancestry populations. As part of the Clinical 
Research Fellowship underlying this thesis an observational cross-sectional study has 
been developed, entitled the GENetics of Ra in individuals of African ancestry 
(GENRA) study. The primary aim of this study is to evaluate whether environmental 
and genetic risk factors for RA identified in European ancestry populations also 
associate with RA in African ancestry individuals living in the UK. Its details are 
outlined in Table 7-4. To date 194 patients have been recruited.  
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Table 7-4. Genetics of RA in Individuals of African Ancestry (GENRA) Study 
 
Aim 
To evaluate whether environmental and genetic risk factors for RA identified in 
European ancestry individuals also represent risk factors in African ancestry 
individuals living in the UK. 
Rationale 
Most studies of predictive factors in RA have focussed on European and North 
American populations. Little is known about how these risk factors apply to 
African ancestry individuals. 
Subjects 
This study will enrol patients of African ancestry from rheumatology outpatient 
clinics in four South London rheumatology units. 
Inclusion Criteria: 
a) A clinical diagnosis of RA by the 1987 and/or 2010 American College of 
Rheumatology RA classification criteria 
b) Self-reported ethnicity that is “Black/African/Caribbean/Black British” 
(classified according to the 2011 Census ethnicity grouping). 
Exclusion Criteria: 
a) Diagnoses of arthropathies other than RA 
b) Self-reported ethnicity other than “Black/African/Caribbean/Black British”. 
 
Environmental risk factor data (on smoking, alcohol and BMI) has been obtained 
from 859 Black African and 1,067 Black Caribbean controls living in the UK that 
contributed to the Health Survey for England (HSE) 2004 ethnic minorities boost 
sample. Genotype data will be used from European ancestry RA patients within 
the WTCCC and CGC datasets. 
Outcome Assessments 
Information is captured on: 
a) Demographics- age, gender, ethnic grouping, ethnic grouping of 
parents/grandparents 
b) Disease duration 
c) Disease activity- DAS28 scores 
d) Radiological erosions 
e) Serology and inflammatory factors- the presence of autoantibodies (such as 
RF and ACPA) and other inflammatory factors (such as the ESR)  
f) Extra-articular features 
g) Disability- measured using HAQ 
h) Quality of Life- measured using EuroQoL  
i) Drug treatments- current and previous medications  
j) Co-morbidities 
k) Clinical risk factors for RA- smoking status, alcohol consumption and BMI 
data is captured at the time of assessment, time of RA diagnosis and 10 years 
before RA diagnosis through patient interview 
Genotyping 
This will be undertaken on the Illumina HumanOmniExpress BeadChip, which 
genotypes 733,202 markers. This platform provides adequate coverage of 
common genome-wide variation in African ancestry individuals; for common 
213 
 
SNPs (MAF>5%) it has coverage with an r
2
 >0.8 of 73% in the 1,000 genomes 
African population panel (Nelson, et al., 2013). 
Statistical Analysis 
Environmental Risk Factors 
Adjusted ORs for RA in GENRA cases compared with HSE controls will be 
calculated with regards to smoking status, alcohol consumption and BMI. The 
first two variables are established RA risk factors in European populations; a link 
with RA in European studies has been reported in several studies for the latter 
factor. Initially cases and controls will be evaluated irrespective of their ethnicity; 
subsequent analyses will be undertaken stratified by ethnic grouping. 
 
Genetic Risk Factors 
A wGRS will be calculated for a) GENRA cases, b) European WTCCC cases, c) 
European CGC cases using validated European susceptibility loci identified by 
Okada et al (Okada et al, 2013) in the same manner as described in chapter 3 of 
this thesis. The cumulative distributions of the wGRSs will be compared across 
these populations to establish the degree of overlap in genetic risks between 
African and European ancestry RA patients. 
BMI = body mass index; WTCCC = Welcome Trust Case Control Consortium; CGC 
= CARDERA Genetics Cohort; wGRS = weighted genetic risk score. 
 
7.8. Conclusion 
This thesis has demonstrated that risk prediction in RA is possible. It has advanced 
the knowledge of which factors predict RA development, the subsequent clinical 
course of the disease, and the responses of patients to different treatment regimens. It 
has shown how these predictive factors can be combined within a novel risk 
prediction modelling framework to stratify individuals to disease risk groups that 
may benefit from preventive treatments. The research in this thesis further highlights 
the requirement to adopt a stratified approach to RA management, using clinical 
characteristics and biomarkers such as ACPA to identify groups of individuals that 
are most likely to respond to specific treatment strategies. 
 
There are several clinical implications from the research presented in this thesis. 
Firstly, the analysis of the CARDERA-1 trial data suggests that not all early, active 
RA patients require identical treatment. The results provide a strong case for 
focusing the use of intensive combination therapy in ACPA-positive disease and 
support using DMARD monotherapy in at least a proportion of ACPA-negative 
patients. Secondly, the analysis of the CGC indicates that non-HLA RA 
susceptibility variants do not provide clinically useful prognostic information in 
214 
 
early, active RA patients, with no association observed between these variants and 
radiological progression over 2 years. This suggests that GWAS derived 
susceptibility loci may be more useful in identifying treatment pathways relevant to 
disease prevention as opposed to the treatment of an established RA phenotype. 
Thirdly, an analysis of risk prediction modelling in the WTCCC and UKRAGG 
cohorts has demonstrated that identifying individuals at a high-risk of developing RA 
is possible; this raises the possibility that primary prevention strategies may be 
evaluated in the future. 
 
There are also a number of research implications arising from this work. Firstly, it 
has confirmed the importance of considering disease heterogeneity when undertaking 
research in RA. RA subsets defined by both ACPA status and age of onset differ in 
their susceptibility factors; a failure to evaluate these subsets separately could explain 
the non-replication of many predictive factors across RA patient cohorts. 
Additionally, the fact that ACPA status determines treatment requirements and 
responses raises the question of whether clinical trials of RA treatments need to 
assess these subsets separately. Secondly, the genome-wide analysis of radiological 
progression predictors suggests that the genetic architecture of X-ray progression in 
RA comprises many variants of a small effect size. This highlights a research 
requirement to undertake GWAS meta-analyses in order to optimise the power to 
detect relevant associations. A collaborative network has been established with 
researchers at Harvard Medical School to undertake such an analysis in the CGC and 
BRASS datasets. Thirdly, as RA risk prediction models are unsuitable for population 
level screening (due to the low numbers of high-risk individuals that would be 
identified) their impact in a priori high-risk groups like FDRs of RA patients 
requires evaluation. In this context they could identify large enough numbers of high-
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ABSTRACT 
Introduction 
Early intensive treatment is now the cornerstone for the management of rheumatoid arthritis. 
In the era of personalised medicine where treatment is becoming more individualised, it is 
unclear from the current literature whether all RA patients benefit from such intensive 
therapies equally. This study investigated the benefit of different treatment regimens on 
remission rates when stratified to clinical and serological factors. 
Methods 
The CARDERA trial recruited patients with RA with less than 2 years disease duration who 
had active disease. The trial compared four treatment regimens: methotrexate monotherapy, 2 
different double therapy regimens (methotrexate and ciclosporin or methotrexate and 
prednisolone) and three-drug therapy. Clinical predictors included age, male and tender joint 
count (TJC) and serological biomarkers included rheumatoid factor (RF) and antibodies to 
citrullinated protein antigens (ACPA).  
Results 
Patients who were male, over 50, had ≥ 6 TJC, RF-IgM positive or ACPA positive were more 
likely to achieve remission at 24 months using three-drug therapy compared to monotherapy 
(OR 2.99, 4.95, 2.71, 2.54 and 3.52 respectively).  There were no differences in response to 
monotherapy and three-drug therapy if patients were female, under 50, had < 6 TJC or 
seronegative. 
Conclusion 
Early intensive regimes have become the gold standard in the treatment of early Rheumatoid 
arthritis. Our study suggests that this intensive approach is only superior to monotherapy in 
certain subsets of patients. Although these are unlikely to be the only predictors of treatment 
response, our study brings us a step closer to achieving personalised medicine in RA. 
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INTRODUCTION 
Rheumatoid arthritis (RA) is a heterogeneous disease with diverse outcomes. Early intensive 
treatment regimens aiming at achieving remission have been shown to reduce disease 
activity, structural damage and long-term disability (1-7). This approach is now widely 
adopted as first-line treatment in routine clinical practice both nationally and internationally 
(8-10). In the era where personalised medicine is becoming a possiblity, treatment of RA 
patients should be more individualised. It is unclear from the current literature whether all 
RA patients benefit from such intensive therapies equally.  
We have shown previously that age, gender and baseline tender joint counts (TJC) predict 
remission at 24 months (11). By using these baseline clinical variables, we developed a 
remission score which predicted the likelihood of achieving remission at 24 months. While 
the score is relevant to both clinical trial and routine practice settings, their interaction with 
treatment was not explored. 
Serological biomarkers including rheumatoid factor (RF) and antibodies to citrullinated 
protein antigens (ACPA) play an important role in the diagnosis of RA (12). The presence of 
these antibodies is associated with radiographic damage, high disease activity and extra-
articular manifestations (13-15). There is emerging evidence that serological status can 
predict treatment response in biological therapies (16, 17), however, evidence in intensive 
DMARD therapy is limited (18). In this study, we assessed the role of ACPA and RF status 
as predictors of remission and evaluated whether clinical and serological biomarkers predict 
remission in response to different DMARD regimens.  
PATIENTS AND METHODS 
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Patients and samples 
The CARDERA trial recruited patients with RA with less than 2 years disease duration who 
had active disease. Details have been published previously (19). The trial compared four 
treatment regimens: methotrexate monotherapy, 2 different double therapy regimens 
(methotrexate and ciclosporin or methotrexate and prednisolone) and three-drug therapy 
(methotrexate, ciclosporin and prednisolone). Serum samples were taken at baseline. 
Autoantibody analysis 
Serum samples were taken at baseline. RF-IgM was determined using commercially available 
ELISA kits (Euroimmun) and expressed as relative units per ml (RU/ml). Testing was 
performed according to the manufacturer’s instructions, at a sample dilution of 1:200. The 
upper limit of the normal range recommended by Euroimmun is 20 RU/ml. Anti-CCP 
antibodies (IgG) were measured using an ELISA based kit from Axis-Shield which detects 
autoantibodies towards a synthetic cyclic peptide containing modified arginine residues 
(CCP2 peptides).  Testing was performed according to the manufacturer’s instructions, at a 
sample dilution of 1:100. The cut-off value for anti-CCP antibody positivity was 5 U/mL.  
Remission score 
The development of the remission score has been published previously (11). In brief, we used 
the CARDERA RCT to develop a predictive model for 24-month remission. This model was 
then validated using data from a UK observational cohort (Early RA Network, ERAN). 
Remission was defined as 28-joint Disease Activity Score < 2.6. Logistic regression models 
were used to estimate the associations between remission and potential baseline predictors. 
Multivariate logistic regression analyses showed age, sex, and tender joint count (TJC) were 
independently associated with 24-month remission. The multivariate remission score 
developed using the trial data correctly classified 80% of patients. The Remission Score was 
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= 0.37 + [-0.03 x age] + [1.1 x gender (1 for males and 0 otherwise] + [-0.07 x Baseline 
28TJC]. By combining data from the trial and ERAN, we also developed a simplified 
remission score that showed that younger men (<50) with a TJC of 5 or lower were most 
likely to achieve 24-month remission. The effect of treatment was not considered in this 
paper as treatment differed considerable between the 2 study groups.  
Statistical Analysis 
Data were analysed using SPSS v20. Analyses were restricted to those individuals with 
complete data at 24 months and with available serum samples. Remission was defined as 
DAS28 <2.6 at 24 months. Individual variables were assessed descriptively as median values 
and interquartile ranges. Categorical data were analysed using Chi-squared test if the n >10 
patients or Fisher’s exact if n <10 per group. Multiple testing was adjusted by using 
bonferroni method.  
The Remission Score was = 0.37 + [-0.03 x age] + [1.1 x gender (1 for males and 0 
otherwise] + [-0.07 x Baseline 28TJC] (11). A higher value indicates a higher probability that 
the patient will achieve remission at 24 months. Logistic regression modelling was carried 
out to assess the ability of the remission score to predict remission at 24 months when 
stratified into different treatment groups. This was adjusted for treatment centre.  
Gender, age and baseline tender joint count were dichotomised using thresholds which were 
used in our previous study (11): Gender – Male or Female, Age - under 50 or over 50 and 
TJC - < 6 or ≥ 6. Logistic regression models were used to estimate the associations between 
treatment regimens and point remission at 24 months when stratified by these clinical 
predictors and serological biomarkers. The effects of treatment on remission rates were first 
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explored. This showed no difference between double vs monotherapy (OR 0.852 95% CI 
0.435 – 1.67, p = ns). The effect of three-drug therapy compared to monotherapy was OR 
2.22 95% CI 1.11-4.46 (p = 0.025). The models were therefore restricted to monotherapy vs 
three-drug therapy with adjustment for treatment centre.  To explore the interaction between 
clinical and serological status, serological status models were also adjusted for baseline 
DAS28, gender and age. 
RESULTS 
Study Population 
In the CARDERA trial 467 patients were randomised; 378 patients had competed dataset 
after 24 months of follow up. 351 of these patients had baseline serum samples available for 
analysis, and so analysis was restricted to these patients. Table 1 summarised their baseline 
characteristics. There was no difference in baseline DAS28 between patients when stratified 
according to RF-IgM and to ACPA status: mean initial DAS28 (SD) of RF-IgM negative and 
positive patients were 5.86 (1.27) and 5.73 (1.29) respectively and of ACPA negative and 
positive patients were 5.84 (1.36) and 5.69 (1.27). 
DAS28 Remission Rates At 24 Months 
In total, 16/87 patients (18%), 29/180 (16%) and 30/90 (33%) patients achieved remission at 
24 months using monotherapy, double therapy and three-drug therapy respectively. There 
were no differences between serological status and remission rates at 24 months: 10/44 (23%) 
of RF-IgM negative and 14/88 (16%) ACPA negative patients achieved remission whereas 
65/313 (21%) RF-IgM positive and 60/262 (23%) ACPA positive achieved remission (chi-
squared p >0.05). 
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The Remission Score And Clinical Predictors Of Remission By Treatment Group 
The mean (SD) Remission Score was -1.7 (0.84). The Remission Score predicted treatment 
response in monotherapy, double and three-drug therapy (OR 3.07 95% CI 1.35-6.96 
p=0.007, OR 1.99 95% CI 1.19, 3.32 p = 0.008 and OR 4.42 95% CI 1.90 – 8.94, p <0.0001 
respectively). This was adjusted for treatment centre. 
The individual clinical predictors were then dichotomised: Gender – Male or Female, age - < 
50 or ≥ 50 and TJC - < 6 or ≥ 6. 245 patients were female, 113 patients were male, 122 were 
< 50, 236 were ≥ 50, 88 had less than 6 tender joints and 270 had 6 or more tender joints. 
Figure 1 shows treatment responses when stratified to different clinical predictors. Females 
achieved low levels of remission across all treatment arms and responded to a similiar extent 
to mono-, double and three-drug therapy [8/14 (14%), 17/131 13%, 13/57 23% respectively, 
p >0.05]. Males responded better to three-drug therapy [17/33, 52%] compared to mono [8/31 
26%, 12/49 25%]. Patients with lower TJCs responded to a similar extent across all the 
treatment groups: mono [6/19, 32%], double [12/44, 27%] and three-drug [10/24, 42%, p = 
ns]. Patients with more than 6 TJCs achieved higher remission rates with three-drug therapy 
(20/66, 30%) when compared to mono (10/68 15%) and double (17/136 13%). Patients under 
50 achieved similar high rates of remission across all the treatment groups: mono (11/32, 
34%), double (14/61 23%) and three-drug (11/29 38%) p = ns). Patients over 50 years of age 
achieved higher remission rates using three-drug therapy (19/61, 31%) when compared to 
mono (5/55, 9%) and double (15/119, 13%). 
Using logistic regression modelling, patients who were male, over 50 or had ≥ 6 TJC were 
more likely to achieve remission at 24 months using three-drug therapy compared to 
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monotherapy (OR 2.99, 4.95 and 2.71 respectively, Table 2).  There were no differences in 
response to monotherapy and three-drug therapy if patients were female, under 50 or had less 
than 6 tender joints (Table 2).  
Serological Predictors Of Remission By Treatment Group 
When stratified according to different treatment groups, serological status did have an impact 
on remission rates (Figure 1). In RF-IgM –ve patients, there was no difference in point 
remission rates between mono, double and three-drug therapies respectively [2/11 (18%), 
5/23 (22%) and 3/10 (30%) p > 0.05]. In RF-IgM +ve patients, fewer patients achieved 
remission using monotherapy and double therapy (14/76, 18% and 24/157, 15%) when 
compared to three-drug therapy (27/80, 34%, p = 0.02). In ACPA -ve patients, 5/24 (21%), 
4/42 (10%) and 5/22 (23%) achieved remission using mono, double and three-drug therapies 
respectively (p >0.05). In ACPA +ve patients, more patients achieved remission using three-
drug therapy (25/67, 37%) than monotherapy (11/63, 17%) and double therapy (24/132, 18%) 
(p=0.007). 
The level of seropositivity was next explored. Patients were stratified into low-positive (< 3 x 
upper limit of normal) and high-positive (≥ 3 x upper limit of normal) as according to 
thresholds adopted in the ACR criteria for Rheumatoid Arthritis in 2010 (12). In low-positive 
RF-IgM, there was no difference between remission rates in the different treatment groups: 
monotherapy 2/8 (25%), double therapy 0/15 (0%) and three-drug therapy 1/3 (33%, p = ns). 
In high-positive RF-IgM, more patients achieved remission with three-drug therapy 26/77 
(33.8%) than monotherapy 12/68 (17.6%) and double 24/142 (16.9%, p = 0.01).  In low-
positive ACPA, there was no significant difference in remission rates between the treatment 
groups: monotherapy 3/5 (60%), double therapy 1/13 (7.7%) and three-drug therapy 2/9 
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(22%, p = ns). In contrast, in the high-positive ACPA group, more patients achieved 
remission with three-drug therapy 23/58 (39.7%) when compared to monotherapy 23/76 
(13.8%) and double 23/119 (19.3%, p = 0.001) groups. 
The associations of treatment regimens and remission according to serological status are 
summarised in Table 2. The benefit of three-drug therapy is only apparent in RF IgM +ve 
(OR 2.28, 95% CI 1.08-4.85) and ACPA +ve (OR 2.99, 95% CI 1.29-6.97). Their effects size 
increased when adjusted for clinical factors (DAS28, age and gender) suggesting that the 
effects of the clinical and serological biomarkers were cumulative (OR 2.54 and 3.52 
respectively Table 3).  
Serological Status And ACR Core Set Remission Measures 
To explore the effects of the individual components of DAS28, the threshold levels for 
remission according to the ACR core set measures were used (12, 20). At 24 months, in total, 
44.7% of patients achieved TJC28 ≤ 1, 22.9% had no swollen joints, 56.2% had ESR ≤ 20 
and 23.2% had PGA ≤ 10. There were no differences between monotherapy and three-drug 
therapy in any of the 4 components at 24 months between RF-IgM positive and negative 
patients (Table 4). In ACPA +ve patients, more patients achieved TJC28 and SJC28 
thresholds of remission in the three-drug therapy group than monotherapy groups at 24 
months than ACPA negative patients (Table 4).  
DISCUSSION 
Early intensive regimes have become the gold standard in the treatment of early Rheumatoid 
arthritis. Our study suggests that this intensive approach is only superior to monotherapy in 
certain subsets of patients. Stratifying patients according to gender, age, tender joint counts 
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(TJC), RF IgM positivity and ACPA positivity can predict those subjects more likely to 
achieve remission states after 24 months of intensive treatment.  
Intensive DMARD therapies are associated with increased drug toxicity (21).  A 
personalised, tailored approach to treatment where each patient receives the appropriate 
intensity of treatment for as long as needed is the goal of treatment. We have shown 
previously that female patients of older age, with high TJC were less likely to achieve 
remission and many other studies have shown similar findings (22-27). However, it may be 
an over-simplification to suggest that patients with poor prognostic factors will respond to 
intensive therapies. The current study suggests that males respond better to three-drug 
therapy compared to monotherapy whereas females respond less well to all treatment 
regimes. Conversely, patients over 50 and with more than 6 TJC respond better to three-drug 
therapy than monotherapy but younger patients with less TJC respond well to all treatment 
regimes. 
Prediction matrices using serological status exist to predict risk of rapid radiological 
progression (RRP) using different DMARD and biological treatment regimens (28). Other 
studies have shown conflicting results using serological status to predict anti-TNF response 
(16, 17, 29). However, no model exists for predicting clinical response to intensive DMARD 
regimes. Our study demonstrates the remission rates of different DMARD regimes are 
dependent on serological status in early RA patients. This suggests that there may be 
fundamental differences in the disease of these subsets of patients and treatment regimens 
should be separated according to serological status.   
The main limitation of our study is that it is a post-hoc analysis of an RCT. The findings of 
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our study will require be further validation in an independent cohort. The treatments used in 
the RCT - methotrexate, ciclosporin and short-term high dose prednisolone - are not widely 
used as initial combinations in contemporary RA treatment. Our findings might not be 
generalisable to all intensive therapies. However, it is a well-recognised combination and 
many RCTs have demonstrated its efficacy (30-34). Ciclosporin is infrequently used in RA, 
though there is extensive evidence base for its use, which has been summarised in a Cochrane 
review by Wells et al. (35). Although it is both effective and relatively safe, other DMARDs 
like sulfasalazine and hydroxychloroquine are usually given in combination with 
methotrexate. Thirdly, our study used fixed treatment regimens rather than the treat-to-target 
approach which is now widely used in early RA management. Our findings suggest further 
research is needed to assess the benefits and risks of “treat-to-target strategies in ACPA 
negative disease. Fourthly, we used the DAS28 remission criteria because it is readily 
achievable in clinical practice. Stricter remission criteria may be preferable in the longer 
term, such as the ACR/EULAR Boolean remission criteria. Finally, the patients enrolled in 
CARDERA had more severe early RA than is generally seen in current routine practice. 
This study shows a role in a range of conventional clinical and serological biomarkers in 
predicting treatment responses to combination DMARD therapy. The results suggest that 
initial combination therapy may only be useful in certain subsets of early RA patients. 
Although other genetic and laboratory biomarkers are likely to be required to achieve an 
personalised approach to treatment of RA, our study does challenge the established view that 
all RA patients should be given combination treatment. Our study favours the more cautious 
approach in the 2013 EULAR guidance.  
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Table 1: Baseline Patient Characteristics In 358 Patients With Complete 2 Year Data And Available Serum Samples. IQR = 
interquartile range, HAQ = Health assessment questionnaire, RF-IgM = Rheumatoid factor IgM isotype, ACPA = antibiodies to 
citrullinated protein antigens  
Clinical Features Baseline Data 
Female n (%) 245 (68%) 
Median Age at onset (IQR) 54 (46, 63) 
Rheumatoid Nodules n (%) 80 (22%) 
Median Baseline DAS28 (IQR) 5.78 (4.88, 6.76) 
Median Baseline HAQ (IQR) 1.62 (1.12, 2.03) 
Median Larsen Score (IQR) 6.5 (2.3, 16) 
RF-IgM positivity n (%) 313 (87%) 
ACPA positivity n (%) 258 (72%) 
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Table 2. Predictive Value Of Achieving Remission At 24 Months Using Three-drug Therapy (Methotrexate, Ciclosporin and 
Prednisolone) When Compared To Methotrexate Monotherapy Adjusted For Treatment Region 
Predictors Of Response Odds Ratio 95% CI P Value 
Female 1.80 0.68 – 4.78 NS 
Male 2.99 1.01 – 8.90 0.049 
Over 50 4.95 1.66-14.75 0.004 
Under 50 1.09 0.38 – 3.16 NS 
≥ 6 TJC 1.56 0.43-5.63 NS 
<6 TJC 2.71 1.11-6.60 0.028 
RF-IgM Negative 1.49 0.17, 12.46 NS 
RF-IgM Positive 2.28 1.08, 4.85 0.032 
ACPA Negative 1.03 0.25, 4.30 NS 
ACPA Positive 2.99 1.29, 6.97 0.011 
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Table 3. The Use Of Serological Status To Predict Remission At 24 Months Using Three-drug Therapy (Methotrexate, Ciclosporin and 
Prednisolone) Compared To Methotrexate Monotherapy. Adjusted For Treatment Region, Baseline DAS28, Gender And Age 
Predictors of response OR 95% CI P Value 
RF-IgM Negative 1.17 0.58, 23.9 NS 
RF-IgM Positive 2.54 1.12, 5.76 0.026 
ACPA Negative 0.91 0.19, 4.28 NS 
ACPA Positive 3.52 1.37, 9.03 0.009 
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Table 4. Comparing the effects of Methotrexate monotherapy and three-drug therapy (Methotrexate, Ciclosporin and Prednisolone) in 
achieving remission scores in the individual components of DAS28 at 24 months when taking into account of serological status. Tender 
joint count (TJC), Swollen Joint count (SJC), Erythrocyte sedimentation rate (ESR), Patient global assessment (PGA) 
TJC28 at 24 months SJC28 at 24 months ESR at 24 months PGA at 24 months Serological 
status 
Treatment 
regimes ≤1 p value <1 p value ≤20 p value ≤10 p value 
Monotherapy 4/8 (50%) 1/4 (25%) 7/15 (47%) 4/6 (67%) RF IgM 








Monotherapy 37/87 (43%) 16/42 (38%) 42/89 (47%) 17/41 (42%) RF IgM 








Monotherapy 14/25 (56%) 5/10 (50%) 12/27 (44%) 7/13 (54%) ACPA 








Monotherapy 27/70 (39%) 12/36 (33%) 37/76 (49%) 14/34 (41%) ACPA 









Figure 1: Remission rates at 24 months in different treatment groups according to clinical and serological predictors: (A) Gender, (B) 
Tender joint count, (C) Age, (D) RF-IgM and (E) ACPA.  Multiple testing was adjusted by using bonferroni method. Monotherapy = 
methotrexate, Double therapy = Methotrexate and Prednsiolone or Methotrexate and Ciclsoporin, Three-drug therapy = Methotrexate, 
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ABSTRACT
Objective. When rheumatoid arthritis 
(RA) patients have achieved sustained 
good clinical responses can their dis-
ease-modifying anti-rheumatic drugs 
(DMARDs) be reduced or discontinued? 
This review addresses this question by 
summarising the clinical evidence about 
DMARD withdrawal. It includes an as-
sessment of predictive factors for sus-
tained DMARD-free remissions.
Methods. We evaluated the evidence 
for discontinuing DMARDs in stable 
RA in both randomised controlled trials 
(RCTs) and observational studies. 
Results. Six RCTs evaluated DMARD 
monotherapy withdrawal in 501 RA 
patients with good clinical responses. 
Flares occurred in 43/248 (17%) pa-
tients who continued DMARD mono-
therapy and in 117/253 (46%) patients 
who discontinued DMARDs. Individu-
als in whom DMARDs were withdrawn 
were three times more likely to have 
flares. Restarting DMARDs post-flare 
was usually successful. Four RCTs 
evaluated step-down DMARD combina-
tions in comparison to DMARD mono-
therapy. Patients achieved good clinical 
responses with combination DMARDs, 
which were maintained after treatment 
was tapered to DMARD monotherapy. 
Four observational studies of tapering 
or stopping DMARDs in patients with 
sustained low disease activity states 
provided supportive evidence for dis-
continuing DMARDs in some patients. 
Flares during drug-free remissions were 
predicted by rheumatoid factor and an-
ti-citrullinated protein antibody status.
Conclusion. Drug-free remission is 
achievable in some RA patients. Dis-
continuation of DMARDs after pa-
tients achieve sustained remissions re-
sults in flares in many patients, which 
can usually be reversed by restarting 
DMARDs. Step-down DMARD com-
binations are effective and achieve 
sustained responses. Further research 
is required to establish predictors of 
drug-free remission; these will iden-
tify individuals most likely to benefit or 
experience disease flares after discon-
tinuing DMARDs.
Introduction
Current rheumatoid arthritis (RA) man-
agement emphasises the benefits of 
early disease-modifying anti-rheumatic 
drugs (DMARDs), particularly metho-
trexate, in active disease. Increasing 
evidence also supports DMARD com-
binations, which may include gluco-
corticoids (1, 2). The benefits from 
using DMARDs extensively must be 
balanced against patients’ wishes to 
minimise drug use, potential toxicities, 
and costs of long-term DMARDs. Dis-
continuing DMARDs when patients 
achieve sustained low disease activity 
ameliorates these concerns. It is par-
ticularly relevant for DMARD combi-
nations. Some international guidelines 
recommend reducing DMARDs when 
patients enter prolonged remissions 
(3, 4).
The main evidence for discontinuing 
DMARDs comes from randomised 
controlled trials (RCTs) in patients with 
stable RA taking long-term DMARD 
monotherapy. These RCTs evaluate the 
impact of stopping treatment on disease 
activity. Additional evidence comes 
from RCTs and observational studies in 
which intensive combination DMARD 
prescribing follows a step-down ap-
proach with combination DMARDs re-
duced to monotherapy alongside obser-
vational studies of stopping DMARDs 
when patients achieve sustained re-
mission. We summarise these various 
strands of evidence to provide an over-
view of the risks and benefits of discon-
tinuing DMARDs. 
DMARD retention rates
Strategies for discontinuing DMARDs 
in good responders must be consid-
Can we discontinue synthetic disease-modifying anti-rheumatic 
drugs in rheumatoid arthritis?
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ered from the perspective of general 
retention rates when using DMARDs 
(5-7). Almost half of patients initiat-
ing DMARDs discontinue treatment 
by 2-3 years. Retention rates differ 
across DMARDs (Fig. 1). One meta-
analysis of 110 studies showed RA 
patients stay longer on methotrexate 
than other DMARDs (8). Yazici et al. 
quantified the low risk of discontinu-
ing methotrexate; in 1007 person-years 
of observation the probability of con-
tinuing methotrexate for five years was 
79% (9). Low retention rates are com-
moner in patients receiving combina-
tion DMARDs and in those with high 
disease activity (10). 
These low retention rates of patients 
starting DMARDs mean it is crucial to 
consider carefully the benefits and risks 
of discontinuing DMARDs in patients 
in whom therapy is controlling RA and 
is not causing adverse effects.
Clinical trials examining 
DMARD withdrawal
Six RCTs published before 2000 evalu-
ated DMARD withdrawal in RA pa-
tients in remission or achieving good 
clinical responses (11-16). The trials, 
which lasted up to 24 months, enrolled 
501 patients. They examined withdraw-
ing a range of DMARD monotherapies 
including methotrexate, gold, penicil-
lamine and azathioprine. DMARDs 
were tapered in one RCT (11) and 
stopped in five RCTs (12-16). The im-
pact of DMARD withdrawal was sub-
sequently evaluated in a meta-analysis 
by O’Mahony et al. (17). It showed that 
remaining on DMARDs substantially 
reduced flares (Table I). There were 
43/248 (17%) flares in patients staying 
on DMARDs and 117/253 (46%) flares 
in patients discontinuing DMARDs. 
The relative risk of a flare in patients re-
maining on DMARDs compared to pa-
tients in whom DMARDs were stopped 
was 0.31 (95% confidence interval 0.16 
to 0.57; p<0.001). Individuals in whom 
DMARDs were withdrawn were three 
times more likely to suffer flares than 
individuals in whom DMARDs were 
continued. 
The largest trial by ten Wolde et al. 
(15) lasted one year and enrolled 285 
RA patients with good long-term 
therapeutic responses. Half the pa-
tients continued DMARDs; the others 
received placebos. The end-point was 
recurrent synovitis due to flares. By 
52 weeks flares had occurred in 38% 
and 22% of patients receiving placebos 
and DMARDs, respectively. The trends 
were similar across all DMARDs (Fig-
ure 2), though the study was not pow-
ered to compare specific drugs. One 
limitation in this trial is that it involved 
very few patients receiving methotrex-
ate. There is evidence that methotrex-
ate achieves better long-term benefits 
(18) and therefore the benefits of re-
maining on DMARDs may be underes-
timated from the perspective of current 
prescribing practice.
A follow-up study (19) assessed 
DMARD resumption after flares occur-
ring post-treatment discontinuation. It 
enrolled 51 patients from the ten Wolde 
et al. trial (15). Patients who had flared 
showed significant improvements in 
disease activity measures within three 
months of restarting DMARDs. Ini-
tially they had worse disease activity 
than before treatment was discontin-
ued. However, by 12 months 35% of 
patients had inactive disease and 43% 
had mild disease activity. Only 8% of 
patients were unable to benefit from re-
sumption of their long-term treatment 
due to inefficacy. 
These studies have a number of limi-
tations: they are small, they include 
DMARDs that are now rarely used, 
they have defined flares in a variety of 
ways and they are of variable quality. 
Although flares could be controlled by 
restarting DMARDs, the overall ben-
efit of this strategy was uncertain.
Fig. 1. Retention times on different DMARDs
MTX: methotrexate; SSZ: sulfasalazine; HCQ: hydroxychloroquine; LEF: leflunomide; “All” 
DMARDs comprise methotrexate, sulfasalazine, hydroxychloroquine, chloroquine, leflunomide, gold, 
D-penicillamine, azathioprine; Figure adapted using data from the report by Aggarwal et al. (5).
Table I. Relative risk of a disease flare in individuals continuing DMARDs compared to 
those in whom DMARDs were withdrawn.
Study Year DMARDs Patients Relative risk
Ahern et al. (11) 1984 Penicillamine 38 0.13 (0.04, 0.50)
De Silva and Hazleman (12) 1981 Azathioprine 32 0.11 (0.02, 0.73)
Gotzsche et al. (13) 1996 Mixed 112 0.25 (0.13, 0.49)
Kremer et al. (14) 1987 Methotrexate 10 0.27 (0.07, 1.11)
ten Wolde et al. (15) 1996 Mixed 285 0.57 (0.39, 0.84)
Van der Leeden et al. (16) 1986 Gold 24 1.18 (0.08, 16.8)
Overall 501 0.31 (0.16, 0.57)
Data from a systematic review and meta-analysis of DMARD withdrawal by O’Mahony et al. (17). 
Pooled relative risks calculated using a random effects model.
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Clinical trials examining 
step-down DMARDs
Three RCTs evaluated tapering com-
bination DMARDs to monotherapy in 
strategies based on step-down inten-
sive combination DMARD therapy in 
early RA. The first step-down RCT was 
the COBRA early RA trial (20). Its in-
tensive treatment comprised high-dose 
reducing prednisolone for 28 weeks, 
low-dose methotrexate for 40 weeks 
with sulfasalazine as maintenance 
therapy. Controls received sulfasala-
zine monotherapy. Both disease activ-
ity and erosive progression were better 
controlled by combination DMARDs. 
Subsequent follow-up in routine prac-
tice settings over 4-5 years showed that 
the benefits of intensive initial treat-
ment on radiological progression were 
maintained after tapering (21).
The FIN-RACo trial also assessed step-
down treatment (22). It evaluated com-
bination therapy with sulphasalazine, 
methotrexate, hydroxychloroquine and 
prednisolone. Treatment was tapered 
in patients achieving remission during 
the first year; prednisolone and metho-
trexate were discontinued. Controls re-
ceived monotherapy with sulfasalazine 
followed by methotrexate for patients 
with adverse effects or non-responders. 
More patients had good clinical re-
sponses and achieved remission with 
intensive treatment. The radiological 
benefits were maintained long-term 
with a subsequent 11-year follow-up 
report showing less radiologic dam-
age in patients receiving initial com-
bination DMARDs compared to those 
receiving monotherapy. Mean Larsen 
score changes over 11 years in the com-
bination and monotherapy groups were 
17 (95% CI 12 to 26) and 27 (95% CI 
22 to 33), respectively (p=0.037) (2).
Marchesoni et al. (23) evaluated main-
tenance therapy with cyclosporine and 
methotrexate after 6 months combi-
nation treatment with both drugs in 
57 early, non-erosive RA patients. 
Stepping down to single agent main-
tenance therapy was successful only 
with methotrexate.
The BeSt study compared four differ-
ent treatment strategies in 508 patients 
with recent-onset RA. These com-
prised DMARD monotherapy, step-up 
DMARD combinations, step-down 
DMARD combinations (based on the 
COBRA regimen) and methotrexate 
combined with infliximab (1). When 
patients achieved remission DMARDs 
were tapered and stopped. Five-year 
follow-up data evaluated the frequency 
and impact of DMARD tapering (24). 
During this period, 23% of patients had 
drug-free remissions. Subsequently, 
46% restarted treatment for increasing 
disease activity and 51% had drug-free 
remissions. The frequencies of drug-
free remissions were similar across 
initial treatment groups (Fig. 3). The 
evidence suggests sustained drug-free 
remission is uncommon and tapering 
DMARDs in patients in remission has 
questionable benefits.
Step-down DMARDs have been evalu-
ated only in a single RCT in estab-
lished RA. Clegg et al. (25) examined 
if hydroxychloroquine monotherapy 
extended the benefits of combination 
therapy with hydroxychloroquine and 
methotrexate. Patients received open-
label combinations of hydroxychloro-
quine and methotrexate for 24 weeks 
followed by a double blind period 
evaluating either methotrexate or hy-
droxychloroquine as maintenance ther-
apy for 36 weeks. Combination thera-
py responders were randomised into 
3 groups: hydroxychloroquine with 
methotrexate for flares (40 patients); 
hydroxychloroquine monotherapy (41 
patients); placebo with methotrexate 
as needed for flares (40 patients). Af-
ter methotrexate withdrawal, hydroxy-
chloroquine maintenance delayed flare 
onset (p=0.023). Whilst supporting 
initial combination therapy, followed 
by hydroxychloroquine maintenance 
treatment, this trial did not evaluate 
methotrexate maintenance therapy, 
which might be more effective and 
Fig. 2. Cumulative frequency of flares in a trial of DMARD withdrawal.
Figure adapted using data from the report by ten Wolde et al. (15).
Fig. 3. Drug-free remission rates during five years of follow-up of the BeST early RA study.
Figure adapted using data from the report by Klarenbeek et al. (24).
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when treatment has been stabilised re-
sults in low levels of adverse effects.
Overall these RCTs in early and estab-
lished RA show that step-down combi-
nation therapy is effective and has sus-
tained benefits. To reduce subsequent 
flares at least one anchor DMARD 
should be retained. The optimal main-
tenance DMARD regimen was not de-
fined in these RCTs.
Observational studies examining 
DMARD withdrawal
Frequency reduction
Two very small historical case series 
examined reducing the frequency of 
DMARD administration. Reducing 
methotrexate from weekly to fortnight-
ly in 15 patients in remission showed 
13 patients remained in remission and 
only two flared (26). Reducing penicil-
lamine over 6 months from every day 
to taking it for one week in four was 
studied in 14 patients in partial remis-
sion on stable treatment (27). Twelve 
patients had unchanged clinical status 
over two years and only two flared. 
Dose reduction
The 12-month iRAMT trial evaluated 
reducing methotrexate to a target dose 
of 5mg/week in patients receiving in-
fliximab (28) in 210 patients. Metho-
trexate was tapered in the 159 patients 
with clinical improvements after 22 
weeks of infliximab; 92 (58%) subse-
quently tapered methotrexate without 
flares. Although it is possible to taper 
methotrexate when patients have re-
sponded to biologics, the overall ben-
efit is uncertain.
Complete withdrawal
The potential of “drug-free” remission 
as a treatment goal has been reviewed 
by Goekoop-Ruiterman and Huizinga 
(29). They noted that in observational 
studies sustained drug-free remis-
sion occurred in 15% of patients in a 
Dutch Early Arthritis Cohort and 9% 
of patients in a British cohort (30). 
The chance of achieving such drug-
free remission had not changed over 
the last two decades. Although stop-
ping DMARDs appears achievable 
in a small proportion of patients, its 
constant frequency in different cohorts 
of patients over time suggests it is the 
‘natural history’ of an RA subset. It 
most likely represents spontaneous re-
mission without any direct relationship 
to treatment. 
One small 15-year observational study 
of DMARD withdrawal by Tiippana-
Kinnunen et al. (31) evaluated DMARD 
continuity in 70 patients treated since 
diagnosis with DMARDs following 
the ‘sawtooth’ strategy. These patients 
formed three distinct groups: “continu-
ous DMARDs” (50 patients) receiving 
continual DMARDs; “discontinued and 
restarted DMARDs” (9 patients) and 
“permanently discontinued DMARDs”’ 
(11 patients). In the latter two groups 
DMARDs were discontinued due to 
remission lasting at least 12 months or 
a prolonged symptom-free phase with 
minor disease activity. Fifteen-year 
remission rates in these three groups 
comprised 6%, 0% and 64% respec-
tively. Although DMARDs could be 
discontinued due to clinical remission 
or low disease activity states in 29% at 
15 years, half of these individuals expe-
rienced flares and the overall benefit of 
stopping treatment is uncertain.
Predicting flare after 
DMARD withdrawal
Several studies have examined which 
factors identify individuals attain-
ing sustained drug-free remission on 
DMARD withdrawal. Van der Woude 
et al evaluated predictive factors for 
DMARD-free sustained remission in 
454 patients from a Dutch early arthri-
tis clinic and 895 patients from the Ear-
ly RA Study (ERAS) [30]. Multivariate 
analyses identified three independent 
predictors of drug-free remission in 
both cohorts. These comprised symp-
tom duration, IgM-rheumatoid factor 
(RF) positivity and presence of the 
HLA-DRB1 shared epitope alleles. Of 
these factors, IgM-RF was by far the 
strongest predictor with an associated 
hazard ratio for achieving sustained 
DMARD-free remission of 0.28 (95% 
CI 0.16–0.49) in ERAS and 0.19 (95% 
CI 0.11–0.35) in the Dutch Early Ar-
thritis Clinic; these results show that 
patients who were IgM-RF positive 
were far less likely to develop remis-
sion that IgM-RF negative patients
Five-year follow-up data from the 
BeST study also showed that serol-
ogy predicts drug-free remission (24). 
Anti-citrullinated protein antibodies 
(ACPA) positivity was the strongest 
independent predictor for a flare dur-
ing drug-free remission (OR 7.5; 95% 
CI 2.9–19.4). Other predictors of flares 
included higher mean DAS scores until 
remission (OR 4.7; 95% CI 1.5–15.2), 
a lower baseline HAQ (OR 0.41; 95% 
CI 0.19–0.88) and the use of sulfasala-




After reviewing the available evidence, 
expert groups have different perspec-
tives about discontinuing DMARDs. 
There appears to be no overall consen-
sus. UK guidelines from the National 
Institute for Health and Clinical Excel-
lence (NICE) recommend that if RA is 
stable, DMARD doses should be cau-
tiously reduced, returning promptly to 
disease controlling doses if there are 
any indications of a flare (3). EULAR 
guidelines are more guarded about 
DMARD tapering (4). They recom-
mend that in sustained long-term re-
mission cautious titration of synthetic 
DMARD dose may be considered. By 
contrast American College of Rheuma-
tology guidelines do not comment on 
DMARD withdrawal (32).
Conclusions
There is strong evidence from RCTs 
that treating active RA with step-down 
DMARD combinations is effective 
and, in early RA, achieves sustained 
responses. There is also good evidence 
that drug-free remission is achievable 
in a small minority of cases. Many if 
not most patients who achieve sus-
tained remissions on DMARDs some-
times flare, and the risks of flaring are 
increased when DMARDs are discon-
tinued, though restarting DMARDs 
usually reverses these flares. The best 
current predictors of flares on discon-
tinuing DMARDs are IgM-RF and 
ACPA-positivity. Further work is re-
quired to identify additional predictors 
of sustained remission on DMARD 
withdrawal; combining these within 
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a predictive framework would allow 
the identification of individuals most 
likely to benefit from DMARD cessa-
tion. Currently, the risks and benefits 
of stopping DMARD monotherapy in 
good responders remain uncertain and 
the evidence for stopping or continuing 
DMARDs is currently incomplete.
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Rheumatoid arthritis severity: its underlying prognostic 
factors and how they can be combined to inform 
treatment decisions
Rheumatoid arthritis (RA) is a heterogeneous 
disease that ranges from a mild, non-erosive 
form to a severe phenotype characterized by per-
sistent inflammation and rapid radiological pro-
gression (RRP). Adopting a uniform, as opposed 
to a stratified, approach for the management of 
all RA cases is, therefore, inappropriate and there 
is a requirement for methods to prospectively 
establish the likely severity of an individual’s 
RA early in the course of their disease, so that 
treatments can be tailored accordingly. This 
‘personalized medicine’ approach would limit 
the development of irreversible articular damage 
from aggressive RA and prevent exposing indi-
viduals with a mild disease course to the poten-
tially toxic effects of multiple drug therapies.
A number of different factors have been 
shown to associate with RA severity. The evi-
dence underlying many of these is, however, 
uncertain with environmental and genetic asso-
ciations often not replicated in independent 
cohorts. Previous reviews of prognostic factors 
for RA have either focused on a single factor 
type, such as genetics [1], described risk factors 
for a single disease outcome, such as radiologi-
cal erosions [2], or have not detailed how prog-
nostic factors could be combined to predict RA 
outcomes [3]. In this review, the authors provide 
a comprehensive overview of RA severity, out-
lining the evidence underlying a wide range of 
prognostic factors – spanning environmental, 
epidemiological, biochemical, radiological and 
genetic domains – for multiple RA outcomes 
with a focus on how they have been combined 
in prognostic modeling to stratify an individual’s 
risk of severe disease.
The relevance of predicting RA se-
verity: facilitating early treatment in 
poor prognosis cases
Much evidence exists to support the notion 
that individuals with RA have better outcomes 
if treated early and aggressively. The benefits of 
early combination treatments are demonstrated 
in several randomized controlled trials (RCTs). 
These include the BeSt and COBRA studies, 
with individuals receiving initial combination 
treatments having significantly better radio-
graphic outcomes compared with those receiving 
monotherapy or step-up combination therapy, 
although both RCTs included high-dose steroids 
or TNF inhibitors in their initial combination 
regimens, which could explain a significant pro-
portion of their efficacy [4,5]. Evidence also exists 
that step-up combination disease-modifying 
antirheumatic drugs (DMARDs) may be as 
effective as initial combination DMARDs, when 
used without oral steroids or biologics [6]. Earlier 
treatment also improves longer-term outcomes: 
one meta-analysis of 12 observational studies 
reported a 33% reduction in rates of long-term 
radiographic progression in patients receiving 
early versus delayed DMARD therapy [7]. The 
beneficial effects of prompt aggressive therapies 
on the natural history of RA have lead to the 
concepts of ‘a window of opportunity’ and ‘treat 
to target’ in which outcomes are improved pro-
vided appropriate treatments are initiated prior 
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to the end of this window and individuals have 
their treatment titrated until remission or low 
disease activity is attained [8,9].
However, despite the benefits of prompt com-
bination therapies, a recent national UK audit of 
prescribing practices in early RA found that only 
50% of 258 rheumatologists surveyed used ini-
tial combination treatments in newly diagnosed 
cases; 81% used sequential monotherapy in at 
least some patients [10]. The main reasons for this 
comprised concerns regarding side effects, moni-
toring requirements and patient acceptability. 
The capacity to stratify individuals’ risks of RA 
severity at disease onset could facilitate aggres-
sive treatment in the poor prognosis cases that 
are most likely to benefit from such a manage-
ment strategy.
Defining RA severity
Although many criteria exist to define remission 
in RA [11], far fewer criteria have been developed 
that focus on the opposing end of the disease 
spectrum, which is defining severe RA. The 
most widely used criteria in clinical practice is a 
28 joint count Disease Activity Score (DAS28) of 
more than 5.1 [12]. This cross-sectional assessment 
fails, however, to consider disease severity at more 
than one time point, disability, erosive disease 
and the extra-articular impacts of RA. Although 
several self-reported scales have been developed to 
assess RA activity, such as the RA Disease Activ-
ity Index [13] and the Rapid Assessment of Disease 
Activity in Rheumatology questionnaire, these 
do not have thresholds to define severe RA [14]. 
They also suffer from the same shortcomings as 
other cross-sectional assessments, and focus on 
disease activity. The Health Assessment Ques-
tionnaire (HAQ) – and more specifically one of 
its components, the HAQ Disability Index – is 
commonly used to assess RA severity indirectly 
through evaluating disability levels. The HAQ 
Disability Index is a self-reported questionnaire 
that evaluates functional ability using 20 ques-
tions spanning eight categories [15]. Scores of 0–1 
are considered to represent mild-to-moderate 
disability, 1–2 moderate-to-severe disability and 
2–3 severe or very severe disability. Separate from 
clinical criteria, many RCTs and observational 
studies use radiological damage as indices of RA 
severity. Two radiological assessments that are 
commonly used comprise the Sharp/van der Hei-
jde score (SHS) and the Scott modification of the 
Larsen method, which give scores out of 448 and 
250, respectively [16]. Consensus opinion suggests 
that a change in the SHS of at least 5.0 represents 
a minimal clinically important difference; the 
minimal clinically important difference for the 
modified Larsen score is less clear [17]. A summary 
of these scoring systems is given in Table 1.
Serological predictors of RA severity
It is increasingly clear that RA is not a single 
disease entity, but represents a spectrum of clini-
cal syndromes spanning distinct disease subsets 
[18]. Historically, RA has been stratified accord-
ing to the presence or absence of rheumatoid 
factor (RF), termed RF-positive RA (when RF 
is present) and RF-negative RA (when RF is 
absent). A more contemporary stratification is 
by antibodies to citrullinated peptide antigens 
(ACPA), with ACPA-positive RA character-
ized by a more aggressive disease course with a 
greater number of swollen joints and more severe 
radiological destruction [19]. Interestingly, both 
ACPA-positive and -negative disease can appear 
similar at initial presentation [19]; they can also 
be phenotypically similar at other disease stages.
The role of RF as a predictor of disease sever-
ity is well established, with cohorts of RF-posi-
tive patients consistently having higher rates of 
joint damage and extra-articular manifestations. 
This is particularly true of the IgA RF isotype, 
which is often reported as having a stronger 
association with severe disease when compared 
with IgM and IgG RF [20]. In one longitudinal 
observational study of 135 women with early 
RA followed-up for a mean duration of 6 years, 
while all three RF isotypes were significantly 
associated with more radiological damage pro-
gression and a greater number of swollen joints, 
IgA RF titers were most strongly correlated with 
the number of erosions, swollen joint counts 
(SJCs), the Ritchie index and HAQ scores [21]. 
Other studies have also shown stronger correla-
tions between IgA RF with radiological erosions 
[22,23] and extra-articular manifestations [24] in 
comparison with other RF isotypes.
The prognostic value of ACPA is also well 
described. In one cohort study of 93 early RA 
patients identified among Swedish blood donors, 
the presence of ACPA prior to and at disease 
onset was significantly associated with radiologi-
cal outcomes [25]. The baseline and 2-year Larsen 
scores in cases positive for ACPA pre-disease 
onset were 8 and 14, respectively; for individuals 
negative for ACPA pre-disease onset they were 
5 and 9. These differences were statistically sig-
nificant (p < 0.001) at both time points. ACPA 
also predicts longer-term radiological damage. 
Lindqvist et al. demonstrated this point in 
183 RA cases followed-up for 10 or more years 
[26]. In multilinear regression analyses, Larsen 
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scores at 10 years were significantly associated 
with ACPA and C-reactive protein (CRP) lev-
els, which accounted for 32% of the variance 
in the score.
The prognostic value of antibodies specific for 
citrullinated peptides in the joint is less certain. 
Current ACPA assays, such as the anti-CCP2 
test, incorporate many peptides derived from 
proteins absent from the synovial joint; they are, 
therefore, unlikely to be pathogenic. Although 
assays specific for citrullinated peptides present 
within the joint could be more prognostic, cur-
rent evidence does not support this with a sys-
tematic literature review reporting similar asso-
ciations between antibodies to modified citrul-
linated vimentin (an intra-articular antigen) and 
ACPA with radiological progression [27].
Environmental & epidemiological 
risk factors for RA severity
A variety of environmental and epidemiologi-
cal factors have been linked with RA severity. 
These are outlined in Table 2, which also pro-
vides examples of which studies have reported 
this relationship.
n Smoking
Cigarette smoking is the dominant environ-
mental risk factor for the development of sero-
positive RA. A recent systematic review on this 
topic demonstrated that smoking has a gender-
related effect, being associated with RA in men 
who have smoked at any point, but only being 
associated with RA in women who have smoked 
heavily [28]. There is some evidence that cigarette 
smoking also influences the natural history of 
RA. In one prospective study of 100 early RA 
patients followed-up for 24 months, baseline 
SJC, tender joint count and pain visual ana-
log scale scores were all significantly higher in 
smokers compared with non-smokers [29]. The 
SJC at 6 months was also significantly associ-
ated with smoking status, with current smok-
ing increasing the number of swollen joints by 
at least three on average in a regression model 
after the elimination of non-significant variables. 
Another observational study of 63 women with 
advanced RA of an average disease duration of 
13.7 years showed that heavy smoking (defined 
as ≥20 pack-years) was significantly associated 
with the presence of rheumatoid nodules, higher 
rates of radiological damage as defined by modi-
fied Sharp scores and higher HAQ scores when 
compared with smokers of <20 pack years or or 
those who had never smoked [30]. Other stud-
ies have, however, failed to demonstrate a clear 
association between smoking and RA severity 
with the QUEST-RA study finding no relation-
ship between smoking status and erosions, severe 
extra-articular disease or DAS28 scores [31]. Any 
impact of smoking on disease severity probably 
stems from the fact that it predisposes to the 
development of ACPA-positive as opposed to 
ACPA-negative RA in genetically predisposed 
individuals and, therefore, leads to the onset of a 
different, more aggressive clinical phenotype [32].
n Alcohol consumption
There has been much interest in the role of alco-
hol consumption as a protective factor against RA 
development. Recent case–control studies have 
found lower rates of alcohol consumption in cases 
compared with controls, implying that it has a 
protective effect [33]. This relationship has not, 
Table 1. Examples of assessment criteria for rheumatoid arthritis severity.
Criteria name Criteria type Description Ref.
DAS28 score Clinical physician 
assessment
Composite score involving assessment of the number of swollen and tender joints on 
a 28 joint count, the ESR and a self-reported VAS of global RA activity
A score of >5.1 indicates severe RA activity
[12]
HAQ-DI Clinical self-reported 
assessment




2–3: severe or very severe disability
[15]




Assesses erosions and joint-space narrowing in 44 and 42 joints, respectively, 
alongside subluxation. The total score ranges from 0 to 448
Higher scores indicate worse disease
[16]




Assesses changes of erosion and joint destruction in the hands, wrists and feet, 
providing a total score ranging from 0 to 250
Higher scores indicate worse disease
[16]
DAS28: 28 joint count Disease Activity Score; ESR: Erythrocyte sedimentation rate; HAQ-DI: Health Assessment Questionnaire Disability Index; RA: Rheumatoid 
arthritis; VAS: Visual analog scale.
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however, been observed in earlier cohort studies. 
There is also evidence that alcohol intake may 
associate with a less severe disease course. In one 
study of 873 erosive RA cases, more frequent 
alcohol consumption correlated significantly with 
lower DAS28-CRP, Larsen and modified HAQ 
scores [34]. These trends are shown in Figure 1. The 
median DAS28-CRP, Larsen and modified HAQ 
scores in individuals drinking no alcohol in the 
month prior to assessment comprised 4.29, 38 
and 1.0, respectively; these scores in individuals 
drinking on more than 10 days in the month prior 
to assessment comprised 3.72, 27 and 0.63. All 
of these differences were statistically significant 
Table 2. Studies evaluating environmental and epidemiological prognostic factors for rheumatoid arthritis 
severity.
Risk factor Study (year) Size Type Severity outcome(s) Main findings Ref.
Smoking Masdottir et al.
(2000) 
63 Ca Cross-sectional Nodules, modified Sharp 
score, SJC, HAQ, grip 
strength
Significant associations between 
≥20 pack years and nodules, higher 
Larsen scores, higher HAQ scores 




100 Ca Longitudinal Joint counts, pain VAS, CRP, 
van der Heijde score
Over 24 months current smokers 
had the highest and those who had 
never smoked the lowest SJC 
(p < 0.001) and TJC (p = 0.02) 
scores, respectively
[29]
Alcohol Maxwell et al. 
(2010) 
873 Ca Cross-sectional Larsen score, DAS28-CRP, 
modified HAQ, pain VAS
Significant trends for reducing 
Larsen scores, DAS28-CRP, CRP, 
modified HAQ and pain VAS with 
increasing alcohol intake
[34]
Nissen et al. 
(2010) 
2908 Ca Longitudinal Ratingen score (radiographic 
damage), HAQ
Non-significant reduced 
radiographic progression in drinkers: 
1-year mean progression 0.99% 
(95% CI: 0.89–1.09) in drinkers vs 
1.13% (95% CI: 1.01–1.26) in 
non-drinkers
[35]





Meta-analysis ORs for RA using hospital- 
or population-derived cases
Pooled OR for studies using hospital 
cases showed significant protective 
effect of OCP use on RA 
development; not observed in 




100 Ca Cross-sectional DAS28, HAQ, Larsen score Periodontitis severity significantly 
correlated with DAS28 score, ESR 
and CRP
[40]
Mercado et al. 
(2001) 




Periodontitis severity significantly 
associated with higher SJCs, higher 
HAQ scores and higher CRP/ESR 
levels
[41]
Gender Jawaheer et al. 
(2010)
292 Ca Longitudinal DAS28, HAQ, pain/fatigue 
VAS, global health scores, 
CRP, Sharp scores
Females had worse disease 
progression reflected by DAS28, 
physician global and TJC scores
[46]
Ahlmén et al. 
(2010) 
549 Ca Longitudinal DAS28, HAQ, SOFI 
instrument, SHS
Females had significantly higher 







814 Ca Longitudinal Pain score, articular index, 
ESR, CRP, HAQ
Cases from deprived areas had 




869 Ca Longitudinal Joint counts, HAQ, pain 
VAS, grip strength, ESR, 
erosive radiological changes
Significantly worse HAQ and joint 
scores, and grip strength in 
individuals with higher deprivation 
scores
[44]
Ca: Case; Co: Control; DAS28: 28 joint count Disease Activity Score; ESR: Erythrocyte sedimentation rate; HAQ: Health assessment questionnaire; OCP: Oral 
contraceptive pill; OR: Odds ratio; RA: Rheumatoid arthritis; SJC: Swollen joint count; SHS: Sharp/van der Heijde score; SOFI: Signals of Functional Impairment; 
TJC: Tender joint count; VAS: Visual analog scale. 
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(p < 0.05) when evaluated by trend tests across 
alcohol intake categories. A protective effect of 
alcohol intake on radiographic progression was 
also demonstrated in a large Swiss observational 
study evaluating 2908 RA cases nested within a 
national database of RA patients [35]. This study 
evaluated the impact of drinking alcohol on the 
progression of x-ray damage, scored according to 
the Ratingen method [36]. It found that in a model 
adjusting for multiple variables (comprising base-
line radiological damage scores, DAS28, HAQ, 
presence of RF, sex, age, disease duration, tobacco 
smoking, education level and medications) radio-
graphic damage at 12 months had progressed 
by an average of 0.99% (95%  CI: 0.89–1.09) 
in drinkers and 1.13% (95% CI: 1.01–1.26) in 
non-drinkers. Interestingly, as with the beneficial 
effects of drinking on cardiovascular disease, a 
J-shaped dose–response effect was seen with occa-
sional and daily alcohol consumers having less 
radiographic progression at 12 months compared 
with non-drinkers and heavy drinkers.
n Oral contraceptive pill use
Although the oral contraceptive pill (OCP) has 
often been considered to protect against RA 
development, a meta-analysis of nine studies 
evaluating this topic by Spector and Hochberg 
indicated that OCP use may protect against the 
progression to a severe RA phenotype as opposed 
to protecting against disease onset [37]. While an 
overall protective effect of OCP use on RA risk 
was observed in case–control studies, when their 
meta-analysis was subdivided by studies using 
cases enrolled from hospitals or the community 
different impacts on disease risk were observed. 
In case–control studies evaluating hospital-based 
cases, the odds ratio (OR) for RA in OCP users 
was 0.49 (95% CI: 0.39–0.63); in those evalu-
ating population-derived cases the OR was 0.95 
(95% CI: 0.78–1.16). The authors considered 
that the most likely explanation for this discrep-
ancy was that rather than preventing RA devel-
opment, OCP use modified the disease process, 
maintaining it as a mild or transient disorder.
n Periodontitis
Periodontitis, a destructive inflammatory dis ease 
of the supporting tissues of the teeth, is prevalent in 
RA patients [38]. The best characterized causative 
organism for periodontitis is Porphyromonas gingi-
valis, but there are others, including the Prevotella 
species. P. gingivalis is the only known bacterium 
to express its own functional peptidylarginine 
deiminase enzyme, the orthologs of the peptidyl-
arginine deiminase family of enzymes responsible 
for the citrullination of arginine residues in mam-
mals [39]. It has, therefore, been hypothesized that 
it contributes to ACPA formation in pre-RA indi-
viduals. It follows from this that, as with smok-
ing, periodontitis could affect disease severity 
through promoting ACPA. This relationship was 
evaluated in a cross-sectional study of 100 patients 
with active RA, which reported significant correla-
tions between periodontitis severity and DAS28 
scores (p < 0.001), erythrocyte sedimentation rate 
(ESR; p < 0.005) and high sensitivity CRP lev-
els (p < 0.003) [40]. Another small observational 
study of 65 RA patients found that individuals 
with moderate-to-severe periodontitis had signifi-
cantly more swollen joints, higher HAQ scores and 
higher CRP levels when compared with patients 
with no or mild periodontitis [41]. Further work 
is required with large longitudinal studies to bet-
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Figure 1. The relationship between alcohol consumption and disease 
outcomes in a case–control study. p-values for trend tests are all p < 0.0001. 
DAS28: 28 joint count Disease Activity Score; mHAQ: Modified Health Assessment 
Questionnaire. 
Data taken from [34].
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impact of aggressive treatment of periodontitis on 
disease onset and/or severity.
n Social deprivation
Several studies have highlighted that individuals 
from socially deprived areas have poorer disease 
outcomes [42,43]. This association was evaluated in 
869 patients from the Early Rheumatoid Arthri-
tis Study (ERAS), which is a large prospective 
cohort study of individuals with RA of less than 
2 years duration [44]. The authors reported that 
the Carstairs score (a composite score of male 
unemployment, social class, overcrowding and 
car access that represents an index of deprivation) 
was associated with more severe disease at presen-
tation, as reflected by HAQ and joint scores; this 
association persisted and remained after 3 years 
of follow-up. The precise underlying mechanism 
for this association is unclear; it may represent 
an association between low socioeconomic status 
and lifestyle factors such as smoking.
n Gender
Gender differences in RA are well described, with 
the incidence of RA greater amongst women com-
pared with men [45]. There is also evidence that 
RA outcomes are worse in females. Jawaheer et al. 
found that in a longitudinal prospective study of 
225 women and 67 men with early seropositive 
DMARD-naive RA, women had worse disease 
progression over 2 years as reflected by DAS28 
scores, physician global scores and tender joint 
counts; this was in spite of similar treatments 
[46]. Men were also more likely to attain remis-
sion. Similarly, the Swedish BARFOT study 
reported that women had significantly higher 
DAS28 and HAQ scores compared with males 
at all time points over a 5-year follow-up period; 
the authors attributed this DAS28 discrepancy 
to a higher number of tender joints and general 
health scores in women compared with men, 
which suggested that gender differences may exist 
in pain experiences in RA [47]. Other studies have 
reported similar female gender influences on RA 
progression [48].
Evidence for a genetic component to 
disease severity
In contrast to the identification of genetic suscep-
tibility variants for RA – with 46 loci identified 
[49] – there is substantially less information on 
which genetic markers influence RA severity. The 
dominant reason for this is a lack of adequately 
sized cohorts containing detailed genotypic and 
longitudinal disease outcome data. Studies on 
this topic have been inadequately powered to 
detect genome-wide significant single nucleotide 
polymorphisms (SNPs), relying on candidate 
gene approaches instead to identify loci. While 
these have had some successes, a candidate gene 
approach fails to consider the entire genome and 
important loci may be overlooked. Despite these 
problems, there is accumulating evidence that 
genetics play an important role in determining 
radiological progression in RA. A twin study 
found that the variance in radiographic joint 
destruction was highest in unrelated patients, 
followed by dizygotic and finally monozygotic 
twins [50]. A more recent study has replicated the 
association between relatedness and radiological 
damage in 325 Icelandic patients with RA; this 
study quantified the heritability of radiological 
joint destruction to be between 45 and 58% [51].
Genetic risk factors for RA severity
n HLA-DRB1 alleles
The HLA-DRB1 alleles, in particular those 
encoding the shared epitope (SE), are the best 
established genetic risk factors for seropositive 
RA, explaining approximately 36% of the herita-
bility of RA [49]. They also associate with a more 
severe phenotype [52]. In one case–control study 
of 309 Caucasian RA patients and 283 controls, 
heterozygous/homozygous SE carriers used sig-
nificantly more DMARDs – an indirect marker 
of disease severity – compared with non-SE car-
riers [53]. Similarly, Wagner et al. found that in 
a prospective study of 55 early RA cases, those 
positive for the SE on HLA-DR4 had an OR for 
erosive disease of 13.75 (p = 0.00083) [54].
More recent studies have employed the classifi-
cation system for HLA-DRB1 alleles proposed by 
du Montcel et al. [55]. This broadly divides HLA-
DRB1 alleles into two groups: S alleles and X alleles, 
which have or do not have the RAA sequence at 
position 72–74, respectively. Some S alleles – such 
as S
2
 (containing HLA-DRB1*04:01) – are associ-
ated with an increased disease risk; other S alleles 
– such as S
1
 (containing HLA-DRB1*13:01) – are
associated with a reduced risk [56]. Using this 
classification system one observational study of 
962 RA cases found that S
2
 allele carriage sig-
nificantly correlated with higher Larsen scores, 
with the median Larsen score for individuals car-
rying one and two S
2
 copies comprising 29 and 
41, respectively [57]. Carriage of S
1
 alleles associ-
ated with less radiological damage (p = 0.011). 
Similar findings come from a prospective study 
of 144 French–Caucasian early RA patients in 
which S
2
 allele carriers had greater radiographic 
damage progression compared with noncarriers 
(p = 0.004); in addition, S
3D
 allele carriers had less 
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radiographic damage progression compared with 
noncarriers (p < 0.0001) [58]. In both instances 
significant gene–dose effects were observed.
It therefore appears that, as with disease sus-
ceptibility, some HLA-DRB1 alleles are risk 
factors for, and some protect against, radio-
logical progression in RA. The association with 
severity may arise from the fact that carrying 
SE alleles predisposes individuals to developing 
ACPA-positive RA [57].
n PTPN22
There is limited evidence that PTPN22 – the 
dominant non-MHC susceptibility allele – con-
tributes to radiological progression. This allele 
encodes a lymphoid-specific tyrosine phospha-
tase, Lyp, which is an important regulator of 
kinases and signaling intermediates that medi-
ate antigen receptor signal transduction and 
T-cell activation [59]. It has been suggested that 
the RA-associated variant represents a gain-of-
function mutation that predisposes to autoim-
mune disease through excessive suppression of 
T-cell receptor signaling leading to the survival 
of autoreactive T cells [60], but this remains 
controversial.
In a cross-sectional study of 964 RA cases, 
Marinou et al. reported a trend towards higher 
rates of x-ray damage in PTPN22 minor allele 
carriers compared with non-carriers. Median 
modified Larsen scores for individuals with zero, 
one or two minor allele copies comprised 25.5, 
33.0 and 50.0, respectively [61]. This finding 
was, however, only of borderline statistical sig-
nificance (p = 0.04) and has not been replicated 
in other cohorts. These include the BRASS in 
which the adjusted OR (95% CI) for an erosive 
phenotype in PTPN22 T allele carriers was 1.14 
(0.77–1.71) [62] and the Leiden Early Arthritis 
Clinic and North American Rheumatoid Arthri-
tis Consortium in which no association was 
demonstrated between the PTPN22 suscepti-
bility risk variant and joint destruction rates in 
RA patients, even when restricting analyses to 
ACPA-positive RA [63].
n IL1B & IL1RN
IL-1 is an important proinflammatory cytokine 
in RA, as demonstrated by the relative efficacy of 
anakinra, an IL-1b receptor antagonist [64]. IL-1 
induces T-cell activation, promotes lymphocyte 
and monocyte chemotaxis and facilitates pan-
nus formation. It is, therefore, an ideal candi-
date gene to examine its role in RA progression. 
IL-1 comprises three inflammatory mediators, 
encoded by the IL1 locus on chromosome  2 [65]. 
These comprise IL-1a, IL-1b and the IL-1 recep-
tor antagonist (IL-1Ra); all bind to the IL-1 
receptor with the initial two mediators stimu-
lating signal transduction and the latter acting 
as a competitive signaling inhibitor.
Cantagrel et al. evaluated the relationship 
between two polymorphisms in the IL1B gene and 
one polymorphism in the IL1RN gene amongst 
108 patients with early RA [66]. Although none 
independently associated with erosion devel-
opment at 2 years, when IL1B exon 5 allele E2 
carriage was combined with the presence of SE 
alleles an increased risk of erosive disease was 
observed: the OR for erosions was 8.20 (95% CI: 
2.59–25.84). This implies that epistasis (gene–
gene interactions) contributes to radiological pro-
gression. Buchs et al. also examined the association 
between radiological damage and polymorphisms 
in the IL1B (within the promoter region at -511 
and in exon 5 at +3954) and IL1RN (in exon 2 
at position +2018) genes amongst 297 RA cases 
[67]. They found a significant relationship between 
destructive RA and the carriage of the rare IL1B 
(+3954) allele  2. The association of the exon 5 
+3953 A2 allele with more active RA – defined by 
higher DAS28 scores and ESR levels – was dem-
onstrated in a smaller study of 93 RA patients [68].
There are a number of studies, however, that 
show no relationship between IL1B loci vari-
ants and RA outcomes. In one report of 756 
RA patients, three SNPs tagging IL1B (rs16944, 
rs1143623 and rs4848306) and one tagging 
IL1A (rs17561) did not correlate with the pres-
ence of rheumatoid nodules, joint replacement 
need or radiographic progression [69]. Another 
report found no robust association between 24 
SNPs from IL1A and IL1B and hand radiograph 
erosions in 712 cases [70].
n IL6
IL-6 is another prominent cytokine in RA. It is 
abundant in the synovial fluid and serum of RA 
patients; its titers positively correlate with disease 
activity and joint damage [71]. An association 
between an IL6 tagging SNP and radiographic 
severity was reported by Marinou et al. [61]. In 
this cross-sectional evaluation of 964 RA cases, 
the SNP, rs1800795, that tags the promoter region 
of the IL6 gene (referred to as the ‘-174’ polymor-
phism) significantly associated with radiological 
damage in seropositive RA. The modified Larsen 
scores in ACPA-positive RA risk allele non-car-
riers, heterozygotes and homozygotes comprised 
29, 32 and 41 (trend test p-value = 0.004), respec-
tively. As this finding has not been validated in 
other cohorts its prognostic relevance is uncertain.
284
Int. J. Clin. Rheumatol. (2013) 8(2) future science group
Review Scott, Lewis, Cope & Steer
n IL10
While many genetic associations in RA are 
restricted to seropositive disease, one research 
group identified a polymorphism in IL10 -592C 
(tagging SNP, rs1800872) specific for erosive 
damage in ACPA-negative RA [61]. In this study, 
ACPA-negative individuals homozygous for the 
risk allele had more severe radiographic dam-
age compared with non-carriers/heterozygous 
individuals (pooled due to small numbers); 
the median modified Larsen score was 6.0 in 
non-carriers/heterozygotes and 16.0 in homozy-
gotes (p-value for trend = 0.002). This suggests 
that, as with susceptibility alleles, genetic risks 
for severity differ serologically. This discrepancy 
by ACPA status is highlighted in Figure 2, which 
also demonstrates an IL6 polymorphism associ-
ated with x-ray damage in ACPA-positive, but 
not ACPA-negative disease. Another IL10 locus 
polymorphism was shown to influence the rate 
of radiological progression in 91 patients in 
The Netherlands [72]. Although this study did 
not subdivide its analysis by ACPA status, the 
presence of the IL10 -1082GG genotype was 
associated with significantly greater increases in 
the Sharp radiographic damage scores at 3 and 
6 years when compared with individuals with the 
-1082AA genotype. Other studies have, however, 
failed to demonstrate an association between 
these polymorphisms and radiographic damage 
in RA [73–75].
n IL15
IL-15 is an innate immune system cytokine. It is 
present in the RA synovium where it plays a func-
tional role, inducing neutrophil activation, gran-
ule release from natural killer cells, endothelial cell 
activation and preventing fibroblast apoptosis [76]. 
Clinical trials suggest that anti-IL-15 monoclonal 
antibody treatments may be effective in RA [77], 
offering further evidence for a pathogenic role. 
A meta-analysis of 1418 RA patients from four 
independent data sets evaluated the relationship 
between polymorphisms in the IL15 locus and 
radiographic progression [78]. This involved an ini-
tial exploratory analysis in 600 patients from the 
largest cohort; significant SNPs were subsequently 
evaluated in the remaining cohorts, with a final 
combined assessment undertaken. In the initial 
analysis, five SNPs significantly associated with 
joint destruction rates. Although not indepen-
dently replicated in the other data sets (possibly 
due to limited power in these smaller cohorts) the 
meta-analysis revealed significant associations for 
four SNPs. These comprised rs6821171 (protec-
tive effect on joint destruction) and rs7667746, 
rs7665842 and rs4371699 (deteriorative effects). 
p-values after multiple testing correction com-
prised rs6821171 (p = 0.03), rs7667746 (p < 0.01), 
rs7665842 (p < 0.01) and rs4371699 (p = 0.02).
n TRAF1/C5
TRAF1 encodes an intracellular protein mem-
ber of the TNF receptor-associated factor family 
involved in TNF-a signaling [79]; the comple-
ment component 5 has been associated with RA 
in animal models [80]. In the Norfolk Arthritis 
Register (NOAR) – a primary care-based incep-
tion cohort of recent-onset inflammatory poly-
arthritis patients – two SNPs mapping to the 
TRAF1/C5 locus (rs2900180 and rs10760130) 
were associated with erosions at 5 years; this was 
independent of ACPA [81]. At 5 years, the ORs for 
developing erosions in inflammatory polyarthritis 
after adjusting for ACPA positivity comprised 1.65 
(95% CI: 1.13–2.42; p = 0.01) for individuals car-
rying the risk allele for rs2900180 and 1.52 (95% 
CI: 1.00–2.29; p = 0.05) for those carrying the 
rs10760130 risk allele. The SNP rs2900180 has 
also been associated with RA patient Larsen scores 
in ERAS [82]. Although another study of 278 cases 
reported a significant association between a SNP 
in this locus (rs10818488), which is in high link-
age disequilibrium with rs10760130, and radio-
logical progression [83], this was not reproduced 
in a meta-analysis of seven data sets (evaluating 
2666 RA patients) [84].
n CD40
The CD40 protein is expressed on the surface of 
multiple immune cells; it plays a pivotal role in 
providing CD4+ T-cell helper activity in immune 
reactions [85]. The association of the CD40 
locus with RA outcomes was shown in 250 and 
393 ACPA-positive RA cases from the Leiden 
Early Arthritis Clinic cohort and North American 
Rheumatoid Arthritis Consortium, respectively 
[86]. In this analysis, the SNP rs4810485 yielded 
a 1.12-times (95% CI: 1.04–1.21) greater increase 
in the Sharp score per year in those carrying the 
risk genotype in the Leiden Early Arthritis Clinic 
(a significant association remained after correcting 
for multiple testing). Using a perfect SNP proxy 
the risk genotype from the Leiden Early Arthri-
tis Clinic cohort also revealed a higher estimated 
radiological progression rate in the North Ameri-
can Rheumatoid Arthritis Consortium cohort.
Ultrasound imaging & MRI as 
 predictors of RA severity
Advances in imaging technology have lead to 
an increased use of MRI and, in particular, 
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musculoskeletal ultrasound scanning (USS) in 
routine clinical practice. The key advantages that 
USS has over MRI are that many peripheral joints 
can be examined multiple times during a consul-
tation with the patient thus improving clinical 
accuracy, prosthetic joints do not interfere with 
imaging, and USS is less costly [87]. In early RA, 
there is evidence that both techniques are able to 
predict longer-term radiological outcomes.
n Ultrasound
Synovial inflammation involves peri-articular 
vasodilation, synovial proliferation and angio-
genesis; this process can be detected by the USS 
power Doppler (PD) modality [88]. USS, and 
more specifically PD, assessments have been 
shown to correlate with radiographic progression 
in several studies. In 42 early RA patients (with 
disease duration of less than 12 months) followed-
up at 0, 3, 6 and 12 months, time-integrated 
values of USS PD parameters had stronger cor-
relations with radiographic progression at 1 year 
(r = 0.59; p < 0.001) than clinical and laboratory 
parameters (r < 0.5) [87]. In another RCT in which 
24 methotrexate-treated RA cases were random-
ized to either placebo or infliximab, in the placebo 
arm there were significant positive correlations 
between both baseline synovial thickness and 
vascularity as measured by USS and progression 
in radiographic severity scores at 54 weeks [89].
USS can also play a role in the pre-RA stage 
by predicting which individuals with an undiffer-
entiated arthritis will develop a persistent disease 
that may progress to a full RA phenotype. In 
a study of 50 patients with inflammatory hand 
symptoms for up to 12 weeks, the presence of a 
PD score in any joint of at least 2 had a similar pre-
dictive value for developing a persistent inflam-
matory arthritis to that of serology [90]. In this 
study, the sensitivities/specificities for RF, ACPA 
and a PD score ≥2 in any joint were reported as 
31.6/100.0, 44.7/100.0 and 50.0/100.0, respec-
tively. Similar findings come from a study by Filer 
et al., who reported that the addition of a 10-joint 
PD index to the Leiden clinical prediction score 
for RA development significantly improved the 
model’s predictive capabilities in individuals with 
very early synovitis (as demonstrated by an area 
under the curve increase from 0.905 to 0.962; 
p < 0.05) [91].
n MRI
Several studies have shown that the presence of 
MRI-detected bone marrow edema at disease 
onset predicts joint damage progression years later. 
In one RCT of 130 early RA patients, baseline 
MRI bone marrow edema was the only signifi-
cant predictor (in a multiple linear regression 
analysis) of radiological progression at the wrist 
and metacarpophalangeal joints, explaining 41% 
of the variation in the SHS [92]. Similarly, in a 
smaller prospective study of 42 RA patients the 
baseline MRI bone edema score was predictive of 
the 6-year total Sharp score (p = 0.01) [93]. Palo-
saari et al. also demonstrated the predictive value 
of bone marrow edema on MRI; in 27 early RA 
patients the baseline MRI bone edema score was 
the only baseline variable that predicted erosive 
progression at 24 months in a multivariate model 

































































Figure 2. The effects of IL6 and IL10 gene polymorphisms on modified 
Larsen scores when evaluated by ACPA status in a recent case–control 
study. p-values are for the comparison of median scores across genotype groups. 
ACPA: Antibodies to citrullinated peptide antigens; RA: Rheumatoid arthritis. 
Data taken from [61].
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Biochemical markers
The best established and most commonly used 
prognostic biomarkers for RA comprise the 
acute phase response indices ESR and CRP, 
both of which correlate with disease severity [26]. 
A number of other markers have been evalu-
ated for their prognostic implications in RA. 
One example is the matrix metalloproteinases 
(MMPs), which are zinc-dependent proteases 
that regulate extracellular matrix proteolysis and 
are involved in the cleavage of cytokines, che-
mokines and their receptors; they are thus con-
sidered to play important roles in inflammation 
[95]. Other examples include the bone turnover 
marker urinary C-telopeptide of type II collagen 
(CTX-II), which is an immunoassay that uses 
antibodies specific for the C-terminal cross-
linking telopeptide of type II collagen in the 
urine [96] and the osteoclast activation markers 
RANKL and osteoprotegerin (OPG). RANKL 
is an essential osteoclastogenesis cytokine; OPG 
is a decoy receptor for RANKL that inhibits 
osteoclast function by interrupting RANKL’s 
interaction with its receptor [97].
Young-Min et al. evaluated the role of sev-
eral serum biomarkers comprising MMP-1, 
MMP-13, MMP-3, TIMP-1 and COMP and 
urinary biomarkers including CTX-II in pre-
dicting radiographic progression in 132 early 
RA patients [98]. They found that although 
multiple biomarkers including MMP-3, COMP 
and TIMP-1 correlated significantly with radio-
graphic progression by multivariate analysis, 
a model consisting of baseline MMP-3 and 
CTX-II provided the best prediction of radio-
graphic progression at study entry (area under 
the curve: 0.76; 95% CI: 0.66–0.85). Other 
research groups have shown MMP-3 to be pre-
dictive of radiographic progression in other RA 
cohorts. In 48 RA patients without radiological 
damage at presentation, serum MMP-3 levels at 
study entry significantly correlated with Sharp 
scores at 6 and 12 months and joint space nar-
rowing at 6, 12 and 24 months [99]. Similarly, 
in 26 patients with early RA baseline serum 
MMP-3 levels were significantly associated 
with Larsen scores at 6 and 12 months after 
study entry; furthermore, when the relation-
ship between percentage increases in serum 
MMP-3 in the first 12 months after entry and 
the percentage increase in Larsen scores in each 
year were evaluated, a significant correlation 
was observed between the increase in serum 
MMP-3 during the first 12 months and the 
increase in the Larsen score in the subsequent 
12–24 months after entry [100].
The role of urinary CTX-II in RA prognostic 
stratification has also been reproduced in several 
studies. The association between baseline urinary 
CTX-I and CTX-II levels and the mean annual 
progression of joint destruction over a median 
of 4 years was examined in the COBRA study. 
In two multivariate logistic regression analyses 
that included each marker separately due to their 
high correlation, baseline urinary CTX-I and 
CTX-II levels both predicted long-term radio-
logic progression independently of treatment, 
disease activity and RF status at baseline [101]. 
In addition, Hashimoto et al. reported that in 
145 patients with active RA of less than 5 years 
duration baseline urinary CTX-II levels corre-
lated significantly with radiological progression 
at week 52 [102].
The prognostic value of the RANKL:OPG 
ratio (representing osteoclast activation) was 
also shown in the COBRA study. In a univari-
ate analysis examining the relationships between 
disease activity measures/bone markers and 
annual radiographic progression, the baseline 
RANKL:OPG ratio was the strongest predictor 
of radiological deterioration [103].
Combining prognostic markers to 
predict RA severity
Several research groups have attempted to com-
bine information on the aforementioned prog-
nostic factors into models that are capable of 
identifying individuals at a high risk of radio-
logical progression. Some have used simple 
clinical parameters and others have integrated 
these with biomarkers and radiological indices. 
Genetic markers have rarely been used. 
Brennan et al. developed one such prediction 
model for the presence of radiological erosions in 
the hands and/or feet after 12 months within the 
NOAR cohort [104]. In this study of 175 patients 
with early RA, the study population was randomly 
split into a prediction sample of 105 patients – in 
which predictor variables for radiological progres-
sion were sought – and a validation sample of 70 
patients – in which the prediction algorithm was 
tested. A simple algorithm using a combination 
of three variables, comprising a positive RF test, 
swelling of at least two large joints and disease 
duration of more than 3 months, was best able to 
predict erosions. This prediction model was able 
to classify eight risk groups, with a probability of 
developing erosions that ranged from 0.13 (if all 
variables were absent) to 0.89 (if all were present). 
It was able to correctly predict the development 
of erosive disease in 79% of cases; its negative 
and positive predictive values were 80 and 76%, 
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respectively. Its predictive abilities are illustrated 
in Figure 3. This model demonstrates that even sim-
ple clinical measurements used in routine practice 
can be useful in estimating disease progression.
Drossaers-Bakker et al. demonstrated that 
prognostic modeling can be undertaken to pre-
dict longer-term disease outcomes at 12 years 
[105]. This study evaluated 112 female RA 
patients with symptoms of less than 5 years’ 
duration (median 1 year) at recruitment. It 
developed prediction models for three different 
disease outcomes: first, radiographic damage 
(measured by the SHS method); second, dis-
ability (measured by the HAQ); and third, a 
severe disease course (measured by calculating 
the area under the curve of all DAS assessments 
alongside the radiographic disease course). Indi-
viduals in the highest tertile of each outcome 
measure were defined as ‘severe’ for that out-
come and individuals in the lowest tertile were 
defined as ‘mild’. Using a model that contained 
the baseline parameters of the SJC, RF, the pres-
ence of erosions, the Ritchie index, ESR, HAQ 
and SHS, the accuracy of the model for pre-
dicting mild radiographic damage, severe radio-
graphic damage, mild HAQ, severe HAQ and 
a severe disease course comprised 87, 84, 88, 84 
and 83%, respectively. Surprisingly additional 
information on HLA typing added little to the 
modeling, improving the correct prediction of 
radiographic damage by only 3%. This finding 
highlights the limitations of including current 
genetic markers, which explain only a minor 
proportion of the heritability of radiological 
progression, in prognostic models.
More recently, two research groups have devel-
oped matrix risk models for RRP, which are orga-
nized into color-coded matrixes similar to that 
which is widely used in predicting the 10-year 
risk of fatal cardiovascular disease [106]. One of 
these matrixes was developed using data from 465 
RA patients enrolled to the BeST RCT. As previ-
ously described, this study randomized patients 
to four treatment arms comprising two arms 
treated with initial monotherapy that could be 
switched or extended to other DMARDs, a third 
arm treated with initial combination DMARDs 
and tapering high-dose corticosteroids and a 
fourth arm treated with initial methotrexate and 
infliximab [107]. Patients were treated with an aim 
of attaining a DAS of ≤2.4. RRP was defined as 
an increase in the SHS of ≥5 after 12 months. 
Predictors of RRP were identified by multivariate 
logistic regression with backward selection. Dif-
ferent models were developed for different treat-
ment groups and included the variables CRP, 
erosion score and serology (RF and ACPA). The 
highest risk group was those individuals in the 
initial monotherapy treatment arm with a CRP 
≥35mg/l, erosion score ≥4 and both RF and 
ACPA positivity; their risk of RRP was 78%. 
The lowest risk groups were those individuals 








































Predicted risk of erosions
Observed risk of erosions
Figure 3. Predicted versus observed risks of developing erosions using a 
prediction model with three clinical variables in the Norfolk Arthritis 
Register cohort. The eight risk groups are defined by the presence or absence of 
the three variables included in the prediction model. The combination of the 
variables comprising a positive rheumatoid factor, disease duration of ≥3 months 
and ≥two large joints involved in risk group 1 is negative/no/no; in group 2 is 
negative/yes/no; in group 3 is negative/no/yes; in group 4 is positive/no/no; in 
group 5 is negative/yes/yes; in group 6 is positive/yes/no; in group 7 is positive/no/
yes; and in group 8 is positive/yes/yes. In risk group 7 there were no individuals 
with this combination of variables in the Norfolk Arthritis Register validation cohort. 
Data taken from [104].
288
Int. J. Clin. Rheumatol. (2013) 8(2) future science group
Review Scott, Lewis, Cope & Steer
infliximab arms with a CRP <10mg/l, erosion 
score of 0 and negative serology; their risk of RRP 
was 1%. The area under the curve of the receiver 
operating curve was 0.81 (95% CI: 0.77–0.86), 
indicating a moderate ability to correctly classify 
individuals who will develop RRP.
The other research group to develop a risk 
matrix for RRP developed prediction models in 
two different cohorts [106]. The first cohort was 
the ASPIRE study, which comprised 1049 meth-
otrexate-naive early RA patients randomized to 
receive methotrexate with or without infliximab; 
and the second cohort was the ATTRACT 
trial, which comprised 428 patients with estab-
lished RA and active disease treated with either 
methotrexate and infliximab or placebo. They 
identified risk factors from the early RA cohort 
(the ASPIRE study) and in order to ensure this 
combination of risk factors had similar predictive 
capabilities in a more advanced RA population 
undergoing similar treatment generated a pre-
diction model in the ATTRACT trial using the 
same variables. RRP was defined as a change in 
the modified SHS of ≥5 units/year. Spearman’s 
rank analysis was used to identify baseline risk 
factors for RRP. Two prediction matrixes were 
developed, which contained either the ESR or 
CRP alongside information on the 28 SJC, 
RF and treatment (monotherapy or combina-
tion therapy). The highest risk group was those 
individuals in the ATTRACT study receiving 
methotrexate monotherapy with a 28 SJC >17, 
RF titer >200 U/ml and an ESR >50 mm/h; their 
risk of RRP was 65%. The lowest risk group was 
those individuals in the ASPIRE study receiv-
ing methotrexate and infliximab with a 28 SJC 
<10, RF <80 U/ml and an ESR <21 mm/h; their 
risk of RRP was 2%. Individuals treated with 
methotrexate monotherapy had higher predicted 
rates of RRP when compared with those receiv-
ing infliximab.
The latter three studies evaluating prognostic 
modeling that we have described developed and 
validated their models within the same patient 
cohorts [105–107]. It is, therefore, expected that 
they could predict disease outcomes with relative 
accuracy and their models require further assess-
ment in alternative cohorts to better define their 
prognostic capabilities.
Conclusion
Research evaluating the prognostic factors for 
RA has lagged substantially behind that evalu-
ating the underlying risk factors for RA sus-
ceptibility. This is particularly true of genetic 
factors; although 46 RA susceptibility loci of 
genome-wide significance have been identified, 
only a handful of risk loci for radiological pro-
gression are known. Furthermore, identified 
loci mainly stem from candidate gene studies 
of limited sample sizes and have rarely been 
replicated in independent data sets. Although 
some evidence suggests an overlap between RA 
susceptibility and severity loci, for the most part 
there appears to be little commonality between 
the two. One key impediment to research in this 
area is the lack of a consistent definition of what 
represents ‘severe disease’ with marked hetero-
geneity present in the disease severity markers 
used between studies. We consider that a better 
classification of severe RA is required to facilitate 
comparability across studies in this important 
research field. Another barrier is the lack of large 
data sets of RA patients with detailed genetic 
and disease outcome data; this greatly limits the 
evaluation of genetic predictors of RA outcomes.
Despite these problems prognostic modeling 
for RA severity has shown some promise, with 
disease severity prediction models incorporating 
variables routinely used in clinical practice, such 
as the ESR and SJCs, showing relative accuracy 
at identifying those individuals at a high risk 
of radiological progression. The inclusion of 
genetic prognostic markers that explain only a 
minor proportion of the heritability of radiologi-
cal progression, have added only minor improve-
ments to current prognostic models, highlight-
ing the limited clinical application of current 
genetic research in this field.
Further work is needed to better define what 
markers are relevant in predicting RA progno-
sis. Ideally large longitudinal cohort studies are 
required that recruit patients at disease onset and 
capture detailed environmental, genotypic and 
disease outcome data. Such an approach should 
identify factors associated with adverse disease 
outcomes. As many of these factors (such as age, 
gender and genotypes) will be non-modifiable, 
the main benefit of their identification lies in 
their incorporation within prognostic modeling, 
although it is only factors of large effect sizes 
that would significantly improve upon existing 
models. Effective prognostic modeling would 
facilitate the advent of personalized medicine, 
allowing treatments to be tailored according to 
an individual’s likelihood of developing severe 
disease, which is an attractive prospect for both 
clinicians and patients.
Future perspective
An increased appreciation of the heritability of 
radiological progression in RA tied in with the 
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rapid advances in genotyping techniques, such 
as next-generation sequencing, has placed a key 
research focus on identifying the genetic variants 
that influence disease outcomes, such as rapid 
radiological progression, in RA. We, therefore, 
envisage that the main area in which this research 
field will progress is in the identification of novel 
risk loci for severe RA, which may substantially 
improve the predictive capabilities of current prog-
nostic models. This could allow the prediction of 
an individual’s risk of severe RA  at disease onset, 
enabling their treatments to be tailored according.
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Executive summary
Requirement for prognostic models to predict rheumatoid arthritis severity
  Rheumatoid arthritis (RA) is a heterogeneous disease that varies markedly in its severity. There is, therefore, a requirement to develop 
methods that can prospectively stratify an individual’s risk of severe disease, enabling treatments to be tailored accordingly.
Prognostic factors for RA severity
  Probable environmental and epidemiological prognostic factors for RA severity include smoking, periodontitis, social deprivation and 
female gender, which are associated with more severe disease, and drinking alcohol and oral contraceptive pill use, which are 
associated with less severe disease.
  The most reproduced genetic markers for RA severity comprise the HLA-DRB1 alleles. 
  Power Doppler signal on ultrasound and the presence of bone marrow edema on MRI both correlate with subsequent radiological joint 
damage.
  Biochemical markers such as MMP-3 and urinary C-telopeptide of type II collagen have shown modest capabilities in predicting joint 
damage.
Current prediction models for RA severity
  Models incorporating clinical prognostic factors have shown some promise in identifying individuals at a high risk of radiological 
progression.
  Many of these models require validation in separate cohorts of RA patients.
Future work
  A globally accepted definition of ‘severe RA’ is required to allow comparability across studies examining prognostic factors for RA.
  Further work is needed to better define what markers are relevant in predicting RA prognosis: large, longitudinal cohort studies are 
required that recruit patients at disease onset and capture detailed environmental, genotypic and disease outcome data.
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Rheumatoid arthritis (RA) is considered to occur when genetic and
environmental factors interact to trigger immunopathological
changes and consequently an inﬂammatory arthritis. Over the last
few decades, epidemiological and genetic studies have identiﬁed
a large number of risk factors for RA development, the most
prominent of which comprise cigarette smoking and the shared
epitope alleles. These risks appear to differ substantially between
anti-cyclic citrullinated peptide (ACPA)-positive and ACPA-
negative disease. In this article, we will summarise the risk
factors for RA development that have currently been identiﬁed,
outlining the speciﬁc gene–environment and gene–gene interac-
tions that may occur to precipitate and perpetuate autoimmunity
and RA. We will also focus on how this knowledge of risk factors
for RA may be implemented in the future to identify individuals at
a high risk of disease development in whom preventative strate-
gies may be undertaken.
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Background
Rheumatoid arthritis (RA) is considered to occur when genetically predisposed individuals are
exposed to speciﬁc environmental risk factors. These genetic and environmental risks interact to
trigger perturbations in the immune system, with auto-antibody – rheumatoid factor (RF) and anti-
cyclic citrullinated peptide antibody (ACPA) – generation in the majority of cases, followed by pro-
inﬂammatory cytokine production and a consequent inﬂammatory arthritis.
Over the last few decades, epidemiological studies have identiﬁed a large number of environmental
risk factors for RA. More recently, advances in genomics research have greatly increased our under-
standing of the genetic architecture underlying RA development, with over 30 risk alleles identiﬁed for
sero-positive disease in individuals of European ancestry [1].
There is however a growing appreciation that RA, as opposed to being a single disease entity, is
a syndrome comprising several distinct phenotypes [2,3]. The best-appreciated subdivision is by the
presence or absence of immune responses to citrullinated protein antigens, termed ACPA-positive and
ACPA-negative RA. Not only do these disease subtypes differ clinically, with ACPA-positive RA having
higher rates of erosions and lower remission rates [4], but they also vary with regard to the genetic and
environmental risk factors that contribute to their development [5].
In this article, we will summarise the genetic and environmental risk factors for RA that have been
identiﬁed to date. We will outline how these factors may interact to precipitate and perpetuate
autoimmunity and RA, focussing on the speciﬁc gene–environment interaction between smo-
king/periodontitis and the shared epitope alleles in the pathogenesis of ACPA-positive RA. Finally, we
will describe how knowledge regarding RA risks may be implemented to identify and prevent RA
development in high risk individuals in the future.
Genetic risk factors for RA development
Genetic factors dominate an individual’s risk of developing RA, accounting for approximately two-
thirds of the overall risk burden for both ACPA-positive and ACPA-negative disease [6]. RA is considered
a complex polygenic disease, with multiple alleles contributing towards its development. Although the
risk conferred by each individual risk allele is small, if several risk loci are present in the same indi-
vidual theymay be highly inﬂuential. To date, themajority of genome-wide associated studies (GWASs)
have focussed on ACPA-positive disease; there is limited information regarding the genetic basis for
ACPA-negative disease.
Genetic risk factors for ACPA-Positive RA
The majority of genetic risk for sero-positive RA is derived from the major histocompatibility
complex, class II, DR beta 1 (HLA-DRB1). This is a group of alleles that encode the HLA class II DRb-
chain, which plays a pivotal role in antigen presentation by inﬂuencing the binding and presentation of
arthritogenic peptides to auto-reactive CD4þ T cells [7]. Although multiple HLA-DRB1 alleles –
particularly DRB1*0401 and *0404 – are associated with RA, they all share a region of structural
similarity termed the shared epitope (SE) [8]
At present over 30 non-MHC risk alleles for ACPA-positive RA have been identiﬁed and validated
through candidate gene studies and GWAS [1]. The most prominent and well understood of these
comprise variants of the PTPN22 and PADI4 genes. The PTPN22 allele, 1858T, encodes the lymphoid-
speciﬁc tyrosine phosphatase, Lyp, which is a negative regulator of T cell antigen receptor (TCR)
signal transduction during T cell activation [9]. The variant associated with RA is a gain-of-function
mutation that probably predisposes to autoimmune disease through excessive suppression of TCR
signalling during thymic development, resulting in the survival of auto-reactive T cells [10]. PADI4 is
a peptidylarginine deiminase enzyme that post-transcriptionally converts arginine residues to
citrulline [11]. It may therefore play a signiﬁcant role in the development of ACPA through inﬂuencing
protein citrullination.
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Other important contributory loci are shown in Table 1, which summarises published odds ratios
(ORs) of validated RA risk alleles from a recent meta-analysis of GWAS RA risk loci in sero-positive
patients of European ancestry [1].
Genetic risk factors for ACPA-Negative RA
In comparison with ACPA-positive RA, there is a paucity of information on the genetic risks for
ACPA-negative disease. Only a few studies exist that have examined the genetic basis of this disease
subset. As with ACPA-positive disease, the HLA domain appears to be a potential area of importance,
albeit one that confers lower risks in ACPA-negative RA. The non-shared epitope HLA-DRB1 alleles,
DRB1*13 and DRB1*03, in combination, have been shown to be associated with ACPA-negative disease
[12]. Additionally, the DRB1*13 allele appears to further contribute to ACPA-negative RA development
by neutralising the effects of the SE alleles.
Variants in C-type lectin domain family 16, member A (CLEC16A), have also been shown in
a candidate gene study to confer susceptibility to ACPA-negative but not ACPA-positive RA [13].
Although the function of this gene is unknown, it is almost exclusively expressed in immune cells and is
associated with other autoimmune diseases such as multiple sclerosis, indicating an important bio-
logical role in autoimmunity.
Table 1
Validated risk alleles associated with sero-Positive RA in individuals of European ancestry [1].
Locus SNP ID Candidate Gene(s) OR (95% CI)
Established Risk Alleles 1p36 rs3890745 TNFRSF14 0.89 (0.85–0.94)
1p13 rs2476601 PTPN22 1.94 (1.81–2.08)
1p13 rs11586238 CD2, CD58 1.13 (1.07–1.19)
1q23 rs12746613 FCGR2A 1.13 (1.06–1.21)
1q31 rs10919563 PTPRC 0.88 (0.82–0.94)
2p16 rs13031237 REL 1.13 (1.07–1.18)
2q11 rs10865035 AFF3 1.12 (1.07–1.17)
2q32 rs7574865 STAT4 1.16 (1.10–1.23)
2q33 rs1980422 CD28 1.12 (1.06–1.18)
2q33 rs3087243 CTLA4 0.87 (0.83–0.91)
4q27 rs6822844 IL2, IL21 0.90 (0.84–0.95)
6p21 rs6910071 HLA-DRB1 (*0401 tag) 2.88 (2.73–3.03)
6q21 rs548234 PRDM1 1.10 (1.05–1.16)
6q23 rs10499194 TNFAIP3 0.91 (0.87–0.96)
6q23 rs6920220 TNFAIP3 1.22 (1.16–1.29)
6q23 rs5029937 TNFAIP3 1.40 (1.24–1.58)
6q25 rs394581 TAGAP 0.91(0.87–0.96)
8p23 rs2736340 BLK 1.12 (1.07–1.18)
9p13 rs2812378 CCL21 1.10 (1.05–1.16)
9q33 rs3761847 TRAF1, C5 1.13 (1.08–1.18)
10p15 rs2104286 IL2RA 0.92 (0.87–0.97)
10p15 rs4750316 PRKCQ 0.87 (0.82–0.92)
11p12 rs540386 TRAF6 0.88 (0.83–0.94)
12q13 rs1678542 KIF5A, PIP4K2C 0.91 (0.87–0.96)
20q13 rs4810485 CD40 0.85(0.80–0.90)
22q12 rs3218253 IL2RB 1.09 (1.03–1.15)
Recently Validated Risk Alleles 2p14 rs934734 SPRED2 1.13 (1.06–1.21)
5q11 rs6859219 ANKRD55, IL6ST 0.85 (0.78–0.93)
5q21 rs26232 C5orf30 0.93 (0.88–0.98)
3p14 rs13315591 PXK 1.13 (1.04–1.23)
4p15 rs874040 RBPJ 1.18 (1.12–1.24)
6q27 rs3093023 CCR6 1.11 (1.06–1.16)
7q32 rs10488631 IRF5 1.25 (1.14–1.37)
2q11 rs11676922 AFF3 1.15 (1.10–1.20)
9p13 rs951005 CCL21 0.87 (0.81–0.93)
10p15 rs706778 IL2RA 1.11 (1.06–1.17)
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A further putative risk allele for ACPA-negative disease is interferon regulatory factor 5 (IRF5),
a factor that induces interferon-alpha (IFN-a) transcription. Sigurdsson and colleagues examined its
potential relationship to RA; they found that four single-nucleotide polymorphisms (SNPs) in the 50
region of IRF5 were associated with ACPA-negative disease in substantially sized cohorts of Swedish
and Dutch RA cases and controls [14]. Although this indicates a likely role for IRF5 and IFN-a in ACPA-
negative RA pathogenesis, their ﬁndings were not reproduced in other European cohorts [15]. Further
conﬁrmatory research is therefore required.
To date, only a single GWAS has been performed that speciﬁcally examines genetic risks in ACPA-
negative RA [16]. It evaluated genetic associations in 774 ACPA-negative patients and 1079 controls,
which are relatively small numbers of participants when compared with GWAS performed in sero-
positive RA patients. Whilst no SNP achieved genome-wide association signiﬁcance, the study had
limited power and possible associations were seen for two new candidate loci, RPS12P4 and IGFBP1,
alongside the previously described IRF5 locus.
Genetic risk factors for RA severity
In addition to being risk factors for disease susceptibility, there is also evidence that genes play
important roles in determining disease phenotype and severity. Van der Helm-van Mil et al. examined
this possibility by evaluating the variability in radiological hand damage in unrelated patients,
monozygotic and dizygotic twins. They found that the variance in joint destruction was highest
between unrelated patients, followed by dizygotic and ﬁnally monozygotic twins [17]. Although this
study was too small to calculate heritability rates, it provides support for genetics as a determinant of
RA severity. Further studies, outlined below, have examined the relationship between speciﬁc genetic
loci (in particular, those that are RA susceptibility markers) and RA severity with some success.
HLA-DRB1 SE
The HLA-DRB1 SE alleles have been shown to associatewith disease severity, with one retrospective
literature review ﬁnding the HLA-DRB1*0401/*0404 genotype to be associated with a higher risk of
early-onset RAwith a more severe phenotype [18]. Similarly, Wagner et al. identiﬁed the same SE allele
genotype to be a genetic marker for radiological damage in RA, being associated with higher rates of X-
ray damage both at presentation and in more established disease [19]. Although these ﬁndings
implicate the SE alleles to be predictors of disease severity, the impact of the SEmay be secondary to its
association with ACPA acting as a confounding variable.
PTPN22
There is some limited evidence that PTN22 may contribute to disease severity. In a cross-sectional
evaluation of 964 RA patients, Marinou et al. reported a trend towards higher rates of X-ray damage in
RA patients carrying the PTPN22 risk allele compared to those without it [20]. This association was
however weak and other studies have failed to replicate their ﬁndings [21].
IL-1 locus
IL-1 is an important pro-inﬂammatory cytokine in RA, contributing to systemic inﬂammation and
articular damage through the stimulation of local ﬁbroblast proliferation and the activation of chon-
drocytes. Several studies have shown an association of polymorphisms at the IL-1 locus with radio-
logical damage in RA. Cantagrel et al. found that a polymorphism in IL-1beta exon 5 enabled prognostic
stratiﬁcation for erosive disease with a high speciﬁcity in 42% of RA patients [22]. This association has
been replicated in other studies [23].
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TRAF1/C5 locus
The TRAF1/C5 locus is an RA risk factor encoding complement component 5 and tumour necrosis
factor (TNF)-receptor associated factor 1, which are important components of the inﬂammatory
cascade. Polymorphisms at this locus have also been shown to be associatedwith the risk of developing
radiological erosions in the Norfolk Arthritis Register (NOAR) cohort by Plant et al. [24]
CD40
CD40 encodes a protein that as a member of the TNF-receptor superfamily is important in a broad
range of immune responses, e.g., memory B-cell development. It is a known genetic risk factor for RA
development. More recently, the SNP, rs4810485, at the CD40 locus has been shown to be associated
with RA severity in the form of radiographic progression rates; this association has been validated and
replicated in two cohorts [25].
Environmental risk factors for RA development
Many environmental factors have been shown in epidemiological case–control and cohort studies
to be associated with the development of RA. The single risk factor that has an unequivocal association
is smoking, which has been repeatedly shown in a variety of cohorts to increase the risk of sero-positive
RA. Other robust associations comprise female gender, age, alcohol consumption and periodontitis.
Many other environmental risk factors with weaker supporting evidence have also been linked to RA
development; these comprise oral contraceptive pill use, vitamin D intake, previous blood transfusions,
obesity, socio-economic status, non-inherited maternal antigens, breast-feeding and birth weight.
Examples of these risk factors are shown in Table 2. As with genetic associations, environmental risk
factors for RA appear to differ between ACPA-positive and ACPA-negative disease. Pederson high-
lighted these differences ﬁnding smoking and alcohol intake to be solely associated with ACPA-positive
disease, and obesity to be predominantly linked to ACPA-negative disease [5].
Cigarette smoking
Cigarette smoking is strongly associated with RA. Its impact however appears limited to individuals
with sero-positive disease [26,27]. Its inﬂuence is also greater in males compared with females [28].
This relationship is highlighted in a recent meta-analysis by Sugiyama et al. [29], who found that in 16
observational studies the summary odds ratio (OR) for developing RAwas 1.89 (95% conﬁdence interval
(CI) 1.56–2.28) for males who had ever smoked and 1.27 (95% CI 1.12–1.44) for females who had ever
smoked. The risks were higher in individuals possessing RF with sero-positive males who had ever
smoked having an OR of 3.02 (95% CI 2.35–3.88) for developing RA.
Smoking has a dose-dependent effect on the risk of RA. Data from the Nurses’ Health Study (NHS)
found a linear relationship between RA and increasing pack-years of smoking with the age adjusted
relative risk (RR) in females with an over 40 pack-year history of smoking comprising 1.99 (1.57–2.53),
compared with 1.08 (0.86–1.36) for a 1–10 pack-year history [30]. This dose-dependent relationship is
shown in Fig. 1.
Table 2
Some environmental risk factors for rheumatoid arthritis.
Risk factor Odds ratio/Relative risk
(95% conﬁdence interval)
Ever smoked [29] 1.40 (1.25–1.58)
High alcohol intake [38] 0.50 (0.40–0.6)
Obesity [5] 1.57 (1.01–2.44)
High vitamin D intake [42] 0.67 (0.44–1.00)
High birthweight [49] 2.10 (1.40–3.30)
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Periodontitis
RA is prevalent in individuals with periodontitis [31]. A cross-sectional survey of 4461 US civilians
who had undergone recent musculoskeletal and dental examinations found that individuals classiﬁed
with RA were far more likely to be edentulous (OR 2.27; 95% CI 1.56–3.31) and have periodontitis (OR
1.82; 95% CI 1.04–3.20) compared with non-RA subjects. This association is greatest in those with sero-
positive RA [32].
Female gender
RA has a predilection for women, being on average 3 times more common in females compared
with males. This relationship is highest in younger age groups, with the incidence of RA 5 times higher
in Oslo females under the age of 50 years compared with age-matched males, but only twice as high in
Fig. 1. Relative risk of rheumatoid Arthritis In Women from the Nurses’ health study Stratiﬁed by Pack-years of smoking. a) all
patients, b) current smokers, c) ex-Smokers. Figure adapted using data from Costenbader et al. [30].
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those aged over 60 years [33]. The mechanism by which female gender increases RA susceptibility
remains elusive. This gender association may represent sex hormone differences with supporting
evidence arising from the fact that RA risk signiﬁcantly increases in the post-partum period, with an OR
of 5.6 (95% CI 1.8–17.6) for developing RA during the ﬁrst 3 months post-partum [34].
Ageing
Although RA can affect any age group, its onset has reproducibly been shown to peak during the
sixth decade of life [35,36]. This may result from immune senescence with the decline in host
immunity with advancing age promoting immune reactivity to self-antigens [37]
Alcohol consumption
Alcohol intake appears protective against the onset of RA. Källberg and colleagues undertook
a combined analysis of two independent case–control studies of RA, the Epidemiological Investigation
of Rheumatoid Arthritis (EIRA) and the Case-Control study in Rheumatoid Arthritis (CACORA) [38].
They found that individuals consuming the highest levels of alcohol (deﬁned as 5 drinks/week) had
half the risk of developing RA in comparison with those consuming little or no alcohol. The risk
reduction was greatest in individuals who were ACPA-positive and/or harbouring the SE. As with
smoking exposure, the protective effects conferred by alcohol intake were dose-dependent with
increasing levels of ethanol consumption further lowering the risk of RA. The dose-dependent effect of
alcohol on RA risk is shown in Fig. 2.
Oral contraceptive pill use
The predilection of RA for females has led several research groups to examine the impact of oral
contraceptive pill (OCP) use – and thus oestrogen exposure – on RA risk. The evidence to date is
uncertain with some studies ﬁnding an increased risk of RA with OCP use, others ﬁnding OCP use to
protect against RA development and some studies failing to identify any relationship between this risk
factor and RA. A Swedish case–control study found that OCP use for 7 years reduced the risk of RA
development (OR 0.37; 95% CI 0.15–0.93) [39]. By contrast, a Danish study found that OCP use increased
the risk of ACPA-positive RA (OR 1.65; 95% CI 1.06–2.57) [5]. Pikwer et al. found no relationship
between RA and OCP use in 136 womenwith RA and 544 age-matched controls [40]. Although in view
of the strong gender association, it seems plausible that OCP use may inﬂuence the risk of RA, further
work is required to better clarify this potential relationship.
Obesity
Obesity increases the risk of RA development. Its impact on RA risk however appears conﬁned to
ACPA-negative disease. Being morbidly obese (deﬁned as a body mass index (BMI) of 30) a decade
prior to RA onset has been shown to triple the risk of developing ACPA-negative RA (OR 3.45; 95% CI
1.73–6.87) [5]
High vitamin D intake
There is a growing appreciation of the role that vitamin D plays in autoimmunity, with its active
form producing and maintaining immunological self-tolerance [41]. As a result, its relationship to RA
development has been examined with contrasting outcomes; its precise impact on the risk of RA
development remains uncertain.
Results from the Iowa women’s health study, a prospective cohort study of 29 368 women aged
55–69 without RA at baseline, 152 of whom developed RA over 11 years of follow-up, found an
inverse relationship between vitamin D intake and RA [42]. In this study, individuals with the highest
level of vitamin D intake had a relative risk of 0.67 (95% CI 0.44–1.00) for RA when compared with
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individuals with the lowest vitamin D intake. This relationship has not been reproduced in other
cohorts [43].
Previous blood transfusion
Allogenic blood transfusions are known to have immunomodulatory effects. The exposure to
foreign antigens in transfused blood has been shown to increase CD5 B cells alongside RF and
Fig. 2. Odds ratios for developing rheumatoid Arthritis In Individuals from the epidemiological investigation of rheumatoid arthritis
(EIRA) and Case-Control study in rheumatoid arthritis (CACORA) studies Stratiﬁed by alcohol intake. a) all cases, b) ACPA-Positive RA,
c) ACPA-Negative RA. Low alcohol intake ¼more than zero units but below or equal to the median level of consumption by controls;
Moderate alcohol intake ¼ more than median but below or equal to the 75th percentile of consumption by controls; high alcohol
intake ¼ above the 75th percentile of consumption of controls. All trends are signiﬁcant apart from the ACPA-negative RA CACORA
group. Figure adapted using data from Källberg et al. [38].
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anti-nuclear antibody titres [44]. Examination of the impact of blood transfusions on RA risk in UK and
US data sets has however provided opposing conclusions.
Analysis of cases and controls enrolled to the Norfolk Arthritis Register, a population-based study
in Norfolk, England, found that previous blood transfusions increased the risk of RA (OR 3.58; 95% CI
1.46–8.81). The risks were approximately double in women (OR 4.36; 95% CI 1.45–13.06) compared
with men (OR 2.69; 95% CI 0.43–16.75). The risks were also greater for sero-positive RA (OR 4.17; 95%
CI 0.46–38.12) compared with sero-negative RA (OR 2.33; 95% CI 0.77–7.09) [45]. By contrast,
examination of the US Iowa cohort gave opposing results with a history of blood transfusion being
inversely associated with RA (RR 0.72; 95% CI 0.48–1.08) [46]. This difference may reﬂect variations
in study methodology or international transfusion practices. Further work is required to clarify this
relationship.
Socio-economic status
RA is more common in individuals from a lower socio-economic background. This ﬁnding has been
highlighted in two independent case–control studies. Firstly EIRA, which found individuals without
a university degree to have a RR of 1.4 (95% CI 1.2–1.8) for RAwhen compared to those with a university
degree [47]. Similarly, in this cohort, the RR of sero-positive RA in non-manual employees compared
with manual employees, assistant and intermediate non-manual employees grouped together was 1.5
(1.0–2.1), after adjustments for confounding variables such as smoking. These ﬁndings were repro-
duced in a Danish cohort, in which education levels were inversely associated with RA risk [48]. In this
study, the RA risk in individuals with the longest formal education period was approximately half that
of individuals with the lowest education levels.
Birth weight
High birth weight has been shown to be associated with RA. Analysis of the NHS cohort identiﬁed
a birth weight of more than 4.5 kg to confer a twofold increased risk of RA compared with a lower birth
weight of 3.2–3.85 kg (RR 2.1; 95% CI 1.4–3.3) [49]. The authors of this article considered that this
relationship may arise from dysregulation of the hypothalamus–pituitary–adrenal (HPA) axis, with
plasma cortisol levels being both inversely related to birthweight and abnormally low in adultswith RA.
Breast-feeding
Breast-feeding has been shown in two large case–control studies to protect against RA. Karlson et al.
examined the impact of breast-feeding on RA risk within the NHS cohort [50], ﬁnding that breast-
feeding for more than a year was inversely related to RA development. As with other environmental
risk factors, this protective effect appeared exposuredependentwith a longer duration of breast-feeding
providing an increasing trend towards risk reduction. For women who had breast-fed compared with
parous women who had not breast-fed, the RR for RA comprised 0.5 (95% CI 0.3–0.8) when breast-
feeding for 24 months; 0.8 (95% CI 0.6–1.0) for 12–23 months; 0.9 (95% CI 0.7–1.1) for 4–11 months;
and 1.0 (95% CI 0.8–1.2) for3months. Similar results were found in a nested case–control study using
information from the Malmö Diet and Cancer Study in Sweden [40]. In this cohort, the OR for RA in
women who had breast-fed for 13 months compared with those who had never breast-fed was 0.46
(95% CI 0.24–0.91); in those who had breast-fed for 1–12 months the OR was 0.74 (95% CI 0.45–1.20).
The impact of breast-feeding on RA risk is however not completely deﬁned. Brennan et al. reported
opposing results in their case–control study ﬁnding breast-feeding to be more common in RA patients
compared with age- and sex-matched controls [51]. This study was however of a smaller size and may
have been confounded by HLA-DR4 status [52]. A further study failed to ﬁnd any association between
breast-feeding and the risk of RA development, although it did identify breast-feeding as a risk factor
for more severe disease [53].
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Non-inherited maternal antigens
Non-inherited maternal antigens (NIMAs) are antigens within the offspring that are encoded by
maternal as opposed to inherited alleles (termed ‘microchimerism’). They can be passed from the
mother to her offspring from 3 months gestation until full term [54]. At the same position in the MHC
molecule as the SE, the amino acid sequence ‘DERRA’ (comprising aspartic acid, glutamic acid, arginine,
alanine and alanine) has been shown to protect against RA. This sequence is encoded by non-SE HLA-
DRB1 alleles, that is, HLA-DRB1*0103. The OR of RA in people carrying HLA-DRB1 alleles expressing the
‘DERRA’ sequence compared with those without the SE or ‘DERRA’ alleles is 0.5–0.7 [55]. DERRA
containing MHC molecules can be presented as NIMA. In these circumstances, they provide the same
level of protection against RA as DERRA expressing alleles inherited directly from a parent.
RA immunopathology – an overview
RA is characterised by chronic systemic and articular inﬂammation. Although the precise immu-
nopathological mechanisms that underlie RA have not been completely deﬁned, this process is driven
by both the innate and adaptive immune systems with T cells, B cells, macrophages, neutrophils and
synovial ﬁbroblasts playing important roles.
Macrophages
Macrophagesandtheirprecursor’smonocytesactboth systemically, through theproductionof classical
RA pro-inﬂammatory cytokines, that is, IL-1 and TNF-a [56] and, locally, through synovial inﬁltrationwith
macrophages/monocytes being enriched in the rheumatoid synovium and destructive pannus tissue [57].
T cells
T cells are well established as key components of RA immunopathology. Evidence for this stems
from the strong association of RA with the SE alleles encoding the MHC (indicating that antigen
presentation to T cells is an important process in RA), the prevalence of CD4þ T cells within rheumatoid
synovium and the efﬁcacy of the selective T-cell co-stimulation modulator, abatacept [58]. Antigen-
dependent T-cell responses may be important in initiating the inﬂammatory response during RA
[59]. They may also act independently of antigenic stimulation to perpetuate inﬂammation through
activatingmonocytes/macrophages to produce pro-inﬂammatory cytokines [60]. Additionally, T helper
17 cells produce IL17, which has pleiotropic effects on many RA effector cells causing inﬂammation and
driving osteoclastogenesis and bone resorption [61].
B cells
The importance of B cells in RA is highlighted by the efﬁcacy of B-cell depletion therapy with the
anti-CD20 monoclonal antibody, rituximab [62]. B cells have multiple functions in RA. They can act as
antigen-presenting cells (APCs), presenting antigens via MHC class II molecules to T cells activating
them with consequent downstream macrophage activation and TNF-a production. They produce pro-
inﬂammatory cytokines and chemokines directly via Toll-like receptor activation [63]. B cells are
responsible for auto-antibody production, with RF and ACPA forming immune complexeswith immune
responses via Fc and complement receptors [64]. Additionally, in many RA patients, synovial extra-
follicular germinal centres develop with B lymphocytes surrounded by T cells, acting as functional
ectopic germinal centres [65].
Synovial ﬁbroblasts
Fibroblast-like synoviocytes are prevalent in RA synovium where they have a unique phenotype
with aggressive and invasive properties; they drive cartilage erosion throughmatrix metalloproteinase
production and are dominant producers of IL-6 [66].
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Gene–Environment interactions precipitating RA
The underlying paradigm of RA pathogenesis is that genetic and environmental risk factors interact
to precipitate immune system changes, autoimmunity and, subsequently, disease. This concept clearly
represents an oversimpliﬁcation of the underlying disease aetiology with some of the identiﬁed RA risk
factors increasing RA risk, some conferring protection against RA, and some interacting with one
another to modify their impact on the development of RA.
Attempts to provide a unifying model inwhich all of these risks interact to precipitate RA have been
to a large extent unsuccessful. However, with the advent of widespread ACPA serology availability,
a clear gene–environment model has been revealed that delineates how two environmental risks
(smoking and chronic periodontitis) may interact with the SE alleles to precipitate ACPA formation and
the development of ACPA-positive RA. In this section, we will outline this biological model in detail,
describing the evidence underlying it.
What are citrullinated peptides
Citrulline is a non-standard amino acid that results from post-translational modiﬁcation of arginine
resides [67]. This modiﬁcation, termed ‘citrullination’ or ‘deimination’, is facilitated by a family of
peptidylarginine deiminase (PAD) enzymes in a calcium-dependent manner. The substitution of
arginine for citrulline results in key changes in the structure and ionic charge of the peptide from
positive to neutral, with a consequent potential for functional differences.
Although citrullinated peptides are present in healthy individuals where they play important
physiological roles aiding in epidermal corniﬁcation and myelin sheath insulation [68], they are far
more abundant in individuals with inﬂammatory disorders including multiple sclerosis, myositis and
non-RA inﬂammatory arthritidies [69,70].
Auto-immunity to citrullinated peptides in RA – evidence for a pathological role
Although citrullinated proteins are not conﬁned to individuals with RA, the presence of antibodies
that target them are almost exclusively present in this disease state. A meta-analysis of 86 studies
showed ACPA had a sensitivity and speciﬁcity of 67% and 95% [71]. Although its sensitivity approxi-
mates that of immunoglobulin M (IgM) RF, it is substantially more speciﬁc.
The currently available ACPA assays are of limited use in attempting to understand disease path-
ogenesis because they incorporate a number of citrulline-containing peptides that fail to correspond
with in vivo citrullinated proteins in the joint. There is, however, an increasing number of citrullinated
peptides that have been established as antigens expressed within the articular environment. These
include ﬁbrinogen/ﬁbrin, vimentin and a-enolase. There is ongoingwork to identify further pathogenic
citrullinated peptides.
The pathological role that ACPA appears to play in causing ACPA-positive RA is indicated by its
presence in the serum of individuals with RA up to 14 years prior to the onset of clinical features of this
disease. Nielen et al. analysed archived blood samples from 79 RA patients who had previously donated
blood. They found that 49% of patients had positive ACPA serology 4.5 years pre-RA onset compared
with less than 1% of 2138 controls [72]. Similarly, through evaluating a biobank of approximately
90 000 blood donors from Sweden that contained 83 incident cases of new-onset RA, Rantapää-
Dahlqvist et al. found that ACPAs were signiﬁcant predictors of RA occurring in 34% of pre-RA patients
compared with only 2% of matched controls [73].
Environmental drivers of protein citrullination in individuals pre-RA
There is substantial evidence that two processes – smoking and periodontitis – are at least in part
responsible for increased protein citrullination pre-RA.
Smoking, shown to be almost exclusively associated with ACPA-positive RA, appears to increase
protein citrullination through promoting expression of PAD enzymes in alveolar cells. Evidence for
this stems from ﬁnding substantial up-regulation of citrullinated proteins with enhanced PAD2
enzyme expression in bronchoalveolar lavage cells from smokers compared with non-smokers [74].
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Furthermore, autoimmunity to citrulline may be promoted through increased thiocyanate ions
produced by tobacco smoke metabolism [75]. Thiocyanate is metabolised to homocitrulline, which is
similar in shape and structure to citrulline. Its increased presence in smokers may promote auto-
antibody formation with cross-reactivity to citrulline.
Periodontitis is a destructive inﬂammatory disease of the supporting tissues of the teeth. It is caused
by speciﬁc microorganisms, one of the best characterised of which is Porphyromonas gingivalis. As
previously discussed, periodontitis is prevalent in RA, particularly ACPA-positive disease. Of crucial
importance is the fact that P. Gingivalis is the only known bacterium that expresses PAD. It may thus
contribute to citrullinated peptide neoepitope generation in pre-RA individuals with periodontitis
through PAD-induced protein citrullination. Further support for the pathogenic role of this microbe in
anti-citrulline immunity comes from the ﬁnding that increased titres of anti-P. Gingivalis antibodies
correlate with ACPA subtypes in RA patients [76].
Genetic inﬂuences on ACPA formation in individuals pre-RA
The crucial issue of how immune tolerance to citrulline could be breached in pre-RA individuals has
been addressed by Hill and colleagues. They examined the T-cell response to citrullinated peptides in
HLA-DRB1*0401 transgenicmice [7]. MHC class II molecules harbouring the SE contain a speciﬁc amino
acid sequencewithin pocket 4 (P4) – a positively charged area inﬂuencing binding of antigenic peptides
that favours negatively charged amino acid residues. Upon citrullination, the positively charged argi-
nine is converted to citrulline, which lacks an ionic charge and has a better structural conformationwith
P4. Hill et al. identiﬁed that as a result of these structural and ionic alterations citrullinated peptides
bound to the MHC P4 in mice possessing the SE with a 100-fold greater afﬁnity when compared with
their arginine-containing precursors. This peptide/SE complex was subsequently presented to CD4þ T
cells activating them. The ability of citrullinated peptides to induce a T-cell response has been replicated
in human subjects by Feitsma et al., who found that naturally occurring citrullinated vimentin peptides
were recognised by T cells from ACPA-positive HLA-DRþ RA patients [77].
The ability of ACPA to drive actual joint inﬂammation was subsequently shown in a mouse model
[78]. HLA-DRB1*0401 transgenic mice were immunised with citrullinated human ﬁbrinogen; their
outcomes were compared to wild-type mice. Only mice possessing the HLA transgene developed an
inﬂammatory arthritis, which directly implicates citrullinated ﬁbrinogen as an arthritogenic peptide in
the context of SE containing MHC class II molecules.
In summary, it appears probable that ACPA formation is triggered by citrullinated peptides binding
with a high-afﬁnity to SE containing MHC molecules. This peptide/SE complex is then presented to
CD4þ T cells, which activate B cells driving ACPA formation.
Progression from asymptomatic ACPA-Positive individuals to clinical RA
Because ACPA can predate clinical RA by many years alongside the fact that not all individuals with
ACPA develop RA, it seems apparent that further factors are required to trigger the shift from being an
asymptomatic individual with ACPA to having established RA with synovitis.
An important feature of pathogenic antibodies is that they possess ﬁne speciﬁcity for certain
antigens. It has been postulated that for ACPA to become pathogenic and elicit articular damage they
need to fully mature and increase their number of antigen speciﬁcities. This would explain the latent
period that exists between ACPA formation and RA onset. Evidence for this maturation process in RA,
termed ‘epitope-spreading’, exists with Van der Woude et al. ﬁnding that the number of citrullinated
antigens recognised by ACPA increased in the time period leading up to RA onset in individuals with an
undifferentiated arthritis [79].
Although the precise mechanisms that stimulate epitope-spreading and the onset of RA remain
elusive, it has been proposed that a second event, that is, infection or trauma occurs, which triggers
a non-speciﬁc synovitis with associated citrullination within the joint [80]. In healthy individuals, this
would resolve without sequela; however, in those possessing ACPA and T cells reactive to them this
would lead to a chronic inﬂammatory arthritis evolving into RA. ACPA-mediated immune complexes
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could subsequently drive macrophage TNF-a production alongside other pro-inﬂammatory cytokine
pathways [81].
Evidence for the smoking-shared epitope interaction
Several prominent case–control studies have conﬁrmed the signiﬁcant gene–environment inter-
action between the SE alleles and smoking in ACPA-positive RA. This supports the concept that
smoking-induced citrullinated peptides interact with the SE to induce autoimmunity and RA. These
studies also show a cumulative genetic effect on RA risk with disease risks being greater in those
possessing more copies of the SE alleles. This implies that a greater phenotypic expression of the SE
increases the degree of citrullinated peptide presentation to CD4þ T cells, driving RA development.
One key study to examine this important interaction evaluated a Swedish population-based case–
control cohort [26]. The impact of different SE and smoking combinations on RA risk was compared to
the RA risk in individuals who had never smoked and possessed no SE alleles. In this analysis, the RR of
sero-positive RAwas 2.4 (95% CI 1.3–4.6) in smokers with no SE genes, 5.5 (95% CI 3.0–10.0) in current
smokers with one SE gene and 15.7 (95% CI 7.2–34.2) in current smokers with two copies of the SE
genes. This multiplicative interaction is highlighted in Fig. 3.
This ﬁnding was reproduced within a Danish case–control study of 309 ACPA-positive and 136
ACPA-negative recent-onset RA cases alongside 533 sex-/age-matched controls [82]. In this cohort, the
risks of ACPA-positive RA also increased exponentially in smokers depending on the number of SE gene
copies they carried. In individuals with a >20 pack-year history of smoking the OR for RA was 1.22
(0.48–3.08) in SE non-carriers, 9.66 (4.38–21.3) in SE heterozygotes and 52.6 (18.0–154) in SE
homozygotes.
Evidence for a gene–gene interaction between HLA-DR4 and PTPN22
The interaction between the SE and smoking is complicated by an additional outside inﬂuence from
PTPN22. This gene interacts with the SE allele, modifying the risk of RA in smokers. Kallberg and
colleagues examined three large case–control studies: EIRA, the North American RA Consortium
(NARAC) study and the Leiden early arthritis cohort [83]. They found a signiﬁcant interaction between
Fig. 3. The interaction between smoking and the number of shared epitope allele copies on the risk of ACPA-Positive rheumatoid
arthritis. Figure adapted using data from Pedersen et al. [82].
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HLA-DRB1 SE alleles and the PTPN22 R620Wallele in smokers. Although in the absence of the SE alleles
PTPN22 had no impact on RA risk, in the presence of the SE it substantially elevated the risk of ACPA-
positive RA. The OR for RA in individuals who had ever smoked and who carried no PTPN22/a single SE
allele was 5.4 (95% CI 3.3–8.9), with any PTPN22/a single SE allele was 11.3 (95% CI 6.2–20.5), with no
PTPN22/a double SE allele was 23.6 (95% CI 12.8–43.8) and with any PTPN22/a double SE allele was 23.4
(95% CI 10.4–52.4). This interaction is shown in Fig. 4.
Hypothetical model for Gene–Environment interactions precipitating ACPA-positive RA
In summary, the following stages represent a biologically plausible model through which genetic
and environmental factors interact to cause ACPA-positive RA (outlined in Fig. 5).
1. Peripheral protein citrullination occurs – either through periodontal infection with P. gingivalis or
through smoking.
2. Structural and ionic changes resulting from protein citrullination enhance the binding of citrulli-
nated self-antigens to MHC class II molecules in individuals possessing the SE alleles.
3. SE/citrullinated peptide complexes are presented by APCs to CD4þ T cells, activating them.
4. These in turn activate B cells driving ACPA formation.
5. A second factor – for example, trauma or infection – precipitates synovial inﬂammation and the
development of citrullinated proteins within the articular environment. These are targeted by
ACPA.
6. ACPA–citrulline immune complexes are formed. These activate macrophages/monocytes driving
inﬂammatory cytokine production and precipitating RA.
Combining genetic and environmental factors to identify individuals at a high risk of RA
An increased knowledge regarding the environmental and genetic risk factors that underlie RA
development not only improves our understanding of RA pathogenesis but may, through the use of
Fig. 4. Odds ratios for developing ACPA-Positive RA In Smokers provided by different HLA-DRB1 SE and Minor R620W PTPN22 allele
combinations. Figure adapted using data from Kallberg et al. [83].
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prediction modelling, also facilitate the identiﬁcation of people at a high risk of developing RA in the
future. Such a prediction model would allow disease-prevention strategies to be evaluated in high risk
individuals. Although each individual RA risk factor confers only a small risk, when used multiplica-
tively they may be highly informative. This is particularly relevant in a priori high-risk groups (e.g.,
individuals with ACPA antibodies or strong family histories of RA).
To date, only one RA prediction model has been successfully developed for use in the general
asymptomatic population [84]. This model combined 22 RA risk alleles with the epidemiological risk
factors smoking, ageing and female gender. It provided signiﬁcant risk stratiﬁcation: patients with the
highest number of genetic risk factors had a three- to sixfold increased odds of sero-positive RA when
compared to patients with an ‘average’ background genetic risk. The addition of genetic risk factors to
a model that used clinical risks alone increased its accuracy improving the area under the curve, which
is a commonly used measurement in risk-prediction models, from 0.63 to 0.75. Although this model
provided some individuals with relatively high ORs of RA, owing to the relatively low lifetime risk of
RA, their absolute risk of RA development remained small and the clinical utility of this prediction
model was therefore limited. Its use would, however, be improved by incorporating factors providing
greater risks of RA, whichmay become availablewith newer genotyping techniques. At present, further
work is required to develop an accurate prediction model that inﬂuences clinical practice.
Preventing RA in high-risk individuals
Current RA treatment strategies focus on the titration of disease-modifying anti-rheumatic drugs
(DMARDs) and biologic agents according to disease activity. This approach is limited, achieving remis-
sion in only 16–42%of cases [85]. There is, therefore, a keyneed to adopt different treatment approaches,
one facet of which could be instituting disease-prevention treatments in individuals at a high risk of RA.
Several small randomised controlled trials (RCTs) have evaluated this approach with some success.
Fig. 5. Hypothetical model for gene–environment interactions precipitating ACPA-Positive RA.
309
I.C. Scott et al. / Best Practice & Research Clinical Rheumatology 25 (2011) 447–468
Primary or secondary RA prevention
Bykerk classiﬁed RA-prevention techniques as belonging to two groups: (1) primary prevention –
undertaken in individuals with genetic risks for RA in whom the pathogenic process has not yet
started – and (2) secondary prevention – in individuals with pre-clinical disease either at an early
asymptomatic stage or in the late pre-clinical stages when symptoms are present [86].
Because no robust systemhas been devised that can accurately identify asymptomatic individuals at
a high risk of RA from the general population, it is currently not possible to undertake primary
prevention strategies. As our knowledge of RA risks advances, this may however become an area of
therapeutic potential.
Secondary prevention strategies have been instituted with some success. In these instances,
patients with pre-clinical RA were identiﬁed by the presence of biological markers such as ACPA
alongside early clinical manifestations associated with progression to RA. All studies examined the
ability of pharmacological treatments comprising corticosteroids, methotrexate or biologics to prevent
the progression of pre-clinical RA to clinically overt disease. To date, no studies have examined the
impact of limiting exposure to environmental risks such as smoking in RA prevention.
Corticosteroids as secondary prevention
Several studies have shown some evidence that corticosteroidsmay play a role in RA prevention. Bos
et al. evaluated83patientswith arthralgia andACPA/RF randomised to receive either intramuscular (IM)
dexamethasone or placebo. Corticosteroid treatment reduced ACPA levels within 1 month (persisting
for 6 months) and reduced disease activity scores at RA onset. Although this suggested that short-term
corticosteroids attenuated the disease process, it had no impact on the number of patients progressing
to synovitis (w20% in both treatment and placebo groups) [87]. Similarly, Verstappen and colleagues
evaluated whether treating very early undifferentiated inﬂammatory polyarthritis (VEIA) with corti-
costeroids reduced the future requirement for DMARDs and RA development. Patients with VEIA were
randomised to once weekly IM 80 mg depomederone injections for 3 weeks or placebo. At 12 months,
the number of placebo-treated patients requiring DMARDs was twice that of those treated with corti-
costeroids [88]. These studies provide some support for a role of corticosteroids in RA prevention, the
efﬁcacy of which may be improved with more intensive and prolonged regimes. Further research is,
however, required to better establish their role in RA secondary prevention pathways.
Methotrexate as secondary prevention
The PRObable rheumatoid arthritis: Methotrexate versus Placebo Treatment (PROMPT) study
evaluated methotrexate as a preventative treatment for RA [89]. In this double-blind, placebo-
controlled randomised controlled trial (RCT), 110 patients with an undifferentiated arthritis fulﬁlling
the American College of Rheumatology (ACR) criteria for probable RA were treated with methotrexate
or placebo. The starting dose of 15mg/weekmethotrexatewas titrated every 3months until the DAS28
was 2.4; at 12 months, treatment was tapered and stopped. By the end of the study period (30
months), 40% of patients in the methotrexate group had progressed to RA compared with 53% of the
placebo group (P ¼ 0.046). Individuals treated with methotrexate also developed RA at a later time
point and had less radiological progression than those treated with placebo. This trial provides some
support for the use of methotrexate for RA prevention.
Biologics as secondary prevention
The ADJUST trial (Abatacept study to Determine the effectiveness in preventing the development of
rheumatoid arthritis in patients with Undifferentiated inﬂammatory arthritis and to evaluate Safety
and Tolerability) examined the impact of T-cell co-stimulationmodulation on the development of RA in
patients with undifferentiated arthritis or very early RA [90]. Patients were randomised to 6 months
treatment with abatacept or placebo. At 2 years, a non-statistically signiﬁcant reduction in individuals
meeting the RA classiﬁcation criteria was observed in those treated with abatacept versus placebo: 46%
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of abatacept-treated patients were classiﬁed with RA compared with 67% of the placebo group.
Placebo-treated patients also more frequently developed magnetic resonance imaging (MRI) structural
changes.
The impact of inﬂiximab on preventing RA development has also been evaluated in a small rand-
omised study [91]. Seventeen patients with an undifferentiated arthritis of less than 12 months
duration were randomised to inﬂiximab or placebo for 14 weeks. Inﬂiximab had no impact on
progression to RA with 100% of patients in the treatment arm developing RA.
Further work – A research agenda
Although the last few decades have seen marked progress in our understanding of the risk factors
for RA alongside it's pathogenesis and immunopathology there remain a large number of unanswered
questions and key areas that require further evaluation. In this section, we will outline some of these
areas, providing a focus for further research.
Clarify key environmental risk factors for RA
Although many environmental risk factors for RA have been identiﬁed, their associations are often
weak, do not have a clear biological relationship to RA and –with the exception of smoking, ageing and
gender – are often not reproducible. There is, therefore, a need to better clarify which environmental
risk factors for RA are truly important. Due to the relative rarity of RA, cohort studies (the gold standard
to examine disease risk factors) are difﬁcult and time consuming to perform. There is therefore a large
reliance on case–control studies to examine environmental risks for RA, which are open to impartiality
in the form of recall and recruitment bias. It is vital to ensure that future case–control studies exam-
ining RA risk factors both recruit newly diagnosed RA patients to minimise recall bias and recruit
controls from the same deﬁned study population as cases. By optimising study design, the likelihood of
ﬁnding true environmental risks for RA will be increased.
Identify the ‘missing heritability’ of RA
There is a need to better characterise the genetic basis of RA. Although over 30 genetic risk loci for
RA have been found, a large amount of the genetic risk for RA remains unidentiﬁed with known genetic
factors only explaining at most 40% of sero-positive RA heritability (37% from HLA; 5% from other loci)
[92]. The remaining genetic risks may be identiﬁed through modern genotyping platforms that better
tag underlying RA causal genetic variants with higher disease relative risks or large-scale sequencing
that detect structural variations such as copy number variants and translocations, which may signif-
icantly contribute to RA development.
Examine genetic risks for RA across ethnic groups
There is a key need to establish the genetic basis of RA in different ethnic groups, with current GWAS
in RA being limited to individuals of European ancestry [1]. The limited published data in this area
indicate that important differences in genetic risks between ethnic groups exist, with Lee et al.
reporting that none of the susceptibility loci in Caucasian RA patients contributed to disease in Koreans
[93]. Although Hughes et al. found overlapping ORs and 95% CIs in 24 of 27 candidate SNPs between
556 sero-positive African Americans with RA and those of European ancestry, only one European risk
allele had a statistically signiﬁcant association in African Americans with RA [94].
Increase understanding of risk factors for ACPA-Negative RA
It is becoming increasingly apparent that ACPA-positive RA differs from ACPA-negative RA with
regard to its genetic and environmental basis. To date, only one GWAS has been undertaken in
ACPA-negative RA [16]. Additionally, many epidemiological studies have examined either sero-positive
RA or RA subsets grouped together. It is therefore vital that future epidemiological and genetic studies
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account for disease heterogeneity when examining risk factors for RA subsets, with increased attention 
given to evaluating ACPA-negative RA.
Increase knowledge of gene–gene and gene–environment interactions
There is a limited amount of information on the gene–environment and gene–gene interactions that
exist between RA risk factors. Previous studies examining this have found key interactions between
smoking/the SE alleles and the SE alleles/PTPN22. It is thus likely that other risk factor interactions
exist, which can substantially modify their risks conferred for disease. Further research is required in
this important area, which is of particular relevance in the development of RA prediction models to
ensure their accuracy.
Indentify Genetic markers for disease severity
There is a need to better establish genetic markers for disease severity, with existing research
showing heritability for disease outcomes such as radiographic erosions [17]. Current clinical param-
eters for identifying individuals at risk of developing severe RA are limited. A recent matrix risk model
for rapid radiological progression using clinical factors had limited accuracy, with positive and negative
predictive values of 62% and 91%, respectively [95]. This highlights a need for improved disease severity
prediction markers to aid early prognostic stratiﬁcation and allow prompt appropriate treatment to be
tailored on an individual basis; this may be provided by genetic markers.
Develop and reﬁne RA risk-prediction models
It is of crucial importance to use the accrued information regarding RA risks in clinical practice
through developing and reﬁning RA risk-prediction models. A clinically useful prediction model
would allow further evaluation of preventative strategies, with short courses of corticosteroids,
methotrexate and abatacept already showing some promise in preventing RA development in pre-
clinical RA. It would also enable the investigation of high risk individuals to gain an increased
understanding of the precise immunopathological changes that occur to precipitate this common and
important disease.
Conclusions
RA is a heterogeneous disease, with ACPA-positive and ACPA-negative disease differing not only
phenotypically but also with regard to the risk factors that underlie their development. Many envi-
ronmental and genetic risks for RA have been identiﬁed; however, these are mainly limited to sero-
positive disease and individuals of European ancestry. Additionally, with the exception of smoking,
age and female gender, many environmental risk factors have weak supporting evidence. Further-
more, the precise risk genes that underlie RA development remain uncertain, with approximately 60%
of the genetic basis for RA unknown. These points highlight key needs for well-designed epidemi-
ological studies to better clarify which environmental associations are important, improved geno-
typing techniques to identify the ‘missing heritability’ of RA, GWAS to be undertaken within different
ethnic groups and, ﬁnally, a requirement for the risks for ACPA-positive and ACPA-negative RA to be
evaluated separately. There is strong evidence for a gene–environment interaction between the SE
alleles and smoking that precipitates ACPA generation, leading to ACPA-positive RA. By gaining an
increased understanding of the risk factors for RA, we will increase our knowledge of disease subtype
pathogenesis. This knowledge may also enable the development of RA prediction models that
accurately identify those individuals at a high risk of RA, enabling disease-prevention strategies to be
employed.
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